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Background: Urinary incontinence in women is a distressing condition that restricts quality of life and
results in a large economic burden to both the NHS and women themselves.
Objective: To evaluate the clinical effectiveness, safety and cost-effectiveness of surgical treatment for
stress urinary incontinence (SUI) in women and explore women’s preferences.
Design: An evidence synthesis, a discrete choice experiment (DCE) and an economic decision model,
with a value-of-information (VOI) analysis. Nine surgical interventions were compared. Previous Cochrane
reviews for each were identified and updated to include additional studies. Systematic review methods
were applied. The outcomes of interest were ‘cure’ and ‘improvement’. Both a pairwise and a network
meta-analysis (NMA) were conducted for all available surgical comparisons. A DCE was undertaken to
assess the preferences of women for treatment outcomes. An economic model assessed the cost-effectiveness
of alternative surgeries and a VOI analysis was undertaken.
Results: Data from 175 studies were included in the effectiveness review. The majority of included
studies were rated as being at high or unclear risk of bias across all risk-of-bias domains. The NMA, which
included 120 studies that reported data on ‘cure’ or ‘improvement’, showed that retropubic mid-urethral
sling (MUS), transobturator MUS, traditional sling and open colposuspension were more effective than
other surgical procedures for both primary outcomes. The results for other interventions were variable.
In general, rate of tape and mesh exposure was higher after transobturator MUS than after retropubic
MUS or single-incision sling, whereas the rate of tape or mesh erosion/extrusion was similar between
transobturator MUS and retropubic MUS. The results of the DCE, in which 789 women completed an
anonymous online questionnaire, indicate that women tend to prefer surgical treatments associated with
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no pain or mild chronic pain and shorter length of hospital stay as well as those treatments that have a
smaller risk for urinary symptoms to reoccur after surgery. The cost-effectiveness results suggest that, over
a lifetime, retropubic MUS is, on average, the least costly and most effective surgery. However, the high
level of uncertainty makes robust estimates difficult to ascertain. The VOI analysis highlighted that further
research around the incidence rates of complications would be of most value.
Limitations: Overall, the quality of the clinical evidence was low, with limited data available for the
assessment of complications. Furthermore, there is a lack of robust evidence and significant uncertainty
around some parameters in the economic modelling.
Conclusions: To our knowledge, this is the most comprehensive assessment of published evidence for the
treatment of SUI. There is some evidence that retropubic MUS, transobturator MUS and traditional sling
are effective in the short to medium term and that retropubic MUS is cost-effective in the medium to
long term. The VOI analysis highlights the value of further research to reduce the uncertainty around the
incidence rates of complications. There is a need to obtain robust clinical data in future work, particularly
around long-term complication rates.
Study registration: This study is registered as PROSPERO CRD42016049339.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Anterior vaginal repair A surgical treatment used to treat stress urinary incontinence by lifting and
supporting the bladder. One or more placating sutures are used to secure the fascia, which elevates the
bladder neck and urethra.
Bladder neck needle suspension A procedure usually performed on women for whom colposuspension
is considered challenging, including women with limited vaginal mobility. The bladder neck is elevated
with a long needle that threads sutures from the vagina to the anterior abdominal fascia.
Laparoscopic colposuspension A relatively minimally invasive surgery that requires one or more small
incisions through the lower abdomen. The aim is also to lift the junction between the urethra and
the bladder.
Open retropubic colposuspension A procedure during which a large incision is made in the lower
abdomen to lift and stitch up the tissues near the bladder neck and urethra.
Retropubic mid-urethral sling operation Mid-urethral sling surgery during which a tape or sling is
placed underneath the urethra. The surgery is retropubic as the sling incision is made through the vagina
with two other incisions made through the lower abdomen.
Single-incision sling operation An operation similar to a mid-urethral sling procedure in that it supports
the urethra through the use of a sling. There is a single access made through the vagina and the sling is
shorter than that used in mid-urethral sling procedures, making it a less invasive procedure than
other slings.
Traditional suburethral sling procedure A procedure that improves urethral support by lifting the
urethra–vesical junction and supporting it with autologous or synthetic material.
Transobturator mid-urethral sling operation Mid-urethral sling surgery that is considered to be
transobturator if one incision is made through the vagina and an incision is made on either inner thigh.
Urethral injection therapy (periurethral injections or injectable bulking agents) A procedure in
which high-pressure devices are required to advance the agents through the bladder neck. Once this is
done, the bulking agents are intended to create cushions within the urethral submucosa.
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Plain English summary
U rinary incontinence, defined as involuntary leakage of urine, is a common condition that varies intype and severity and can have a huge impact on the quality of life of women. The aim of this project
was to summarise the evidence on the clinical effectiveness, safety and cost-effectiveness of nine surgical
operations for stress urinary incontinence in women and assess the need for further research. Women’s
preferences for surgery were also explored. Currently there is no agreement among decision-makers,
doctors and patients about which of the available surgical operations is best.
Based on previous Cochrane reviews, the effects and safety of each operation were systematically reviewed
and analysed. Their cost-effectiveness and the value of conducting further research were also evaluated.
To better understand the preference of women, an online survey containing a discrete choice experiment
was conducted. Finally, patient representatives were consulted to help us to understand the consequences
of the findings from a patient’s perspective.
The evidence on surgical operations was predominantly short to medium term (up to 12 months).
This analysis found that the quality of the evidence varied, with the majority of trials being subject to high
or unclear risk of bias, making the conclusions that can be drawn less robust. The findings of the clinical
evidence review suggest that retropubic sling procedures, transobturator sling procedures and traditional
sling procedures are more effective than other surgical procedures for both ‘cure’ and ‘improvement’ of
stress urinary incontinence. The results of the economic analyses support these findings, suggesting that
retropubic mid-urethral sling is the most cost-effective surgical operation. However, data on complications
were lacking, limiting any strong conclusions. The results suggest that there is value in undertaking further
research to reduce the uncertainty around the medium- to long-term complications of all surgical treatments
and this was reflected in patients’ views.
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Scientific summary
Background
Urinary incontinence (UI) in women is a distressing and common condition that impairs quality of life and
results in a large economic burden to both the NHS and women themselves. The prevalence of UI varies
during life but is high in women who have had children and in older women (20–50%). The incidence of
stress urinary incontinence (SUI) increases following menopause because of lowered oestrogen levels.
Many women access conservative treatment with physiotherapy to deliver pelvic floor muscle training
(PFMT) and bladder training initially but, if this fails, surgery is the mainstay of treatment.
Incontinence varies in degree of severity from several drops of urine to complete bladder emptying. It may
occur daily, many times a day or only occasionally, perhaps once a month or related to a certain activity.
It may be predictable or very unpredictable. These different factors – severity, frequency and predictability –
all play a role in evaluating the impact of incontinence on behaviour, treatment choice, quality of life and
economic burden. The precise economic burden has proved difficult to calculate.
There are several surgical treatment options for the management of women with SUI, with many variations
on most options, but, essentially, they fall into nine distinct categories: anterior vaginal repair; bladder neck
needle suspension; open abdominal retropubic colposuspension; laparoscopic retropubic colposuspension;
traditional suburethral retropubic sling procedures; mid-urethral sling (MUS) procedures, comprising two
distinct categories (retropubic MUS and transobturator MUS); single-incision sling procedures (‘mini-slings’);
and periurethral injection (injectable bulking agents).
The high failure rates of early surgical techniques led to the development of colposuspension, but this
approach, though efficacious, was associated with greater morbidity and a longer recovery time. The
development of laparoscopic colposuspension, a more minimally invasive variation of colposuspension,
was considered slightly less effective than the open surgery, but reduced morbidity and length-of-stay
outcomes. Innovation and unmet need led to the development of traditional suburethral sling procedures
in which a piece of material, which could be biological or synthetic, is placed under the urethra and the
free ends secured in one of a number of different ways. The advent of a new minimally invasive technique
that enabled the sling/mesh to be placed without tension ushered in a new era of simpler, potentially
effective and cheaper treatment.
The number of women having surgery has increased and the choice of operation has changed over the last
decade. In 2013–14, Hospital Episode Statistics (HES) data for England show that around 12,000 women
had a MUS operation, with around 500 having another type of continence procedure (colposuspension
≈300, traditional slings ≈200) and just over 700 having periurethral injections. In contrast, 10 years earlier
just under 7000 women had a MUS operation and ≈1400 had a colposuspension and ≈250 had a
traditional sling. Records of how many vaginal mesh implants are implanted or removed per year in women
with SUI are scant. However, until recently it would appear that the trend has shifted to the majority of
women having a minimally invasive MUS, which in turn has led to a substantial increase in the total number
of women having continence surgery. These trends are likely to be driven, in part, by the perception of
improved effectiveness and safety. However, over the past decade safety concerns raised by patients over
mesh implants have been growing. These concerns led to a patients’ campaign, which was followed by a
non-mandatory recommendation by the Scottish Government not to use mesh implants. An independent
enquiry followed within Scotland and the suspension of use of any vaginal mesh (including MUSs) was
maintained, with UK parliamentary questions, a mandatory national audit and a national campaign, Hear
Our Voice, joining the discussions. The debate encompasses the wider use of vaginal mesh in conditions not
being considered in this report. There remains a lot of uncertainty surrounding the optimal choice of surgery,
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especially related to long-term safety, with recent news and media headlines adding to the ambiguity faced
by all involved. What is unclear is the strength of evidence to support the choice of any one surgery
over another.
Objectives
The aim of this project was to evaluate the clinical effectiveness, safety and cost-effectiveness of surgical
treatments for SUI and stress-predominant mixed urinary incontinence (MUI) in women based on
published evidence.
The key objectives were to:
l undertake an evidence synthesis using systematic review methods, including a network meta-analysis
(NMA) to estimate the relative clinical effectiveness of the different types of surgery
l undertake a review of safety/adverse effects associated with each type of surgical intervention
l develop a decision model to estimate the cost-effectiveness of surgical treatments for SUI and
stress-predominant MUI
l utilise the decision model to undertake a value-of-information (VOI) analysis to assess the need and
focus of further primary research
l undertake a discrete choice experiment (DCE) to explore the preferences of women.
Methods of the clinical effectiveness review
A systematic review was undertaken to evaluate the effectiveness and safety of surgical treatment options
for SUI. The Cochrane Incontinence Group has published eight systematic reviews assessing nine distinct
surgical procedures for the treatment of SUI in women. These existing Cochrane systematic reviews form
the foundation of our work and were used to identify studies that meet our prespecified inclusion criteria.
An additional search of the Cochrane Incontinence Group Specialised Trials Register was performed (date
of last search 8 June 2017) to identify additional trials that met our inclusion criteria but had not been
included in the published Cochrane reviews.
To be eligible for inclusion, studies had to compare two or more of the surgical interventions listed above.
Studies that compared a surgical intervention with PFMT were also considered suitable for inclusion. The
primary effectiveness outcomes of interest were the number of women cured (defined as resolution of
clinical symptoms) and the number of women improved (defined as any improvement in clinical symptoms
from baseline). Standard systematic review methods were applied. Both pairwise and network meta-analyses
were undertaken for the primary outcomes. The Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach was adopted to assess the quality of evidence of the primary outcomes.
A number of adverse effect outcomes were also evaluated (i.e. repeat continence surgery, de novo symptoms
of urgency or urgency incontinence, bladder or urethral perforation, tape/mesh extrusion or exposure, pain,
infection and death) as well as outcomes assessing use of resources (i.e. length of hospital stay and operation
time). Pairwise meta-analyses were undertaken for these outcomes.
Results of the clinical effectiveness review
Data from 175 studies were included in the review; 147 were from the Cochrane reviews and 28 were
from additional searches. The included studies reported 21 treatment comparisons; the majority involved
MUSs (retropubic or transobturator) as part of their interventions (n = 97). Open colposuspension versus
other surgery was another common comparison (46 studies), followed by laparoscopic colposuspension
(21 studies) and traditional sling (20 studies). Only one study comparing injectable bulking agents with
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traditional slings was identified. The majority of included studies had high or unclear risk of bias across all
risk-of-bias domains, but most notably for allocation concealment (selection bias).
The NMA, which combined evidence from direct head-to-head comparisons and indirect comparisons,
included 120 studies that reported data on ‘cure’ or ‘improvement’. The results suggest that retropubic
MUS and transobturator MUS are more effective than other surgical procedures for both primary
outcomes. Direct evidence was available mainly for the comparisons involving retropubic MUS,
transobturator MUS or single-incision sling. Follow-up time was generally short (median of 12 months).
However, assessment of adverse events for all procedures was hampered by sparse data. Transobturator
MUS had a higher rate of further SUI procedures than retropubic MUS but a lower rate compared with
single-incision sling. Rate of tape and mesh exposure was higher after transobturator MUS compared with
after retropubic MUS or single-incision sling, whereas the rate of tape or mesh erosion or extrusion was
similar between transobturator MUS and retropubic MUS. Retropubic MUS had a higher rate of major
vascular complications, voiding difficulties and bladder or urethral perforation than transobturator MUS but
a lower rate of groin pain. Rate of postoperative pain was higher after retropubic than single-incision sling
whereas rate of unspecified ‘pain’ was higher after transobturator MUS than single-incision sling. Rate of
infection (including urinary tract infection, wound infection and infection related to mesh) was similar
between single incision sling and transobturator MUS.
Methods of the discrete choice experiment
An online survey containing a DCE was designed to explore women’s preferences for different aspects of
surgical treatments. Five attributes framed the hypothetical scenarios: adverse events, chronic pain, length of
hospital stay, time to return to normal activities, and risk of recurrence during 12 months after surgery. The
analytic approach considered conditional and mixed logit models to account for preference heterogeneity.
Discrete choice experiment results
Responses from a general population sample of women (n = 789) were collected by means of an online
survey. The sample consisted of 436 non-patients and 353 patients with one or more types of UI. Results
suggest that women in general would prefer a surgical treatment over no surgery. This preference was
stronger for patients but was mediated by the respondent’s health status. As expected, respondents
preferred shorter hospital stays and surgical treatments that were associated with a lower risk of recurrence.
Whereas preferences for chronic pain did not vary between groups, patients appeared to care less about
adverse events and more about a shorter period to return to normal activities. Infections and pain during
intercourse were preferred to the reference category of new urinary symptoms, whereas damage to organs
or nerves and voiding difficulties were less preferred.
Methods of the cost-effectiveness model
The review of cost-effectiveness studies identified 17 published modelling studies. However, none of
the published models was deemed robust enough to be used within this analysis. Therefore, a new
cost-effectiveness model was developed to assess the cost-effectiveness of the different surgical techniques
and estimate the VOI to help inform decisions about further research. The model took a lifetime horizon
and an NHS and personal social services perspective. A Markov microsimulation (MM) model, with
3-monthly cycles, was developed in TreeAge Pro® (TreeAge Software, Inc., Williamstown, MA, USA).
Quality-adjusted life-years (QALYs) and costs were discounted at an annual rate of 3.5%. The model
assumes that patients can receive a maximum of three surgical treatments for the treatment of SUI.
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The main probabilities for the model were the success rates of the different interventions (i.e. subjective
cure), rates of retreatment, complications/adverse events and mortality rates. The clinical evidence was
based on the results of the systematic NMA. Long-term effectiveness estimates were extrapolated from
these data. EuroQol-5 Dimensions (EQ-5D) utility estimates were derived from UK studies; however, utility
decrements for complications were only available from a study based on elicitation from experts. Both
deterministic and probabilistic sensitivity analyses were used to explore uncertainty surrounding estimates
of cost-effectiveness.
Cost-effectiveness, expected value of perfect information and expected
value of partial perfect information results
Over a lifetime time horizon, retropubic MUS is, on average, the least costly (£8099) and the most effective
(24.22 QALYs) surgical treatment. With the exception of traditional sling, all other surgical treatments are
dominated as they are more costly and less effective than retropubic MUS. Similarly, over a shorter time
horizon (10 years), retropubic MUS remains the dominant strategy.
Over a lifetime time horizon, retropubic MUS has a > 26% probability of being cost-effective at a
willingness to pay (WTP) threshold value of £20,000. Given the number of comparators, if all of the
interventions were comparable we would expect each to have an 11% chance of being cost-effective.
The only other strategies with reasonable size probabilities of being cost-effective are traditional sling
(≈27% across all WTP values presented, suggesting little difference between retropubic MUS and
traditional sling) and open colposuspension (≈14–16% across all WTP thresholds > £10,000). All other
strategies have a < 10.5% probability of being cost-effective across all WTP values presented.
Seventeen individual sensitivity/scenario analyses were carried out on the base-case model results.
The expected value of perfect information (EVPI) per woman per year is £11,180. The EVPI for the
population was also estimated based on an assumed 15,000 surgical interventions for SUI in the UK
each year. Therefore, the population EVPI for 1 year is estimated to be £167.7M. Expected value of partial
perfect information (EVPPI) analyses were conducted to estimate the value of removing uncertainty around
particular parameters/groups of parameters. The largest value appears to be in removing uncertainty
around the complications incidence rates, relative treatment effectiveness and health utility values.
Conclusions
The evidence for the effectiveness and safety of surgical treatments for SUI is limited, making robust
conclusions difficult to draw. Overall, studies were rated as being at a high or unclear risk of bias. The
NMA based on cure and improvement suggested that retropubic MUS, transobturator MUS and traditional
sling were more effective, but this ranking does not consider the complication profile of these techniques.
The short- to medium-term adverse event data were sparse. The DCE found that although women with
a treatment history had a negative preference for surgical treatments, those with forms of UI that were
extremely or moderately limiting in daily activities preferred a surgical treatment option. Further research
investigating a woman’s choice for or against surgery needs to explore treatment history in greater detail
while considering more individual characteristics, including personal beliefs and perceptions that may act
as a barrier to seeking professional advice. The economic model suggests that retropubic MUS is the most
cost-effective technique based on the current evidence base, although sensitivity analysis to increase mesh
complication rates and persistent pain after mesh surgery made traditional sling the more cost-effective
option. The VOI analysis supports the need for further research to reduce the current uncertainty around
complication rates. The wider literature and recent independent reviews have also highlighted the lack of
robust adverse event long-term data.
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Recommendations for research
Further robust evidence is required on long-term adverse effects and quality of life. Trials to ascertain these
data may not be feasible; it would be more realistic to promote awareness as well as adequate reporting
and monitoring of complications among surgeons and health professionals. In addition, more needs to be
done to understand and quantify the relationship between different levels of severity of SUI and quality
of life.
Most importantly, further research should focus on adverse events that, although infrequent, can have
devastating impacts on women’s quality of life when they occur.
Study registration
The study is registered as PROSPERO CRD42016049339.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of underlying health problem
Urinary incontinence (UI) is defined as an involuntary loss of urine. It is a common condition that is
believed to affect millions of people. There are several types of UI; the focus of this research is stress
urinary incontinence (SUI). SUI is the loss of urine when coughing, laughing, sneezing or exercising.
It is a common and distressing condition, greatly affecting quality of life. The prevalence of SUI varies
during life but is greater in women who have had children and in older women (20–50%).1 The physical
changes resulting from pregnancy, childbirth and menopause often contribute to SUI. For many women,
SUI can worsen during the week before the menstrual period. Lower oestrogen levels can lead to lower
muscular pressure around the urethra, which in turn increases the chances of leakage. Many women
access conservative treatment with physiotherapy to deliver pelvic floor muscle training (PFMT) and bladder
training initially but, if this fails, surgery is the mainstay of treatment. Data suggest that women have a
10% lifetime risk of having continence surgery.1
The aim of surgery is to support or partially obstruct the bladder neck and/or urethra, thus blocking the
leakage of urine on exertion or coughing. Women with mixed urinary incontinence (MUI) (a combination
of SUI and urgency UI) may also be helped because they are better able to defer voiding and leakage.
However, urinary urgency and urgency UI can be both caused by and made worse by SUI surgery.1
Incontinence varies in degree of severity from several drops of urine to complete bladder emptying. It may
occur daily, many times a day or only occasionally, perhaps once a month. It may be predictable or very
unpredictable. These different factors – severity, frequency and predictability – all play a role in evaluating
the impact of incontinence on behaviour, treatment choice, quality of life and economic burden. The
precise economic burden has proved difficult to calculate. One published UK study suggests an estimated
total figure for combined health, personal and societal expenditure of £818M for SUI at 1999/2000 prices
(upwards of £1.1B at 2017 prices),2 whereas another study published in 2004 suggests a health-care cost
to the UK NHS (SUI only) of £117M per year.3
One of the main purposes of this research is to comparatively draw together all the relevant evidence
from published randomised controlled trials (RCTs), accomplished through a network meta-analysis (NMA)
and associated economic model. This allows all the available surgical treatments to be simultaneously
compared with each other, for what we believe to be the first time, to determine which treatments should
be offered in clinical practice on the basis of being the most clinically effective, safest and most cost-effective.
Description of current service provision
Women are likely to have tried many things prior to presenting to their general practitioner (GP), including
lifestyle changes, PFMT and incontinence pants or pads. Embarrassment stops many seeking help from
their GP until symptoms become unmanageable or begin to have a greater impact on everyday life. The
treatment offered within primary care will depend on the type and severity of incontinence. Conservative
treatments are usually tried first before moving on to medication. Conservative treatments can overlap
with treatments tried by women prior to presenting and may include lifestyle changes (e.g. reduced
caffeine intake, adjusted fluid intake, weight loss); PFMT, which can be aided by biofeedback, vaginal
cones or electrical stimulation; and bladder training.
If these treatments are unsuccessful, medication is available. For SUI only one medication is available:
duloxetine. The National Institute for Health and Care Excellence (NICE) recommends (as of September 2013)
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that duloxetine not be routinely offered as first-line treatment and that it be offered as second-line therapy
only to women wishing to avoid other therapy (i.e. surgery). The guidelines further state that women should
be counselled regarding the drug’s side effects. The evidence for duloxetine is uncertain. The drug failed
to receive Food and Drug Administration (FDA) approval for SUI owing to concerns over liver toxicity and
suicidal events. In the UK, as mentioned previously, it is currently recommended as an add-on medication for
SUI instead of surgery. Its safety and utility for SUI have been evaluated in a number of meta-analyses, the
latest of which, published in 2016 and based on clinical trial reports, found that, although effective for SUI,
duloxetine’s associated harms were high and, when individual patient data were analysed, outweighed
the benefits.4
There are several surgical treatment options for the management of women who have failed first-line
treatment for SUI. Furthermore, there are a number of variations on most techniques, but, essentially,
they fall into nine distinct categories:
l anterior vaginal repair (anterior colporrhaphy)
l bladder neck needle suspension
l open abdominal retropubic colposuspension
l laparoscopic retropubic colposuspension
l traditional suburethral retropubic sling procedures
l mid-urethral sling (MUS) procedures
¢ retropubic MUS
¢ transobturator MUS
l single-incision sling procedures (‘mini-slings’)
l periurethral injection (injectable bulking agents).
One of the earliest operations described for SUI was anterior repair with urethral buttressing sutures (Kelly
sutures). Although curing over half of women, the high failure rate (and that of another operation, bladder
neck needle suspension) led to the development of colposuspension, which is an open abdominal method
of elevating the bladder neck. The evidence base suggested that this was more effective but with greater
morbidity and a longer recovery time than the previous options. Laparoscopic colposuspension, although a
minimally invasive variation of colposuspension, was considered slightly less effective than open surgery.
These issues led to the development of traditional suburethral sling procedures, in which a piece of
material, which could be biological (such as a rectus sheath graft) or synthetic (such as a polypropylene
mesh sling), is placed under the urethra and the free ends secured in one of a number of different ways.
The advent of a new minimally invasive technique that enabled the sling to be placed without tension
ushered in a new era of simpler, effective and cheaper treatment. This brief summary of the evidence
concurs with the conclusions of the Cochrane reviews that have collated the relevant evidence for these
types of procedures.5–12
The number of women having surgery has been rising and the choice of operations has changed
over the past decade. In 2013–14, Hospital Episode Statistics (HES) data for England show that around
12,000 women had a MUS operation, with around 500 having another type of continence procedure
(colposuspension, ≈300; traditional slings, ≈200) and just over 700 having periurethral injections. In
contrast, 10 years earlier just under 7000 women had a MUS operation, ≈1400 had a colposuspension
and ≈250 had a traditional sling. There is no single database that records how many vaginal mesh
implants are implanted or removed each year in women with SUI, making an assessment of trends
difficult. However, it would appear that, until recently, there had been a shift towards minimally invasive
MUS, with the majority of women choosing this procedure, which in turn led to a substantial increase
in the total number of women having continence surgery. These trends are likely to have been driven,
in part, by the perception of improved effectiveness and safety.
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In 2014 the American Urogynecologic Society and Society of Urodynamics, Female Pelvic Medicine and
Urogenital Reconstruction published a position statement: ‘The polypropylene mesh mid-urethral sling
is the recognized worldwide standard of care for the surgical treatment of stress urinary incontinence.
The procedure is safe, effective, and has improved the quality of life for millions of women’.13 However,
subsequent international media publicity regarding supposed long-term severe adverse effects from vaginal
mesh procedures has caused anxiety in women, many of whom have decided, owing to high levels of
uncertainty, to avoid any type of surgery involving synthetic material, including MUS, despite the lack of
any robust new evidence to support this view.
Women’s concerns about the safety of vaginal mesh implants led to a patients’ campaign, which in
turn led to an independent enquiry and the suspension of use of any vaginal mesh (including MUSs) in
Scotland, UK parliamentary questions, a mandatory national audit and a national campaign, Hear Our
Voice (www.scottishmeshsurvivors.com/). The debate encompasses the wider use of vaginal mesh in
conditions not being considered in this report. There remains a lot of uncertainty surrounding the optimal
choice of surgery, especially related to long-term safety, with recent news and media headlines adding
to the ambiguity that clinicians and women face when making decisions regarding treatment options. It is
likely that the trend in the use of minimally invasive MUSs has taken a downwards turn; however, what is
currently unclear is the strength of evidence to support the choice of any one of the other surgery options.
Description of technologies under assessment
The technologies under assessment are the surgical techniques anterior vaginal repair (anterior colporrhaphy);
bladder neck needle suspension; open abdominal retropubic colposuspension; laparoscopic retropubic
colposuspension; traditional suburethral retropubic sling procedures; retropubic MUS; transobturator MUS;
and single-incision sling procedures (mini-slings).
Decision problem
Currently there is no clear evidence to indicate which surgery is the best choice. It is unclear if the older
operations that were previously available (such as anterior repair and colposuspension) really result in
equivalent or better outcomes than the polypropylene MUS. However, the feeling of our clinical experts
who used to offer colposuspension and traditional slings is that these techniques had more frequent and
severe associated complications and returning to them may be detrimental to women. To enable women
to make an evidence-based choice and inform practice guidelines, it is essential to collect reliable evidence
in a transparent, concise manner to allow impartial counselling of women regarding the benefits and risks
of the alternative surgical operations for the management of SUI.
The wide range of surgical operations available, the different techniques used to perform these operations
and the lack of a consensus among surgeons make it challenging to establish which procedure is the most
effective. The existing evidence base, including the Cochrane systematic reviews, has focused on discrete
two-way comparisons, with no attempt being made to collate all of the evidence on the surgical options
available and rank them in terms of clinical effectiveness, safety and cost-effectiveness. This has resulted in
a piecemeal evidence base that is difficult for women and clinicians to interpret. This assessment includes
an evidence synthesis of all available RCTs to determine the relative clinical effectiveness and safety of
interventions, a discrete choice experiment (DCE) to explore women’s preferences, an economic decision
model to determine the most cost-effective treatment and a value-of-information (VOI) analysis to help
inform the focus of further research.
DOI: 10.3310/hta23140 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 14
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Brazzelli et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3
Aims and objectives of the research
The aim of this project was to evaluate the clinical effectiveness, safety and cost-effectiveness of surgical
treatment for SUI and stress-predominant MUI in women.
The key objectives were to:
l undertake an evidence synthesis using systematic review methods, including a NMA to estimate the
relative clinical effectiveness of the different types of surgery and inform key clinical parameters for a
decision model
l undertake a review of safety/adverse effects associated with each type of surgical intervention
l undertake a DCE to explore the preferences of women
l develop a decision model to estimate the cost-effectiveness of surgical treatments for SUI and
stress-predominant MUI
l utilise the decision model to undertake a VOI analysis to assess the need for further primary research.
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Chapter 2 Methods of clinical effectiveness
review(s)
This chapter reports the methods used for conducting an objective synthesis of the current evidencefor assessing the clinical effectiveness and safety of surgical interventions for the treatment of SUI or
stress-predominant MUI in women. The evidence synthesis was carried out according to the general
principles of the Centre for Reviews and Dissemination (CRD) guidance for undertaking reviews in health
care,14 the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions15 and
the NICE guide to the methods of technology appraisal16 and was reported according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).17 The methods were prespecified
in a research protocol (PROSPERO database registration number CRD42016049339).
Search strategy
Literature searching was performed in two stages. First, relevant studies were identified from the existing
relevant Cochrane systematic reviews published in the Cochrane Database of Systematic Reviews. Second,
the Cochrane Incontinence Group Specialised Register was searched to identify new studies added since
the publication of the Cochrane systematic reviews (henceforth ‘updated literature searches’).
The Cochrane Incontinence Group has published eight systematic reviews assessing nine distinct surgical
procedures for the treatment of SUI in women. Two Cochrane systematic reviews that were obtained through
personal communication and were in the process of being updated (review on traditional suburethral slings
for UI in women: Dr Lucky Saraswat, Aberdeen Royal Infirmary, 2016; review on laparoscopic colposuspension
for UI in women: Dr Muhammad Imran Omar, University of Aberdeen, 2016) were also used as source data.
Both reviews have currently completed the peer-review process. On approval, the final versions of these
systematic reviews are expected to be published in the Cochrane Database of Systematic Reviews.
We used these Cochrane systematic reviews to identify studies that met our prespecified inclusion criteria.
To avoid duplicates, the studies were taken from the reviews in the following order:
1. Lapitan et al.5 – open retropubic colposuspension for UI in women
2. Ford et al.8 and Ogah et al.18 – MUS operations for SUI in women
3. Nambiar et al.9 – single-incision sling operations for UI in women
4. Saraswat et al.7 and Rehman et al.19 – traditional suburethral sling operations for UI in women
5. Freites et al.6 and Dean et al.20 – laparoscopic colposuspension for UI in women
6. Glazener and Cooper11 – bladder neck needle suspension for UI in women
7. Glazener and Cooper10 – anterior vaginal repair for UI in women
8. Kirchin et al.12 – urethral injection therapy for UI in women.
There was a certain degree of overlap between systematic reviews, with some primary studies included in
more than one review. The additional reports of primary studies included as second/multiple publications
were checked across reviews.
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The Cochrane Incontinence Group Specialised Trials Register was searched (date of last search: 8 June 2017)
using the terms given in Appendix 1 to identify studies published since the conduct of the Cochrane
systematic review. The Cochrane Incontinence Group Specialised Trials Register is updated regularly and
contains studies from the following databases and other sources:
l Cochrane Central Register of Controlled Trials (CENTRAL) [via Cochrane Register of Studies Online
(CRSO)] (inception to 15 May 2017) (searched 15 May 2017)
l MEDLINE (via OvidSP) (1946 to April week 3 2017)
l MEDLINE In-Process & Other Non-Indexed Citations (via OvidSP) (covering 28 April 2017)
l MEDLINE Epub Ahead of Print (via OvidSP) (covering 2 May 2017)
l ClinicalTrials.gov via Cochrane Register of Studies (CRS) standalone
l World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP)
l hand-searching of journals and conference proceedings.
EMBASE is not included in the above list because the Cochrane Centralised Search Service already searches
EMBASE for identification of RCTs and adds them to CENTRAL. Details of the search methods used to
build the Specialised Register are available from the group’s module in The Cochrane Library.21
Inclusion and exclusion criteria
Types of studies
Randomised controlled trials or quasi-RCTs (using alternate allocation) were eligible for the assessment of
clinical effectiveness. There was no restriction on the trials’ publication status (published or unpublished) or
on the year or the language in which they were reported.
Population
The type of participants considered for this assessment were adult women with SUI or stress-predominant
MUI. Either a clinical or a urodynamic diagnosis of SUI was considered suitable. We accepted the diagnoses
as defined by the authors of the included trials. Women who underwent continence surgery as a primary
or repeated procedure, women with SUI and concomitant prolapse and women who received concomitant
prolapse surgery were deemed suitable for inclusion. Studies that did not specify the type of incontinence
(stress, urge, mixed) or the predominant MUI symptoms (stress or urge) were excluded.
Interventions
The interventions detailed below were deemed suitable for inclusion. There are a number of variations on
most surgical techniques, but, essentially, they fall into nine distinct categories, each of which has been
previously evaluated in systematic reviews published in The Cochrane Library:
1. retropubic MUS operations
2. transobturator MUS operations
3. open retropubic colposuspension
4. laparoscopic colposuspension
5. traditional suburethral sling procedures
6. single-incision sling operations
7. anterior vaginal repair
8. bladder neck needle suspension
9. urethral injection therapy (periurethral injections/injectable bulking agents).
To be eligible for inclusion, studies had to compare two or more of the surgical interventions listed above.
Studies that compared a surgical intervention with PFMT were also considered suitable for inclusion as they
were useful for the development of a NMA treatment diagram for assessing direct and indirect treatment
comparisons. For the purpose of this assessment, we considered eligible for inclusion PFMT programmes
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taught and monitored by health professionals, clinicians or instructors (defined as ‘supervised PFMT’).22
PFMT programmes for which instructions were delivered using written material only (e.g. leaflets or flyers
delivered to women), without any interaction or face-to-face contact with health-care professionals,
were considered to be equivalent to no treatment and, therefore, excluded from this assessment.
We excluded, post hoc, studies that compared surgery with pharmacological treatments or no treatment,
as they were not considered useful for the development of the treatment network diagram. We did not
include studies comparing specific technical variations of the relevant surgical techniques (e.g. inside-out
vs. outside-in transobturator MUS operations, or one injectable agent vs. another) as it was beyond the
scope of this review to assess specific technical approaches within each surgical category.
Outcomes
The following outcome measures were considered.
Primary outcomes
l Number of women cured (defined as resolution of clinical symptoms).
l Number of women cured or improved (henceforth referred to as ‘improvement’).
Secondary outcomes
l Long-term data:
¢ number of women having repeated continence surgery.
l Adverse events:
¢ haemorrhage/major vascular complications, including haematoma
¢ infection, including wound infection and urinary tract infection (UTI)
¢ infection related to use of synthetic mesh
¢ de novo symptoms of urgency or urgency incontinence
¢ voiding difficulties including urinary retention
¢ bladder or urethral perforation
¢ tape/mesh/implant exposure
¢ tape/mesh erosion or extrusion
¢ persistent pain or discomfort, including osteitis, which is pertinent to the Marshall-Marchetti-Krantz
procedure
¢ dyspareunia (pain with intercourse)
¢ death.
l Resource use:
¢ operating time
¢ length of hospital stay.
We considered outcomes measured at 12 months or the nearest time point available as well as longer-term
outcomes (e.g. at 2 years or 5 years). Studies with a time point of < 2 weeks were excluded.
The measurement of these outcomes was not used as an eligibility criterion for selecting studies for
inclusion in this assessment.
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Primary outcomes (cure and improvement) were defined in many different ways. For example, authors of
individual studies defined cure as ‘no stress incontinence symptoms’, ‘negative testing’ or subjective reports
of being ‘continent’, ‘dry’, ‘satisfied’ or ‘very much improved’. To have a more consistent definition of
cure, we checked the original definitions used by the authors of each included study to ensure that ‘cure’
was used to refer to the resolution of SUI symptoms. We also accepted cases where authors reported
resolution of ‘incontinence symptoms’ without specifying stress symptoms. Any indication of satisfactory
improvement in SUI symptoms was defined as ‘improvement’.
A variety of measures could be used to define cure or improvement in SUI symptoms, including subjective
(women-reported) measures such as women’s observations and objective measures such as quantification
of symptoms (e.g. pad tests) and urodynamic tests. We chose to extract data based on a hierarchy of
reported outcomes. For ‘cure’, women’s self-report of cure was given priority when available. When this
measure was not available, a composite measure (a combination of women-reported and objective
measures) was used instead. Pad test and urodynamic test results were considered only when the previous
two outcome measures were not available. For ‘improvement’, the women’s self-report of improvement
was preferred but if this was not available the women’s satisfaction rate was used as a proxy. If satisfaction
rate was also not available, we considered improvement rates based on pad tests and then on urodynamic
tests. Cough stress tests or diaries were considered less reliable measures for the assessment of cure
and improvement.
Adverse event outcomes were extracted verbatim from the relevant Cochrane systematic reviews. The
classification of secondary outcomes and time points of outcome measurements were only consistent
within each Cochrane systematic review, but not necessarily across different Cochrane systematic reviews.
For example, in certain reviews pain outcomes were classified by time (short term and long term) whereas
in others this was by location (e.g. groin or abdominal). Haematoma was reported as either a distinct
outcome (haematoma) or part of a group of outcomes (e.g. perioperative complications). Though some
outcomes were redefined by Cochrane authors to facilitate meta-analysis, the definitions used were not
always clearly reported. No attempt was made to standardise adverse event outcomes extracted from
different Cochrane systematic reviews.
The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach,23
which takes into account five criteria – study design (judged according to the Cochrane risk-of-bias tool),
inconsistency, imprecision, indirectness and publication bias24 – was used for rating the quality of evidence
of the two primary outcomes included in the NMA (cure and improvement). The following steps were
taken: (1) assess the quality of evidence of direct treatment effect (head-to-head comparison), when
available; (2) assess the quality of evidence of indirect treatment effect (i.e. two pairwise comparisons
contributing to the first-order loop; the lower confidence rating of the two pairwise comparisons was used
to indicate the overall quality of indirect treatment effect); (3) use the higher of the two quality ratings
when both direct and indirect estimates of treatment effect are available; and (4) when only a direct or
indirect estimate of treatment effect is available, base the network quality on that estimate. As GRADEpro
GDT (McMaster University and Evidence Prime Inc, Hamilton, ON, Canada; https://gradepro.org) is a
web-based tool that does not support assessment of the quality of evidence of network meta-analyses,
we used Microsoft Excel® 2013 (Microsoft Corporation, Redmond, WA, USA). There are four levels of
quality of evidence: high, moderate, low or very low. ‘High quality’ means that the authors have a lot of
confidence that the true effect lies close to that of the estimated effect. ‘Moderate quality’ means that the
authors believe that the true effect is probably close to the estimated effect but there is a possibility that
it is substantially different. ‘Low quality’ means that the true effect might be markedly different from the
estimated effect. ‘Very low quality’ means that the true effect is probably markedly different from the
estimated effect.
Owing to the lack of suitable data and the fact that the risk-of-bias assessment in the relevant Cochrane
systematic reviews was not always provided for individual outcomes, it proved unfeasible to use the
GRADE approach for grading the quality of other outcomes.
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Data collection
Selection of studies
The selection of studies included in the Cochrane systematic reviews was established by one reviewer (SW)
and checked by a second reviewer (MI). Screening of the titles and abstracts of all citations identified by
the updated literature searches was conducted by one reviewer (SW). Full text copies of all potentially
relevant reports were retrieved by the same reviewer for eligibility and checked by a second reviewer
(MI or MS) to ensure that they met the prespecified inclusion criteria.
Data extraction
Studies selected from Cochrane systematic reviews
The original data extraction performed by the authors of the individual Cochrane systematic reviews was
used as a basis for the assessment of clinical effectiveness. The characteristics of included studies were
extracted as reported in the relevant Cochrane systematic reviews. Outcome data presented in forest plots
of each Cochrane systematic review were exported using RevMan version 5.3 (Nordic Cochrane Centre,
The Cochrane Collaboration, Copenhagen, Denmark). Of these, data for primary outcomes (cure and
improvement) were cross-checked against the original study reports and supplementary information
(such as definitions and time points) was extracted to enable the performance of a NMA.
Cross-checking of secondary outcome data was performed only when there was inconsistency in the
extracted data or when studies were originally included as abstracts in the Cochrane systematic reviews
but subsequently published in full (eight studies).25–32 In other cases, adverse event data were accepted as
reported in the Cochrane reviews.
Some Cochrane systematic review authors attempted to contact the corresponding authors of included
studies to obtain key missing data or have full-text copies of non-English-language translations. Any
relevant information retrieved in such a manner was included in this assessment. In some cases, reports
published in languages other than English were translated by the authors of the Cochrane reviews.
When a translation could not be arranged, the information used in the Cochrane reviews was limited to
the content of the English abstracts.
Studies identified by the updated literature searches
For new studies identified by the updated literature searches, data extraction was carried out by one
reviewer and checked by a second reviewer (MI and MS) for errors or inconsistencies. Any disagreement
was resolved through consensus or arbitration by a third party. A data extraction form was designed and
piloted for the purpose of this assessment (see Appendix 2). Details related to study design, characteristics
of participants, settings, characteristics of interventions and outcome measures were recorded. Outcome
data were extracted as needed to allow calculation of summary statistics and measures of variance.
Numbers of events and total number of participants in each treatment group were extracted for the
assessment of dichotomous outcomes, and means and standard deviations (SDs) were extracted for the
assessment of continuous outcomes. Missing data were not imputed and there was no attempt to contact
study authors for missing data.
Risk-of-bias assessment of included studies
Studies selected from Cochrane systematic reviews
We relied on the original risk-of-bias assessments performed by the authors of the Cochrane systematic
reviews. Assessment criteria varied across different Cochrane systematic reviews, which were accepted as
reported. We updated the risk-of-bias assessments using the new criteria described below only for those
studies that were initially included in the Cochrane systematic reviews as abstracts but subsequently
published in full (eight studies).25–32
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Studies identified by the updated literature searches
For the studies identified by the updated literature searches, the Cochrane risk-of-bias assessment tool
was used.15 Critical judgments were made for the following domains: selection bias (random sequence
generation, allocation concealment), performance bias (blinding of participants and personnel), detection
bias (blinding of outcome assessor), attrition bias (incomplete outcome data), reporting bias (free of
selective reporting) and other bias. Each included study was judged to be at ‘low risk of bias’, ‘high risk
of bias’ or ‘unclear risk of bias’. The assessment was conducted by one reviewer (MI or MS) and checked
by a second reviewer (MI or MS). Any disagreements were resolved by consensus or arbitration with a
third reviewer (MB). Studies were not included or excluded on the basis of their methodological quality.
Data analysis
Network meta-analysis
Network meta-analysis aims to synthesise all of the available evidence within a distinct framework.
It enables the integration of direct evidence with indirect evidence from a network of studies involving all
possible intervention comparisons. Direct evidence is obtained from all possible head-to-head comparisons
between the different interventions, whereas indirect evidence is obtained from comparisons of two or more
interventions that share a common comparator. For example, direct evidence from comparing intervention A
with B and B with C can be combined to provide indirect evidence for intervention A versus C.
We conducted a NMA to assess the effects of the surgical interventions for SUI in terms of the number of
women who were cured or experienced an improvement in their incontinence symptoms (primary outcomes).
Studies that reported 100% events in all arms (all participants were cured or improved) were excluded from the
analysis as they provide no evidence for the analysis. The NMA included outcomes measured at 12 months or at
a time point closest to 12 months (studies with a time point of < 2 weeks or > 36 months were excluded).
Convergence was assessed using Brooks–Gelman–Rubin plots, trace plots and autocorrelation plots.
The NMA analysis was undertaken within a Bayesian framework, using WinBUGS 1.4.3 (MRC Biostatistics
Unit, Cambridge, UK)33 and using code provided by Dias et al.34 (see Appendix 3). The analysis used vague
uniform prior and adjusted for multi-arm trials using conditional distributions. Consistency, which is where
direct and indirect evidence are in agreement, was assessed by comparing the individual data point’s
posterior mean deviance contributions for the consistency and inconsistency model and node splitting
analysis35 using R 3.4.1 (R Foundation, Vienna, Austria).
In the results section, network diagrams are presented for each outcome and effect sizes are reported as
posterior median odds ratios (ORs) and 95% credible intervals (Crls). We also present rankograms for
all surgical interventions, which gives probabilities of an intervention being ranked 1 (the highest) to
9 (the lowest) as well as reporting the surface under the cumulative ranking curve (SUCRA), which is a
numerical presentation of the overall ranking and presents a single number associated with each intervention.
SUCRA values range from 0% to 100%. The closer to 100% the SUCRA value, the more likely that an
intervention is in the top rank or one of the top ranks; the closer to 0 the SUCRA value, the more likely that
an intervention is in the bottom rank or one of the bottom ranks.36
Direct pairwise (head-to-head) meta-analyses
Adverse event outcomes as well as cure and improvement were summarised as direct head-to-head
comparisons using a random effects model. Effect sizes are reported as ORs with 95% confidence intervals
(CIs) for dichotomous outcomes and as mean differences with 95% CI for continuous outcomes. When
data were available, meta-analyses assessing adverse events were performed at different time points
(e.g. 6 months, 12 months, 24 months). Heterogeneity was assessed using the I2 statistic. Analyses were
performed using Stata version 14 (StataCorp LP, College Station, TX, USA).
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Subgroup analysis
We planned to undertake subgroup analyses for the following groups: women with stress-predominant
MUI versus women with SUI alone; repeated surgery (after failed previous continence surgery) versus
primary procedures; women with and without coexisting vaginal prolapse/having concomitant prolapse
surgery. However, these were not performed owing to the lack of available data. For example, lack of
clarity in some trial reports made it difficult to decipher whether study participants had SUI, MUI or both.
Moreover, outcome data for each patient subgroup were not reported separately in all trials. Owing to
such inconsistencies and limited reporting of suitable data in the included studies, we were unable to
perform these analyses.
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Chapter 3 Results of clinical effectiveness review(s)
Number of studies identified
Studies identified from Cochrane systematic reviews
From the eight published Cochrane systematic reviews that provided data suitable for this assessment,
a total of 166 studies (in 443 reports) were initially selected as potentially relevant. Of these, 147 studies
(in 406 reports) were included as they met the prespecified inclusion criteria for this assessment, 17 studies
were excluded and one was merged with another study.37 The number of included studies from each
Cochrane systematic review is shown in Table 1.
Studies identified from updated literature searches
The updated literature searches identified 591 potentially relevant titles and abstracts from which 216 reports
were selected for full-text evaluation. Of these, 65 reports (describing 28 new studies) were considered
suitable for inclusion. In addition, 100 reports were identified as additional references of studies already
included in the relevant Cochrane systematic reviews and two reports were additional references of studies
originally included in the Cochrane systematic reviews but subsequently excluded from the effectiveness and
cost-effectiveness of surgical treatments for women with stress urinary incontinence (ESTER) report. A total
of 26 reports of 23 ongoing trials were also identified and two further reports were included as ‘awaiting
assessment’ and 21 reports were excluded.
In total, 175 studies were included in the assessment of clinical effectiveness. Of these, 43 studies were
available only as conference abstracts.38–80 A PRISMA flow chart summarising the study selection process is
provided in Appendix 4. The list of included studies and associated references is reported in Appendix 5.
Reasons for exclusion for a sample of excluded studies are described in Appendix 6. The list of ongoing
trials is provided in Appendix 7.
TABLE 1 Number of studies selected from eight Cochrane systematic reviews and new studies identified by
updated literature searches
Source of studies
Number of studies
selected
(a) Selected from published Cochrane systematic reviews
Lapitan et al.:5 open retropubic colposuspension for UI in women 47
Ford et al.8 and Ogah et al.:18 MUS operations for SUI in women 68
Nambiar et al.:9 single-incision sling operations for UI in women 24
Saraswat et al.7 and Rehman et al.:19 traditional suburethral sling operations for UI in women 6
Freites et al.6 and Dean et al.:20 laparoscopic colposuspension for UI in women 1
Glazener and Cooper:11 bladder neck needle suspension for UI in women 1
Glazener and Cooper:10 anterior vaginal repair for UI in women 0
Kirchin et al.:12 urethral injection therapy for UI in women 0
Subtotal 147
(b) Identified via updated literature searches
Subtotal 28
Total number of included studies (a + b) 175
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Characteristics of included studies
The characteristics of the included studies are detailed in Appendix 8. The included studies involved a total
of 21,598 women, with a median follow-up of 12 months, ranging from 1 month80 to 126 months.81
Sample size ranged from 1570 to 65582 participants, with a median of 91 participants per study. There were
25 studies with a sample size of ≥ 200 participants.28,37,61,65,72,82–101 The largest study assessed 655 women
treated with either open colposuspension or traditional slings.82 The mean or median age of women
ranged from 34.338 to 65.0102 years.
There were 10 quasi-randomised trials (out of 175 included studies; 6%) considered to be at high risk of
selection bias, as participants were allocated to treatment by alternation,103–110 date of birth111 or medical
history numbers.112
The primary references of the included studies (either the first publication or the first full-text publication)
were published between 1978105 and 2016.65,91,113–115 Around 10% (17 out of 175) of the included studies
were published before 2000, 81 (46%) were published between 2000 and 2009 and 77 (44%) were
published in 2010 or thereafter. All of those published before 2000 compared open colposuspension
with other surgical procedures, whereas those published from 2000 onwards tended to include MUSs
(retropubic or transobturator route) or single-incision slings as one of the study arms.
The number and type of intervention comparisons are shown in Table 2. Altogether, the included studies
reported 21 treatment comparisons. The majority of included studies involved MUSs (retropubic or
transobturator route) as part of their interventions. The most common intervention comparisons were
between retropubic MUSs and transobturator MUSs (58 studies) and between transobturator MUS and
single-incision slings (39 studies). The latter comparisons included 17 new studies, nearly two-thirds of
the 28 new studies identified by the updated literature searches (17 out of 28; 61%). Another common
comparison was between open colposuspension and other surgery (46 studies), followed by laparoscopic
colposuspension (21 studies) and traditional slings (20 studies). Few studies were available for most
other comparisons.
Six trials were based on a three-arm design.47,49,88,116,145,188 One four-arm trial was also converted to a three-
arm trial because two of the four arms compared two variations of the same treatment and were therefore
combined [i.e. tension-free vaginal tape-obturator (TVT-O) and transobturator tape (TOT) were combined
as transobturator MUS].72
Some of the three-arm trials were converted into two-arm trials because either two of the three treatment
arms compared two variations of the same surgical operation,91,92,117–119,167–169,189,200 or one of the three arms
assessed a treatment that did not meet our inclusion criteria [e.g. de Olivera et al.44 included pre-pubic
tension-free vaginal tape (TVT) and Tapp et al.78 included PFMT plus electrical stimulation].
The characteristics of the participants enrolled in the included studies are summarised in Table 3. The
majority of studies (91 out of 175; 52%) included women with urodynamically confirmed SUI.25,30,31,37,39,40,43,
49,51,53–55,57,58,60,61,67–69,76–78,81,83,85,87–93,97,100–103,106,107,109,111,113,115,118,122–131,138,140–142,145–152,155,160–162,166,167,171,173,178,180,182,
183,185,187–190,193–196,198,201–203 Eight studies included women with a clinical diagnosis based on either
urodynamic tests or symptoms of SUI27,28,120,157,165,168,172,191 and the remaining studies appeared to use a
diagnosis based on symptoms of SUI.
In general, it was difficult to determine from the relevant Cochrane systematic reviews whether or not
the patient populations had other specified characteristics (e.g. mixed incontinence or mixed symptoms,
previous incontinence surgery, co-existing prolapse) as information on participants’ characteristics was not
reported consistently across reviews.
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TABLE 2 Number of included studies by treatment comparison
Intervention
Number
randomised Number of studies
Number of
new studies References1 (control) 2 (experiment)
Retro-MUS Transob-MUS 8876 58 4 Darabi Mahboub et al.,26 Tarcan et al.,31 Wang,37 Cervigni et al.,41 Choe
et al.,42 de Oliveira et al.,44 Diab et al.,45 El-Hefnawy et al.,48 Elshawaf and
Al bahaie,49 Hammoud et al.,56 Kamel,58 Leanza et al.,61 Mansoor et al.,64
Palomba and Zullo,70 Riva et al.,71 Rudnicki et al.,72 Salem et al.,73
Aigmüller et al.,83 Aniuliene,84 Araco et al.,86 Chen et al.,90 Krofta et al.,94
Laurikainen et al.,96 Meschia et al.,97 Rechberger et al.,98 Richter et al.,99
Enzelsberger et al.,104 Lee et al.,107 Nerli et al.,110 Wang et al.,116 Andonian
et al.,117 Chen et al.,118 Scheiner et al.,119 Alkady and Eid,120 Aniuliene
et al.,121 Barber et al.,122 Barry et al.,123 David-Montefiore et al.,124 deTayrac
et al.,125 Deffieux et al.,126 El-Hefnawy et al.,127 Freeman et al.,128 Jakimiuk
et al.,129 Karateke et al.,130 Kiliç et al.,131 Kim et al.,132 Liapis et al.,133
Mehdiyev et al.,134 Nyyssönen et al.,135 Porena et al.,136 Ross et al.,137
Schierlitz et al.,138 Tanuri et al.,139 Teo et al.,140 Wang et al.,141 Wang et al.,142
Zhang and Zhu143 and Zullo et al.144
Retro-MUS Open colpo 1240 13 0 Trabuco et al.,32 Drahoradova et al.,46 Elshawaf and Al bahaie49 Halaska
et al.,55 Han,57 Koelbl et al.,60 O’Sullivan et al.,69 Ward et al.,100 Liapis et al.,108
Bai et al.,145 Foote et al.146 and Paraiso et al.147
Retro-MUS Lap colpo 651 8 0 Adile et al.,39 Maher et al.,63 Mirosh and Epp,67 Foote et al.,146
Paraiso et al.,147 Persson et al.,148 Ustün et al.149 and Valpas et al.150
Retro-MUS Trad sling 868 9 0 Abouhashem et al.,38 Sharifiaghdas and Mortazavi,81 Guerrero et al.,92
Kondo et al.,106 Bai et al.,145 Amaro et al.,151 Arunkalaivanan and
Barrington,152 Basok et al.153 and Song et al.154
Retro-MUS Single incision 1092 9 3 Lee et al.,62 Rudnicki et al.,72 Barber et al.,87 Wang et al.,116 Abdelwahab
et al.,155 Andrada Hamer et al.,156 Basu and Duckett,157 Gopinath et al.158
and Ross et al.159
Retro-MUS Ant repair 53 1 0 Wadie et al.160
Transob-MUS Open colpo 272 4 0 El-Din Shawki et al.,47 Elshawaf and Al bahaie,49 Bandarian et al.161 and
Sivaslioglu et al.162
Transob-MUS Lap colpo 35 1 0 Samiee et al.163
Transob-MUS Trad sling 141 3 1 Al-Azzawi,164 Silva-Filho et al.165 and Tcherniakovsky et al.166
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TABLE 2 Number of included studies by treatment comparison (continued )
Intervention
Number
randomised Number of studies
Number of
new studies References1 (control) 2 (experiment)
Transob-MUS Single incision 4612 39 17 Bianchi et al.,25 Djehdian et al.,27 Lee et al.,28 Schweitzer et al.,29 Smith
et al.,30 Dati et al.,43 Enzelsberger et al.,50 Fernandez et al.,52 Friedman,54
Kim et al.,59 Melendez Munoz et al.,65 Merali et al.,66 Rudnicki et al.,72 Seo
et al.,74 Shawky et al.,75 Van Rensburg et al.,79 Yoon et al.,80 Gaber et al.,91
Masata et al.,101 Amat I Tardiu et al.,112 Jurakova et al.,113 Pastore et al.,114
Xin et al.,115 Wang et al.,116 Masata et al.,167 Oliveira et al.,168 Sottner
et al.,169 Enzelsberger et al.,170 Foote,171 Hinoul et al.,172 Hota et al.,173
Mackintosh,174 Maslow et al.,175 Campos et al.,176 Schellart and Roovers,177
Sivaslioglu et al.,178 Tang et al.179 and Tommaselli et al.180
Transob-MUS Ant repair 120 2 1 El-Din Shawki et al.47 and Salari and Sohbati181
Transob-MUS PFMT 460 1 1 Labrie et al.95
Open colpo Lap colpo 1402 12 N/A Burton et al.,40 Fatthy et al.,51 Morris et al.,68 Stangel-Wojcikiewicz,76
Summitt et al.,77 Ankardal et al.,85 Carey et al.,89 Kitchener et al.,93
Mak et al.,182 Su et al.,183 Tuygun et al.184 and Ustün et al.185
Open colpo Trad sling 922 7 N/A Fischer et al.,53 Albo et al.,82 Demirci and Yucel,103 Henriksson and
Ulmsten,105 Bai et al.,145 Enzelsberger et al.186 and Sand et al.187
Open colpo Bladder neck needle 639 7 N/A Bergman et al.,88 Mundy,109 Athanassopoulos and Barbalias,111 Bergman
et al.,188 Gilja et al.,189 German et al.190 and Palma et al.191
Open colpo Ant repair 690 8 N/A El-Din Shawki et al.,47 Bergman et al.,88,188 Berglund and Lalos,192
Colombo et al.,193 Holmes et al.,194 Kammerer-Doak et al.195 and Liapis et al.196
Open colpo PFMT 45 1 N/A Tapp et al.78
Trad sling Single incision 72 1 1 Sharifiaghdas et al.197
Trad sling Injectable 45 1 N/A Maher et al.102
Trad sling Bladder neck needle 20 1 N/A Hilton198
Bladder neck needle Ant repair 346 3 N/A Bergman et al.88,188 and Di Palumbo199
Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle suspension; injectable, urethral injection therapy; lap colpo, laparoscopic colposuspension; N/A, not applicable;
open colpo, open colposuspension; retro-MUS, retropubic MUS; single incision, single-incision sling; trad sling, traditional sling; transob-MUS, transobturator MUS.
Note
Study numbers do not add up to 175 as three-arm trials are shown as pairwise comparisons.
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It was ascertained that, based on the reported information, 23 studies included women with SUI
alone37,60,67,78,90,91,94,104,105,108,114,118,129,139,142,143,161,162,178,179,181,192,201 as they specifically mentioned exclusion of
urgency UI or MUI. A total of 53 studies included women with SUI as well as some with MUI.26,30–32,48,52,56,72,
79,81,82,85,87,89,99,101,106,107,110,112,113,115–117,119,120,122,124–128,135,136,148,153,154,156,159,160,164,167–169,173,174,176,180,187,194,198,199
The majority of studies excluded women with any previous UI surgery (81 out of 175 studies)29–31,38,39,43,52,58,
67,69–72,78,85,86,88,89,91,92,94–97,100,101,103,104,108,113–116,118,120,126,128–130,133,136,137,140,141,143,144,147,148,155–157,159–163,165,167,168,170,172,
174–178,180–185,188,192–194,196,201–204 or certain types of incontinence surgery (16 out of 175 studies).28,65,77,83,87,93,102,
119,121,122,127,135,146,150,171,173 A total of 31 studies (out of 175; 18%) included women presenting with recurrent
incontinence after failed surgery.25,27,32,37,51,56,63,79,82,84,99,106,107,109,117,123–125,138,139,142,151,152,166,186,187,190,191,195,197,198
Of these, one study included only recurrent cases.186 The remaining studies (47 out of 175) did not indicate
whether study participants had primary or recurrent incontinence, or both.
TABLE 3 Summary of patient characteristics
UI diagnosis Number of studies
Urodynamically confirmed stress incontinence 91
Symptom diagnosis of stress incontinence 76
Either urodynamic or symptom diagnosis of stress incontinence 8
MUI
SUI/USI only, no MUI 23
SUI/USI or MUI 53
SUI/USI, unclear if MUI is included or excluded 99
Previous UI surgery
Excluded 81
Excluded specific surgery only 16
Included 31
Not reported 47
Co-existing prolapse at recruitment
Excluded 11
Excluded ≥ 2 degree only 28
Excluded ≥ 3 degree only 28
Excluded ‘major’ or ‘significant’ prolapse only 11
Included 36
Not reported 61
Concomitant prolapse surgery performed
No 39
Yes 35
Yes (hysterectomy) 6
Not reported 95
USI, urodynamic stress incontinence.
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In 45% of the studies (78 out of 175) women presenting with coexisting prolapse were excluded either
completely (11 studies)60,63,86,104,105,107,113,125,129,149,203 or if they presented with moderate to severe prolapse
(67 studies). Six studies included exclusively women with coexisting prolapse.32,70,88,181,193,199 A total of 30
studies included a proportion of women with prolapse of varying degrees28,30,37,41,48,52,61,64,79,82,87,90,91,99,108,111,
112,117,119,122,123,142,154,166,173,176,184,192,194,195 and the remaining 61 studies did not specify whether women with
prolapse were included or excluded.
A total of 39 studies did not allow concomitant prolapse surgery to be performed.39,50,60,63,67,77,81,83,85,86,93,94,
100–102,104,105,107,113,116,125,126,129,133,135,137,146,148–150,156,159,167,171,174,179,186,188,203 Three studies reported that prolapse
surgery was performed in all included women32,41,88 and 32 studies reported that some women received
prolapse surgery.28,30,31,37,43,48,52–54,61,79,82,87,89,99,106,112,117,119,120,122,123,127,138,160,173,176,185,187,193,195,196 Six studies
explicitly reported that hysterectomy was performed.103,147,182,183,194,199 The remaining 95 studies did not
indicate whether or not concomitant prolapse surgery was performed.
The source of funding and the setting of included studies were not consistently reported in the relevant
Cochrane systematic reviews. Out of the 36 studies with available information (28 studies identified by
the updated searches and eight studies identified from the Cochrane systematic reviews), five studies
appeared to be funded by industry28,29,159,176,177 and seven studies were conducted in more than one
clinical centre.28,72,79,95,159,176,177
The clinical experience of the surgeon performing the procedures was not consistently reported in the
Cochrane systematic reviews. Among the 36 studies providing this information, the surgeon’s clinical
experience varied from ‘having inserted a minimum of one sling prior to the study’29 to ‘having performed
200 surgical procedures’.115 Five studies reported that surgeons tended to be less experienced in performing
sling procedures than the comparator surgical intervention.25,101,113,159
Risk-of-bias assessment of included studies
There is wide variation across Cochrane systematic reviews in the number and types of criteria (domains)
used to assess risk of bias. For example, the number of risk-of-bias domains was four,7,11 five,8,9,18 six5 or
seven6 across reviews. The 28 new studies identified by the updated literature searches, and the eight
studies originally included as abstracts in the Cochrane systematic reviews and subsequently updated
based on new full-text reports, were assessed using the current version of the Cochrane risk-of-bias tool,
which involved a total of nine domains. An overall assessment of risk of bias is presented in Table 4 below.
Appendix 9 provides the risk-of-bias results for all individual studies included in this assessment.
Selection bias (adequate sequence generation/allocation concealment)
For all 175 included studies, risk of selection bias was assessed in two domains: random sequence
generation and allocation concealment. A total of 43 studies (out of 175; 25%) reporting both adequate
sequence generation and adequate allocation concealment were considered to have an overall low risk of
selection bias.25,27–29,32,51,63,64,83,86,87,92,93,96,97,100,101,116,120,122,124–126,128,135–137,140,144,147,148,150,157,159,160,167,174–176,182,183,185
A further six studies (out of 175; 3%) reported adequate allocation concealment but they did not
describe the method used for random sequence generation.77,85,127,156,173,199 A total of 40 studies (out of
175; 23%) reported adequate sequence generation but did not provide information on allocation
concealment.26,30,31,37,41,52,60,65,72,79,82,88,89,91,94,99,101,114,119,129,130,138,141,143,146,162,164,172,178,180,181,186–189,194–196,198,203 Two
studies (out of 175; 1%) with adequate random sequence generation specifically mentioned that the
treatment allocations were not concealed.95,193
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There were eight quasi-randomised trials (out of 175 included studies; 5%) in which treatment allocation
was based on a method of alternation103–107,109,110 or on date of birth.111 These were considered to be at
high risk of selection bias in terms of both allocation sequence generation and concealment of allocation.
Two further studies (out of 175; 1%) allocated participants by alternation108 or by medical history
numbers112 and were considered to be at high risk of selection bias, although allocation concealment was
considered to be at unclear (rather than high) risk of bias by the authors of the Cochrane systematic
reviews.5,9 The remaining studies (74 out of 175; 42%) did not provide this information.
Performance and detection bias (blinding)
Blinding of patients and personnel provides a safeguard against performance bias and blinding of outcome
assessors protects against detection bias. It is worth noting that, owing to the nature of the interventions,
blinding of participants and personnel, especially the surgeon performing the operation, is not possible.
Blinding of outcome assessment for patient-reported outcomes would similarly be difficult in this clinical
context (with unblinded patients being the assessors), although it should be possible to blind health-care
professionals who assess clinical outcomes.
In seven studies identified from the Cochrane systematic reviews assessing traditional slings7 and bladder
neck needle suspension,11 risk of performance bias and detection bias was assessed using a single criterion
(whether or not a lack of blinding could introduce performance and detection bias). One study (out of 7;
14%) was judged to be at low risk of bias92 and the other six studies (86%) at high or unclear risk
of bias.38,81,102,166,198,199
Risk of performance and detection bias was assessed separately in the 168 included studies identified
from sources other than the two Cochrane reviews mentioned above. With respect to the assessment of
whether or not lack of blinding of patients and personnel could introduce performance bias, eight studies
(out of 168; 5%) were judged to be at low risk of bias87,89,117,128,129,151,157,191 and the other 160 studies
(95%) were judged to be at high or unclear risk of bias.25–32,37,39–80,82–86,88,90,91,93–101,103–114,116,118–127,130–150,152–156,
158–165,167–190,192–197,201–203
TABLE 4 Summary of risk-of-bias assessment
Items
Risk, n (%) Number
of studies
assessedLow Unclear High
1. Random sequence generation (selection bias) 85 (49) 80 (46) 10 (6) 175
2. Allocation concealment (selection bias) 49 (28) 116 (66) 10 (6) 175
3. Blinding of participants and personnel (performance bias) 8 (5) 123 (73) 37 (22) 168
4a. Blinding of outcome assessment (detection bias): all outcomes 20 (15) 107 (81) 5 (4) 132
4b. Blinding of outcome assessment (detection bias): patient reported
outcomes
4 (11) 17 (47) 15 (42) 36
4c. Blinding of outcome assessment (detection bias): clinician-measured
outcomes
8 (22) 20 (56) 8 (22) 36
5. Blinding (performance bias and detection bias) 1 (14) 6 (86) 0 (0) 7
6a. Incomplete outcome data (attrition bias): all outcomes 54 (39) 76 (55) 9 (6) 139
6b. Incomplete outcome data (attrition bias): patient-reported outcomes 18 (50) 16 (44) 2 (6) 36
6c. Incomplete outcome data (attrition bias): clinician-measured outcomes 21 (58) 13 (36) 2 (6) 36
7. Selective reporting (reporting bias) 24 (65) 7 (19) 6 (16) 37
8. Other bias 0 (0) 82 (100) 0 (0) 82
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Risk of detection bias in the 132 studies identified from Cochrane systematic reviews on MUS,8,18 open
colposuspension,5 laparoscopic colposuspension6 and single-incision slings9 was assessed in terms of whether
or not lack of blinding of outcome assessors could affect results. A total of 20 studies (out of 132; 15%)
were judged to be at low risk of bias37,86,87,89,94,117,122,125,127,130,136,141,142,144,148,156,174,178,191,204 and the remaining
112 studies (85%) were judged to be at high or unclear risk of bias.39–42,44–47,49,51,53–61,63,64,67–71,73,74,76–78,80,82–85,88,
90,93,96–100,103–112,116,118–120,123,124,126,128,129,131–135,137–140,145–147,149–155,157,160–163,165,167–170,172,173,180,182–190,192–196,201–203
Detection bias in the 36 studies identified from other sources (e.g. new studies from the update literature
searches) was assessed on a per outcome basis in terms of whether or not lack of blinding of outcome
assessors could affect effect estimates of patient-reported outcomes such as subjective perception of cure
of UI (where outcomes are assessed directly by women) and of clinician-measured outcomes such as
urodynamic tests (where outcomes are assessed by care providers). One study (out of 36; 3%) was judged
to be at low risk for patient-reported outcomes,159 five studies (14%) at low risk for clinician-measured
outcomes,25,115,143,175,181 and three studies (8%) at low risk for both patient-reported and clinician-measured
outcomes.29,32,91 The remaining 27 studies (75%) were judged to be at high or unclear risk for either
outcome.26–28,30,31,43,48,50,52,62,65,66,72,75,79,95,101,113,114,121,158,164,171,176,177,179,197
Attrition bias (incomplete outcome data)
In 139 studies included in the relevant Cochrane systematic reviews, risk of bias was assessed for all
outcomes concerned. A total of 54 were judged to be at low risk of attrition bias, with missing data either
balanced between treatment groups or imputed using appropriate methods, or with no missing data;37,40,41,
54,67,81–84,88,92–94,96–98,100,102,106,116,119,120,122,123,126–128,130,133,135–137,139,141,142,144,147–150,155,157,160,162,166,168,170,174,178,184,185,193,198,199
nine were judged to be at high risk of bias;86,87,112,140,156,172,173,180,189 and 76 were judged to be at unclear risk
of bias.38,39,42,44–47,49,51,53,55–61,63,64,68–71,73,74,76–78,80,85,89,90,99,103–105,107–111,116–118,124,125,129,131,132,134,138,145,146,151–154,161,163,165,
167,169,182,183,186–188,190–192,194–196,201–203
In 36 studies identified from other sources (e.g. new studies from the updated literature searches), risk of
attrition bias was assessed on a per outcome basis in terms of patient-reported outcomes and clinician-
measured outcomes. Of these, 18 studies were judged to be at low risk for both patient-reported and
clinician-measured outcomes,25,27,30,52,91,95,101,113,114,121,143,159,164,171,176,177,179,181 three studies were judged to be at
low risk for clinician-measured outcomes but unclear for patient-reported outcomes,66,72,75 two studies were
judged to be at high risk for both patient-reported and clinician-measured outcomes29,175 and the remaining
13 studies were judged to be at unclear risk of bias for both outcomes.26,28,31,32,43,48,50,62,65,79,115,158,197
Reporting bias (free of selective reporting)
Few of the relevant Cochrane systematic reviews assessed the risk of reporting bias. Information was available
from one study identified from the Cochrane systematic review assessing laparoscopic colposuspension6 and
from 36 further studies (28 new studies and the eight studies originally included as abstracts in the Cochrane
systematic reviews and subsequently published in full). Of these, 24 studies (out of 37; 65%) were judged to
be at low risk of reporting bias on the basis that all outcomes specified in the methods section were reported
in the results section of the study report,25,27–32,52,62,65,79,95,101,113–115,143,159,171,175,177,179,181,197 six studies (16%) were
judged to be at high risk of bias on the basis that they did not report the results for all the outcomes specified
in the method section of the study report,26,43,72,75,91,176 and the remaining seven studies (19%) did not provide
sufficient information to formulate a judgement.48,50,66,121,158,163,164
Other sources of bias
Information on which to assess ‘other sources of bias’ was available for 82 of the included studies. In these
studies, there was no clear evidence that other sources of bias were present.25–32,40,43,46–53,55,57,60,62,65,66,68,69,72,
75–79,82,85,88,89,91,93,95,100,101,103,105,108,109,111,113–115,121,143,145,158,159,161–164,171,175,177,179,181–195,197,200–203
RESULTS OF CLINICAL EFFECTIVENESS REVIEW(S)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
20
Assessment of clinical effectiveness
Network meta-analysis of primary outcomes: number of women cured and number of
women who experienced an improvement in their incontinence symptoms
Technical information about the model
The NMA included eight surgical procedures for SUI:
l retropubic MUS operations
l transobturator MUS operations
l open colposuspension
l laparoscopic colposuspension
l traditional sling operations
l single-incision sling operations
l bladder neck needle suspension
l anterior vaginal repair.
The ninth procedure, urethral injection therapy, did not add any information to the network and was
excluded from analysis (for the cure outcome analysis, urethral injection therapy was only connected to
one intervention). Separate models were developed for the two primary outcomes: the number of women
cured (defined as resolution of symptoms) and the number of women improved (defined as women
experiencing an improvement in their incontinence symptoms, including cure). Figure 1 shows the network
diagrams for the number of women cured and improved, respectively. The size of the circles reflects the
number of participants and the line width reflects the number of direct comparisons. Figure 1 also includes
the total number of women for each surgical intervention included in the NMA.
(a)
Ant repair (n = 220)
Bladder neck needle (n = 281)
Trad sling (n = 422)
Transob-MUS (n = 4218)
PFMT (n = 184)
Single incision (n = 1663)
Retro-MUS (n = 3907)
Lap colpo (n = 596)
Open colpo (n = 1351)
FIGURE 1 Network plot for (a) the number of women cured; and (b) the number of women improved. Note: circle
size reflects the number of participants; line width reflects the number of direct comparisons. Ant repair, anterior
vaginal repair; bladder neck needle, bladder neck needle suspension; open colpo, open colposuspension; lap colpo,
laparoscopic colposuspension; retro-MUS, retropubic MUS; single incision, single-incision sling; trad sling, traditional
sling; transob-MUS, transobturator MUS. (continued )
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Cure or improvement of incontinence symptoms was assessed subjectively (by the woman), objectively
(by a clinician) or by a combination of subjective and objective measures (composite measure). When more
than one of these outcome measures were reported within a study, only one measure was included in the
NMA. This measure was selected in the following order: women’s self-report assessment was given priority
and, if this was unavailable, the composite outcome measure followed by the objective outcome measure
were chosen as a proxy. The NMA included outcomes measured at 12 months or at a time point closest to
12 months.
The number of studies providing direct head-to-head (pairwise) evidence for each intervention that
contributed data to the NMA is shown in Tables 5 and 6. The searches identified 125 trials that reported
cure or improvement, or both. Three trials67,76,105 were excluded from the cure data set and four
trials67,76,105,124 from the improvement dataset because they reported ‘100% events’ in all treatment arms
(i.e. all participants in the study were cured or improved), providing no information for the NMA. Thus,
105 trials contributed to the NMA for assessing the number of women cured, and 120 trials were included
in the analysis assessing the number of women improved. For ‘cure’, the analysis included four three-arm
trials and 101 two-arm trials and generated a total of 17 direct comparisons, whereas for ‘improvement’
the analysis included five three-arm trials and 115 two-arm trials and generated a total of 18 direct
comparisons. Appendix 10 shows the total number of trials for each treatment comparison for the
assessment of both primary outcomes.
The direct pairwise analyses showed some heterogeneity in four direct comparisons for the number of
women cured (single-incision sling vs. retropubic MUS; single-incision sling vs. transobturator MUS;
laparoscopic colposuspension vs. open colposuspension; and anterior vaginal repair vs. open colposuspension)
and one comparison for the number of women improved (laparoscopic colposuspension vs. retropubic MUS)
(see Appendices 10 and 11).
(b)
Bladder neck needle (n = 281)
Ant repair (n = 220)
PFMT (n = 184)
Transob-MUS (n = 4809)
Single incision (n = 2259)
Trad sling (n = 459)
Retro-MUS (n = 4282)
Lap colpo (n = 671)
Open colpo (n = 1342)
FIGURE 1 Network plot for (a) the number of women cured; and (b) the number of women improved. Note: circle
size reflects the number of participants; line width reflects the number of direct comparisons. Ant repair, anterior
vaginal repair; bladder neck needle, bladder neck needle suspension; open colpo, open colposuspension; lap colpo,
laparoscopic colposuspension; retro-MUS, retropubic MUS; single incision, single-incision sling; trad sling, traditional
sling; transob-MUS, transobturator MUS.
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TABLE 5 Results for number of women cured
Treatment Direct evidence NMA
GRADE1 2
Number
of trials ORa 95% CI ORa 95% CrI
Transob-MUS Retro-MUS 36b 0.83 0.71 to 0.97 0.74 0.59 to 0.92 Moderate
Open colpo Retro-MUS 6b 0.95 0.68 to 1.32 0.85 0.54 to 1.33 Low
Lap colpo Retro-MUS 2 0.40 0.11 to 1.45 0.58 0.31 to 1.05 Low
Trad sling Retro-MUS 6b 0.87 0.58 to 1.29 1.06 0.62 to 1.85 Very low
Single incision Retro-MUS 6b 0.42 0.20 to 0.87 0.50 0.36 to 0.70 Low
Bladder neck needle Retro-MUS N/A N/A N/A 0.34 0.15 to 0.75 Low
Ant repair Retro-MUS N/A N/A N/A 0.22 0.10 to 0.45 Very low
PFMT Retro-MUS N/A N/A N/A 0.12 0.04 to 0.32 Low
Open colpo Transob-MUS 1 0.90 0.30 to 2.69 1.16 0.72 to 1.86 Low
Lap colpo Transob-MUS N/A N/A N/A 0.79 0.42 to 1.46 Low
Trad sling Transob-MUS 1 2.00 0.17 to 23.96 1.44 0.81 to 2.62 Very low
Single incision Transob-MUS 21b 0.74 0.54 to 1.00 0.68 0.51 to 0.91 Low
Bladder neck needle Transob-MUS N/A N/A N/A 0.46 0.21 to 1.02 Very low
Ant repair Transob-MUS 1 0.50 0.15 to 1.62 0.30 0.14 to 0.62 Very low
PFMT Transob-MUS 1 0.20 0.12 to 0.33 0.16 0.06 to 0.43 Low
Lap colpo Open colpo 9 0.74 0.43 to 1.30 0.68 0.42 to 1.08 Low
Trad sling Open colpo 3b 2.47 0.73 to 8.40 1.24 0.66 to 2.45 Very low
Single incision Open colpo N/A N/A N/A 0.59 0.34 to 1.01 Low
Bladder neck needle Open colpo 3b 0.41 0.25 to 0.68 0.40 0.20 to 0.78 Low
Ant repair Open colpo 3b 0.20 0.07 to 0.60 0.26 0.14 to 0.48 Very low
PFMT Open colpo 1 0.08 0.01 to 0.51 0.14 0.05 to 0.39 Low
Trad sling Lap colpo N/A N/A N/A 1.83 0.86 to 4.04 Very low
Single incision Lap colpo N/A N/A N/A 0.87 0.44 to 1.70 Low
Bladder neck needle Lap colpo N/A N/A N/A 0.59 0.26 to 1.33 Very low
Ant repair Lap colpo N/A N/A N/A 0.38 0.18 to 0.82 Very low
PFMT Lap colpo N/A N/A N/A 0.21 0.07 to 0.63 N/A
Single incision Trad sling N/A N/A N/A 0.47 0.25 to 0.88 Very low
Bladder neck needle Trad sling 1 1.00 0.05 to 18.57 0.32 0.13 to 0.79 Very low
Ant repair Trad sling N/A N/A N/A 0.21 0.09 to 0.49 Very low
PFMT Trad sling N/A N/A N/A 0.11 0.04 to 0.34 Very low
Bladder neck needle Single incision N/A N/A N/A 0.67 0.29 to 1.56 N/A
Ant repair Single incision N/A N/A N/A 0.44 0.20 to 0.96 Very low
PFMT Single incision N/A N/A N/A 0.24 0.08 to 0.65 Low
continued
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TABLE 5 Results for number of women cured (continued )
Treatment Direct evidence NMA
GRADE1 2
Number
of trials ORa 95% CI ORa 95% CrI
Ant repair Bladder neck needle 1b 0.92 0.55 to 1.55 0.65 0.30 to 1.36 Very low
PFMT Bladder neck needle N/A N/A N/A 0.35 0.10 to 1.17 Low
PFMT Ant repair N/A N/A N/A 0.55 0.17 to 1.77 Very low
Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle suspension; injectable, urethral injection
therapy; open colpo, open colposuspension; lap colpo, laparoscopic colposuspension; N/A, not applicable; retro-MUS,
retropubic MUS; single incision, single-incision sling; trad sling, traditional sling; transob-MUS, transobturator MUS.
a An OR of > 1 favours the first treatment, i.e. more events (cure) occur; an OR of < 1 favours the second treatment,
i.e. fewer events occur.
b These analyses are also informed by three-arm trials, including one comparing retropubic MUS, transobturator MUS and
single-incision sling, one comparing retropubic MUS, open colposuspension and traditional sling, and two comparing
open colposuspension, bladder neck needle and anterior vaginal repair.
TABLE 6 Results for number of women improved
Treatment Direct evidence NMA
GRADE1 2
Number
of trials ORa 95% CI ORa 95% CrI
Transob-MUS Retro-MUS 40b 0.86 0.70 to 1.06 0.76 0.59 to 0.98 Moderate
Open colpo Retro-MUS 6b 0.83 0.55 to 1.24 0.65 0.41 to 1.02 Low
Lap colpo Retro-MUS 4 0.49 0.18 to 1.35 0.52 0.29 to 0.91 Low
Trad sling Retro-MUS 6b 0.62 0.38 to 1.02 0.69 0.39 to 1.26 Low
Single incision Retro-MUS 6b 0.42 0.20 to 0.89 0.50 0.35 to 0.71 Moderate
Bladder neck needle Retro-MUS N/A N/A N/A 0.25 0.11 to 0.58 Low
Ant repair Retro-MUS N/A N/A N/A 0.18 0.08 to 0.39 Very low
PFMT Retro-MUS N/A N/A N/A 0.43 0.14 to 1.37 Low
Open colpo Transob-MUS 1 0.90 0.30 to 2.69 0.85 0.52 to 1.41 Low
Lap colpo Transob-MUS N/A N/A N/A 0.69 0.37 to 1.26 Low
Trad sling Transob-MUS 1 2.00 0.17 to 23.96 0.91 0.49 to 1.72 Very low
Single incision Transob-MUS 28b 0.74 0.57 to 0.96 0.66 0.49 to 0.89 Moderate
Bladder neck needle Transob-MUS N/A N/A N/A 0.33 0.14 to 0.79 Very low
Ant repair Transob-MUS 1 1.00 0.26 to 3.89 0.24 0.10 to 0.53 Very low
PFMT Transob-MUS 1 0.18 0.10 to 0.33 0.56 0.19 to 1.78 Low
Lap colpo Open colpo 9 0.93 0.58 to 1.48 0.81 0.49 to 1.31 Low
Trad sling Open colpo 3b 2.47 0.73 to 8.40 1.07 0.54 to 2.15 Low
Single incision Open colpo N/A N/A N/A 0.78 0.44 to 1.36 Low
Bladder neck needle Open colpo 3b 0.38 0.22 to 0.63 0.38 0.18 to 0.81 Low
Ant repair Open colpo 3b 0.20 0.07 to 0.60 0.28 0.14 to 0.55 Very low
PFMT Open colpo 1 8.87 1.66 to 47.25 0.66 0.21 to 2.16 Low
Trad sling Lap colpo N/A N/A N/A 1.32 0.62 to 2.98 Low
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Number of women cured
Table 5 shows the estimates of treatment effect from the direct pairwise meta-analyses and the NMA for
the number of women cured (the direct meta-analysis results for all the included studies are presented in
Appendix 11). The NMA showed that, on average, women who underwent a traditional sling or retropubic
MUS operation were more likely to be cured compared with those who had other surgical procedures.
Some of the comparisons had a limited number of studies and there is considerable uncertainty around
the estimates of effect, for example for the comparison between retropubic MUS and traditional sling
[OR 1.06, 95% CrI 0.62 to 1.85 (quality of evidence: very low)], between retropubic MUS and open
colposuspension [OR 0.85, 95% CrI 0.54 to 1.33 (quality of evidence: very low)] and between retropubic
MUS and laparoscopic colposuspension [OR 0.58, 95% CrI 0.31 to 1.05 (quality of evidence: very low)].
Number of women who experienced an improvement in their incontinence symptoms
Table 6 shows the estimates of treatment effect from the NMA and the overall estimates from the direct
pairwise meta-analyses for the number of women with improvement in incontinence symptoms (the full
set of direct meta-analyses results is presented in Appendix 12). The NMA showed that women who
had retropubic MUS or transobturator MUS were more likely to experience an improvement in their
incontinence symptoms. However, there is some uncertainty around the estimates of effect for some
of the comparisons, for example the comparisons between retropubic MUS and open colposuspension
[OR 0.65, 95% CrI 0.41 to 1.02 (quality of evidence: low)] and between retropubic MUS and traditional
sling [OR 0.69, 95% CrI 0.39 to 1.26 (quality of evidence: low)].
TABLE 6 Results for number of women improved (continued )
Treatment Direct evidence NMA
GRADE1 2
Number
of trials ORa 95% CI ORa 95% CrI
Single incision Lap colpo N/A N/A N/A 0.97 0.50 to 1.87 Low
Bladder neck needle Lap colpo N/A N/A N/A 0.47 0.20 to 1.17 Very low
Ant repair Lap colpo N/A N/A N/A 0.34 0.15 to 0.79 Very low
PFMT Lap colpo N/A N/A N/A 0.82 0.25 to 2.88 Very low
Single incision Trad sling 1 1.92 0.65 to 5.64 0.73 0.37 to 1.39 Low
Bladder neck needle Trad sling 1 1.00 0.05 to 18.57 0.36 0.13 to 0.95 Very low
Ant repair Trad sling N/A N/A N/A 0.26 0.10 to 0.65 Very low
PFMT Trad sling N/A N/A N/A 0.62 0.18 to 2.18 Very low
Bladder neck needle Single incision N/A N/A N/A 0.49 0.20 to 1.24 Very low
Ant repair Single incision N/A N/A N/A 0.36 0.15 to 0.82 Very low
PFMT Single incision N/A N/A N/A 0.84 0.28 to 2.78 Low
Ant repair Bladder neck needle 1b 0.92 0.55 to 1.55 0.72 0.31 to 1.63 Very low
PFMT Bladder neck needle N/A N/A N/A 1.72 0.45 to 6.89 Low
PFMT Ant repair N/A N/A N/A 2.38 0.65 to 9.30 Very low
Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle suspension; injectable, urethral injection
therapy; open colpo, open colposuspension; lap colpo, laparoscopic colposuspension; N/A, not applicable; retro-MUS,
retropubic MUS; single incision, single-incision sling; trad sling, traditional sling; transob-MUS, transobturator MUS.
a An OR of > 1 favours the first treatment, i.e. more events (improvement) occur; an OR of < 1 favours the second
treatment, i.e. fewer events occur.
b These analyses are also informed by two three-arm trials comparing retropubic MUS, transobturator MUS and
single-incision sling.
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Ranking of treatment effectiveness
Figure 2 shows the SUCRA values for all surgical interventions. The rankograms are reported in Appendix 13.
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FIGURE 2 Surface under the cumulative ranking curve values for (a) the number of women cured; and (b) the
number of women improved. Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle
suspension; open colpo, open colposuspension; lap colpo, laparoscopic colposuspension; retro-MUS, retropubic
MUS; single incision, single-incision sling; trad sling, traditional sling; transob-MUS, transobturator MUS.
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Traditional sling and retropubic MUS (see Figure 2a) are the treatments most likely to result in the highest
proportion of women cured (89.4% and 89.1%, respectively), followed by open colposuspension (76.7%),
transobturator MUS (64.1%), laparoscopic colposuspension (48.9%), single-incision sling (39.8%), bladder
neck needle suspension (26.9%), anterior vaginal repair (12.5%) and PFMT (2.6%). On the other hand,
retropubic MUS (97.0%) and transobturator MUS (76.1%) are the most likely treatments to result in
the highest proportion of women with an improvement in their incontinence symptoms (see Figure 2b),
followed by traditional sling (67.7%), open colposuspension (63.8%), laparoscopic colposuspension
(45.8%), single-incision sling (42.0%), PFMT (39.2%), bladder neck needle suspension (14.3%) and
anterior repair (4.1%).
Consistency between direct and indirect evidence
In the NMA there was no evidence of inconsistency for the cure outcome (see Appendix 14, Figure 45 and
Table 33 for full details) and some evidence of inconsistency for the improvement outcome (see Appendix 14,
Figure 46 and Appendix 14, Table 34). Consistency assessed using the node-splitting method (see Appendix 14,
Table 34) showed inconsistencies for PFMT compared with transobturator MUS and for traditional sling
and PFMT compared with open colposuspension. However, caution is required here, as the node splitting
method can have low statistical power to detect inconsistency.
Adverse events: direct pairwise comparisons
The adverse event results are shown in Appendix 15. Full meta-analyses results for all included studies are
available in Report Supplementary Material 1.
Overall, few studies reported adverse events. Numbers of events included in the analyses were generally
small and, therefore, CIs were wide. It is worth noting that many of the adverse events meta-analyses were
based on < 5 studies. This is mainly owing to the dearth of available data but also to the inconsistencies
with regard to the type and definition of adverse events as well as to the time points at which these were
measured across individual trials and across Cochrane systematic reviews. In particular, the lack of common
definitions made it difficult to combine results and to incorporate data extracted from newly identified
studies into the pool of data extracted from the relevant Cochrane reviews. For some of the included
studies, follow-up time was unknown, as it could not be extracted from the relevant Cochrane systematic
reviews. Below we summarise the most relevant meta-analyses results, focusing on comparisons for which
most data were available (in terms of the number of studies and number of participants).
Repeat continence surgery
Appendix 15, Figure 47 shows a summary of the meta-analyses results (overall ORs and the 95% CI) for
different treatment comparisons for repeat continence surgery based on the 30 studies that reported this
outcome. The majority of studies compared retropubic MUS or transobturator MUS with other surgical
procedures at different time points. In general, fewer repeat surgeries were observed after retropubic MUS
compared with other interventions. However, the number of studies was generally small and CIs were wide.
For the comparison of transobturator MUS and retropubic MUS (seven studies, assessments conducted
12 months post surgery), the number of women requiring further surgery was 21 (out of 585; 3.6%) and
14 (out of 641; 2.2%), respectively. Pooled analysis of these studies showed wide CIs and considerable
uncertainly around the estimated OR (seven studies, 12-month post-surgery: OR 1.37, 95% CI 0.55 to
3.46). At 12 to 60 months after the procedure, rates of repeat continence surgery were considerably
higher in women undergoing transobturator MUS (32 out of 175; 18.3%) compared with retropubic
MUS (1 out of 180; 0.5%), although only two studies were available for the analysis (OR 24.57, 95% CI
4.67 to 129.35). A similar trend was observed in studies with a longer follow-up period (i.e. > 60 months)
but the pooled analysis of these studies showed wide CIs [five studies: 40 out of 422 (9.4%) vs. 7 out of
438 (1.5%); OR 4.06, 95% CI 0.80 to 20.74].
DOI: 10.3310/hta23140 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 14
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Brazzelli et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27
For the comparison of single-incision sling versus transobturator MUS (10 studies, assessments conducted
12 months post surgery), single-incision sling was associated with more repeat surgeries compared with
transobturator MUS [35 out of 685 (5.1%) vs. 18 out of 614 (2.9%), respectively], but the pooled analyses
showed some uncertainty around the estimated OR (OR 1.57, 95% CI 0.83 to 2.95). At > 36 months after
the procedure, there were 19 (out of 185; 10.3%) versus 14 (out of 185; 7.6%) repeat surgery events,
respectively (three studies: OR 1.42, 95% CI 0.68 to 2.97).
Open colposuspension was associated with fewer repeat surgeries than anterior vaginal repair, although
only two studies were available for this analysis [assessments conducted 24 months post surgery: 22 out of
74 (29.7%) vs. 3 out of 129 (2.3%); OR 13.95, 95% CI 4.22 to 46.09].
Haemorrhage and major vascular complications including haematoma
Appendix 15, Figures 48–50 show a summary of the meta-analyses results for different treatment
comparisons for haemorrhage, haematoma and other major vascular complications. The majority of the
treatment comparisons compared retropubic MUS or transobturator MUS with other surgical interventions.
Outcomes were reported using different definitions and assessed at different time points. For the
comparison of transobturator MUS with retropubic MUS, the pooled analysis of 22 studies showed that
major vascular complications were less likely to occur after transobturator MUS than after retropubic
MUS [see Appendix 15, Figure 49; 10 out of 2008 (0.5%) vs. 47 out of 1966 (2.4%); OR 0.36, 95% CI
0.21 to 0.64]. Other comparisons were based on a smaller number of studies as well as a smaller number
of events and were therefore insufficient to draw any meaningful conclusion.
De novo symptoms of urgency or urgency incontinence
Appendix 15, Figures 51 and 52 show the meta-analyses results for different treatment comparisons for
de novo symptoms of urgency or UI and ‘detrusor instability’ (detrusor overactivity). The comparisons with
the largest number of studies compared transobturator MUS with retropubic MUS within 12 months
[see Appendix 15, Figure 51; 28 studies, within 12 months post surgery: 172 out of 2264 (7.6%) vs. 183
out of 2321 (9.5%); OR 0.93, 95% CI 0.74 to 1.17] and single-incision sling with transobturator MUS
at 12 months [13 studies, 12 months post surgery: 63 out of 665 (9.5%) vs. 55 out of 597 (9.2%); OR
0.98, 95% CI 0.66 to 1.46]. The summary estimates did not favour one intervention over another. The
comparison of single-incision sling with transobturator MUS at 6 months favoured transobturator MUS,
even though there was considerable uncertainty around the estimate of effect [see Appendix 15, Figure 51;
three studies, 6 months post surgery: 14 out of 118 (11.9%) vs. 4 out of 117 (3.4%); OR 3.33, CrI 1.08
to 10.23]. None of the other comparisons assessing de novo symptoms showed evidence of a difference
between interventions. The incidence of detrusor instability appeared to be similar between interventions
(see Appendix 15, Figure 52).
Voiding difficulties including urinary retention
Appendix 15, Figure 53 shows a summary of the meta-analysis for different treatment comparisons for
voiding difficulties. The summary estimate of 36 studies comparing transobturator MUS with retropubic
MUS favoured transobturator MUS [36 studies: 116 out of 3110 (3.7%) vs. 234 out of 3109 (7.5%);
OR 0.51, 95% CI 0.40 to 0.64]. Fewer women treated with single-incision sling than women treated with
transobturator MUS reported voiding difficulties during the perioperative period [23 out of 835 (2.8%) vs.
31 out of 689 (4.5%); OR 0.60, 95% 0.33 to 1.08] and at 12 months [43 out of 899 (4.8%) vs. 45 out
of 802 (5.6%); OR 0.74, 95% CI 0.45 to 1.21]. Voiding difficulties appeared to be more common after
laparoscopic colposuspension [12 out of 161 (7.5%) vs. 9 out of 177 (5.1%); OR 1.34, 95% CI 0.54 to
3.34] and traditional sling [40 out of 259 (15.4%) vs. 26 out of 255 (10.2%); OR 1.46, 95% CI 0.84 to
2.53] than after retropubic MUS. However, the summary estimates of these comparisons showed wide
CIs indicating a certain degree of uncertainty. There was no evidence of a difference for the comparison
assessing open colposuspension versus retropubic MUS [29 out of 374 (7.8%) vs. 31 out of 413 (7.5%);
OR 0.87, 95% CI 0.41 to 1.82].
RESULTS OF CLINICAL EFFECTIVENESS REVIEW(S)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
Bladder or urethral perforation
Appendix 15, Figure 54 shows a summary of the meta-analyses results for different treatment comparisons
for bladder or urethral perforation. Compared with other surgical interventions, retropubic MUS was
generally associated with a higher incidence of bladder or urethral perforation. In particular, there were
more cases of bladder or urethral perforation after retropubic MUS than after transobturator MUS
[38 studies: 5 out of 3161 (0.2%) vs. 157 out of 3171 (5.0%); OR 0.15, 95% CI 0.09 to 0.24], open
colposuspension [six studies: 5 out of 338 (1.5%) vs. 28 out of 362 (7.7%); OR 0.23, 95% CI 0.10 to
0.55] and traditional sling [six studies: 16 out of 305 (5.2%) vs. 28 out of 276 (10.1%); OR 0.50, 95% CI
0.28 to 0.98]. Compared with open colposuspension, the rate of bladder or urethral perforation was
higher for laparoscopic colposuspension [10 out of 267 (3.7%) vs. 2 out of 284 (0.7%); OR 4.65, 95% CI
1.15 to 18.75] but lower for traditional sling [2 out of 326 (0.6%) vs. 10 out of 329 (3.0%); OR 0.20,
95% CI 0.04 to 0.91].
Tape/mesh extrusion or exposure
Appendix 15, Figures 55 and 56 show a summary of the meta-analyses results for the different treatment
comparisons for tape or mesh erosion or extrusion and tape or mesh exposure. It was not clear whether
or not the terms ‘erosion’, ‘extrusion’ and ‘exposure’ were used consistently across individual studies and
across Cochrane systematic reviews. The majority of the comparisons compared surgical interventions with
either retropubic or transobturator MUS.
The meta-analysis results for the comparison between transobturator MUS and retropubic MUS showed
similar rates of tape/mesh erosion or extrusion between the two surgical procedures [see Appendix 15,
Figure 55; 27 studies: 53 out of 2225 (2.4%) vs. 48 out of 2298 (2.1%); OR 1.10, 95% CI 0.70 to 1.70].
The exact time points at which measurements occurred could not be derived from the Cochrane systematic
reviews but most studies were reported to have a short follow-up period (≤ 12 months), with only a few
studies having a follow-up period of ≥ 2 years.
The meta-analysis results for the comparison between single-incision sling and transobturator MUS
(see Appendix 15, Figure 55; seven studies, 12-month post-surgery assessment) showed similar rates of
mesh erosion or extrusion between interventions [19 out of 399 (4.8%) vs. 13 out of 354 (3.7%),
respectively; OR 1.23, 95% CI 0.57 to 2.68]. Incidence of tape/mesh erosion or extrusion was lower for
open colposuspension than for retropubic MUS [see Appendix 15, Figure 55; three studies: 0 out of
230 (0%) vs. 9 out of 273 (3.3%); OR 0.20, 95% CI 0.03 to 1.19].
Fewer data were available for the assessment of tape or mesh exposure. This may be owing to unclear
distinction between the terms (‘extrusion’ and ‘exposure’) in the studies that assessed these outcomes.
Rate of tape or mesh exposure was higher after transobturator MUS than after retropubic MUS [2 studies,
60–95 months post-surgery assessment: 12 out of 140 (8.6%) vs. 4 out of 145 (2.8%); OR 3.25, 95% CI
1.02 to 10.36]. Similarly, more women treated with transobturator MUS experienced tape or mesh
exposure than those treated with single-incision sling, but CIs around the summary estimate were wide
[see Appendix 15, Figure 56; seven studies, 12 months post surgery: 25 out of 494 (5.1%) vs. 11 out of
463 (2.4%); OR 1.74, 95% CI 0.59 to 5.07].
Pain
Appendix 15, Figures 57–59 show a summary of the meta-analyses results for different treatment
comparisons for outcomes related to pain. It is worth pointing out that pain was defined and measured in
many different ways across individual trials and across Cochrane systematic reviews. Some pain outcomes
were categorised by location (e.g. suprapubic) or time (e.g. short or long term). These discrepancies made
it difficult to combine data from different studies. Data were available mainly for the comparison between
retropubic MUS and transobturator MUS and other surgical procedures.
Transobturator MUS was associated with a higher rate of groin pain than retropubic MUS [see Appendix 15,
Figure 57; 22 studies: 116 out of 1833 (6.3%) vs. 24 out of 1798 (1.3%); OR 3.80, 95% CI 2.45 to 5.89]
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but with a lower rate of suprapubic pain [see Appendix 15, Figure 58; eight studies: 8 out of 687 (1.2%)
vs. 27 out of 681 (4.0%); OR 0.37, 95% CI 0.17 to 0.84]. The time points at which measurements occurred
could not be derived from the Cochrane systematic reviews, but most studies were reported to have a short
follow-up period (≤ 12 months), with only a few studies having a follow-up of ≥ 2 years.
Rate of ‘post-operative pain’ was higher after retropubic MUS (176 out of 916, 19.2%) than after
single-incision sling (64 out of 946; 6.8%) (see Appendix 15, Figure 59; 14 studies; OR 0.21, 95% CI
0.12 to 0.39). Rate of unspecified pain was higher after transobturator MUS than after single-incision sling
both at 12 months [six studies; 4 out of 412 (1.0%) vs. 17 out of 328 (5.2%)] and at 24 months [two
studies; 2 out of 138 (1.4%) vs. 13 out of 125 (10.4%)] (see Appendix 15, Figure 59; OR 0.24, 95% CI
0.06 to 0.92, and OR 0.16, 95% CI 0.04 to 0.62, respectively).
Dyspareunia
Limited evidence was available for the assessment of dyspareunia (see Appendix 15, Figure 60). In general,
the number of studies included in the meta-analyses for the different treatment comparisons was small
and CIs were wide.
Infection (including urinary tract infection, wound infection and infection related to
mesh) and other complications
The number of available studies for the assessment of infection (see Appendix 15, Figures 61–63) was
limited. Our meta-analyses results indicate that the rate of UTI was similar between single-incision sling
and transobturator MUS [see Appendix 15, Figure 61; seven studies, 12 months post surgery: 36 out
of 544 (6.6%) vs. 26 out of 447 (5.8%); OR 1.11, 95% CI 0.63 to 1.96]. For the other treatment
comparisons the number of studies was small and CIs were wide.
Appendix 15, Figure 63 shows the summary estimate for the different treatment comparisons for the
assessment of ‘complications’ as defined by the authors of the individual trials and of the Cochrane
systematic reviewers. It is worth pointing out that perioperative complications may include outcomes
such as haemorrhage, haematoma, cardiovascular events and pain as well as other unspecified outcomes.
Transobturator MUS and retropubic MUS showed similar rates of perioperative complications [see Appendix 15,
Figure 63; 15 studies: 127 out of 1084 (11.7%) vs. 150 out of 1153 (13.0%); OR 0.81, 95% CI 0.55 to 1.19].
Death
No deaths (related to surgery) were reported in any of the included studies.
Resource utilisation: pairwise comparison
Appendix 15, Figure 64 reports the meta-analyses results for the different treatment comparisons for the
assessment of resource utilisation. For some comparisons only a limited number of studies were available
and no firm conclusions can be drawn.
Length of hospital stay
Length of hospital stay after transobturator MUS was shorter than after retropubic MUS [17 studies:
transobturator MUS vs. retropubic MUS, standardised mean difference (SMD) –0.38, 95% CI –0.70 to
–0.06], open colposuspension (two studies: open colposuspension vs. transobturator MUS; SMD 1.83,
95% CI 1.36 to 2.30) and traditional sling (two studies: traditional sling vs. transobturator MUS;
SMD 1.71, 95% CI 1.25 to 2.17).
Length of hospital stay after colposuspension was longer than after retropubic MUS (four studies: open
colposuspension vs. retropubic MUS, SMD 2.26, 95% CI 1.98 to 2.55) or laparoscopic colposuspension
(seven studies: laparoscopic colposuspension vs. open colposuspension; SMD –1.64, 95% CI –2.45 to
–0.84) but shorter than after anterior repair (one study: anterior repair vs. open colposuspension;
SMD 0.90, 95% CI 0.37 to 1.43).
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Operation time
Operation time for transobturator MUS was shorter than that for retropubic MUS (32 studies: SMD –0.12,
95% CI –1.29 to –0.74) but longer than that for single-incision sling (18 studies: single-incision sling vs.
transobturator MUS; SMD –0.53, 95% CI –0.86 to –0.19).
Summary of clinical effectiveness assessment
The systematic review of clinical effectiveness was based on data from 175 studies (21,598 women in
total) comparing one surgical procedure with another for the treatment of SUI in women. The number
of included studies identified from the eight published Cochrane systematic reviews was 147 (84%).
A further 28 studies (16%) were identified through an updated literature search conducted in May 2017.
This updated search used the same search strategy and eligibility criteria as those used for the included
Cochrane systematic reviews.
A further, more recent, updated search was conducted in October 2017 and identified an additional
10 articles that appeared to meet our inclusion criteria. These studies have not been incorporated into the
current assessment, but are listed, for information, in Appendix 16.
The majority of included studies had a high or unclear risk of bias across all risk-of-bias parameters but
most notably for allocation concealment (selection bias). As blinding of participants and personnel is not
feasible in trials assessing surgical interventions, protection against performance bias and detection bias
was likely to be compromised in the included studies. This is a general issue with all surgical trials.
The assessment of effectiveness focused on two primary outcomes: the number of women cured from
incontinence and the number of women who experienced an improvement in their incontinence
symptoms. The NMA, which combined evidence from direct head-to-head comparisons and indirect
comparisons, included 120 studies that reported data on cure or improvement. The NMA results indicate
that retropubic MUS, transobturator MUS and traditional sling are more effective than other surgical
procedures for both primary outcomes. Open colposuspension appears to be relatively effective for both
outcomes (see the SUCRA ranking in Figure 2). For both primary outcomes, cure and improvement, the
overall quality of evidence was low. As we were unable to extract study characteristics, we were unable
to check the transitivity assumption (studies are similar with regard to important characteristics).
Assessment of adverse events was hampered by the dearth of available data. Direct head-to-head
meta-analyses were available mainly for treatment comparisons involving retropubic MUS, transobturator
MUS or single-incision sling. Follow-up time was generally short, with a median of 12 months.
Compared with retropubic MUS, transobturator MUS was associated with lower rates of major vascular
complications and voiding difficulties but higher rates of repeat surgery.
For other intervention comparisons, the number of studies was generally small and the CIs wide. However,
there was some evidence to suggest that bladder perforation was more likely to occur after retropubic
MUS than after transobturator MUS, open colposuspension or traditional sling. Rate of tape or mesh
erosion or extrusion was similar between transobturator MUS and retropubic MUS (27 studies with a total
of 4523 women).
Transobturator MUS was associated with a higher rate of groin pain but a lower rate of suprapubic pain
than retropubic MUS. Retropubic MUS had a higher rate of post-operative pain than single-incision sling
and transobturator MUS had a higher rate of unspecified pain than single-incision sling. Studies that
assessed pain had usually short follow-up periods (i.e. ≤ 12 months).
The main area of uncertainty for all surgical interventions relates to the lack of long-term data for the
assessment of their safety.
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Chapter 4 Discrete choice experiment
Introduction
To estimate women’s preferences for key aspects of surgical interventions being evaluated in this research
we designed and conducted a DCE. DCEs describe an intervention or service in terms of a number of
characteristics or attributes (e.g. post-operative complications, post-operative pain). The extent to which an
individual values an intervention is expected to depend upon the level these characteristics take (e.g. whether
or not patients could experience chronic post-operative pain). In other words, DCEs explore relative preferences
for treatments with differing attributes,205 which allows an exploration of the relative importance of each
attribute of a surgical treatment that may influence a patient’s decision for or against surgery.
Discrete choice experiments are used regularly in health economics to elicit preferences over health-care
products and programmes and in the valuation of preference for health states206–208 and they offer an
additional approach to investigate acceptability of different surgical treatments among patients. Several
reviews have been conducted to compile the evidence of the use of DCEs in the health-care setting.209–212
DCEs usually involve three inter-related components: (1) an experimental design used to implement a
survey that aims to assess individual choices and generate choice data, (2) a quantitative analysis to
estimate preferences from choice data and (3) the use of the estimated preferences to either derive
welfare measures or construct other policy analyses.205
A DCE was conducted to explore women’s preferences for surgical treatment options for SUI assessing
differing attributes. Data were collected by means of a self-completed online survey. Best practice
guidance for DCEs were followed throughout.205,211 The DCE results provide policy-relevant information on
average preferences for treatments and outcomes for women with SUI.
Aims
The DCE will answer the following research questions:
l What are the key attributes of surgical treatments for SUI as expressed by female patients?
l What are the relative preferences for different levels of these attributes among women and, more
specifically, female patients?
l What trade-offs are women/female patients willing to make between the different attributes?
Methods
The methods that were employed in the DCE study were informed by the Lancsar and Louviere205 and
Ryan and Gerard211 reviews of the applications of DCEs in health care, considered to provide best practice
guidance for DCEs. The methods can be broken down into four key steps: step 1 – identification of
attributes and levels; step 2 – experimental design; step 3 – data collection; and step 4 – data analysis and
interpretation. Details of the four steps, with regard to the current study, are provided below.
Step 1: identification of attributes and levels
The findings from the clinical effectiveness review (section 3) were consolidated to facilitate the creation of
key attributes and associated levels related to women’s preferences for the different surgical treatment
options. The chosen attributes and levels were plausible in both clinical and policy terms.205 Once the
attributes and levels were finalised a DCE design was generated (see Step 2: experimental design).
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It is recognised that a reasonable number of attributes to be included within a DCE is around six, as more
than this might lead to an unmanageable number of options to be meaningfully considered by the
respondent.213 The more attributes that are included in a DCE, the less likely respondents are to fully
consider the pros and cons of different choices as described by differences in the attribute levels.
Therefore, it may prove more difficult to identify trade-offs between attribute levels that a respondent is
willing to make during the decision-making process, which is crucial when estimating marginal rates of
substitution (MRS) (an estimation of the ratio between values that individuals place on different attributes,
quantifying the trade-off a respondent is willing to make between two attributes). Probabilities for all
adverse events included in the choice tasks were assumed to be similar and were therefore considered
constant for all scenarios.
The final list of attributes and corresponding levels is reported in Table 7.
Step 2: experimental design
The DCE survey consisted of a number of possible clinical scenarios based on the attributes and
levels identified in step 1. Each scenario was made up of all five attributes and the associated levels
contained in each attribute. The combination of attributes and levels presented in Table 7 would generate
> 4000 possible scenarios [4320 (5 × 4 × 6 × 6 × 6)]. We reduced the number of scenarios to a manageable
number by using a measure known as D-efficiency, which provides an efficient choice design by minimising
the overlap in attribute levels between scenarios. The D-efficient design was used to reduce the number
of scenarios to the minimum required to estimate all main effects and higher order interactions while still
providing sufficient data to estimate preferences from responses.205,209 We applied one restriction that
implied that an adverse event of infection could only occur with a hospital stay of ≥ 2 days to mirror clinical
practice in which post-operative infections extend the hospital stay.
The design for the DCE was generated using Ngene 1.1 (ChoiceMetrics, Sydney, NSW, Australia). The best
design generated by Ngene was chosen with the aim of minimising standard errors. The reliability of the
model parameters to be estimated can be quantified in terms of the asymptotic standard errors and
covariances; thus, improvements in reliability indicate a reduction in the asymptotic standard errors (i.e.
variance around preference estimates).215 A blocked design of DCE choice sets was used to ensure greater
variance in the data. We used three blocks of 12 questions to minimise respondents’ burden, randomly
allocating respondents to a block of DCE choices. Based on a pilot run of the DCE, we updated the design
to improve the validity of the results.
An example of a pairwise choice set is shown in Table 8. Respondents were asked to choose their
preferred scenario from each pairwise choice set. An opt-out option was given, which in this instance was
defined as the choice of no treatment (i.e. ‘I would choose not to undergo surgery’).
The DCE survey was part of a full questionnaire that included (1) questions on basic sociodemographics
(including age, ethnicity and employment status), (2) questions on potential incontinence history, (3) an
introductory text explaining the DCE task and (4) the main DCE survey.
Step 3: pretesting and data collection
Pretesting
Pretesting of the DCE component of the questionnaire was conducted to (1) test the wording used to
describe attributes and levels, (2) assess ease of use and (3) identify missing attributes and levels. Members
of the general public (n = 5) and the Cochrane Consumer Network (n = 5) were consulted to pretest and
refine the draft questionnaire using cognitive interviewing and semistructured ‘think-aloud’ interviews.216
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TABLE 7 Attributes and levels of surgical treatments for use in the DCE survey
Characteristic Available options Comments
Adverse events New urinary symptoms
(including UUI)a
Need to understand women’s preferences for
certain types of adverse events and which adverse
events are least preferred
Infections (post-operative or
urinary tract)
Damage to organs/nerves
Pain during intercourse
(dyspareunia)
Voiding difficulties
Chronic pain Noa Need to understand women’s preferences for being
pain free after the operation. By definition, chronic
pain refers to pain lasting for > 6 monthsMild
Moderate
Severe
Length of hospital stay (days) 1 The average duration for a hospital stay in the UK is
≈2.5 days.214 We are interested if women may trade
off a longer hospital stay for an improvement in
other attributes, so also include longer durations
2
3
4
5
6
Time to return to normal activities
(weeks)
2 We are interested in identifying women’s
preferences for recovery time and if they might be
willing to trade off a longer duration for an
improvement in other attributes
4
6
8
10
12
Risk of recurrence during 12 months
after surgery (%)
0 We are interested in identifying women’s
preferences for the recurrence risk and if they might
be willing to trade off a higher risk for an
improvement in other attributes
10
20
30
40
50
UUI, urge urinary incontinence.
a Reference category in regression models.
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Data collection
Data were collected via the online platform Qualtrics (Qualtrics, Provo, UT, USA), which is a standard
provider of data collection and analysis products for academic research. The main data collection took
place via an online survey and was conducted by a market research company (Research Now, Plano, TX,
USA) between August and September 2017. Ethics approval for all aspects of the DCE study was granted
from Newcastle University Ethics Committee (reference 11664/2016).
Participants
All participants were aged ≥ 18 years, resident in the UK and members of Research Now’s online panel.
As part of the data collection process (and in accordance with Research Now’s procedure), participants
received a small financial incentive (in the form of a voucher) to take part. Quota sampling was used to
guarantee the representativeness of participants according to the age distribution of incontinence patients.
Sample size
Lancsar and Louviere205 highlight the complexities and problems of performing sample size calculations for
DCEs and stress the need for further research in this area. Based on findings from previous health-related
DCEs, where robust models have been estimated from samples sizes of 50 respondents,217 we aimed to
collect data from 800 participants, which – following a rule of thumb of a minimum of 10 observations per
parameter plus 50 – provided a more than sufficient sample size and allowed for some subgroup analyses.
Piloting the full questionnaire
The full questionnaire was piloted in a subset of the target population. The pilot sample size was
big enough (n = 61) to conduct preliminary regression analyses, allowing for detection of potential
inconsistencies (e.g. positive relations where negative ones were anticipated) and adjusting of the DCE
design accordingly. The pilot sample was part of the main survey sample.
Step 4: data analysis and interpretation
Data were returned to the research team in an anonymised format. The research team did not receive
contact details or any personal identifier information from survey participants.
Data were analysed using a random utility model framework and appropriate logistic regression techniques
to estimate the mean change in utility that women place on different attribute levels compared with the
reference level. This assumes that respondents choose the alternative in a choice set that gives them
greatest utility out of the available options218 and that therefore the choices individuals make in a DCE
reveal the utility they place on the alternatives presented.
Analyses were undertaken on the full study sample of the general population and separately for subgroups
of women with and women without any type of UI.
TABLE 8 Illustrative scenario pair to be used in the DCE survey: question 1 – ‘If you could choose only ONE out of
the three options, which would you prefer?’
Attribute
Option
Scenario A Scenario B
Neither – I would choose
not to undergo surgery
Adverse event Infections
(post-operative or
urinary tract)
New urinary
symptoms
Chronic pain No Moderate
Length of hospital stay (days) 5 3
Time until return to normal activities (weeks) 4 6
Risk of recurrence during 12 months after surgery (%) 10 20
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Analysis methods
The sociodemographic profile and characteristics of respondents in the full sample and the subgroups were
calculated in the univariate descriptive analyses in which means (and SDs) and number of observations
(and proportions) were calculated for continuous and categorical variables, respectively.
Using bivariate analyses, we assessed whether or not preferences were influenced by characteristics of
respondents (e.g. experience of previous treatments, socioeconomic factors). The standard approach to
elicit responses and analyse data from choice sets with more than two options are conditional probit or
logit models. Therefore, data were analysed using a random utility model framework and conditional
and mixed logistic regressions to estimate mean change in utility placed on an attribute level compared
with the reference level. The initial analysis employing a conditional logit model219 may have violated the
assumption of independence compared with irrelevant alternatives assumption (IIA). This assumption
requires the ratio of probabilities for any two alternatives to be independent of the attribute levels in a
third alternative. To overcome this potential problem, we used a mixed logit (MXL) model that accounted
for preference heterogeneity within the specified random variable. It allowed investigation of unobserved
preference heterogeneity, that is, identifying if preferences for a specific attribute vary across respondents.
If preference heterogeneity was present, the final coefficient for the specific attribute may have disguised
the variation in preferences between respondents. The MXL model is a more general approach to a
subgroup analysis because no assumptions are required regarding how individual characteristics may
influence individual preferences. The alternative specific constant (ASC) variable was considered to be
the random, normally distributed parameter and all other model parameters remained fixed. We used
100 Halton draws for the simulation of maximum likelihood.
Main effects parameters were estimated from the utility function (µ) (equation 1). The functional form
incorporated 22 dummy attribute-level coefficients (see Table 7) so that:
µq j = ∝ + λ
′Xqj + εq j, (1)
where µ is the indirect utility function of individual q for alternative j, α is the ASC term, λ′Xqj is the vector
of attribute levels included in the DCE survey and ϵqj is the random element that is added to reflect the
unobservable factors affecting the estimation of the indirect utility function.
Different regression models were employed to analyse the effect of attribute levels on individual preferences
for different characteristics of surgical treatments. Interaction terms were included to identify if and how
individual characteristics mediated choices. The chosen interaction terms were used to explore whether or
not preferences differed (e.g. between women with and without UI). For those without UI, the effect of
knowing someone close with UI on overall preferences was also investigated. Given the sufficiently large
sample size, subgroup analyses were run to identify potential differences in preferences between the total
sample and subgroups of women with any type of UI and those women who did not have UI.
An ASC for options A or B was included in the regression model to account for any latent or unobserved
factors that may have been associated with choosing an alternative of surgical treatment (option A or B)
compared with no treatment (opt-out option). Dummy coding was used for the attributes adverse events
and chronic pain and all other attributes (length of hospital stay, time until return to normal activities,
risk of recurrence) were considered continuous variables and assumed to be linear. Reference levels for
the DCE attributes used in the regression models were new urinary symptoms, including urge urinary
incontinence (UUI), and no pain. Length of hospital stay, time until return to normal activities and risk of
recurrence were included as continuous (linear) variables.
Model goodness of fit was assessed using the likelihood ratio (LR) test statistic.
Marginal rates of substitution were calculated for all attributes included in the DCE based on average
willingness to wait for a return to normal activities (i.e. how much longer an individual would be willing to
wait, on average, for a change in the utility of another attribute).
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This analysis enables the estimation of the trade-offs between attribute levels and the magnitude of the
coefficient in the regression models to be interpreted (i.e. the willingness to wait values can be directly
compared in order to determine relative strength of preference across the remaining attributes).
Predictive uptake rates were also calculated based on the best-case scenario (as observed in the DCE)
versus no surgery and worst case scenario versus no surgery. The statistics are presented as percentages
and compare the variation in uptake rates associated with different configurations/outcomes of surgery.
Both MRS and predictive uptake rates were based on results from the MXL model (see Table 10).
Results
Descriptive analysis
A total of 789 women completed the DCE. Each of the respondents provided responses for 12 choices,
resulting in a total of 9468 choices that were included in the analysis. Table 9 describes the sample
population. The number of missing data for some of the characteristics describing the women responding
to the survey was ≲ 1%.
TABLE 9 Descriptive statistics
Characteristic
Respondents, n (%)
All (N= 789) With UI (N= 353; 44.7%) Without UI (N= 436; 55.3%)
Age (years), mean (SD) 53.1 (12.3) 51.5 (12.1) 54.4 (12.3)
Declared, n (%) 786 (99.6) 352 (99.7) 434 (99.5)
Missing, n (%) 3 (0.4) 1 (0.3) 2 (0.5)
Country
England 632 (80.1) 280 (79.3) 352 (80.7)
Northern Ireland 18 (2.3) 9 (2.5) 9 (2.1)
Scotland 92 (11.7) 42 (11.9) 50 (11.5)
Wales 47 (6.0) 22 (6.2) 25 (5.7)
Children
Yes 559 (70.8) 285 (80.7) 274 (62.8)
No 223 (28.3) 66 (18.7) 157 (36.0)
Prefer not to say 5 (0.6) 2 (0.6) 3 (0.7)
Missing 2 (< 1.0) 0 (0.0) 2 (< 1.0)
Marital status
Single 126 (16.0) 47 (13.3) 79 (18.1)
Cohabiting/married/civil partnership 537 (68.1) 251 (71.1) 286 (65.6)
Separated/divorced 93 (11.8) 41 (11.6) 52 (11.9)
Widowed 24 (3.0) 11 (3.1) 13 (3.0)
Other 1 (0.1) 1 (0.3) 0 (0.0)
Prefer not to say 5 (0.6) 1 (0.3) 4 (0.9)
Missing 3 (< 1.0) 1 (< 1.0) 2 (< 1.0)
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TABLE 9 Descriptive statistics (continued )
Characteristic
Respondents, n (%)
All (N= 789) With UI (N= 353; 44.7%) Without UI (N= 436; 55.3%)
Employment status
Yes (full-/part-time) 394 (49.9) 186 (52.7) 208 (47.7)
Self-employed 41 (5.2) 9 (2.5) 32 (7.3)
Retired 206 (26.1) 75 (21.2) 131 (30.0)
Unemployed 74 (9.4) 35 (9.9) 39 (8.9)
Looking after children 27 (3.4) 16 (4.5) 11 (2.5)
Other 43 (5.4) 30 (8.5) 13 (3.0)
Prefer not to say 4 (0.5) 2 (0.6) 2 (0.5)
Annual household income (£)
< 15,000 125 (15.8) 64 (18.1) 61 (14.0)
15,000–25,999 170 (21.5) 79 (22.4) 91 (20.9)
26,000–34,999 127 (16.1) 53 (15.0) 74 (17.0)
35,000–49,999 147 (18.6) 60 (17.0) 87 (20.0)
50,000–69,999 65 (8.2) 25 (7.1) 40 (9.2)
≥ 70,000 85 (10.8) 46 (13.0) 39 (8.9)
Prefer not to say 58 (7.4) 17 (4.8) 41 (9.4)
Do not know 9 (1.1) 7 (2.0) 2 (0.5)
Missing 3 (< 1) 2 (< 1) 1 (< 1)
Highest level of education
None 14 (1.8) 2 (0.6) 12 (2.8)
Secondary school 244 (30.9) 104 (29.5) 140 (32.1)
College 206 (26.1) 92 (26.1) 114 (26.1)
University 295 (37.4) 143 (40.5) 152 (34.9)
Other 27 (3.4) 11 (3.1) 16 (3.7)
Prefer not to say 1 (0.1) 0 (0.0) 0 (0.0)
Missing 2 (< 1.0) 1 (< 1.0) 1 (< 1.0)
Ethnicity
White 735 (93.2) 331 (93.8) 404 (92.7)
Other 54 (6.8) 22 (6.2) 32 (7.3)
Health status
Excellent 95 (12.0) 33 (9.3) 62 (14.2)
Good 354 (44.9) 121 (34.3) 233 (53.4)
Fair 219 (27.8) 112 (31.7) 107 (24.5)
Poor 93 (11.8) 64 (18.1) 29 (6.7)
Very poor 28 (3.5) 23 (6.5) 5 (1.1)
continued
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TABLE 9 Descriptive statistics (continued )
Characteristic
Respondents, n (%)
All (N= 789) With UI (N= 353; 44.7%) Without UI (N= 436; 55.3%)
Type of UI
Stress 128 (36.3)
Urge 90 (25.5)
Both 116 (32.9)
Do not know 5 (1.4)
Other 12 (3.4)
Missing 2 (< 1.0)
UI limiting daily activities
Extremely 34 (9.6)
Moderately 102 (28.9)
Slightly 168 (47.6)
Not at all 45 (12.7)
Missing 4 (1.1)
UI treatment history
Yes 151 (42.8)
No 202 (57.2)
Type of previous UI treatment
Surgical 32 (9.1)
Non-surgical 94 (26.6)
Both 19 (5.4)
Do not know 5 (1.4)
Missing 1 (< 1.0)
SUI treatment scheduled
Yes 51 (14.4)
No 297 (84.1)
Missing 5 (1.4)
Member of incontinence support group
Yes 25 (7.1)
No 328 (92.9)
Know someone close with UI (if not UI patient themselves)
Yes 123 (28.2)
No 307 (70.4)
Missing 6 (1.4)
DCE responses (n) 9468 4236 5232
Option A (%) 34.4 35.5 33.5
Option B (%) 31.9 31.5 32.1
Opt-out option (no treatment) (%) 33.7 33.0 34.4
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The average age was 53 years and significantly lower in the patients group than in the non-patients
group. The majority of respondents lived in England (80%), followed by Scotland (12%), Wales (6%)
and Northern Ireland (2%). The percentage of women with children differed significantly between both
groups: 81% of women with UI reported having children, whereas only 63% of women without UI
reported having children. This is intuitively sensible, as having had children is a risk factor for developing
some forms of incontinence. The majority of respondents in both groups lived with their partner (with UI,
71%; without UI, 66%) and around half were in full- or part-time employment (with UI, 53%; without UI,
48%), 21–30% were retired and 3–7% were self-employed. Most respondents in either group had an
annual household income of £15,000–25,999 and between 15–20% reported an annual household
income of ≤ £15,000 or £26,000–34,999 and £35,000–49,999, respectively. The distribution of
educational attainments was relatively even between both groups, although a higher proportion of
patients had a university degree (with UI, 41%; without UI, 35%). The majority of respondents (92–93%)
had a white ethnic background. Health status varied significantly between both groups. On average,
women with UI reported poorer health than those without UI and around two-thirds of non-patients
described their general health to be ‘excellent’ or ‘good’.
Among women with UI, the most common type of UI was SUI (36%), followed by MUI (33%) and UUI
(26%). The majority of women with UI found their incontinence to be not or only slightly limiting in their
daily activities (13% and 48%, respectively), 29% reported it to be moderately limiting and 10% reported
it to be extremely limiting. Around 43% had received treatment previously. However, the majority of
previous treatment took the form of management of incontinence (i.e. non-surgical treatment). Out of the
128 patients with SUI, nearly half reported to have treatment scheduled and 7% reported to be a member
of an incontinence support group.
Among women without UI, 28% knew someone close to them with UI.
Statistical analyses
Two-thirds of women were prepared to make a choice between surgical options and one-third of women
declared that they would rather choose no surgery. Responses to the three choices were evenly split:
around one-third of all responses was allocated to each of the options (A, B and the opt-out option),
indicating that the majority of respondents would choose surgery (options A and B) over no surgical
treatment (opt-out option).
Table 10 reports the marginal effects of each attribute on utility for the conditional models (1–7) and the
MXL model (8). Conditional logistic regressions were run for all respondents (models 1–2), women with UI
(models 3–6) and women without UI (model 7). Marginal utility values indicate relative preferences for
levels within an attribute (for example, relative preferences against mild/moderate/severe pain compared
with no pain). Positive marginal utility values indicate an attribute level is preferred to the reference level
and negative marginal utility values indicate that the attribute level is valued less than the reference level.
For the MXL model, means and SDs are reported for the random parameter. The sign of SDs is irrelevant;
significant SDs imply preference heterogeneity among respondents for that specific attribute, suggesting
that the reported coefficient may disguise differences in the underlying preferences. To identify which
differences are statistically significant, p-values are included.
The results were found to be very similar across all models, except for the marginal effect of the ASC
capturing a preference for or against surgical treatment in general. Preferences for surgical treatment
varied significantly in both the significance and direction of the effect depending on model specifications.
The coefficient for the ASC was only significant in some of the models for women with UI (model 4–6)
and the mixed-effects model (model 8), whereas the estimations for the full sample and women without UI
suggest no significant result (i.e. no preference for or against surgical treatment in general). Significant
coefficients for both the mean and SD from the mixed-effects model suggest that preference heterogeneity
is present among respondents.
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TABLE 10 Marginal utility values from logistic regression models
Variable
Model
Conditional logit MXL
1 (all) 2 (all) 3 (patients) 4 (patients) 5 (patients) 6 (patients) 7 (non-patients) 8 (all)
ASC (option A or B)
Mean 0.100 0.071 –0.087 0.394*** 0.274*** –0.362** 0.075 1.361***
SD N/A N/A N/A N/A N/A N/A N/A 4.029***
Adverse event
New urinary symptomsa N/A N/A N/A N/A N/A N/A N/A N/A
Infections 0.231*** 0.231*** 0.244*** 0.245*** 0.247*** 0.248*** 0.213*** 0.280***
Damage to organs/nerves –0.107** –0.106** –0.127* –0.151** –0.136* –0.140* –0.084 –0.088*
Pain during intercourse 0.107** 0.107** 0.123* 0.142** 0.131* 0.142** 0.090 0.135***
Voiding difficulties –0.274*** –0.274*** –0.218*** –0.217*** –0.223*** –0.219*** –0.325*** –0.278***
Chronic pain
Noa N/A N/A N/A N/A N/A N/A N/A N/A
Mild –0.036 –0.036 0.034 0.044 0.037 0.036 –0.099* –0.053
Moderate –0.171*** –0.171*** –0.073 –0.061 –0.071 –0.057 –0.245*** –0.185***
Severe –0.204*** –0.204*** –0.112* –0.119** –0.107* –0.110* –0.279*** –0.204***
Length of hospital stay –0.031*** –0.031*** –0.030** –0.030** –0.028** –0.032** –0.032*** –0.030***
Time until return to normal activities 0.021*** 0.021*** 0.022*** 0.022*** 0.022*** 0.022*** 0.023*** 0.023***
Risk of recurrence during 12 months after surgery –0.002* –0.002** –0.001 –0.001 –0.001 –0.001 –0.003** –0.002***
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Variable
Model
Conditional logit MXL
1 (all) 2 (all) 3 (patients) 4 (patients) 5 (patients) 6 (patients) 7 (non-patients) 8 (all)
Interactions and additional variables
ASC × UI patient
Patient N/A 0.063 N/A N/A N/A N/A N/A N/A
ASC × UI type (reference category: mixed)
SUI N/A N/A 0.348*** N/A N/A 0.686*** N/A N/A
UUI N/A N/A 0.123 N/A N/A 0.221** N/A N/A
Other N/A N/A 0.752*** N/A N/A 0.569*** N/A N/A
ASC × limiting UI (reference category: extremely)
Moderately N/A N/A N/A 0.150 N/A 0.339** N/A N/A
Slightly N/A N/A N/A 0.437*** N/A –0.158 N/A N/A
Not N/A N/A N/A 1.303*** N/A 1.079*** N/A N/A
ASC × treatment history
Previous treatment N/A N/A N/A N/A 0.754*** 0.690*** N/A N/A
ASC × knowing someone with UI N/A N/A N/A N/A N/A N/A 0.272 N/A
Log (pseudo)likelihood –10293.3 –10292.2 –4557.8 –4462.4 –4550.5 –4359.2 –5587.6 –7838.0
*p < 0.1, **p < 0.05, ***p < 0.01.
N/A, not applicable.
a Reference category.
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Preferences for the different types of adverse events were relatively robust to varying model specifications.
Infections and pain during intercourse were found to be associated with a utility gain and, therefore, not
disliked as much as the reference category of new urinary symptoms, and damage to organs or nerves and
voiding difficulties were less preferred.
The results for different levels of chronic pain were in line with expectations, describing a gradient of
increasingly negative preferences with higher levels of pain. Compared with the reference level of no pain,
mild chronic pain was not found to affect utility significantly across most models, whereas moderate and
severe pain were associated with a greater negative preference. However, the results were mediated in
models for women with UI that included interactions between the ASC and how limiting the type of
UI was perceived with regard to daily activities (models 4 and 6) and between the ASC and a positive
treatment history (models 5 and 6). In these models, the negative gradient could still be observed but was
no longer statistically significant. Instead, if respondents had had treatment before, and the more limiting
their UI, the more likely they were to choose surgery.
As expected, women would prefer not to experience longer hospital stays or a higher risk of recurrence.
However, the negative preference for a higher risk of recurrence was not significant in models for women
with UI (models 3–6) in which interaction terms between the ASC (and, therefore, the overall preference
for surgery) and different characteristics capturing patient experiences may have dominated the impact of
different levels of pain. The sample of women without UI showed the strongest gradient of negative
preferences for higher levels of pain. A longer time to return to normal activities was associated with a
utility gain and, therefore, described a positive preference.
Adding interactions between ASCs and additional variables improved the goodness of fit for all patient
models, and model 6 was found to be the best-fitted model. Compared with patients with a mixed form of
UI, those suffering from SUI were more likely to choose surgery. Similarly, patients with a positive treatment
history and a more limiting form of UI gained more utility from choosing surgical treatment options.
Comparing the log LRs between model 1 (conditional logit) and model 8 (MXL) that used the same
variables and same study populations showed that the MXL model provided better model estimates when
accounting for preference heterogeneity around the ASC. In the non-patient model 7, knowing someone
close with UI did not significantly increase the preference for surgical treatment.
Marginal rates of substitution were calculated for all attributes included in the DCE based on average
willingness to wait for a return to normal activities (i.e. how much longer an individual would be willing
to wait, on average, for a change in the utility of another attribute). In comparison with new urinary
symptoms, individuals would, on average, be willing to wait an additional 3.8 weeks to return to normal
activities to avoid damage to their nerves or organs and up to an additional 12 weeks, on average, to avoid
voiding difficulties. Individuals were not willing to wait any additional time to avoid infections or pain during
intercourse in comparison with new urinary symptoms.
To avoid chronic pain, individuals would, on average, be willing to wait an additional 2.3 weeks to avoid
mild pain compared with no pain. Individuals would be willing to wait an additional 8 and 9 weeks, on
average, to avoid moderate and severe pain, respectively.
For a one-night reduction in their hospital stay an individual would, on average, be willing to wait 1 additional
week to return to normal activities. To reduce the risk of recurrence by 1%, an individual would on average
be willing to wait an additional 15 hours.
Predicted uptake rates, based on a hypothetical best-case surgery (adverse event of infection, no pain,
a length of stay of 2 days, 12 weeks to return to normal activities and 0% risk of recurrence) versus a no
surgery option were calculated. Given this option, it is predicted that 62% of respondents would choose
the surgical option over no surgery. Similarly, for the hypothetical worst-case surgery (voiding difficulties,
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severe pain, length of stay of 6 days, 2 weeks to return to normal activities and 50% risk of recurrence)
versus the no surgery option, the predicted uptake rates were estimated as 33% for the worst-case
scenario. In this case, 67% of respondents would, on average, choose no surgery.
Discussion
Summary of results
To our knowledge, this is the first DCE to investigate differential characteristics of surgical treatment
options for UI and their potential impact on women’s decisions to undergo surgery. Analysis of choice
set data from the DCE revealed that around two-thirds of respondents chose a treatment option over no
surgery. However, we found evidence that preferences around the choice of surgical treatment may vary
across individuals.
In terms of types of adverse event associated with surgical treatment, infections and pain during intercourse
were preferred to the reference category of new urinary symptoms, whereas damage to organs or nerves
and voiding difficulties were less preferred. These preferences were relatively robust across all models, but
the results, although confirming the same trend in preferences, were not statistically significant for damage
to organs or nerves and pain during intercourse in non-patient respondents. Respondents associated
increasing levels of disutility (i.e. negative preference) with higher levels of chronic pain, longer durations of
hospital stay and higher risk of recurrence. We also found evidence that longer durations to return to normal
activities after the surgery was associated with a statistically significant, positive preference.
Interpretation of results
The heterogeneity around a general preference for or against surgical treatment may be explained by the
range of surgical treatments available, their level of invasiveness and, therefore, their varying impact on
some of the attributes included in the DCE. The different subgroups in our sample may have contributed
to the heterogeneity around the preference for surgical treatment in general. Comparing results across all
models suggests that general preferences concerning surgical treatment vary not only between patients
and non-patients but also within the patient subgroup, as implied by the change in sign of the ASC
coefficient between model 4 and models 5 and 6. Although the results for the full sample suggest a
preference for surgery, this finding may have been driven by the majority of non-patients within the
sample. We found some evidence that patients in general may associate a negative preference with
surgery for UI. However, those patients with SUI, who reported their UI to be extremely limiting with
regard to daily activities and who had undergone surgical treatment before were more likely to choose
surgery again. This may indicate that patients who have never undergone surgery fear the surgical
procedure and are more reluctant to choose surgical treatment. One reason for this finding may be that
patients are more used to managing their UI and may consider non-surgical treatment as long as their
condition is not experienced as limiting their daily activities too much. Interviews conducted with patients
during the pretesting stage of the DCE provided further support for this finding.
Preferences around different types of adverse event following surgery were captured compared with the
reference of new urinary symptoms. Our findings suggest that infections and pain during intercourse are
considered to be more acceptable adverse events, whereas damage to organs or nerves and voiding
difficulties were less acceptable and reduced the likelihood of respondents choosing a surgical treatment
option. This is also confirmed by the MRS analysis, which showed that individuals were willing to wait
longer to recover to avoid damage to organs or nerves and to avoid voiding difficulties but were not
willing to wait to avoid infections or pain during intercourse.
As expected, we found evidence for higher levels of chronic pain and increased risk of recurrence to be
associated with negative preferences. However, although the same trend could be observed in all models,
the statistical significance varied, which may indicate the difference in importance of these attributes for
patients and non-patients. When accounting for patient characteristics around their type of UI, the degree
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to which it was limiting them in daily activities and their treatment history, preferences for chronic pain
and risk of recurrence were less significant. Patients with SUI or UUI, extremely or moderately limiting UI
and a treatment history had a stronger preference for surgery regardless of the associated level of pain or
risk of recurrence.
There was a strong preference for shorter hospital stays, suggesting that the less invasive may be the
preferred treatment options, with reduced risk of infections that may increase the length of hospital stay
following surgery.
Other than expected, we found evidence for a preference for longer durations to return to normal
activities, although the pilot data had suggested a negative preference for this attribute. A reason for this
finding may be that respondents may have interpreted ‘return to normal activities’ as ‘return to work’
(assumes that they would not lose any wages). Alternatively, and especially for those who had never
experienced any surgical treatment, respondents may have found the attribute levels to be unrealistic,
expecting the recovery after surgery to be longer than the stated maximum of 12 weeks.
Strengths and weaknesses
A major strength of our study, which elicited preferences for different characteristics of surgical treatment
options of UI is the use of a DCE in combination with an online panel. It allowed us to use a relatively large
sample size and control for differences in respondent characteristics accordingly. The anonymity of the online
setting may have allowed the responding UI patients to be more honest and report their problems in greater
detail than they may feel comfortable to report in a health-care setting. The advantage of using a DCE for
preference elicitation is that it allows consideration of real-life choice situations in which multiple factors may
influence the decision-making process. The combined influence of those factors and potential trade-offs
between their varying levels cannot be readily elucidated or quantified by other methods.
However, DCEs have been criticised as difficult for participants to understand. We aimed to minimise this
risk by following best practice guidelines for the design and development of DCEs205,211 and engaged
members of the general public and patients in the development process to maximise internal and
external validity.
We acknowledge that the sample recruited by the research company is a convenience (i.e. non-random)
sample that may not be representative of the target population and did not allow us to determine
response rates to the survey. Some of our analyses were aimed at identifying differences in preferences
between subgroups of patients and non-patients; however, the characteristics of those subgroups may
have differed by definition (e.g. see the lower average health status and higher proportion of respondents
with children in the patient subgroup). Alternative methods of recruitment and data collection in the
context of DCEs, such as postal or telephone surveys, have been found to achieve very low response rates,
thereby potentially reducing the representativeness and validity of results.220
Implications of findings for research
To our knowledge, this research provides the first insights into what women (with and without) UI want
their treatment options to be like and which fundamental surgical treatment characteristics they prefer.
More than half of respondents had UI or knew someone close with UI. However, given the wide range
of surgical treatments and significant differences between them, capturing specific influences on and
preferences for or against certain treatment characteristics is a complex process. Our patient subsample
was not large enough to capture sufficient variation beyond the interaction effects for patient experience
already included in our analyses. More research is needed to distinguish trade-offs between different
characteristics of surgical treatment options. One study found that women suffering from UI would choose
the treatment with the lowest risk of recurrence.221 Our results provide further support but suggest that
this preference may be mediated by other factors such as previous treatment experience and that this
finding cannot necessarily be generalised without further research.
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Although UI can have a substantial impact on a woman’s daily activities and quality of life, previous
research suggests that women under-report their condition and manage their incontinence before seeking
treatment.222 Barriers to seeking professional help may be imposed by a lack of awareness of treatment
options, by the perception that these symptoms are normal after childbirth or in older age, or by feelings
of shame or embarrassment.223,224 Considering women’s preferences and trying to reduce those barriers
may help to reduce the levels of unmet need for incontinence services and to improve the organisation
of surgical services.
Conclusion
To our knowledge, this is the first DCE to investigate differential characteristics of surgical treatment
options for UI and their potential impact on women’s decisions to undergo surgery. We found that women
are less likely to choose surgical treatments that are associated with longer hospital stays, higher risks of
recurrence and increased levels of chronic pain. However, although women with a treatment history had a
negative preference for surgical treatments, those with forms of UI that were reported to be extremely or
moderately limiting in daily activities preferred the surgical treatment option to no surgery. Further research
investigating a woman’s choice for or against surgery needs to investigate treatment history in greater
detail and consider more individual characteristics including personal beliefs and perceptions that may act
as a barrier to seeking professional advice.
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Chapter 5 Review of cost-effectiveness evidence
Methods
In addition to the review of the clinical effectiveness of surgical treatments for SUI, a review of full model-
based economic evaluations was conducted. The purpose of the review of model-based evaluations was to
identify robust models and inputs to inform the economic modelling in this study. Specifically, the objective
was to perform a critique of existing economic models to identify a model suitable for augmentation or
to justify the development of a new economic model. Additionally, the review would be used to identify
clinical and health economic data that were used in the identified models that could also be used in a new
economic model. Trial-based economic evaluations were not included in the review to minimise the time
commitment required for this aspect of the work. The review work was conducted in accordance with the
Centre for Reviews and Dissemination’s guidance for undertaking reviews in health care.14
Search strategy
The search strategy is outlined in Appendix 17.
Data sources
The following databases were searched during the review process:
l MEDLINE (via Ovid)
l MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
l Excerpta Medica Database (EMBASE) (via Ovid)
l NHS Economic Evaluation Database (NHS EED) (via Ovid)
l Health Management Information Consortium (via Ovid)
l Cost-effectiveness Analysis (CEA) Registry.
All databases were searched using the Ovid interface, except for the CEA Registry, which was searched
through the CEA Registry website (https://cevr.tuftsmedicalcenter.org/databases/cea-registry).
Study selection
Two researchers undertook the screening of titles and abstracts obtained through the search using
EndNote® X7 [Clarivate Analytics (formerly Thomson Reuters), Philadelphia, PA, USA] reference
management software. Prior to initial screening, deduplication of records was undertaken. After initial
screening, all potentially relevant articles were obtained for further scrutiny against the full selection
criteria, with any disagreements resolved by discussion. The inclusion criteria were as follows:
l Study design: full economic evaluations involving a decision model-based analysis. A full economic
evaluation can be defined as a comparative study including both costs and effects.
l Population: women with SUI and stress-predominant MUI (adult women of any ethnic background).
l Intervention: any of the surgical treatments for UI being evaluated in our own study (as either a primary
or a repeat surgery).
l Comparator: alternative treatment (surgical and non-surgical) or no treatment for UI.
l Outcome: cost-effectiveness, cost estimates, utilisation estimates and quality-of-life estimates.
l Language: studies with full text in English.
No restrictions were placed on the publication time frame or the study country. Modelling studies where
data were imputed from multiple sources, without specific reference to the age and ethnic background
of women, were included in the review. Studies comparing diagnostic/screening techniques or other
non-surgical procedures without considering surgical interventions in the model pathway were excluded.
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Data extraction
Relevant data were extracted into an Excel spreadsheet. Data on the following, where available, were
extracted from included studies by one reviewer and checked by another:
l study characteristics, such as study question, form of economic analysis, population, interventions,
comparators, perspective, time horizon and form of modelling
l clinical effectiveness and cost parameters, such as effectiveness data, health-state valuations (utilities),
resource use data, unit cost data, cost year, discounting and key assumptions
l results and sensitivity analyses.
Findings
A total of 821 titles and abstracts were identified from the original search, with 732 remaining after
deduplication. Following title and abstract screening, 30 studies remained. Full-text copies of these
30 studies were obtained for scrutiny against the full selection criteria and 13 were excluded. Therefore,
17 studies were included in the final review. A flow diagram presenting the process of selecting studies
can be found in Figure 3.
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FIGURE 3 Flow diagram showing study selection for the economic evaluations review.
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Summary of review data from included model-based economic evaluations
A total of 17 studies were included in the final review. An overview of the key data extracted from these
studies is presented in Table 11. In the section that follows, a more comprehensive description of the data
extracted from the included studies is presented. Finally, a descriptive quality assessment of the included
studies is presented, based on the criteria defined in the Drummond checklist for economic evaluations.242
Comprehensive overview of data extracted from included model-based
economic evaluations
Country
Nine studies were based in the USA,225,226,230,233,235–237,239,240 four in the UK,227–229,241 three in Canada231,232,234
and one in the Netherlands.238
Cost year
The cost year of four studies was 2012,226,233–235 of one study was 2007,228 of one study was 2001,229 of
four studies was 1998,231,236,239,240 of one study was 2005,237 of one study was 2010,232 of two studies was
2013,225,238 of one study was 2008241 and of two studies was not reported.227,230
Currency
Currency matched the country in all studies.225–241
Study population
All studies were conducted among a population of women with UI, SUI or MUI.225–241
Population age
Three studies reported a population age of 45 years, based on the age of peak incidence of SUI.226,229,241
One study reported a population aged ≤ 65 years.240 One study reported a population aged > 65 years,
chosen because elderly patients are likely to have a greater unmet need.238 In all other studies, population
age was not reported.225,227–237,239,241
Analysis type
A total of 11 studies were cost–utility analyses,225–230,233,235,237,238,241 five were cost-effectiveness
analyses231,232,234,236,240 and one was a cost–consequences analysis.239
Perspective
Four studies reported a societal perspective,226,236,238,240 nine studies reported a health service
perspective,225,228,229,231,232,234,235,237,241 one study reported a third-party payer perspective233 and three studies
did not report a perspective.227,230,239 However, on the basis of the costs included the perspective was
interpreted as the health-care system for two of these studies230,239 and societal for the third.227
Model structure and comparators
Model type
A total of 10 studies used a Markov model.226–230,234,235,237,238,241 The remaining seven studies used a
decision tree.225,231–233,236,239,240
Time horizon
One study reported a lifetime time horizon,226 five studies reported a 10-year time horizon,228–230,235,237
seven studies reported a 1-year time horizon,225,231–233,236,239,240 two studies reported a 3-year time
horizon,234,238 one study reported a 2- to 5-year time horizon227 and one study reported a 40-year
time horizon.241
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TABLE 11 Overview of included model-based economic evaluations
Number Study Population
Analysis
type Intervention Comparator
Model
type Perspective
Time
horizon
Time
cycle
QoL
measure CE measure Results
1 Kunkle et al.225 SUI CUA MUS Urethral BA Decision
tree
Health-care
system
1 year N/A NR Cost/QALY MUS compared with BA leads to an
ICER of US$70,400 per utility gained
2 Von Bargen
et al.226
SUI CUA MUS 1. Expectant management
2. PFMT
3. PFMT+ES
4. Vaginal cone/biofeedback
5. Incontinence pessary
Markov
model
Societal Lifetime 1 year NR Cost/QALY Incontinence pessary was the more
cost-effective option with US$11,411
cost/QALY
With a WTP of US$60,000, MUS
would be the most cost-effective
option
3 Das Gupta
et al.227
SUI CUA Duloxetine 1. PFMT
2. Surgery
Markov
model
NR 2–5 years 3 months NR Cost/QALY First-line use of duloxetine alone
and in combination with PFMT is
more cost-effective than standard
treatment, with ICERs of £8730 and
£5854, respectively
Second-line use of duloxetine alone
and in combination with PFMT is less
costly and more effective than
standard treatment
4 Jacklin et al.228 SUI CUA TVT Duloxetine Markov
model
Health-care
system
10 years 1 day NR Cost/QALY TVT had an ICER of £7710
(US$12,651) at 10 years
5 Kilonzo et al.229 SUI CUA TVT 1. Open colposuspension
2. Laparoscopic colposuspension
3. Traditional suburethral
sling procedures
4. Periurethral urethral
injection therapy
Markov
model
Health-care
system
10 years 1 year EQ-5D Cost/QALY TVT dominates open colposuspension
(lower cost and same QALYs) within
5 years after surgery
6 Laudano et al.230 SUI CUA TVT Open Burch colposuspension Markov
model
NR 10 years NR NR Cost/QALY At 10-year follow-up, TVT was more
cost-effective (CE, US$1495/QALY)
than BC (CE, US$1824/QALY)
7 Oremus et al.231 SUI CEA Collagen 1. Retropubic suspension
2. Transvaginal suspension
3. Sling procedure
Decision
tree
Health-care
system
1 year N/A N/A Cost/treated
woman
Retropubic suspension vs. collagen
ICER: CA$1824
Transvaginal suspension vs. collagen
ICER: CA$5151
Sling procedure vs. collagen ICER:
CA$6814
8 Oremus and
Tarride232
SUI CEA Collagen 1. Needle bladder neck suspension
2. Burch colposuspension
3. Slings
Decision
tree
Health-care
system
1 year N/A N/A Cost/treated
woman
ICER is CA$341.35 for Québec
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Number Study Population
Analysis
type Intervention Comparator
Model
type Perspective
Time
horizon
Time
cycle
QoL
measure CE measure Results
9 Richardson and
Sokol233
SUI CUA MUS 1. Continence pessary
2. PFMT
Decision
tree
Third-party
payer
1 year N/A HUI Cost/QALY MUS was the more cost-effective
strategy with an ICER of
US$32,132/QALY
10 Sand et al.234 SUI CEA Transurethral
radiofrequency
micro-modelling
1. TVT
2. TOT
3. Burch colposuspension
4. Traditional bladder neck
autologous sling
Markov
model
Health-care
system
3 years 3 months N/A Cost Procedure costs for RF-SUI were
less than half of the cost of sling
treatments and were one-fifth of the
cost of Burch surgery
11 Seklehner
et al.235
SUI CUA Retropubic MUS Transobturator MUS Markov
model
Health-care
system
10 years NR NR Cost/QALY Transobturator MUS was more
cost-effective than retropubic MUS
with an ICER of US$177,027/QALY
12 Weber and
Walters236
SUI CCA Burch
colposuspension
Sling procedure Decision
tree
NR 10 years N/A N/A Costs and
clinical
outcomes
N/A
13 Wu et al.237 SUI CUA Burch
colposuspension
TVT Markov
model
Health-care
system
10 years 1 year NR Cost/QALY The ICER was US$98,755 per QALY
14 Holtzer-Goor
et al.238
UI CUA Global optimum
continence
service
specification
Current care pathway for UI in the
Netherlands
Markov
model
Societal 3 years 3 months EQ-5D Cost/QALY The PSA results show that, with 95%
certainty, the new care intervention
dominates current care (i.e. it is more
effective and cost-saving)
15 Weber and
Walters239
Symptomatic
pelvic organ
prolapse and SUI
CEA Office evaluation
and no further
testing
Office evaluation and subsequent
testing
Decision
tree
Societal 1 year N/A N/A Cost/additional
cure
In the base case, the strategy of
basic office evaluation was more
cost-effective than the strategy of
urodynamic testing. In the short model
the incremental cost-effectiveness
(cost per additional cure of UI) was
US$55,495 for urodynamic testing
relative to basic office evaluation.
In the full model a single additional
cure of UI was achieved by urodynamic
testing at a cost of US$328,601 relative
to basic office evaluation
16 Weber et al.240 SUI CEA Office evaluation
and no further
testing
Office evaluation and subsequent
testing
Decision
tree
Societal 1 year N/A N/A Cost/additional
cure
In the base case, the strategy of
basic office evaluation was more
cost-effective than the strategy of
urodynamic testing. In the short model
the incremental cost-effectiveness
(cost per additional cure of UI) was
US$55,495 for urodynamic testing
relative to basic office evaluation.
In the full model a single additional
cure of UI was achieved by urodynamic
testing at a cost of US$328,601
relative to basic office evaluation
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TABLE 11 Overview of included model-based economic evaluations (continued )
Number Study Population
Analysis
type Intervention Comparator
Model
type Perspective
Time
horizon
Time
cycle
QoL
measure CE measure Results
17 Imamura et al.241 SUI CUA Treatment
sequence 1
Treatment sequence 2–8 Markov
model
Health-care
system
40 years 3 months EQ-5D Cost/QALY The strategy employing lifestyle
changes and PFMT with extra
sessions followed by TVT surgery has
a > 70% probability of being
considered cost-effective for all
threshold values for WTP for a QALY
presented. The other five strategies
each have a probability of < 20% of
being considered cost-effective
BA, bulking agent; BC, Burch colposuspension; CCA, cost–consequences analysis; CE, cost-effectiveness; CUA, cost–utility analysis; EQ-5D, EuroQol-5 Dimensions; HUI, health utility index; ICER, incremental cost-effectiveness ratio; N/A, not
applicable; NR, not recorded; PFMT+ES, PFMT with electrical stimulation; PSA, probabilistic sensitivity analysis; QoL, quality of life; RF-SUI, radiofrequency stress urinary incontinence; WTP, willingness to pay.
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Cycle length
Three studies used a 1-year cycle length,226,229,237 one study used a 1-day cycle length,228 four studies used
a 3-month cycle length,227,234,238,241 two studies did not report cycle length230,235 and for seven studies cycle
length was not applicable as they adopted a decision-tree approach.225,231–233,236,239,240
Intervention
Three studies looked at MUS,225,226,233 three studies looked at TVT,228–230 one study looked at transurethral
radiofrequency micro-remodelling,234 one study looked at retropubic MUS,235 two studies looked at Burch
colposuspension,237,239 two studies looked at collagen injection,231,232 one study looked at duloxetine,227 one
study looked at global optimum continence service specification,238 two studies looked at office evaluation
and no further testing236,240 and one study looked at initial treatment with conservative therapies.241
Comparator
One study compared the intervention with expectant management, PFMT, PFMT with electrical stimulation,
vaginal cone or biofeedback and incontinence pessary,226 one study compared the intervention with
duloxetine,228 one study compared the intervention with open colposuspension, laparoscopic colposuspension,
traditional suburethral sling procedures and periurethral injectables,229 one study compared the intervention
with open Burch colposuspension,230 one study compared the intervention with continence pessary and
PFMT,233 one study compared the intervention with TVT, retropubic mid-urethral synthetic sling procedures,
TOT, transobturator mid-urethral synthetic sling procedures, Burch colposuspension surgery and traditional
bladder-neck autologous sling procedures,234 one study compared the intervention with transobturator MUS,235
one study compared the intervention with sling procedures,239 one study compared the intervention with
TVT,237 one study compared the intervention with bladder neck needle suspension and Burch slings,231 one
study compared the intervention with retropubic suspension, transvaginal suspension and sling procedures,231
one study compared the intervention with urethral bulking agents,225 one study compared the intervention with
PFMT and surgery, colposuspension and traditional slings,227 one study compared the intervention with the
current care pathway for UI in the Netherlands,238 two studies compared the intervention with office evaluation
and subsequent urodynamic testing236,240 and one study compared the intervention with initial treatment
with MUS.241
Model inputs and analysis
Discounting
Three studies applied a 3.5% discount rate,227,228,241 two of which228,241 justified this rate on the basis of it
being the discount rate recommended for the reference case in the NICE technical manual.243 Two studies
applied a 3% discount rate but did not justify this choice of rate.226,237 One study applied a 4.54% discount
rate based on the 10-year AAA corporate bond yield for that year.230 One study applied a 5% discount
rate but did not justify this choice of rate.234 One study applied a 2.26% discount rate based on the
10-year AAA corporate bond yield for that year.235 One study applied a 6% discount rate for costs and
a 1.5% discount rate for quality-adjusted life years (QALYs);229 however, these rates were not justified in
the text. For six studies, a discount rate was not applicable as the time horizon of the included model
was only 1 year,225,231–233,236,240 and for two studies discounting was applicable but a discount rate was
not reported.238,239
Clinical effectiveness measure(s)
Eight studies used cure rate (objective or subjective) only,226,229,231,232,236,237,239,240 three studies used
improvement rate (objective or subjective) only,233–235 one study used both cure rate and improvement rate,241
one study used the percentage of women continent,238 one study used probability of cure, probability of
retreatment and probability of cure after retreatment,230 one study used success rate (defined as dry, which is
resolution of symptoms),225 one study used reduction in incontinence episode frequency227 and one study
used a change in incontinence episode frequency as the measure of clinical effectiveness.228
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Quality of life measure(s)
Three studies used EuroQol-5 Dimensions (EQ-5D),229,238,241 with one of those229 using data derived from
Manca et al.244 One238 used data derived from a cross-sectional study of quality of life in a general female
population in the Netherlands aged 45–85 years, whereas another241 used data derived from Manca et al.244
and Haywood et al.245 Eight studies that used quality of life estimates in their analysis did not report a quality
of life measure in their study225–228,230,233,235,237 and for six studies a quality of life measure was not applicable
as they were conducted as either a CEA or a cost–consequences analysis (CCA), for which a quality of life
measure is not required.231,232,234,236,239,240
Cost-effectiveness measure
A total of 11 studies used cost per QALY,225–230,233,235,237,238,241 two studies reported costs and clinical outcomes in
a disaggregated manner,234,239 two studies reported cost per increased probability of successful treatment231,232
and two studies reported cost per additional cure.236,240
Complications/adverse events
One study reported UTI, voiding dysfunction, mesh erosion and intra-/post-operative adverse events;226 one
study reported haematoma, urinary retention, detrusor overactivity, UTI, abscess, mesh or suture erosion,
recurrent stress incontinence, pelvic organ prolapse, incisional hernia, bladder perforation and revision;230
one study reported voiding dysfunction, wound complication, mesh exposure or erosion and recurrent
cystitis;234 one study reported mesh erosion/exposure, urinary retention, lower urinary tract symptoms,
bladder perforation, infection, bleeding, neurological symptoms, catheterisation, anticholinergics,
antibiotics, blood transfusion and drainage of haematoma;235 one study reported recurrent incontinence,
detrusor instability and urinary retention;239 one study reported UTIs, fractures and skin breakdown;238
one study reported adverse events related to drugs only;241 one study reported mesh erosion;237 one study
reported retention, voiding, infection and haematuria;231 one study reported immediate haemorrhage,
immediate bladder injury, short-term urinary retention, short-term pain, short-term haematuria, long-term
persistent urinary retention, long-term UTI, long-term mesh complication and long-term recurrent SUI; and
seven studies did not report complications/adverse events.227–229,231,233,236,240
Mortality modelling
Two studies incorporated all-cause mortality,226,237 one study incorporated all-cause mortality and surgery-
specific mortality,241 three studies did not incorporate all-cause mortality,228–230 seven studies did not include
mortality in their economic model,227,234–236,238–240 and for four studies mortality was not applicable owing to
the short time horizon of their model.225,231–233
Sensitivity analysis
One study conducted multivariable sensitivity analysis (SA),226 seven studies conducted deterministic SA
only,228,230,231,233,234,237,239 seven studies conducted deterministic SA and probabilistic sensitivity analysis
(PSA)225,227,229,231,235,238,241 and two studies conducted deterministic SA and a threshold analysis.236,240
Resource use costs
Two studies used Medicare reimbursement codes to derive cost of treatment;226,233 one study239 collected
costs using codes from Medicare diagnostic-related groups and the International Classification of Diseases,
Ninth Edition (ICD-9); one study used a combination of literature (routine UK sources) and assumption;228
and two studies used a combination of relevant literature, such as reports from manufacturers, and advice
from experts in the field.229,241 One study derived costs from 2003 Medicare reimbursement data and
diagnosis-related group codes,237 one study used only the Medicare fee schedule,225 two studies used the
Medicare resource-based relative value scale,230,235 one study used a combination of Medicare and expert
opinion,234 one study used previous economic evaluations to derive cost information,231 one study used a
combination of hospital records and expert opinion,232 one study used a combination of HES, assumptions
and literature227 and two studies236,240 used an issue of the Federal Register. One study used a combination
of expert opinion, reimbursement prices and previous literature.238
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Data source for clinical effectiveness
Twelve studies used literature as a source,225–230,234,235,237–239,241 one study used data from the ATLAS
(Ambulatory Treatments for Leakage Associated with Stress Incontinence) trial,233 one study used data from
a RCT,231 one study used data from clinical guidelines231 and two studies used data from a combination of
literature and consensus from the study team.239,240
Quality assessment
The completed Drummond checklist for each of the included studies is presented in Appendix 18.
In this section, a descriptive summary of the quality assessment of all included studies is presented.
1. Was a well-defined question posed in answerable form?
All of the included studies had a well-defined question posed in an answerable form and examined both
the costs and the effects of the alternative options.225–241 Only three of the included studies did not state a
viewpoint for the analysis or place the study in any particular decision-making context.225,230,239
2. Was a comprehensive description of the competing alternatives given (i.e. can you tell
who did what to whom, where, and how often)?
Only three of the included studies did not provide a comprehensive description of the competing
alternatives or provided only a comprehensive description of the intervention without focusing sufficiently
on the comparator(s).230,232,235 Only one study did not omit important alternatives from the analysis.241
None of the studies included a do-nothing alternative in their comparison.
3. Was the effectiveness of the programme or services established?
All of the included studies established the effectiveness of the programme or services included in the
model.225–241 Of the studies that did establish effectiveness, three determined effectiveness through a clinical
RCT.227,232,233 A total of 13 studies established effectiveness through an overview of clinical studies.226,228–231,
233–237,239–241 Five studies used observational data or assumptions to establish effectiveness.225,227,233,237,238
4. Were all the important and relevant costs and consequences for each
alternative identified?
All of the included studies identified the important and relevant costs and consequences for the
alternatives being compared.225–241 The range of relevant costs and consequences was wide enough for
the research question at hand in all studies other than in four, in which the range was unclear.225,226,228,238
In one study it was determined that the range was not wide enough for the research question at hand.231
Costs and consequences were covered from all relevant viewpoints (community or social viewpoint and
those of patients and third-party payers) in only five studies.226,236,238–240 In one study, the perspective was
not clear.230 In all remaining studies, at least one perspective (primarily patient perspective) was not
considered.225,227–235,237,241 Capital costs were included in eight studies;226–228,236,238–241 in the other nine
studies, capital costs were not included.225,229–235,237
5. Were costs and consequences measured accurately in appropriate physical units?
All of the included studies measured costs and consequences accurately in appropriate physical units.225–241
None of the studies omitted identified items from its analysis. Only two of the included studies encountered
circumstances (joint use of resources) that made measurement of costs and consequences difficult.225,231
These circumstances were handled appropriately in the studies.
6. Were the costs and consequences valued credibly?
All of the included studies valued costs and consequences credibly and clearly identified the sources of all
values.225–241 Only one of these studies did not clearly identify the sources of all values.231 In only four of the
included studies was the valuation of consequences not appropriate for the question posed.231,234,236,240
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7. Were costs and consequences adjusted for differential timing?
In nine of the included studies, costs and consequences were adjusted for differential timing (and
discounted).226–230,234,235,237,241 In six studies, this was not applicable.225,231–233,236,240 In two studies, this was
not reported.238,239 Of the studies that applied discounting, only four did not provide any justification for
the discount rate used.226,227,229,234
8. Was an incremental analysis of costs and consequences of alternatives performed?
Only two of the included studies did not conduct an incremental analysis of the costs and consequences
of alternatives.234,236 Only one of these studies did not compare the additional costs generated by one
alternative over another with the additional effects, benefits or utilities generated.236
9. Was allowance made for uncertainty in the estimates of costs and consequences?
Only four of the included studies did not make any allowance for uncertainty in the estimates of costs
and consequences.228,231,236,240 Eight of the included studies performed appropriate statistical analysis on
stochastic data, meaning that the data incorporated in the model had a random probability distribution
and an appropriate PSA was conducted.225,227,229,230,232,235,238,241 Five studies did not perform appropriate
statistical analysis on stochastic data.228,231,233,236,240 In three studies this was not applicable as probabilistic
distributions were not assigned to the model data.234,237,239 Rather, these studies included a deterministic
SA only. In one study, this was not clear.226 Twelve studies provided justification for the range of values
used in SA.225–227,232–234,236–241 Five studies did not provide justification.228–231,234 In 13 studies, the study results
were sensitive to the change in values.225,227–230,232,233,235–237,239–241 In three studies, study results were not
sensitive to the change in values231,234,238 and in one study this was unclear.226
10. Did the presentation and discussion of study results include all issues of concern
to users?
Only in one of the included studies did the presentation and discussion of study results not include all
issues of concern to users.238 In 15 of the studies, the conclusions of the analysis were based on some
overall index or ratio of costs to consequences. 225–233,235–238,240,241 In one study, an overall index was not
presented239 and in one study this was not applicable.234 Only one of the included studies did not compare
their results with those of others who have investigated the same question.233 Eight studies discussed the
generalisability of the results to other settings and patient/client groups.226,231–235,237,239 In the other nine
studies, the authors did not discuss the generalisability of the results.225,227–230,236,238,240,241 Only one of the
included studies alluded to, or took account of, other important factors in the choice or decision under
consideration.241 Finally, none of the included studies discussed issues of implementation, such as the
feasibility of adopting the ‘preferred’ programme given existing financial or other constraints,
or whether or not any freed resources could be redeployed to other worthwhile programmes.
Limitations of identified model-based economic evaluations in informing
economic analysis
A total of 17 model-based economic evaluations were identified through the systematic review. All studies
were conducted among women with SUI or stress-predominant MUI and included at least one of the
surgical treatments for UI being evaluated in this study (as either a primary or a repeat surgery). However,
none of the models was sufficient for the analysis required for our own study.
First, the time horizons of the models identified were generally of insufficient length, with only one of the
included studies assessing costs and consequences over a lifetime time horizon.226 One study did report a
40-year time horizon, but even this would not be of sufficient length to capture the entire lifetime of all
patients being modelled in our own analysis (patient starting age, 45–55 years). The majority of studies
extended to a maximum time horizon of 10 years.
Second, only 11 of the identified studies were conducted as pure cost–utility analyses.225–230,233,235,237,238,241
Of these, only three used EQ-5D as a quality of life measure in their analysis (the measure proposed for
our own analysis).229,238,241 The other eight studies that conducted a cost–utility analysis did not report a
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quality of life measure and this was noted as a generally poorly reported feature among the studies
identified.225–228,230,233,235,237
Furthermore, very few studies had used appropriate utility weights estimated using tools like EQ-5D and the
Health Utilities Index227,229,233,235,241 for cured and incontinence health states in the economic models.227,235
Because the intended outcome of the surgical treatments is increased quality of life, estimating effectiveness
using an appropriate tool is essential for the estimation of actual treatment outcomes. Moreover, not all of
the studies had included complications in the models. Complication after surgical treatment is another
important factor that affects women’s quality of life, which highlights the importance of including major
complications in the calculations.
Finally, only one of the identified models did not omit important alternatives from their analysis.241 As highlighted
during the quality assessment, all other studies failed to include at least one important alternative.225–240
Given these limitations, and the information presented in this chapter, it was decided that a new economic
model needed to be developed to estimate the relative cost-effectiveness of the nine surgical interventions.
Summary
A systematic review of economic studies modelling the management of women with UI was conducted.
Specifically, the focus was on studies that included surgical treatments for SUI and stress-predominant
MUI. In total, 17 studies were included in the final review. All data of interest were extracted from these
studies, and studies were quality assessed using the Drummond checklist for economic evaluations.242
None of the identified studies was considered suitable for use in the economic evaluation component of
this study.
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Chapter 6 Development of a new
cost-effectiveness model
This chapter provides a detailed description of the modelling approach, the estimation of inputparameters used to populate the model and the key assumptions underpinning the cost-effectiveness
results. The results from the economic model are presented in two sections. In the first section, the results
of the economic model are presented. In the second section, results from a VOI analysis, which can be
used to aid decisions about the direction of further research, are presented (see Chapter 5, Summary).
The chapter concludes with a summary of the results for all comparators and of the factors deemed to be most
critical in affecting the cost-effectiveness of different surgical treatments for SUI and stress-predominant MUI.
Model overview
As seen in the review of model-based economic evaluations, no existing research has compared all the
relevant comparators. Therefore, a decision-analytic model was developed to evaluate the cost-effectiveness
of nine different surgical interventions for the treatment of women with SUI or stress-predominant MUI:
1. retropubic MUS
2. anterior vaginal repair
3. bladder neck needle suspension
4. open abdominal retropubic colposuspension (open colposuspension)
5. laparoscopic retropubic colposuspension (laparoscopic colposuspension)
6. traditional suburethral retropubic sling (traditional sling)
7. transobturator MUS
8. single-incision sling
9. periurethral bulking agents (urethral injection therapy).
The model is based on a hypothetical cohort of women (age range, 45–55 years) with either SUI (52%)
or stress-predominant MUI (48%).246 Health outcomes from the model were expressed in terms of QALYs, the
year of the cost data is 2016 and the currency is pound sterling (GBP). The costs were estimated from a NHS
and Personal Social Services (PSS) perspective. Both costs and QALYs were evaluated over 1-year, 10-year and
lifetime time horizons and discounted using a 3.5% annual discount rate.16 The expected cost and QALYs for
each of the strategies were estimated and compared using incremental cost-effectiveness ratios (ICERs) where
appropriate. The ICER represents the incremental cost per additional QALY associated with a more costly and
effective strategy. The ICER can be compared with thresholds used by NICE to establish value for money in
the NHS (i.e. £20,000–30,000 per additional QALY gained). These thresholds can be used to identify the
optimal strategy in terms of cost-effectiveness considerations, based on existing evidence.
The model is probabilistic, meaning that most of the input parameters were entered into the model as
probability distributions to reflect parameter uncertainty (i.e. uncertainty in the mean estimates). Monte
Carlo simulation was used to address the uncertainty in input parameters in such a way that the results of
the analysis can also be presented with their associated uncertainty.
Model structure
A Markov microsimulation (MM) model was developed to estimate the relative cost-effectiveness of the nine
surgical interventions. The MM model is a computer modelling technique that simulates an individual’s life
course from initial surgical treatment until death. Within the model, each person is represented by a record
containing a unique identifier and a set of associated attributes (e.g. age, disease condition). A set of rules
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(transition probabilities) and state rewards (cost and health state utility) are then applied based on these
characteristics. These rules may be deterministic or stochastic. The model applies all defined parameters and
rules to simulate the passage of an individual through the model. This is then repeated for each individual in
the cohort, thereby generating individual life histories for a specific population of women. The main reason
that a microsimulation model was used as opposed to a cohort-based Markov model was to overcome the
memorylessness of cohort-based Markov models. Building the MM model in TreeAge Pro® (TreeAge
Software, Inc., Williamstown, MA, USA) enabled us to keep track of simulated patients about their treatment
history and time since last treatment. Unfortunately, individual-level data were not available; therefore, we
assumed a uniform distribution for age groups (45–55 years) and women were randomly selected and
simulated within the model. In the model, 52% of the randomly selected women have SUI only, and are
modelled as receiving treatments for SUI only. However, some women with SUI may experience UUI as a
result of complications of surgical treatments for SUI, and these women receive UUI treatment as well. In
48% of random draws, women have MUI (SUI and UUI). Therefore, after receiving surgical treatments for
SUI they would receive three lines of treatment for UUI, which could be successful or unsuccessful.
The structure of the model is shown in Figure 4. We assumed a 3-month cycle length. The reason for this
assumption is that it will take between 3 and 6 months to determine if a procedure has worked and to
decide if further treatment if required.
The MM model incorporates both the temporal and the logical sequences of treatment, including the
events and complications that may happen after each procedure (e.g. pain), and the outcomes for the
woman associated with each possible scenario. Hypothetical individual women pass through the model
one at a time and are followed up until death. Treatment history for both SUI/stress-predominant MUI and
UUI was recorded for each simulated woman and used to define the woman’s transition to different
health states and treatment types. For example, if a woman with MUI is being simulated and she has
already received a first repeat surgery for SUI and second-line treatment for UUI, then in the event of a
recurrence of SUI or UUI she may only be given second repeat surgery for SUI or third-line treatment for
UUI, respectively. The model was developed in TreeAge Pro.
Initial surgery
ContainmentSUI cured and
no UUI
First SUI
retreatment
Second SUI
retreatment
Retreatment for SUI
UUI
UUI
first-line Tx
UUI
second-line Tx
Death
UUI
third-line Tx
FIGURE 4 Markov model structure. Tx, treatment.
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On entry into the model, a woman can have either SUI or MUI (based on the specified proportion of
women with SUI or MUI). Both groups of women will initially have one of the nine surgical treatments.
The surgical treatment is for SUI, but a woman may still need further treatment for symptoms of UUI,
which is a component of MUI, or develop UUI as a side effect of surgical treatment of SUI or the SUI
component of MUI. After initial surgery, a woman can move into one of the following five health states:
1. cured and no UUI (continent) by subjective measures
2. cured from SUI but UUI exists (UUI caused as a side effect of the initial surgery or because the woman
has MUI)
3. surgery fails to resolve the SUI but the woman proceeds to retreatment (as women can be offered a
second or third surgery if initial surgery fails)
4. permanent state of incontinence (containment) (e.g. resorting to containment management of their
incontinence by using pads)
5. death due to all-cause mortality or operation-related mortality, which can occur when a woman
is exposed to the risks of open surgery such as colposuspension or traditional sling procedures
(see Figure 4 and the detailed model structure in Appendix 19).
The model assumes that women can receive a maximum of three surgical treatments for treatment of
SUI/MUI, which includes the initial surgery and two subsequent retreatments. If all three surgeries fail then
the woman has to manage her symptoms using containment products. The model allows for individuals to
elect to move to containment treatments at any point after initial failure. Women with MUI who still have
UUI after successful treatment of SUI, or those who develop UUI owing to surgery, will receive three lines
of treatment including first-line (bladder training), second-line (drug, i.e. oxybutynin hydrochloride) and
third-line treatment (botulinum toxin type A).
Model inputs
In this section, the data required to populate the model are presented. Initially, clinical data are detailed.
The main clinical data required for the model were the success rates of the different interventions (i.e.
subjective cure rate), rates of retreatment and complications/adverse events and mortality rates, which
were mainly sourced from the review of clinical effectiveness (see Chapter 3) and supplemented with UK
data on mortality rates. Following on from this, information on resource use and unit costs utilised in the
model are presented. These data were primarily sourced from the review of previous economic evaluation,
supplemented by further information from the literature and UK databases. Finally, the utility data included
in the model are presented. All the utility values were sourced from the review of economic evaluations.
Relative effectiveness of surgical treatments
The relative effectiveness of surgical treatments, in terms of subjective cure rates, were based on the
results of the NMA reported in Chapter 3. Table 12 describes the mean and median ORs for different
surgical treatments versus retropubic MUS, which was taken to be the reference treatment. The reported
values for mean and median ORs were used to define log-normal distributions in the model.
Estimation of absolute cure rates
The absolute cure rates were calculated in the model by combining the information on relative cure rates
described in Table 13 with the absolute cure rates for retropubic MUS. The absolute cure rates at 1 year
for retropubic MUS were estimated to be 84%, based on a meta-analysis of retropubic MUS trials
(44 studies were included).
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To calculate the absolute probability of success for each surgical treatment, the OR of a given intervention
compared with the baseline treatment (retropubic MUS) was derived from the NMA. This figure was then
converted into a relative risk (RR) using the following formula:
Absolute risk = baseline risk × RR, (2)
where:
RR = OR / ½1−baseline risk + (baseline risk × OR). (3)
The RR for each treatment was then applied to the baseline risk247 to estimate the absolute probability of
success for each surgical treatment.
Transition probabilities
Because the comparative effectiveness of surgical treatments may wane/decline over time, an additional search
was conducted to identify studies on the long-term effectiveness (> 1 year) of the baseline intervention. After
extensive searching, very few data were identified on the long-term effectiveness of the baseline intervention.
Therefore, estimates used in the model were based on extrapolation of the available data.
Results from the review of clinical effectiveness data showed that there were six trials that had reported cure
rates at 2 years after retropubic MUS and three studies that had reported cure rates at 5 years. A meta-analysis
TABLE 12 Odds ratios of cure rates for surgical interventions compared with retropubic MUS
Treatment
OR
95% CrIMean Median
Transobturator MUS vs. retropubic MUS 0.742 0.738 0.588 to 0.923
Open colposuspension vs. retropubic MUS 0.874 0.853 0.544 to 1.325
Laparoscopic colposuspension vs. retropubic MUS 0.605 0.580 0.315 to 1.046
Traditional sling vs. retropubic MUS 1.106 1.061 0.623 to 1.846
Single-incision sling vs. retropubic MUS 0.511 0.504 0.360 to 0.699
Bladder neck needle suspension vs. retropubic MUS 0.368 0.340 0.154 to 0.745
Anterior vaginal repair vs. retropubic MUS 0.235 0.220 0.105 to 0.452
Laparoscopic colposuspension, laparoscopic retropubic colposuspension; open colposuspension, open abdominal retropubic
colposuspension; traditional sling, traditional suburethral retropubic sling.
TABLE 13 Estimation of absolute cure rate after retropubic MUS at different time points: results from meta-analysis
Time (months) Median 95% CrI
Number of
Studies Participants
6 0.776 0.175 to 0.983 17 908
12 0.841 0.214 to 0.990 44 2882
24 0.784 0.454 to 0.941 6 315
36 0.341 0.001 to 0.995 5 205
60 0.329 0.005 to 0.979 3 377
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was conducted on each set of studies. Table 13 shows the absolute probabilities for retropubic MUS at
different time points along with the number of studies and participants. The probability that participants are
cured at 6, 12, 24, 36 and 60 months are 78%, 84%, 78%, 87% and 68%, respectively. For 24, 36 and
60 months, there are considerably fewer studies and participants than for the other time points.
The long-term recurrence rates after retropubic MUS were used to estimate long-term recurrence rates
for surgical treatments using a parametric survival model from the data reported in Table 14. Parametric methods
are commonly used to extrapolate survival times beyond the duration of the studies. These methods assume that
recurrence rates for women follow a given theoretical distribution, such as Weibull, exponential and log-normal.
Scale and shape parameters were estimated for a Weibull distribution using the reported cure rates.
This distribution was chosen because it was felt to provide a reasonable representation of the estimated
long-term recurrence rates and has been used in a previous study.241 The scale parameter (λ) describes the
probability that the woman becomes incontinent during the next cycle of the model, given that she is
continent during the current time period. The shape parameter (γ) describes the hazard function of the
Weibull function for the survival time. The hazard function for Weibull survival time could be increasing or
decreasing with time, depending on the value of the parameter. If the shape parameter is < 1, the hazard
decreases with time, and if the value is > 1, the hazard rate increases with time. If the shape parameter is
equal to 1, the Weibull distribution is equivalent to an exponential distribution.
To estimate alternative values to explore in SA, the long-term recurrence rates of retropubic MUS were derived
using the long-term cure rates of a trial conducted in the UK comparing TVT with Burch colposuspension,248
which provides an optimistic estimate of cure rates after retropubic MUS and has been used in a previous
study, which included an economic evaluation of non-surgical and surgical treatments for SUI in the UK.241
In the trial, the data from reported cure rates for ≤ 5 years were used to estimate longer-term recurrence
rates using a Weibull survival model. In addition, we derived data from the study with the longest follow-up,
which was conducted by Song et al,249 in which the reported cure rates at 1 year and 13 years were 78%
and 67.5%, respectively, to estimate long-term cure rates after retropubic MUS.
The following survival hazard formula was used:
S(t) = exp(–λtγ), (4)
where S(t) is the probability of cure, t is time (measured in terms of the number of cycles, where each cycle is
equivalent to 3 months), λ is the scale parameter (which describes the probability that the woman becomes
incontinent during the next time period, given that she is continent during the current time period) and γ is
the shape parameter (which describes the hazard function of the Weibull function for the survival time).
It was assumed that proportional hazards stand; therefore, the transition probabilities for other surgical
treatments were estimated by combining the respective RR and long-term probabilities for retropubic MUS
(Figure 5).
TABLE 14 Long-term cure rates after retropubic MUS used for extrapolation
Scenario Time (years) Cure rate (%) Source
Parameter
Scale (λ) Shape (γ)
Base-case analysis 1 84.0 Meta-analysis 0.08799444 0.4932644
2 78.4
Ward et al.248 1 85.0 Ward et al.248 0.1969761 0.12368398
5 80.0
Song et al.249 1 78.0 Ward et al.248 0.19391258 0.1788069
13 67.5
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FIGURE 5 Extrapolated long-term cure rates after retropubic MUS surgery. Note that each cycle is 3 months long.
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Because urethral injection therapy was not included in the NMA, the estimated short-term and long-term
cure rates were obtained from a study by Ghoniem and Miller.250 They performed a systematic review and
meta-analysis to investigate the safety and effectiveness of silicon particles (Macroplastique®; Cogentix
Medical, Inc, Orangeburg, NY, USA) for women with SUI (958 women from 23 cohorts were analysed).
The cure rates were 43% (95% CI 33 to 54) in the short-term (< 6 months), 37% (95% CI 28 to 46)
in the mid-term (6–18 months) and 36% (95% CI 27 to 46) in the long-term (> 18 months). Their
meta-analysis suggested that long-term therapeutic benefit was frequently maintained. Cure rates in the
short- and long-term were used to estimate longer-term success rates using Weibull survival models.102
The parameters for the Weibull hazard functions for the cure rates are presented in Table 15 and cure
rates are presented in Figure 6.
Repeat surgery
Because data from HES for England in 2013–14 and data for hospital discharge in Scotland in 1996–2014
show that around 91% to 96% of SUI surgeries were for MUS (retropubic, 55%; transobturator, 45%),
and given that, from a clinical point of view, MUS (either retropubic or transobturator) can be offered after
all types of surgery, it was assumed that all subsequent surgeries were either retropubic MUS (55%) or
transobturator MUS (45%).251 Owing to data limitations, subgroup analysis was not conducted to explore
success rates after repeat surgery (after failed previous continence surgery) versus primary procedures.
Therefore, it was assumed in the model that repeated MUS surgeries after failed primary surgeries are
almost as effective as primary MUS surgeries, based on the finding from Kociszewski et al.252 Kociszewski
et al.252 showed that 96% of women after primary sling implantation, and 88.46% of women after
repeated sling, were dry at 6 months. The difference in percentage of negative pad test after primary
and repeated procedure was not statistically significant. However, some previous studies show a lower
success rate for retreatment with the same procedure. For example, Black and Downs253 showed that
retreatment colposuspension was 78.4% less effective on average than primary colposuspension.
Therefore, we tested two scenarios: in the first scenario it was assumed that subsequent surgeries
(retropubic and transobturator MUS) are 90% as effective as they would have been as a primary surgery,
and in the second scenario it was assumed that the subsequent surgeries are 75% as effective as primary
retropubic and transobturator MUS.
Long-term repeat surgery rates estimation
To estimate the rate at which women choose to remain incontinent rather than seek retreatment in the
model, individual-level data from a previous study was obtained.254 In brief, the study used data from
Aberdeen Maternity and Neonatal Databank (AMND) to estimate the lifetime risk of undergoing pelvic
floor surgery in a cohort of UK parous women. The AMND stores linked information on all obstetric-
related events occurring in women living in Aberdeen city and district since 1950 and currently contains
data for approximately 200,000 women. Within the cohort of women, 762 (2.2%) had an operation for
UI. We utilised this subset of data to estimate the risk of reoperation over time after different types of SUI
surgeries. We excluded 11 women who had urogenital fistula repair surgery as it is not a SUI procedure.
We analysed 751 cases that had SUI surgery. The number of women with one, two, three and four
surgeries for each type of surgery are reported in Appendix 20. As some of the surgical treatments are no
longer popular, this dataset was used because it contains data for those surgical treatments.
TABLE 15 Weibull hazard function parameters for estimation of long term cure rates after urethral
injection therapy
Weibull parameters
Cure rate
Lower limit Mean Upper limit
Lambda 1.020173 0.767078 0.548895
Gamma 0.120006 0.137820 0.166837
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FIGURE 6 Extrapolated long-term cure rates after urethral injection therapy. Note that each cycle is 3 months long. LL, lower limit; UL, upper limit.
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These data were analysed to estimate the rate at which women chose to remain incontinent rather than
seek retreatment in the model. Parametric methods were used to extrapolate survival times beyond the
follow-up duration in the data. We analysed the data using graphical exploration and statistical criteria of
goodness of fit. First, Kaplan–Meier curves and survival, hazard and other related functions were examined
graphically. The exponential, Gompertz, log-logistic, Weibull and log-normal distributions were fitted to the
data and their fit was assessed visually and compared using statistical criteria based on log-likelihood, the
Akaike information criterion (AIC) and the Bayesian information criterion (BIC); the model with the lowest
AIC and BIC is preferred.255 A log-normal distribution was applied to estimate the long-term rates of repeat
surgery based on the AIC and BIC criteria. All fitted and observed survival data for different types of SUI
surgeries are presented in Appendix 20.
Finally, the rate at which women choose to remain incontinent rather than seek retreatment was estimated
based on the estimated cure rates and estimated repeat surgery rates at each time point. For example,
if 1-year cure and repeat surgery rates after a particular surgery were 80% and 10%, respectively, the
following formula was used to estimate the proportion of women who seek a second treatment following
failure of the first treatment:
Proportion = Prt / (1 – pcure) = >10%/ (1–80%) = 50%, (5)
where Prt is the probability of having repeat surgery after a given surgery at time t and pcure is the
probability of a surgery still being successful at time t.
The observed repeat surgery rates were compared with data from the included RCTs and pairwise meta-
analysis results for repeat surgery rates after different surgical treatments. We felt that the observed repeat
surgery rates were underestimating the actual rates. For example, results from the analysis show that the
rate of repeat surgery after anterior vaginal repair (colporrhaphy) in 2 years is about 3%, whereas data
from two trials show that the rate is ranging from 26.0% to 37.5%.194,196 Therefore, in the base-case
analysis it was assumed that (based on the data from previous assessment of surgical treatments for SUI)
75% of women whose first treatment was not successful would seek retreatment and 30% of women
whose first retreatment failed would seek second retreatment in the base-case analysis.256 We used the
results from the analysis of AMND data in the SA to inform the model in terms of the proportion of
women who will seek retreatment after failure of first surgery.
Complication rates after surgical treatments
There are different types of complications that can happen after each surgical treatment. The model
incorporates only severe complications/adverse events that are important in terms of their effect on women’s
quality of life, the cost and duration of treatments and data availability. To estimate complication incidence
rates, random-effect meta-analysis models were fitted using WinBUGS software.33 A Bayesian approach
was used to combine existing knowledge with prior information based on established rules of probability.
We checked the convergence of the model in different number of iterations; 50,000 Markov chain Monte
Carlo iterations after a burn-in period of 20,000 iterations was chosen to get posterior distributions. The
convergence was checked graphically using trace and autocorrelation plots. All the complications included
in the model, and estimated incidence rates, are presented in Table 16. The estimated incidence rates were
defined as distributions in the economic model (beta distribution). Lastly, the rates were used to estimate
health-care costs and utility decrements associated with each treatment (see Resource use and unit costs and
Health utility for more details).
All-cause mortality rates
In the model, women were at risk of death (from any cause) during any given cycle period. The cycle-specific
risk of mortality was dependent on the simulated woman’s age. The risk of mortality will therefore increase
with each cycle period (the ‘all-cause ageing effect’). Age-specific all-cause mortality rates were derived from
general population mortality statistics reported in national life tables (Office for National Statistics).232 The
model incorporated the risk of operation-related death also. A rate of 0.0005 has been applied for open
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TABLE 16 Complications incidence rates after different surgical treatments (results from random-effect meta-analysis)
Surgery
Complication (%), mean (SD)
Infection
De novo symptoms
of urgency or UI
Voiding difficulties
including urinary
retention
Bladder or urethral
perforation
Tape/mesh erosion/
extrusion/exposure
Short-term
pain
Persistent pain
or discomfort
Anterior vaginal repair NA 15.84 (11.83) 0.01 (0.15) NA NA NA NA
Bladder neck needle suspension NA 8.14 (4.87) 1.67 (2.61) NA NA 57.64 (30.08) NA
Open colposuspension 24.33 (21.82) 5.78 (1.15) 3.00 (1.04) 1.02 (0.50) 0.0 (NA) 20.94 (25.65) 0.15 (2.58)
Laparoscopic colposuspension NA 8.38 (3.98) 6.32 (2.35) 2.10 (1.22) 0.0 (NA) NA NA
Traditional sling 14.85 (12.49) 7.85 (3.23) 11.63 (3.60) 1.82 (1.11) 0.17 (0.34) 28.99 (28.12) 7.00 (8.98)
Retropubic MUS 3.91 (4.72) 4.30 (0.66) 6.75 (0.95) 4.89 (0.50) 1.40 (0.31) 4.36 (1.14) 5.09 (2.37)
Transobturator MUS 2.84 (1.03) 5.31 (0.51) 2.88 (0.44) 5.13 (0.50) 2.08 (0.26) 7.04 (2.08) 4.93 (1.22)
Single-incision sling 3.22 (1.20) 6.47 (0.81) 2.15 (0.45) 0.37 (0.18) 2.38 (0.55) 4.54 (3.21) 1.28 (1.39)
Urethral injection therapy 17.94 (24.59) 17.94 (24.59) 11.47 (20.70) NA NA NA NA
Laparoscopic colposuspension, laparoscopic retropubic colposuspension; NA, not available; open colposuspension, open abdominal retropubic colposuspension; traditional sling, traditional
suburethral retropubic sling procedure.
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surgeries in previous studies241,256 based on the results from a report by Leach et al.257 In addition, a recent
study showed that urethral injection therapy had a higher mortality rate than open colposuspension
[adjusted incidence rate ratio (IRR) 1.98, 95% CI 1.36 to 2.91]. They also showed retropubic MUS had a
lower mortality rate than open colposuspension251 (adjusted IRR 0.65, 95% CI 0.44 to 0.96).
Clinical inputs for effectiveness of urge incontinence treatments
For those women with MUI who have UUI following surgery for SUI, or those SUI women who develop
de novo UUI after surgery for SUI, three lines of treatment were assumed. Although it is possible to get
more than three types of treatment for UUI, to simplify the model only three types of treatment were
incorporated:
1. first-line treatment: bladder training
2. second-line treatment: anticholinergics drugs (oxybutynin hydrochloride)
3. third-line treatment: botulinum toxin type A.
The results from a systematic review undertaken by Lee et al.258 showed that the efficacy of bladder
training on symptoms of urgency ranges from 12% to 90%. In the base-case analysis, a 32% cure rate
after bladder training was assumed.
The results from another NMA, which was conducted recently, showed that the absolute probability of being
continent at 12 weeks after oxybutynin hydrochloride treatment is 21%.259 Oxybutynin hydrochloride (5 mg
twice daily) was used as an index second-line treatment. After 3 months, probabilities were assumed to be
constant, which is consistent with the evidence from a long-term study suggesting that the treatment effect
of antimuscarinic therapy at 4 months is maintained to 24 months.260 Failure rates after botulinum toxin type
A treatment at different time points were obtained from a previous economic evaluation that was conducted
within the development of clinical guidelines for UI.259 It was assumed that the cure rate at 6 months using
botulinum toxin type A is 36%.259
Resource use and unit costs
As mentioned in Model overview, the analysis was undertaken from a NHS and PSS perspective. Information
on the precise description of resources required for each individual surgical treatment was based partially
on data derived from the review of economic modelling studies, augmented where necessary by clinical
experts in the study group and published economic literature. Unit costs were taken from appropriate
routine sources, such as NHS Reference Costs,261 the Personal Social Services Research Unit (PSSRU)262
and the most recent British National Formulary (BNF)263 for medication.
Surgery costs
Surgeries for SUI and stress-predominant MUI vary in terms of the complexity of the procedure and the
setting in which surgery would be conducted. For women undergoing anterior vaginal repair, bladder neck
needle suspension, open colposuspension, laparoscopic colposuspension and traditional sling procedures,
surgery would typically be conducted in an inpatient setting, based on expert clinical input. Women
undergoing retropubic MUS and transobturator MUS procedures would typically be treated in a day case
setting, based on expert clinical input. Costs for each of these individual surgeries were derived from NHS
Reference Costs 2015/16.261 Finally, both single-incision sling procedures and urethral injection therapy
would be conducted in a day case setting, on the basis of clinical advice. No appropriate NHS reference
costs were identified for these procedures and, therefore, costs for both of these surgeries were derived
from previous literature, with costs inflated to a 2015/16 price year using the hospital and community
health services (HCHS) index listed in the Unit Costs of Health and Social Care 2016.262 The cost of each
surgery is presented in Table 17.
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TABLE 17 Cost inputs
Resources Cost (£) Source HRG code
Type of surgery
Anterior vaginal repair 2236.50 NHS Reference Costs
2015/16261
MA04C/D: intermediate
open lower genital tract
procedures – elective
inpatient
Bladder neck needle
suspension
1819.72 NHS Reference Costs
2015/16261
LB26A/B: intermediate
endoscopic, prostate or
bladder neck procedures –
elective inpatient
Open colposuspension 3909.55 NHS Reference Costs
2015/16261
LB59Z: major, open or
laparoscopic bladder neck
procedures – elective
inpatient
Laparoscopic
colposuspension
3909.55 NHS Reference Costs
2015/16261
LB59Z: major, open or
laparoscopic bladder neck
procedures – elective
inpatient
Traditional sling 1924.32 NHS Reference Costs
2015/16261
LB51A/B: vaginal tape
operations for UI – elective
inpatient
Retropubic MUS 1351.10 NHS Reference Costs
2015/16261
LB51A/B: vaginal tape
operations for UI – day
case
Transobturator MUS 1351.10 NHS Reference Costs
2015/16261
LB51A/B: vaginal tape
operations for UI – day
case
Single-incision sling 1040.54 Boyers et al.264 N/A
Urethral injection therapy 1820.29 Kilonzo et al.229 N/A
Additional resource use associated with surgery
Incontinence pads 106.20 (3-month cost
estimate)
NICE guidance
document214
N/A
Urodynamic test 155.00 NHS Reference Costs
2015/16261
N/A
Consultation pre surgery
(20-minute consultation
with surgical consultant)
46.00 PSSRU’s Unit Costs of
Health and Social
Care, 2016262
N/A
Urine dipstick analysis 3.94 NICE clinical
guidelines214
N/A
Full blood count 6.31 NICE clinical
guidelines214
N/A
Diagnostic flexible
cystoscopy
152.00 NHS Reference Costs
2015/16261
LB72A: diagnostic flexible
cystoscopy
500 mg of paracetamol
(AAH Pharmaceuticals
Ltd) × 32
0.16 (daily cost based on a
recommended dose of 4 g
a day)
BNF, 2016263 N/A
10g/15 ml of lactulose
(AAH Pharmaceuticals
Ltd) × 10 sachets
0.50 (daily cost based on a
recommended dose of
15 ml twice a day)
BNF, 2016263 N/A
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Additional costs associated with surgery
In addition to the cost of individual surgeries, costs associated with complementary tests, treatments and
consultations that would typically be carried out in advance of, and following, each surgery were also
considered. Clinical experts advised that women undergoing surgery for SUI and stress-predominant MUI
would typically use incontinence pads until their condition had been resolved. The weekly cost of pads was
estimated from a NICE guidance document214 with costs based on a guidance development group opinion
on estimated pad usage per week. Costs reported were inflated to the current price year and converted
to a 3-monthly cost to fit the model time cycle. Clinical experts advised that a urodynamic test would be
conducted in a separate consultation before each surgery, and that the woman would also have a
separate 20-minute consultation before undergoing surgery with the clinician carrying out the surgery.
Costs for test and consultation were derived from NHS Reference Costs 2015/16261 and PSSRU 2016262
respectively.
TABLE 17 Cost inputs (continued )
Resources Cost (£) Source HRG code
Urge incontinence treatment
Bladder training 97.81 (3-month cost
estimate)
Appendices of NICE
guidelines214
N/A
Band 6 hospital-based
physiotherapist
consultation (1-hour
consultation)
45.00 PSSRU 2016262 N/A
5mg of oxybutynin
hydrochloride (AAH
Pharmaceuticals Ltd) × 56
0.05 (daily cost based on a
recommended dose of
5 mg twice a day)
BNF 2016263 N/A
Consultant-led non-admitted
follow-up face-to-face
attendance in urology
100.00 NHS Reference Costs
2015/16261
N/A
Intermediate endoscopic
bladder procedure (day case)
971.00 NHS Reference Costs
2015/16261
N/A
Botulinum toxin type A
100-unit powder for
solution for injection vials
(Allergan Ltd)
138.20 BNF 2016263 N/A
Adverse event treatment
250/125mg of
co-amoxiclav (AAH
Pharmaceuticals Ltd) × 21
0.27 (daily cost based on a
recommended dose of
250/125 mg every 8 hours)
BNF 2016263 N/A
Attention to bladder
catheter (outpatient,
urology)
123.00 NHS Reference Costs
2015/16261
N/A
Self-catheterisation 6.20 (daily cost based on
4 catheters required per day)
NICE guidance
document214
N/A
Mesh excision or repair 1316.85 NHS Reference Costs
2015/16261
MA04: intermediate
open lower genital tract
procedures – day case
300 mg of aspirin (AAH
Pharmaceuticals Ltd) × 28
0.40 (daily cost based on
a recommended dose of
300 mg every 6 hours)
BNF 2016263 N/A
HRG, Healthcare Resource Group; N/A, not applicable.
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Clinical experts involved in the study advised that a urine dipstick analysis and full blood count would
need to be taken prior to each surgery, excluding injectable agent procedures, for which only a urine
dipstick analysis would be required. Costs for both were obtained from NICE clinical guidelines for
routine pre-operative tests for elective surgery.214 In addition, it was advised that a cystoscopy on the
day of the procedure would be mandatory for women undergoing a retropubic MUS or transobturator
MUS procedure. The cost of a diagnostic flexible cystoscopy in an outpatient setting was obtained from
NHS Reference Costs 2015/16.261 Finally, the cost of medication needed for pain relief post surgery
(paracetamol) was considered, with the duration of pain relief required greater for inpatient procedures
(7 days) than for the less invasive day case procedures (3 days). It was also advised that lactulose would be
taken as pain relief for 1 day following anterior vaginal repair only. Costs of medication were obtained
from the BNF 2016.263 All additional costs are reported in Table 17. Omitting the cost of incontinence
pads, which are used by all women with incontinence regardless of the type of initial surgery, the
total additional costs associated with anterior vaginal repair, bladder neck needle suspension, open
colposuspension, laparoscopic colposuspension, traditional sling, retropubic MUS, transobturator MUS,
single-incision sling and urethral injection therapy were £212.87, £212.37, £212.37, £212.37, £212.37,
£363.73, £363.73, £211.73 and £205.42, respectively.
Urge urinary incontinence costs
As well as the cost of surgical treatments for SUI and stress-predominant MUI, the costs associated
with treatment for UUI were also considered. The NICE clinical guidelines on the management of urge
incontinence recommend three broad lines of treatment for women with this type of incontinence:214
1. conservative measures such as bladder training
2. antimuscarinic drugs, most typically oxybutynin hydrochloride
3. invasive therapy such as botulinum toxin type A.
This treatment pathway was confirmed by clinical experts in the study team. The cost of bladder training
was obtained from the appendices of a NICE draft for consultation on guidelines for UI in women.214 Costs
reported in this document were based on women being seen 5 times over a 4-month period (i.e. initial
consultation and once in each of the 4 months). To estimate 3-monthly bladder training costs to fit the
model time cycle, it was assumed that the woman would have an initial consultation with a band 6
hospital-based physiotherapist and would be seen for training once in each of the 3 months. The cost of a
consultation was based on data obtained from PSSRU 2016.262 The cost of consumables required during
training were obtained directly from the guidelines214 and were also included in the estimate. These costs
were inflated to the current price year using the HCHS index listed in PSSRU 2016.262
Antimuscarinic medication taken was assumed to be oxybutynin hydrochloride, on the basis of
recommendations from the clinical guidelines214 and expert clinical advice. Appropriate costs were obtained
from the BNF 2016.263 Additionally, it was assumed that the woman would require a consultation with a
specialist before beginning medication, and this cost was based on the average unit cost of a consultant-led
non-admitted face-to-face follow-up attendance in urology, obtained from NHS Reference Costs 2015/16.261
Cost of medication was estimated for 3 months. Finally, the cost of a botulinum toxin type A procedures was
based on micro-costing details presented in a NICE draft for consultation on guidelines for UI in women.214
Included in this overall procedure cost was the cost of an intermediate endoscopic bladder procedure (day
case) and the cost of botulinum toxin type A 100-unit powder for solution for injection vials. These costs
were obtained from NHS Reference Costs 2015/16261 and the BNF 2016,263 respectively. Additionally, it was
assumed that the woman would require a consultation with a specialist before undergoing a botulinum
toxin type A procedure, and this cost was based on the average unit cost of a consultant-led non-admitted
face-to-face follow-up attendance in urology, obtained from NHS Reference Costs 2015/16.261 Costs of urge
incontinence treatments are reported in Table 17.
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Adverse events treatment costs
The cost of treating complications associated with surgical treatments was also considered in the model.
Typical treatments were informed by expert clinical advice and costs were obtained through routine
sources. The cost of treating an infection was based on the cost (obtained from the BNF 2016263) of
co-amoxiclav antibiotic medication over a 2-week period (advised duration of infection). It was advised
that women experiencing voiding difficulties (including urinary retention), or bladder or urethral
perforation, would require catheterisation. This cost was based on the cost, obtained from NHS Reference
Costs 2015/16,261 of a bladder catheter procedure in an out-patient setting. As voiding difficulties may
impact the woman for up to 3 months, the cost of self-catheterisation over this period was also estimated.
For a bladder injury the cost of a suprapubic bladder catheter procedure in an out-patient setting was
applied, as well as the cost of self-catheterisation over a 12-day period (based on expert clinical advice).
The cost of a single catheter was obtained from the NICE draft for consultation on guidelines for UI in
women214 and inflated to the 2016 price. It was assumed that the woman would require four catheters per
day, based on data presented in the NICE guidelines.214
The cost of a mesh excision or repair to treat mesh erosion was based on the cost of a partial removal of
TVT [HRG (Healthcare Resource Group) code MA04: intermediate open lower genital tract procedures –
day case], obtained from NHS Reference Costs 2015/16.261 Based on the reference cost schedule, a
relatively small percentage (16%) of these procedures will be major procedures. The intermediate option
was chosen, reflecting that the greatest percentage of procedures are intermediate. The cost difference
between the major and intermediate procedure is in the region of £200. This was assumed to be a
one-off cost. It was advised that persistent pain would typically be treated through the use of non-steroidal
anti-inflammatory drugs. For the purpose of this costing, medication taken for pain was assumed to be
aspirin (based on expert clinical advice) and relevant costs were obtained from the BNF 2016.263 The
estimated incidence rates for each complication were used to estimate cost associated with complications
after each surgical treatment by multiplying respective incidence rates by the cost of each complication.
All costs associated with treating adverse events are reported in Table 17.
Health utility
The identified papers from the review of economic evaluation studies were screened specifically for utility
estimates for women with SUI, stress-predominant MUI and UUI. The focus of the screening was to identify
studies (economic evaluations or otherwise) that included populations of these women and were conducted
in the UK (or elsewhere but included a UK-based subpopulation or population that was generalisable to a
UK population). The baseline value for pretreatment SUI was derived from a previous UK-based economic
evaluation comparing two types of surgical intervention for this condition.244 The utility value for a successful
treatment was derived from a UK-based study exploring health outcomes in women with UI.245 This study
was also used to estimate the utility values for health states following failed surgical treatment (Table 18).
The same data were used to inform the utility weights in two previous studies of surgical and non-surgical
treatment of SUI in the UK.85,241
The availability of utility values for outcomes and complications of surgical treatment for SUI, stress-
predominant MUI and UUI were sparse. Only one study identified through the review of economic
evaluation studies had reported appropriate utility data related to adverse events, conducted by Shepherd
et al.265 Owing to the unavailability of utility values for complications related to surgery, values in Shepherd
et al.’s study were assigned by an expert panel of six urogynecologists by matching complications included
in the model to published data on similar conditions in different groups of women. This study was used to
derive utility values for all adverse events included in the model. Utility decrements for all adverse events
included in the model, as well as their duration in the economic model, are presented in Table 18. In the
model, utility decrements were assigned only to the proportion of the woman population experiencing
that complication for the duration each complication was expected to last.
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Main modelling assumptions
l As data from HES for England in 2013–14, and data for hospital discharge in Scotland in 1996–2014,
showed that around 91% and 96% of SUI surgeries were MUS procedures (retropubic MUS, 55%;
transobturator MUS, 45%), and given that, from a clinical point of view, MUS can be offered after all
types of surgeries, it was assumed that all subsequent surgeries are either retropubic MUS or
transobturator MUS.
l No further conservative (i.e. PFMT, medication or lifestyle change) management of SUI were considered
as a comparator, or within the treatment pathway, after surgery.
l It was assumed that all women in containment, retreatment and urge incontinence states will use
containment products.
l For women with MUI, and those who develop UUI after surgical treatments for SUI, first-line treatment
of UUI (bladder training) will be offered, and if the first line treatment fails they will be offered second-
line treatment (drug, i.e. oxybutynin hydrochloride). In the event that second-line treatment fails, they
will be offered third-line treatment (botulinum toxin type A) for UUI. We appreciate that there are
multiple options for treating UUI, but for reasons of simplification we have used the most common
treatments for UUI.
l SUI and UUI are modelled independently, meaning that any treatment that has been received for SUI
will not affect the effectiveness of UUI treatment and vice versa.
l It was assumed that the time interval between initial surgery and any subsequent surgery for SUI is
1 year. The reason behind this assumption is that it will take up to 1 year to find out about results from
surgical treatments and to decide if further surgery is required.
l It was assumed that the time interval between first-line treatment for UUI and any subsequent
treatment is 3 months.
l The model assumes that women can receive a total of three treatments, which includes the initial
surgery plus two subsequent repeat surgeries, if required.
l Utility decrements associated with complications were incorporated based on their duration, utility
decrement weights and respective incidence rates.
TABLE 18 Utility values for different health states and utility decrement associated with complications
EQ-5D Utility value Source Duration
SUI pretreatment 0.78 Manca et al.244 Variable
Mixed pretreatment 0.78 Manca et al.244 Variable
Cured from SUI and no urge UI 0.85 Haywood et al.245 Variable
UUI 0.74 Haywood et al.245 Variable
Pure SUI retreatment 0.74 Haywood et al.245 Variable
Mixed retreatment 0.74 Haywood et al.245 Variable
SUI failure of treatment (containment) 0.74 Haywood et al.245 Variable
Mixed failure of treatment (containment) 0.74 Haywood et al.245 Variable
Adverse event Utility decrement Source Duration
Infection –0.19 Shepherd et al.265 2 weeks
Voiding difficulties (long term) –0.23 Shepherd et al.265 3 months
Bladder/urethral perforation –0.08 Shepherd et al.265 2 weeks
Tape/mesh exposure/erosion –0.25 Shepherd et al.265 3 months
Short-term pain –0.25 Shepherd et al.265 2 weeks
Persistent pain –0.25 Shepherd et al.265 6 months
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Incremental cost-effectiveness analysis
The joint estimates of costs and effects were combined in an incremental analysis, and presented in terms
of the mean ICER for each comparator. The ICERs were calculated as the difference in costs divided by the
difference in effects (QALYs) between treatment options. The ICERs were calculated for each successive
alternative, from the least to the most costly. To help identify the optimal approach, the net monetary
benefit (NMB) framework was used, where the NMB for a given strategy is equal to the accrued QALYs
multiplied by the ceiling ratio (CR) of willingness to pay (WTP) per QALY, minus the strategy costs:
NMB = (QALYs × CR) – costs. (6)
The value of £20,000, which is typically used by NICE as a threshold to inform judgements on
cost-effectiveness, was placed on the CR.16 The threshold means NICE is prepared to pay £20,000 for
each extra QALY gained through different interventions. Measures of variance for the joint incremental
costs and effects were obtained using Monte Carlo simulation within the PSA and presented graphically
using cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs).
Sensitivity analyses
Both deterministic SA and, as noted above, PSA were used to explore parameter and other forms of
uncertainty surrounding estimates of cost-effectiveness. Deterministic sensitivity analyses were performed
to determine the impact of changing key parameters on the model results. Therefore, many of the
model parameters were subject to one- and two-way sensitivity analyses, using hypothetical increases or
decreases, to determine the key drivers of the model results. Deterministic sensitivity analyses were also
carried out to test for the effect of assumptions and variability. These analyses are described in this section.
When available, data were also entered into the model as distributions to fully incorporate the uncertainty
around parameter values so that a PSA could be undertaken. In decision modelling, many of the parameter
values are often estimated with a degree of uncertainty. The probabilistic distribution for each parameter was
defined by considering the mean, standard error and anticipated shape of the distribution. The PSA was run
with 10,000 simulations for each woman, and CEACs were produced to identify the probability of the
different surgeries being cost-effective across a range of WTP thresholds. Estimation of costs and QALYs
were calculated as the expectation over the joint distribution of the parameters. This quantification of
decision uncertainty also provided the starting point for assessing the value of additional research.
This section details the technical specification of the sensitivity analyses conducted.
Applying higher incidence rates of mesh complications after mid-urethral
sling procedures
As mentioned in the methods section, data from the trials were used to estimate the complications incidence
rates after each surgical treatment. As some of the complications may happen over the longer term, and
given that the trials are short in terms of the follow-up time, results from a very recent study on MUS were
used to estimate the mesh complication incidence rates after retropubic MUS and transobturator MUS in the
model. Keltie et al.266 conducted a study to investigate the rate of adverse events after MUS procedures using
data from the HES database. The mean follow-up time was 4.2 years (unconfounded cohort). They showed
that the readmissions for further surgery after initial retropubic MUS and transobturator MUS were 3.7%
[removal (2.7%), repair (1%), renewal (0%)] and 2.8% [removal (1.9%), repair (0.9%), renewal (0%)],
respectively. These values were used within the SA for retropubic MUS and transobturator MUS. In addition,
we explored the effect of assuming both a 10% and a 20% incidence rate of mesh complications both after
retropubic MUS and after transobturator MUS on the results.
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Incorporating longer duration for persistent pain complication
In the base-case analysis, it was assumed that persistent pain complication will last for, on average,
6 months. In this SA, the effect of longer-term suffering from persistent pain was explored: we tested
scenarios in which women suffer for 3 years and women suffer for 5 years.
Applying higher incidence rates of persistent pain after mid-urethral sling procedures
In the base-case analysis, it was assumed that the incidence rate for persistent pain complication after
retropubic MUS and transobturator MUS are 5.09% and 4.93%, respectively, based on the results from
meta-analysis. In these sensitivity analyses, the effect of higher incidence rates of persistent pain (10% and
20%) after MUS procedures was explored.
Applying higher incidence rates and longer duration for persistent pain after
mid-urethral sling procedures
A scenario analysis was also conducted by incorporating higher incidence rates of persistent pain after MUS
procedures and longer duration. It was assumed that the incidence rates for persistent pain complication
after retropubic MUS and transobturator MUS are 20% and that, on average, women with persistent pain
will suffer for 5 years.
Assuming that all the women in the model have stress urinary incontinence
A SA was performed to investigate the disease type of women in the model. Owing to data limitations, it
was not possible to do a full subgroup analysis and estimate different success rates for two subpopulations
(i.e. women with SUI and women with MUI). In this SA it was assumed that all the women in the model
have SUI and the success rates are the same as the base-case analysis.
Assuming alternative values for the proportion of women who will seek retreatment
after failure of each surgical treatment
In the base-case analysis, it was assumed that 75% of women whose first treatment was not successful
would seek retreatment and 30% of women whose first retreatment failed would seek second
retreatment. This SA was conducted to explore results using data from the linked database (AMND) to
estimate the proportion of women who will seek retreatment after failure of each surgical treatment.
As mentioned in the methods section, primary data from linked databases were analysed to estimate repeat
surgery incidence rates over time and were then used to estimate the proportion of women who will seek
retreatment after failure of the previous surgery. Because the linked database may not be complete, the
health economists felt that the rates of repeat surgery were underestimated. In this SA, the method described
in Repeat surgery was used to estimate the proportion of women who will seek retreatment. In addition, in
this SA lower probabilities of repeat surgeries (50% and 10% for first retreatment and 20% and 0% for
second retreatment) were explored.
Applying different values for short- and long-term success rates after retropubic
mid-urethral sling
As indicated in the estimation of model probabilities, the short-term and long-term cure rates after retropubic
MUS were estimated using a random-effects meta-analysis. There are some uncertainties associated with
these estimates and it is probable that these values are either an overestimate or an underestimate because
of small sample size. We have explored the effect of using two different sources of data (Ward et al.248 and
Song et al.249) for extrapolation of long-term success rate after retropubic MUS in this SA. The short- and
long-term cure rates were used to estimate an appropriate shape and scale parameter for a Weibull hazard
function, and these parameters were used to estimate failure rates at each time point after retropubic MUS,
as described in Transition probabilities.
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Applying lower success rates when repeating same surgeries
This SA was conducted to explore the effect of assuming lower cure rates when the same surgeries are
being conducted for a second or third time. In the base-case analysis it was assumed that all surgical
treatments have the same effectiveness as a primary procedure, whereas in this SA the subsequent
treatments are assumed to have less effectiveness: 90% and 75%, respectively.
Incorporating different health utility values and effect of natural decline in health utility
over time
As mentioned in Health utility, the same values were used for SUI and MUI women using data from Manca
et al.244 and Haywood et al.245 in the base-case analysis. Tincello et al.267 showed that MUI (EQ-5D 0.75)
may have a greater impact on the EQ-5D score than SUI (EQ-5D 0.85). SA was performed by adjusting
the EQ-5D scores used in the base-case analysis with lower values applied to MUI health states. EQ-5D
scores used for the MUI pretreatment and MUI after failure of first/second treatment states were 0.69
and 0.65, respectively. The impact of the natural decline in health utility over time was also considered
in further SA. The values for the age-related reduction were derived based on published values for
age-related health utility.268
Results
Monte Carlo simulation was performed to obtain probabilistic estimates of the cost-effectiveness of
retropubic MUS compared with all other surgical treatments. The results, in terms of total and incremental
costs and effectiveness, and incremental cost per QALY, are presented in Table 19, and in the form of a
CEAC in Figure 7. Table 19 reports strategies from least to most costly; the last column reports the ICERs.
Over a lifetime time horizon, retropubic MUS is on average the least costly (£8099) and the most effective
(24.22 QALYs) surgical treatment. All other surgical treatments are dominated as they are more costly
and less effective than retropubic MUS except for traditional sling. Over a shorter time horizon (10 years),
retropubic MUS remains the dominant strategy. However, over a 1-year time horizon single-incision sling is
TABLE 19 Results of the probabilistic analysis for 1-year, 10-year and lifetime time horizons
Time
horizon Strategy
Cost
(£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective
(%) at WTP
threshold (£)
20,000 30,000
1 year Single-incision sling 1953 0.76 96.6 92.3
Retropubic MUS 2310 357 0.75 –0.01 Dominated 2.9 5.6
Transobturator MUS 2352 399 0.75 –0.01 Dominated 0.5 1.4
Bladder neck needle
suspension
2756 803 0.75 –0.01 Dominated 0.1 0.5
Traditional sling 2772 819 0.72 –0.04 Dominated 0.0 0.0
Urethral injection
therapy
2848 895 0.74 –0.02 Dominated 0.0 0.1
Anterior vaginal
repair
3249 1296 0.76 0.00 Dominated 0.0 0.2
Open
colposuspension
4710 2757 0.77 0.01 233,209 0.0 0.0
Laparoscopic
colposuspension
4804 95 0.76 –0.01 Dominated 0.0 0.0
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dominant compared with all other strategies except for open colposuspension. Figure 7 shows that over a
lifetime time horizon retropubic MUS has a > 26% probability of being cost-effective at a WTP threshold
value of £20,000. Given the number of comparators, if the interventions were comparable we would
expect an 11% chance of being cost-effective. The only other strategies with reasonably sized probabilities
of being cost-effective are traditional sling (≈27% across all WTP values presented, suggesting not much
difference between retropubic MUS and traditional sling) and open colposuspension (≈14–16% across all
WTP thresholds > £10,000). All other strategies have a < 10.5% probability of being cost-effective across
all WTP values presented.
TABLE 19 Results of the probabilistic analysis for 1-year, 10-year and lifetime time horizons (continued )
Time
horizon Strategy
Cost
(£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective
(%) at WTP
threshold (£)
20,000 30,000
10 years Retropubic MUS 4649 7.33 51.0 44.9
Traditional sling 5235 585 7.28 –0.05 Dominated 20.4 20.5
Single-incision sling 5274 625 7.14 –0.19 Dominated 3.7 3.5
Transobturator MUS 5414 765 7.20 –0.13 Dominated 4.3 4.4
Urethral injection
therapy
5676 1027 7.19 –0.14 Dominated 8.8 9.5
Bladder neck needle
suspension
5958 1309 7.14 –0.19 Dominated 4.0 4.3
Anterior vaginal
repair
6655 2006 7.11 –0.22 Dominated 1.8 2.4
Open
colposuspension
7375 2725 7.29 –0.04 Dominated 4.7 8.1
Laparoscopic
colposuspension
7818 3169 7.20 –0.13 Dominated 1.3 2.5
Lifetime Retropubic MUS 8099 24.22 25.8 24.6
Traditional sling 8522 423 24.22 0.01 60,863 27.0 26.2
Urethral injection
therapy
9554 1032 23.86 –0.36 Dominated 10.5 10.5
Single-incision sling 9649 1127 23.59 –0.63 Dominated 3.2 3.2
Transobturator MUS 9665 1142 23.71 –0.51 Dominated 4.1 4.1
Bladder neck needle
suspension
10,125 1603 23.69 –0.53 Dominated 5.4 5.4
Open
colposuspension
10,977 2455 24.10 –0.12 Dominated 14.1 15.0
Anterior vaginal
repair
11,057 2535 23.54 –0.69 Dominated 3.9 4.1
Laparoscopic
colposuspension
11,797 3274 23.83 –0.40 Dominated 6.2 6.8
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FIGURE 7 Cost-effectiveness acceptability curves for the nine surgical treatments. Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle suspension;
lap colpo, laparoscopic retropubic colposuspension; open colpo, open abdominal retropubic colposuspension; retro-MUS, retropubic mid-urethral sling; single incision,
single-incision sling; transob-MUS, transobturator mid-urethral sling; trad sling, traditional suburethral retropubic sling.
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Deterministic sensitivity analyses
Applying higher incidence rates for mesh complications after mid-urethral
sling procedures
In this SA, results from the study by Keltie et al.266 were used to inform the mesh complication incidence
rate after retropubic MUS and transobturator MUS. The results from this SA show that retropubic MUS
remains the least costly strategy compared with the alternative surgical interventions and is the most
cost-effective option, at a WTP threshold value of £20,000 (Table 20). However, when 10% and 20%
incidence rates are used, traditional sling is the most cost-effective option, with an ICER of < £20,000 per
each QALY gained.
TABLE 20 Results from deterministic sensitivity analyses applying higher incidence rates of mesh complications
after MUS procedures (lifetime time horizon)
Strategy Cost (£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective
(%) at WTP
threshold (£)
20,000 30,000
Base-case analysis estimating the incidence rate of mesh complications after MUS procedures based on the data from trials
Retropubic MUS 8099 24.22 25.8 24.6
Traditional sling 8522 423 24.22 0.01 60,863 27.0 26.2
Urethral injection therapy 9554 1032 23.86 –0.36 Dominated 10.5 10.5
Single-incision sling 9649 1127 23.59 –0.63 Dominated 3.2 3.2
Transobturator MUS 9665 1142 23.71 –0.51 Dominated 4.1 4.1
Bladder neck needle
suspension
10,125 1603 23.69 –0.53 Dominated 5.4 5.4
Open colposuspension 10,977 2455 24.10 –0.12 Dominated 14.1 15.0
Anterior vaginal repair 11,057 2535 23.54 –0.69 Dominated 3.9 4.1
Laparoscopic
colposuspension
11,797 3274 23.83 –0.40 Dominated 6.2 6.8
SA estimating the incidence rate of mesh complications for retropubic MUS (3.7%) and transobturator MUS (2.8%) based
on the data from Keltie et al.266
Retropubic MUS 8138 24.20 24.5 23.5
Traditional sling 8530 392 24.22 0.01 26,311 27.8 26.8
Urethral injection therapy 9560 1030 23.85 –0.37 Dominated 10.7 10.7
Single-incision sling 9656 1125 23.58 –0.63 Dominated 3.3 3.2
Transobturator MUS 9683 1153 23.69 –0.53 Dominated 4.1 4.0
Bladder neck needle
suspension
10,131 1601 23.67 –0.55 Dominated 5.9 6.0
Open colposuspension 10,978 2448 24.09 –0.13 Dominated 14.1 15.0
Anterior vaginal repair 11,073 2543 23.53 –0.69 Dominated 3.9 4.2
Laparoscopic
colposuspension
11,805 3275 23.81 –0.41 Dominated 5.9 6.7
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Incorporating longer duration for persistent pain complication
In the base-case analysis, it was assumed that persistent pain complication will last for, on average,
6 months. In these sensitivity analyses, the effect of longer-term suffering from persistent pain was
explored and it was assumed that, on average, women with persistent pain will suffer for 3 and 5 years.
The results from these sensitivity analyses show that with longer duration of persistent pain, the probability
of retropubic MUS being the most cost-effective option decreases and the respective probability for open
colposuspension increases (Table 21).
Applying higher incidence rates of persistent pain after mid-urethral sling procedures
Results from these sensitivity analyses show that when a higher incidence rate (10% and 20%) of
persistent pain after retropubic MUS and transobturator MUS was assumed, the probability of retropubic
MUS being the most cost-effective option decreases and the respective probability for traditional sling
increases (Table 22). The probability of retropubic MUS and traditional sling being the most cost-effective
are 23–24% and 28–29%, respectively.
TABLE 20 Results from deterministic sensitivity analyses applying higher incidence rates of mesh complications
after MUS procedures (lifetime time horizon) (continued )
Strategy Cost (£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective
(%) at WTP
threshold (£)
20,000 30,000
SA assuming 10% incidence rate of mesh complications after retropubic MUS and transobturator MUS
Retropubic MUS 8238 24.19 23.9 22.5
Traditional sling 8550 312 24.24 0.05 6631 29.1 28.1
Urethral injection therapy 9596 1045 23.86 –0.37 Dominated 11.2 11.2
Single-incision sling 9705 1155 23.58 –0.65 Dominated 3.2 3.1
Transobturator MUS 9817 1267 23.69 –0.55 Dominated 4.0 4.2
Bladder neck needle
suspension
10,180 1629 23.69 –0.55 Dominated 5.8 5.9
Open colposuspension 11,010 2460 24.08 –0.16 Dominated 13.1 14.2
Anterior vaginal repair 11,120 2570 23.54 –0.70 Dominated 3.7 4.1
Laparoscopic
colposuspension
11,843 3292 23.84 –0.40 Dominated 6.0 6.8
SA assuming 20% incidence rate of mesh complications after retropubic MUS and transobturator MUS
Retropubic MUS 8381 24.17 0.00 23.6 22.4
Traditional sling 8579 198 24.21 0.04 4558 28.6 27.6
Urethral injection therapy 9644 1064 23.86 –0.35 Dominated 10.7 10.8
Single-incision sling 9766 1186 23.58 –0.64 Dominated 3.4 3.3
Transobturator MUS 9987 1407 23.66 –0.56 Dominated 3.7 3.8
Bladder neck needle
suspension
10,237 1657 23.67 –0.54 Dominated 5.6 5.8
Open colposuspension 11,048 2469 24.07 –0.14 Dominated 14.1 15.0
Anterior vaginal repair 11,185 2606 23.52 –0.69 Dominated 3.6 3.8
Laparoscopic
colposuspension
11,892 3312 23.82 –0.39 Dominated 6.7 7.5
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TABLE 21 Results from deterministic sensitivity analyses incorporating longer duration for persistent pain
complication (lifetime time horizon)
Strategy Cost (£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective
(%) at WTP
threshold (£)
20,000 30,000
Base-case analysis assuming that persistent pain complication will last on average for 6 months
Retropubic MUS 8099 24.22 25.8 24.6
Traditional sling 8522 423 24.22 0.01 60,863 27.0 26.2
Urethral injection therapy 9554 1032 23.86 –0.36 Dominated 10.5 10.5
Single-incision sling 9649 1127 23.59 –0.63 Dominated 3.2 3.2
Transobturator MUS 9665 1142 23.71 –0.51 Dominated 4.1 4.1
Bladder neck needle
suspension
10,125 1603 23.69 –0.53 Dominated 5.4 5.4
Open colposuspension 10,977 2455 24.10 –0.12 Dominated 14.1 15.0
Anterior vaginal repair 11,057 2535 23.54 –0.69 Dominated 3.9 4.1
Laparoscopic colposuspension 11,797 3274 23.83 –0.40 Dominated 6.2 6.8
SA assuming that persistent pain complication will last on average for 36 months
Retropubic MUS 8097 24.02 22.3 20.9
Traditional sling 8523 426 24.01 –0.01 Dominated 23.7 22.8
Urethral injection therapy 9547 1450 23.78 –0.24 Dominated 12.7 12.6
Single-incision sling 9646 1549 23.45 –0.56 Dominated 3.4 3.3
Transobturator MUS 9665 1567 23.50 –0.52 Dominated 3.2 3.3
Bladder neck needle
suspension
10,126 2029 23.59 –0.43 Dominated 6.6 6.7
Open colposuspension 10,970 2872 24.02 0.00 1,134,541 17.1 18.2
Anterior vaginal repair 11,060 90 23.43 –0.59 Dominated 4.0 4.1
Laparoscopic colposuspension 11,791 821 23.75 –0.27 Dominated 7.1 8.1
SA assuming that persistent pain complication will last on average for 60 months
Retropubic MUS 8103 23.90 20.8 19.3
Traditional sling 8524 421 23.87 –0.03 Dominated 20.7 19.9
Urethral injection therapy 9550 1447 23.74 –0.17 Dominated 13.8 13.7
Single-incision sling 9648 1545 23.38 –0.52 Dominated 3.3 3.2
Transobturator MUS 9666 1563 23.35 –0.56 Dominated 2.5 2.6
Bladder neck needle
suspension
10,127 2024 23.54 –0.36 Dominated 7.1 7.3
Open colposuspension 10,976 2872 23.99 0.09 33,380 19.4 20.5
Anterior vaginal repair 11,059 83 23.38 –0.61 Dominated 4.1 4.4
Laparoscopic colposuspension 11,793 818 23.71 –0.28 Dominated 8.3 9.3
DEVELOPMENT OF A NEW COST-EFFECTIVENESS MODEL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
84
TABLE 22 Results from deterministic sensitivity analyses incorporating higher incidence rate for persistent pain
complication after MUS procedures (lifetime time horizon)
Strategy Cost (£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective
(%) at WTP
threshold (£)
20,000 30,000
Base-case analysis assuming that incidence rate of persistent pain after retropubic MUS and transobturator MUS are 5.09%
and 4.93%, respectively
Retropubic MUS 8099 24.22 25.8 24.6
Traditional sling 8522 423 24.22 0.01 60,863 27.0 26.2
Urethral injection therapy 9554 1032 23.86 –0.36 Dominated 10.5 10.5
Single-incision sling 9649 1127 23.59 –0.63 Dominated 3.2 3.2
Transobturator MUS 9665 1142 23.71 –0.51 Dominated 4.1 4.1
Bladder neck needle
suspension
10,125 1603 23.69 –0.53 Dominated 5.4 5.4
Open colposuspension 10,977 2455 24.10 –0.12 Dominated 14.1 15.0
Anterior vaginal repair 11,057 2535 23.54 –0.69 Dominated 3.9 4.1
Laparoscopic colposuspension 11,797 3274 23.83 –0.40 Dominated 6.2 6.8
SA assuming that incidence rate of persistent pain after retropubic MUS and transobturator MUS is 10%
Retropubic MUS 8104 24.18 24.2 23.0
Traditional sling 8523 419 24.20 0.03 15,067 28.4 27.6
Urethral injection therapy 9557 1034 23.84 –0.37 Dominated 11.1 11.1
Single-incision sling 9649 1126 23.57 –0.63 Dominated 3.2 3.2
Transobturator MUS 9672 1148 23.67 –0.54 Dominated 3.8 3.8
Bladder neck needle
suspension
10,128 1605 23.66 –0.54 Dominated 5.7 5.8
Open colposuspension 10,977 2454 24.07 –0.13 Dominated 13.8 14.8
Anterior vaginal repair 11,063 2540 23.51 –0.69 Dominated 3.7 3.9
Laparoscopic colposuspension 11,799 3275 23.81 –0.39 Dominated 6.2 7.0
SA assuming that incidence rate of persistent pain after retropubic MUS and transobturator MUS is 20%
Retropubic MUS 8109 24.13 23.3 22.1
Traditional sling 8520 410 24.19 0.06 6593 28.6 27.5
Urethral injection therapy 9557 1037 23.83 –0.36 Dominated 10.8 10.9
Single-incision sling 9645 1125 23.56 –0.63 Dominated 3.5 3.5
Transobturator MUS 9677 1158 23.61 –0.58 Dominated 3.8 3.8
Bladder neck needle
suspension
10,131 1612 23.65 –0.54 Dominated 6.2 6.3
Open colposuspension 10,975 2455 24.07 –0.12 Dominated 14.0 15.1
Anterior vaginal repair 11,063 2543 23.49 –0.70 Dominated 3.5 3.8
Laparoscopic colposuspension 11,796 3277 23.80 –0.39 Dominated 6.3 7.1
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Applying higher incidence rates and longer duration for persistent pain after
mid-urethral sling procedures
In this scenario analysis, the impact of incorporating higher incidence rates of persistent pain after MUS
procedures and longer mean duration for persistent pain was tested on the base-case results. As would be
expected, the probability of retropubic MUS being the most cost-effective with a £20,000 WTP decreases
from 26% to 4.2% and the corresponding probability for traditional sling increases from 27% to 30.8%.
The estimated ICER for traditional sling is £619 per QALY gained. Open colposuspension is not a
dominated strategy and has a 25.8% probability of being cost-effective (Table 23).
TABLE 23 Results from deterministic sensitivity analyses applying higher incidence rates and longer duration for
persistent pain after MUS procedures (lifetime time horizon)
Strategy Cost (£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective
(%) at WTP
threshold (£)
20,000 30,000
Base-case analysis assuming that incidence rate of persistent pain after retropubic MUS and transobturator MUS are 5.09%
and 4.93%, respectively, and average duration of persistent pain is 6 months
Retropubic MUS 8099 24.22 25.8 24.6
Traditional sling 8522 423 24.22 0.01 60,863 27.0 26.2
Urethral injection therapy 9554 1032 23.86 –0.36 Dominated 10.5 10.5
Single-incision sling 9649 1127 23.59 –0.63 Dominated 3.2 3.2
Transobturator MUS 9665 1142 23.71 –0.51 Dominated 4.1 4.1
Bladder neck needle
suspension
10,125 1603 23.69 –0.53 Dominated 5.4 5.4
Open colposuspension 10,977 2455 24.10 –0.12 Dominated 14.1 15.0
Anterior vaginal repair 11,057 2535 23.54 –0.69 Dominated 3.9 4.1
Laparoscopic colposuspension 11,797 3274 23.83 –0.40 Dominated 6.2 6.8
SA assuming that incidence rate of persistent pain after retropubic MUS and transobturator MUS are 20% and average
duration of persistent pain is 60 months
Retropubic MUS 8118 22.97 4.2 3.8
Traditional sling 8527 409 23.63 0.66 619 30.8 29.5
Urethral injection therapy 9560 1033 23.37 –0.26 Dominated 17.0 16.6
Single-incision sling 9652 1125 22.90 –0.72 Dominated 2.8 2.7
Transobturator MUS 9683 1156 22.25 –1.38 Dominated 0.1 0.1
Bladder neck needle
suspension
10,130 1604 23.11 –0.52 Dominated 7.0 7.0
Open colposuspension 10,978 2451 23.68 0.05 46,732 25.8 27.0
Anterior vaginal repair 11,064 86 22.89 –0.79 Dominated 3.4 3.5
Laparoscopic colposuspension 11,797 819 23.32 –0.36 Dominated 9.0 9.9
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Applying different values for short- and long-term cure rates after retropubic
mid-urethral sling
When data on long-term cure rates derived from the UK trial248 comparing TVT with Burch colposuspension
were applied, the results show that the effectiveness of most of the strategies increased, as women spend
more time continent over the modelling time horizon and have lower costs. The probability of retropubic
MUS being cost-effective also increased, compared with the base-case analysis. When the data from
Song et al.249 were applied, the findings are broadly similar (Table 24).
Detailed results from the following sensitivity analyses are reported in Appendix 21, assuming that all of the
women in the model have SUI; alternative values for the proportion of women who will seek retreatment
after failure of each surgical treatment; applying lower success rate for repeating same surgeries; and
incorporating different health utility values and effect of natural decline in health utility over time.
Value-of-information analysis
In addition to assessing the relative effectiveness and cost-effectiveness of the alternative surgical treatments,
the economic model was used to quantify the main uncertainties facing decision-makers and to help inform
decisions about the direction of future research. This was explored through variants of VOI analysis: expected
value of perfect information (EVPI) and expected value of partial perfect information (EVPPI) analysis.
Expected value of perfect information
Decision-makers are interested in understanding the amount of uncertainty associated with a decision and
this can be quantified directly from the PSA results. An assessment of the significance of this uncertainty
also requires consideration of the consequences associated with uncertainty, in terms of the costs or
equivalent health forgone if an incorrect decision is made. The scale and magnitude of these consequences
needs to be reflected in the entire population who stand to be affected by a particular decision.
Value-of-information analysis can quantify the expected gain in net benefit from obtaining further
information to inform a decision. Quantifying the value of an incorrect decision, alongside the probability
of making an incorrect decision, allows us to estimate EVPI. The maximum amount that policy-makers
should be willing to invest to reduce uncertainty in the decision can be informed by the EVPI. If the EVPI
for a decision problem exceeds the cost of future research, additional investigation may be worthwhile.
As well as determining EVPI around the decision as a whole, VOI approaches can also be used for particular
elements of the decision with the purpose of focusing research in areas where the elimination of uncertainty
might have the most value. Partial EVPI, or EVPPI, analysis can be used to estimate the expected value of
removing uncertainty surrounding specific parameters or groups of parameters to identify where future
research should focus on identifying more precise and reliable estimates of specific pieces of information,
e.g. relative effectiveness, costs or utilities. EVPI places an upper value on conducting further research overall,
whereas EVPPI places an upper value on conducting further research on a specific area of information. On
the basis of EVPI and EVPPI calculations, the potential value of a future trial, or other research designs, can
be evaluated.
Population EVPI is calculated by multiplying the individual EVPI estimate by the expected number of people
who would be affected by the information over the anticipated lifetime of the technology. Population size was
calculated based on previous studies. HES data for England show that in 2013–14 around 12,000 women had
a MUS operation, with around 500 having another type of continence procedure (colposuspension ≈300,
traditional slings ≈200), and just over 700 having periurethral injections (13,200 in total). In Scotland, the total
number of surgical procedure for treatment of SUI in the same period was 929.251 In total, it was assumed
that in the UK there are 15,000 surgical treatments conducted annually for the treatment of SUI. Two-level
simulations were conducted to estimate the EVPI and EVPPI. The first level occurred within the microsimulation
by randomly selecting women aged 45–55 years. Each selected woman was simulated 10,000 times (PSA) and
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TABLE 24 Results from deterministic sensitivity analyses applying different values for short- and long-term cure
rates after retropubic MUS (lifetime time horizon)
Strategy Cost (£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective
(%) at WTP
threshold (£)
20,000 30,000
Base-case analysis applying estimated mean values from the meta-analysis for short- and long-term cure rates after
retropubic MUS
Retropubic MUS 8099 24.22 25.8 24.6
Traditional sling 8522 423 24.22 0.01 60,863 27.0 26.2
Urethral injection therapy 9554 1032 23.86 –0.36 Dominated 10.5 10.5
Single-incision sling 9649 1127 23.59 –0.63 Dominated 3.2 3.2
Transobturator MUS 9665 1142 23.71 –0.51 Dominated 4.1 4.1
Bladder neck needle
suspension
10,125 1603 23.69 –0.53 Dominated 5.4 5.4
Open colposuspension 10,977 2455 24.10 –0.12 Dominated 14.1 15.0
Anterior vaginal repair 11,057 2535 23.54 –0.69 Dominated 3.9 4.1
Laparoscopic colposuspension 11,797 3274 23.83 –0.40 Dominated 6.2 6.8
SA applying values from Ward et al.248 for short- and long-term cure rates after retropubic MUS
Retropubic MUS 7163 24.55 45.7 43.3
Traditional sling 8493 1330 24.22 –0.33 Dominated 16.6 16.7
Urethral injection therapy 9418 2255 23.89 –0.66 Dominated 8.3 8.5
Transobturator MUS 9422 2260 23.77 –0.77 Dominated 4.2 4.3
Single-incision sling 9429 2267 23.65 –0.90 Dominated 3.3 3.2
Bladder neck needle
suspension
9944 2782 23.72 –0.82 Dominated 4.6 4.9
Anterior vaginal repair 10,855 3692 23.58 –0.97 Dominated 3.5 3.8
Open colposuspension 10,878 3715 24.11 –0.44 Dominated 9.0 9.9
Laparoscopic colposuspension 11,653 4490 23.86 –0.69 Dominated 4.9 5.6
SA applying data from Song et al.249 for short- and long-term cure rates after retropubic MUS
Retropubic MUS 7394 24.49 42.1 39.9
Traditional sling 8522 1128 24.22 –0.27 Dominated 19.3 19.0
Urethral injection therapy 9437 2043 23.90 –0.59 Dominated 8.1 8.3
Single-incision sling 9464 2070 23.64 –0.85 Dominated 3.1 3.2
Transobturator MUS 9475 2080 23.77 –0.72 Dominated 4.1 4.2
Bladder neck needle
suspension
9979 2585 23.73 –0.76 Dominated 5.3 5.4
Anterior vaginal repair 10,881 3486 23.59 –0.90 Dominated 3.6 3.9
Open colposuspension 10,916 3522 24.11 –0.38 Dominated 9.8 10.7
Laparoscopic colposuspension 11,680 4286 23.85 –0.64 Dominated 4.6 5.3
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values for the parameters were selected from the prespecified distributions. Results from the PSA were
exported to Excel files and then SAVI 2.1.2 (University of Sheffield, Sheffield, UK; http://savi.shef.ac.uk/SAVI/)
was used to estimate the EVPI and EVPPI.
The EVPI estimates in Table 25 quantify the expected value to decision-makers in the UK of removing all
current decision uncertainty at a threshold of £20,000 per QALY gained. This will enable a comparison
to be made with previous analyses, providing an idea of the scale of decision uncertainty in this topic
compared with other previous decisions. If the number of people affected by the decision per year is
15,000, then the overall EVPI per year is £167.7M for the UK.
When thinking about the overall expected value of removing decision uncertainty, one needs to consider
how long the current comparison will remain relevant. If the relevant time horizon is 20 years for the
decision, then the overall expected value of removing decision uncertainty for the UK would be £3.345B.
Expected value of partial perfect information results
As mentioned earlier, the value of reducing uncertainty surrounding particular input parameters in the
model can also be established by estimating EVPPI. The EVPPI could be used to calculate the maximum
value of reducing uncertainty around particular parameters (or groups of parameters), allowing future
research to be more specifically targeted at the parameters for which more precise estimates would be
most valuable. There are four groups of uncertain parameters considered in the EVPPI analysis. These
relate to:
1. health utility values
2. relative treatment effectiveness (cure rates)
3. operation-related mortality rates
4. combinations of parameters associated with all the complications
5. combinations of parameters associated with short-term and persistent pain
6. combinations of parameters associated with short-term and persistent pain and mesh erosion/removal.
Table 26 reports the EVPPI for a number of groups of parameters that were considered to represent
groupings that were relevant to both broader policy questions and the actual design of further research.
The EVPPI associated with all the complications incidence rates, relative treatment effectiveness, short-term
and persistent pain, and health utility values consistently emerge as having significant influence on overall
decision uncertainty, having the highest estimate across the different groups of parameters.
TABLE 25 Results from VOI analysis
The expected value of removing all current decision uncertainty
Overall EVPI
£ QALY
Per person affected by the decision 11,180 0.56
Per year in UK assuming 15,000 persons affected per year 167,700,000 8385
> 5 years 838,500,000 41,930
> 10 years 1,677,000,000 83,850
> 15 years 2,516,000,000 125,800
> 20 years 3,354,000,000 167,700
DOI: 10.3310/hta23140 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 14
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Brazzelli et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89
Summary of cost-effectiveness and value-of-information analysis
The economic model presented in this report compared nine different strategical treatments for treatment
of SUI and stress-predominant MUI. Data from network meta-analyses and standard databases were
used to populate the economic model. The model compared cumulative costs and QALYs for a 1-year,
10-year and lifetime time horizon. The results suggest that retropubic MUS is less costly and more effective
than all other surgical interventions over a lifetime time horizon; therefore, it is a dominant strategy. The
probabilistic results show that retropubic MUS and traditional sling have the highest probabilities of being
cost-effective across all WTP thresholds over a lifetime time horizon. Retropubic MUS remains dominant
over a 10-year time horizon in the cure model. The only major deviation from these findings is when
the time horizon is reduced to 1 year. In this scenario, the most cost-effective surgical intervention is
single-incision sling.
Retropubic MUS was the least costly and a cost saving option owing in part to its lower initial cost. This is
primarily because this procedure is conducted in a day case setting, and there is less chance of having
retropubic MUS after repeat surgery owing to its higher cure rate than all other surgical treatments (except
for traditional sling in the cure model). Results also showed that there were relatively small differences
between retropubic MUS and traditional sling, in terms of total QALYs, in the cure model. Although the
incremental cost-effectiveness estimates showed that retropubic MUS is less costly (£423 less than traditional
sling), the probability of being cost-effective with a £20,000 WTP were 25.8% and 27.0% for retropubic
MUS and traditional sling, respectively.
A total of 17 individual sensitivity/scenario analyses were carried out on the base-case model results.
Traditional sling was a cost-effective option when the following scenarios were explored: assuming that all
of the women in the model have SUI; using a linked database to estimate the proportion of women who
will seek retreatment after failure of each surgical treatment; assuming lower cure rates when the same
surgeries are being conducted for a second or third time; assuming a 10% and 20% incidence rate for
mesh complications after retropubic MUS and transobturator MUS; assuming a 10% and 20% incidence
rate for persistent pain complication after retropubic MUS and transobturator MUS; assuming lower health
utility value for MUI health states; and assuming that the incidence rate of persistent pain after retropubic
MUS and transobturator MUS is 20% and that the average duration of persistent pain is 60 months.
Value-of-information analyses were also carried out on the base-case probabilistic results. The EVPI per
woman is £11,180. The population EVPI was also estimated based on an assumed 15,000 surgical
interventions for SUI in the UK each year. Therefore, the population EVPI for 1 year is £167.7M. This figure
increases as the time horizon (or period of time over which the information would be useful) is increased.
TABLE 26 The EVPPI for a number of groups of parameters
Parameters
Per-person EVPPI
per year (£)
EVPPI for UK (£)
Per year Over 20 years
Health utility values 158 2,362,774 47,255,488
Operation related mortality rates 57 855,159 17,103,176
Relative treatment effectiveness 1315 19,717,921 394,358,420
Combinations of parameters associated with all the
complications
3746 56,195,710 1,123,914,202
Combinations of parameters associated with short-term and
persistent pain
405 6,068,657 121,373,135
Combinations of parameters associated with short-term and
persistent pain and mesh erosion/removal
1766 26,488,639 529,772,777
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The cost of future research to remove uncertainty around all model parameters would need to be less
than these presented amounts, otherwise it would not be considered an efficient use of resources. EVPPI
analyses were also conducted to estimate the value of removing uncertainty around particular parameters/
groups of parameters. The largest value appears to be in removing uncertainty around the complications
incidence rates, relative treatment effectiveness and health utility values.
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Chapter 7 Discussion
S tress urinary incontinence is a common condition that may cause substantial disability and reducewomen’s quality of life.269 The insertion of synthetic mesh tapes has become the most common
surgical procedure worldwide for the treatment of SUI in women.266,270 Mesh tape procedures were initially
adopted using a retropubic approach. A transobturator approach has been developed more recently with
the aim of reducing the likelihood of damaging the bladder during the operation. A number of RCTs
have assessed the use of mesh for the treatment of SUI in women. Recent trials have compared the
retropubic approach with the transobturator approach to assess clinical effectiveness and complications.
However, long-term data are scarce. In particular, the growing patient-led concern about the safety
profile of these procedures has culminated in an international debate with a number of legal cases raised
against the companies that manufacture the mesh tapes. The patients’ initial campaign has led to further
national campaigns against the use of mesh [e.g. the Scottish Mesh Survivors’ campaign Hear Our Voice
(www.scottishmeshsurvivors.com)], recent independent inquiries and an updating of existing clinical guidelines.
An independent review commissioned by the Scottish Government, which considered and analysed
administrative data (routinely reported Scottish hospital inpatient data), reported that immediate
complications were experienced by 3.7% of women after retropubic mesh procedures, 2.5% of women
after transobturator mesh procedures, 7.1% of women after unspecified mesh procedures and 7.8%
of women after open colposuspension (non-mesh open surgery).271 Moreover, mesh procedures were
reported to carry a similar risk of being readmitted for repeat surgery or for later complications compared
with open colposuspension. The independent review concluded that the management of women with SUI
should take place in the context of a multidisciplinary team supported by a quality assurance framework.
Women must receive adequate information on all appropriate treatments (mesh and non-mesh) to make
informed choices. When surgery involving the use of a synthetic mesh tape is considered, a retropubic
approach should be recommended.271 The findings of the Scottish Independent Review are in line with
those of a large Scottish study published in 2017, which assessed a cohort of 13,133 women, identified in
the same way as the Independent Review (i.e. from a national hospital admission database).272 The cohort
comprised women who underwent a first single incontinence surgical procedure between April 1997 and
March 2016. This cohort study found that, compared with colposuspension, mesh procedures had a lower
risk of immediate complications and subsequent prolapse surgery and a similar risk of further incontinence
surgery and later complications.272 The authors concluded that mesh procedures for SUI should be
considered among possible surgical options and that further research on longer-term outcomes would be
beneficial. Another large study of surgical mesh procedures for SUI (92,244 procedures, including 68,002
unconfounded procedures) published in 2017 investigated the rate of adverse events in NHS England over
8 years.266 Cases were identified from the HES database. The study reported that 9.8% of women who
underwent a surgical mesh procedure for SUI experienced a post-operative complication within 30 days
or within 5 years. Perioperative complications and 30-day complications occurred in 2.4% and 1.7% of
women, respectively. The proportion of women who required readmission for further mesh surgery within
5 years of the index procedure was 5.9%. The risk of readmission was higher during the first 2 years.
It is worth noting that the results of the two large cohort studies and the Scottish Independent Review
mentioned above were all based on administrative data: routinely reported hospital inpatient data.266,271,272
However, the rate of complications managed in outpatient or primary care settings were not captured by
these reports. Moreover, the accuracy of the coding system for national databases and hospital records is
known to be less than optimal owing to the lack of specific codes to identify particular complications of
interest and the lag (sometimes of a few years) between the introduction of new surgical procedures
(e.g. retropubic and TOT procedures) and the introduction of specific codes to identify these procedures.
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The NHS England Mesh Oversight Group Report published in July 2017273 concluded that mesh procedures
for the treatment of women with SUI are a safe option, though a number of recommendations need
to be implemented to ensure better quality of care. These recommendations included improvements to
surgical practice and training, updating of clinical guidance and standards, raising awareness of possible
post-operative complications among GPs and offering quicker and improved access to clinical expertise
for women with post-operative complications.273 In particular, the Mesh Oversight Group Report stressed
the importance of better reporting of adverse events and better HES coding procedures to gain a more
complete picture of the level and seriousness of complications after SUI surgery.273
The recent Consensus Statement of the European Urology Association and the European Urogynaecological
Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary
Incontinence274 indicates that the use of synthetic MUS procedures for the surgical treatment of SUI has good
efficacy and acceptable morbidity. Patients should be adequately informed regarding the potential success
rates and the mesh-related adverse events compared with non-mesh procedures and should be engaged in
the decision-making process.274
In general, recent cohort studies, consensus statements from clinical associations, and national inquiries
seem to be in agreement that mesh procedures may be effective in the treatment of SUI, but there is
uncertainty about long-term outcomes. Post-operative complications, as well as repeat SUI surgery,
need to be carefully considered when weighing the benefits and risks of these interventions. In particular,
it is worth mentioning that mesh implants with their anchoring system are intended to be permanent;
therefore, their removal, if something goes wrong, can be extremely challenging if not impossible.
The NICE guidance on the safety of single-incision short sling mesh insertion for SUI published in
October 2016275 maintains that complications including pain, discomfort and failure of the mesh procedure
are infrequent but serious. The guidance recommends that patient selection should be performed by a
multidisciplinary team with experience in the management of women with SUI and the surgical insertion
performed by clinicians with specific training in mesh techniques. Moreover, the NICE clinical guidance
on the management of SUI (CG171, updated Nov 2015)276 points out that ‘surgery for UI should be
undertaken only by surgeons who have received appropriate training in the management of UI and
associated disorders or who work within a multidisciplinary team with this training, and who regularly
carry out surgery for UI in women’, and again that ‘when recommending optimal management the
multidisciplinary team should take into account women’s preference, past management, comorbidities
and treatment options’. NICE is currently updating its clinical guidance on the management of SUI.
The new guidance is expected to be released in early 2019.
To our knowledge, the current evidence synthesis, discrete choice experiment and economic evaluation
is the most comprehensive assessment of published evidence for the treatment of SUI (a total of 175
studies were included in the effectiveness evidence synthesis). The risk of bias was high or unclear across
all risk-of-bias domains in the majority of included studies. The NMA, which combined evidence from
direct and indirect comparisons, included 120 studies that reported data on the two primary outcomes:
the number of women ‘cured’ from SUI and the number of women who experienced an ‘improvement’ in
their SUI symptoms. The NMA results suggest that retropubic MUS, transobturator MUS and traditional
sling are more effective than other surgical procedures for both primary outcomes. Open colposuspension
also appears relatively effective in terms of cure and improvement rates compared with other surgical
procedures. Results for other surgical interventions were variable.
An adequate assessment of adverse events was hampered by the dearth of suitable data and by the
inconsistency in the way adverse events were defined and reported in individual studies. Direct head-to-head
meta-analyses were available mainly for the comparisons involving retropubic MUS, transobturator MUS or
single-incision sling. Follow-up time was generally short (median of 12 months). Transobturator MUS had a
higher rate of further SUI procedures than retropubic MUS but a lower rate than single-incision sling.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
The rate of tape and mesh exposure was higher after transobturator MUS than after retropubic MUS or
single-incision sling, whereas it was similar between transobturator MUS and retropubic MUS. Retropubic
MUS had a higher rate of major vascular complications, voiding difficulties and bladder or urethral perforation
than transobturator MUS but a lower rate of groin pain. The rate of post-operative pain was higher after
retropubic than single-incision sling and the rate of unspecified pain was higher after transobturator MUS
than single-incision sling. The rate of infection (including UTI, wound infection and infection related to mesh)
was similar between single-incision sling and transobturator MUS.
Our economic model used data from the systematic review and other published sources but was also limited
by the lack of availability of robust evidence. The model results suggest that retropubic MUS is the least
costly and the most effective option. However, the results from the PSA suggest that the retropubic MUS
and traditional sling have comparable probabilities of being cost-effective (26% and 27%, respectively,
using a £20,000 threshold). The findings from the model are in general agreement with other published
cost-effectiveness findings.
One of the strengths of our economic model is the evaluation of nine different surgical treatments in one
analysis, informed by data from a network meta-analyses in which all the direct and indirect evidence
(120 trials) was used to estimate the relative effectiveness of different surgical treatments in terms of cure
rates. Very few studies have included complications within the cost-effectiveness analyses, despite the fact
that the incidence of each complication can have an impact on women’s quality of life and incur costs for
the health system. Therefore, in the present study the impact of incident complications, such as infection,
de novo symptoms of urgency incontinence, voiding difficulties, bladder or urethral perforation, tape/mesh
erosion/extrusion/exposure, short-term pain and persistent pain, on cost and effect have been incorporated
into the model and explored in SA. As about 50% of women who have SUI246 are also suffering from
UUI symptoms, and given that UUI affects women’s quality of life potentially more than SUI,267 we have
incorporated treatment pathways for SUI and UUI at the same time in the model to estimate absolute
QALYs more accurately. Finally, the analysis was conducted using best practice methods277 and used a
comprehensive range of sensitivity analyses to account for uncertainty. Our conclusions were broadly
robust to the range of sensitivity analyses undertaken and comparable to the findings of other
published evaluations.
There are a number of published cost-effectiveness analyses evaluating some of the surgeries that we have
assessed, the general findings of which are presented to allow comparison. Two studies compared the
single-incision sling versus MUS procedures over a 1-year time horizon, concluding that single-incision sling
was less costly and of similar effectiveness.264,278 Another compared the cost-effectiveness of TVT versus
vaginoplasty, finding that TVT was a cost-effective option compared with vaginoplasty.173 A UK study
compared the cost-effectiveness of TVT versus open colposuspension, laparoscopic colposuspension,
traditional sling and injectable agents, concluding that TVT dominated open colposuspension using a 5-year
time horizon.229 A US study compared the cost-effectiveness of TVT versus open Burch colposuspension,
finding over a 10-year horizon that TVT was more cost-effective than open Burch colposuspension.230
A cost–utility analysis in the UK to assess the cost-effectiveness of TVT compared with open Burch
colposuspension found that TVT was less costly and more effective than open Burch colposuspension.244
A further study to assess cost-effectiveness of TVT versus laparoscopic mesh colposuspension concluded
that TVT was more cost-effective than laparoscopic mesh colposuspension over a 1-year time horizon.279
A study based on US-based parameters compared TVT versus Burch colposuspension, finding that Burch
colposuspension was more expensive than TVT but that the resulting ICER (US$98,755 per QALY gained)
was above any WTP threshold used in the UK, making TVT the more cost-effective option.237 Further analysis
to assess the cost-effectiveness of collagen versus retropubic suspension, transvaginal suspension and sling
procedure found that retropubic suspension was the most cost-effective option (ICER US$1824).231 Although
there are limitations with many of these studies and heterogeneity in methods, the results from all the above
studies are largely in agreement with findings from our economic model, generally supporting the finding
that retropubic MUS is likely to be the most cost-effective option when compared with the other types of
surgeries for treatment of SUI.
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However, there are some conflicting findings. Another study to evaluate the cost-effectiveness of MUS
(either retropubic or transobturator) versus urethral bulking agents concluded that bulking agents are more
cost-effective than MUS over a 1-year time horizon (this was in a population of SUI patients without urethral
hypermobility).225 Another examined the cost-effectiveness of retropubic MUS versus transobturator MUS
over a 10-year time horizon and concluded that transobturator MUS is the cost-effective option compared
with retropubic MUS.235 A Canadian study examined the cost-effectiveness of transobturator MUS versus
TVT over a 5-year time horizon, with results suggesting that transobturator MUS was more cost-effective
than TVT.137 The results from our model show that retropubic MUS has a slightly lower cost and higher
effectiveness than transobturator MUS.
Three separate studies280–282 have investigated the cost-effectiveness of laparoscopic Burch colposuspension
versus open Burch colposuspension with a relatively short-term time horizon. Two of these studies280,282
concluded that laparoscopic Burch colposuspension may be more cost-effective than open Burch
colposuspension, whereas the third281 showed that laparoscopic colposuspension is not cost-effective
when compared with open colposuspension during the first 6 months following surgery, but it may be
cost-effective over 24 months.
The results from our study show that open colposuspension is associated with a slightly lower cost and
higher effectiveness than is laparoscopic colposuspension. The findings from the model are in general
agreement with other published cost-effectiveness findings.
Uncertainty about the assessment
The majority of the evidence for the assessment of the clinical effectiveness came from trials evaluating
the effects of retropubic MUS or transobturator MUS. More than half of the included studies compared
transobturator MUS with retropubic MUS (58 studies), or transobturator MUS with single-incision sling
(39 studies). The majority of trials identified by the updated literature searches seem to focus on
transobturator MUS, which is a more recent surgical procedure than retropubic MUS, or single-incision
sling. However, few studies were available for other treatment comparisons, particularly mesh versus
non-mesh procedures.
The definitions and measurements of cure and improvement were not consistent across included studies.
We considered women-reported outcomes to be the best outcomes on which to judge the effectiveness of
surgical treatments. However, patient-reported measures were not always available. We therefore opted
for proxy measures based on the quantification of symptoms derived from pad or urodynamic tests.
This decision was based on the assumption that subjective and objective measures correlate sufficiently,
although this assumption could not be empirically tested within the current assessment.
The NMA assessed the primary outcomes of cure and improvement at 12 months or at a time point closest
to 12 months. The availability of long-term data beyond 12 months was limited.
Assessment of adverse events was hampered by the lack of suitable data and, in particular, of long-term
data. The median follow-up time for all included studies was 12 months.
A further challenge was the lack of consistency in the way adverse events were defined and reported
in the published Cochrane systematic reviews.5–12,18–20 Some of these outcomes were recategorised by
Cochrane authors to conduct meta-analyses but outcome definitions and exact time points at which these
outcomes were measured were often not explicitly reported. Most studies were reported to have a short
follow-up period (up to 12 months), with only a few studies having a follow-up of ≥ 2 years. Inconsistent
time points and outcome categories became problematic when we had to analyse and summarise a large
number of studies across different Cochrane systematic reviews.
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As a result of resource constraints and the inconsistency of reporting across studies, we graded the level of
evidence for the two primary outcomes, but not for adverse events.
We focused on the main mesh surgical procedures for the treatment of SUI and did not consider
procedure subtypes (e.g. up-down vs. down-up retropubic mesh insertion or inside-out vs. outside-in
transobturator mesh insertion). There is a large volume of published literature comparing the different
techniques that are available for one type of surgery; however, this was beyond the remit of the question
that our work was addressing. It should be noted, however, that there remains uncertainty about the
relative effectiveness and cost-effectiveness of these subtypes. In addition, there is likely to be a lack of
consistency in their use within the NHS. This decision uncertainty still needs to be addressed through
robust evidence collection and analysis.
The professional experience of the surgeons performing the operations was not consistently reported
in the included studies and relevant Cochrane systematic reviews. Among studies that provided this
information, the surgeon’s clinical experience varied from ‘having inserted a minimum of one sling prior to
the study’29 to ‘having performed 200 surgical procedures’.115 A few studies reported that surgeons tended
to be less experienced in performing sling procedures than the comparator surgical intervention. The
current NICE guideline on the management of SUI (CG171, updated November 2015)276 states that ‘an
annual workload of at least 20 cases of each primary procedure for stress UI is recommended. Surgeons
undertaking fewer than 5 cases of any procedure annually should do so only with the support of their
clinical governance committee’. However, from current published studies it seems that, at present, there is
considerable variation in clinical practice and it is unclear whether or not (and how) the surgeons must
demonstrate their ability in performing these operations.
As with all modelling studies, several limitations exist within our study that should be considered when
interpreting the results. One of the main limitations of the current study is the lack of long-term data,
which necessitated the extrapolation of relatively short-term data to 10 years and over the lifetime of
women included in the analyses. The results achieved would only apply in a situation where relative
differences in effectiveness of retropubic MUS compared with the comparators do not change with longer
follow-up. The long-term incidence of complications after the surgical treatments are currently not reliably
known. Therefore, all the estimated incidence rates for complications after each surgical treatment were
based on the data from trials with relatively short-term follow-up times. Nevertheless, we tested the impact
of possible higher incidence rates of some of the complications on the results. It should be mentioned
that a clinical trial is currently being conducted to estimate the 3-year outcome after standard tension-free
MUS and single-incision mini-sling procedures.283 Another limitation of our study is that urethral injection
therapy was not included in the NMA; therefore, the short-term and long-term cure rates after urethral
injection therapy were obtained from a meta-analysis that reported effectiveness of silicon particles
(Macroplastique) for women with SUI (958 women from 23 cohorts were included in the analysis).250
Furthermore, the economic model has focused on costs to the NHS. It has been assumed that certain
costs, such as those for containment products, may be incurred by the NHS. In practice, women may also
buy different products and may well incur the costs of containment management themselves. Other costs
that may be incurred by women have not been included. These include the other costs of managing
symptoms, such as laundry costs, and the time and travel costs related to receiving the treatments. It might
be expected that the more effective treatments would reduce the costs of managing symptoms borne
by the women and their families. Therefore, we expect that including those costs would probably improve
the cost-effectiveness of retropubic MUS. Finally, we had intended to use results from the DCE to inform
the economic model. One potential way to have done this would have been to have included cost as
an attribute in the DCE, which would have enabled a cost–benefit/net benefit analysis to have been
undertaken. However, it was decided at an early stage in the DCE design process that cost would not be
an appropriate attribute for inclusion given the hypothetical nature of the DCE and that we were not
asking women to choose between different surgical options but rather asking for their preferences
regarding outcomes of surgery.
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Chapter 8 Conclusions
The following implications for practice and research are based on the results of our evidence synthesisand economic evaluation, the information collected through our DCE and the findings of recent
national inquiries, reviews and consensus statements from relevant clinical associations.
Implications for practice
l The results of this evidence synthesis, although associated with some uncertainty and a lack of
long-term data, indicated that cure and improvement rates were generally better for retropubic MUS,
transobturator MUS and traditional sling compared with other surgical procedures. Open
colposuspension appeared relatively effective in terms of cure and improvement rates compared with
other interventions.
l The current evidence base on long-term safety of mesh and non-mesh procedures is inadequate in
quantity and quality.
l Women should receive adequate information on the benefits and risks associated with the different
types of surgical procedures for the treatment of SUI. In particular, women should be aware that mesh
implants are intended to be permanent and their removal could be challenging, if not impossible.
Implications for research
l The main uncertainty relates to the long-term assessment of surgical procedures for SUI. In particular,
further evidence is required on long-term adverse effects and quality of life. The long-term assessment
of complications and subsequent surgery after mesh and non-mesh procedures would require a large
multicentre trial with an extended follow-up period (many years). More realistic would be to promote
awareness, as well as adequate reporting and monitoring, of complications among surgeons and
health professionals.
l Studies of quality of life need to address the relationship between different levels of severity of SUI,
quality of life and the average duration of each complication’s effects, as well as investigate the
multiplicative effect of different complications on quality of life.
l Further research investigating a woman’s choice regarding surgery as a treatment option needs to
explore treatment history in greater detail while considering more individual characteristics, including
personal beliefs and perceptions that may act as a barrier to seeking professional advice.
l Although there is significant uncertainty in many of the parameters informing the modelling, the results
from the VOI analysis indicate that further research should focus on adverse events that, although not
very frequent, may have devastating effects on women’s quality of life when they do occur (e.g. tape
extrusion/exposure). In particular, information on the incidence of complications in both primary and
secondary care as well as accurate measures of the spectrum of possible complications and their impact
on women’s quality of life would be useful.
l Future research would be of greater value if investigators could improve the quality of their study reports
and agree on common definitions of outcomes and measures for recording outcomes, in accordance
with the COMET (Core Outcome Measures in Effectiveness Trials) Initiative (www.comet-initiative.org).
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Appendix 1 Literature search strategies
To bring the searches for all reviews up to date, a search of the Cochrane Incontinence GroupSpecialised Trials Register was performed (date of last search: 8 June 2017) containing trials identified,
at that time, from:
l CENTRAL (via CRSO) (searched 15 May 2017)
l MEDLINE (via OvidSP) (1946 to April Week 3 2017) (searched 1 May 2017)
l MEDLINE In-Process & Other Non-Indexed Citations (via OvidSP) covering 28 April 2017
(searched 1 May 2017)
l MEDLINE Epub Ahead of Print (via OvidSP) (covering 2 May 2017) (searched 3 May 2017)
l ClinicalTrials.gov via CRS standalone (searched 29 May 2017)
l WHO ICTRP (searched 6 June 2017).
Trials were identified by searching the Cochrane Incontinence Group Specialised Register using the terms
given below. For each review, searches were tailored to bring the searching up to date, that is, searching
was designed to retrieve any potentially relevant reports of studies added to the register since the date of
the last search for each Cochrane review.
1. Lapitan et al.5 – open retropubic colposuspension for UI in women
2. Ford et al.8 and Ogah et al.18 – MUS operations for SUI in women
3. Nambiar et al.9 – single-incision sling operations for UI in women
4. Saraswat et al.7 and Rehman et al.19 – traditional suburethral sling operations for UI in women
5. Freites et al.6 and Dean et al.20 – laparoscopic colposuspension for UI in women
6. Glazener and Cooper11 – bladder neck needle suspension for UI in women
7. Glazener and Cooper10 – anterior vaginal repair for UI in women
8. Kirchin et al.12 – urethral injection therapy for UI in women.
Search terms used for each review
All searches were of the keyword field in Reference Manager Professional Edition Version 12
(Thomson ResearchSoft, San Francisco, CA, USA) using the Cochrane Incontinence Group’s own keywords.
Lapitan et al.:5 open retropubic colposuspension for urinary incontinence
in women
Search terms used
topic.urine.incon* AND ({design.cct*} OR {design.rct*}) AND ({intvent.surg.abdo.} OR
{intvent.surg.abdo.burch.} OR {intvent.surg.abdo.colposusp.} OR {intvent.surg.abdo.mmk.} OR
{intvent.surg.burch.} OR {intvent.surg.colpo*} OR {intvent.surg.endopelvicFasciaPlication.})
Freites et al.6 and Dean et al.:20 laparoscopic colposuspension for urinary
incontinence in women
Search terms used
topic.urine.incon* AND ({design.cct*} OR {design.rct*}) AND39
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Ford et al.8 and Ogah et al.:18 mid-urethral sling operations for stress
urinary incontinence in women
Search terms used
topic.urine.incon* AND ({design.cct*} OR {design.rct*}) AND {INTVENT.SURG.SLIN*} OR
{INTVENT.SURG.SUBURETHRAL SLING.} OR {INTVENT.SURG.ABDO.SLING.}
Saraswat et al.7 and Rehman et al.:19 traditional suburethral sling
operations for urinary incontinence in women
Search terms used
topic.urine.incon* AND ({design.cct*} OR {design.rct*}) AND ({INTVENT.SURG.SLIN*} OR
{INTVENT.SURG.SUBURETHRAL SLING.} OR {INTVENT.SURG.ABDO.SLING.})
Glazener and Cooper:11 bladder neck needle suspension for urinary
incontinence in women
Search terms used
topic.urine.incon* AND ({design.cct*} OR {design.rct*}) AND ({intvent.surg.bladnecsusp.*}
OR {intvent.surg.needle.*})
Nambiar et al.:9 single-incision sling operations for urinary incontinence
in women
Search terms used
topic.urine.incon* AND ({design.cct*} OR {design.rct*}) AND {INTVENT.SURG.SLINGS.MINISLING*}
Glazener and Cooper:10 anterior vaginal repair for urinary incontinence
in women
Search terms used
topic.urine.incon* AND ({design.cct*} OR {design.rct*}) AND ({INTVENT.SURG.} OR
{INTVENT.SURG.ABDO.*} OR {INTVENT.SURG.ASSESS.} OR {INTVENT.SURG.colpofixation.staple.} OR
{INTVENT.SURG.COLPORRHAPHY.ANTERIOR.} OR {INTVENT.SURG.CYSTOPLASTY.} OR
{INTVENT.SURG.DIATHERMY.} OR {intvent.surg.endopelvicFasciaPlication.} OR {INTVENT.SURG.KELLY.} OR
{INTVENT.SURG.PARVAGINALdefectrepair.} OR {INTVENT.SURG.PELVICFLOORREPAIR.} OR
{INTVENT.SURG.PEREYRA*} OR {INTVENT.SURG.PERINEAL*} OR {INTVENT.SURG.RAMIREZ.} OR
{INTVENT.SURG.RAZ.} OR {INTVENT.SURG.STAPLING.} OR {INTVENT.SURG.SUSPENSION.URETHRAL.} OR
{INTVENT.SURG.URETHROCYSTOPEXY.ABDO.} OR {INTVENT.SURG.URETHROPEXY.MODPEREYRA.} OR
{INTVENT.SURG.VAGINAL/PERINEAL.} OR {INTVENT.SURG.VAGINAL/PERINEAL.ANTERIOR REPAIR} OR
{INTVENT.SURG.VAGINAL/PERINEAL.COLPORRHAPHY} OR
{INTVENT.SURG.VAGINAL/PERINEAL.MICROWAVE})
Kirchin et al.:12 urethral injection therapy for urinary incontinence
in women
Search terms used
topic.urine.incon* AND ({design.cct*} OR {design.rct*}) AND (INTVENT.SURG.INJECTIONS*)
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Appendix 2 Data extraction forms
TABLE 27 Study characteristics
Group 1 Group 2 Group 3
ID
Source Cochrane Review
Study name
Abstract or full-text publication
Study setting
Recruitment period
Follow-up (months)
Funding source
Intervention category (e.g. retropubic MUS)
Name of surgical procedure (e.g. tension-free vaginal tape)
Note
Number randomised
Number analysed
Number and reasons for loss to follow-up
Note
Number of surgeons involved
Surgeon experience
Inclusion criteria
Exclusion criteria
Type of stress incontinence diagnosis (e.g. symptom based or urodynamics)
UI status (e.g. stress-predominant MUI)
% MUI
Note
Age (mean, SD)
% women with previous UI surgery
% women with existing POP
% women with concurrent POP surgery
For ongoing trials only
Trial registration number
Trial start date
Trial end date
ID, identifier; POP, pelvic organ prolapse.
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TABLE 28 Cure and improvement outcome
Group 1 Group 2 Group 3
ID
Study name
Intervention category
Outcome
Description (e.g. definition, how measured)
Time (months)
Event n
Total n
ID, identifier.
TABLE 29 Adverse event outcomes
Group 1 Group 2 Group 3
ID
Study name
Intervention category
Outcome
Description (e.g. definition, how measured)
Time (months)
Event n
Mean
SD
Total n
ID, identifier.
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TABLE 30 Risk-of-bias assessment
ID
Judgement
(low, high, unclear risk)
Support for
judgementStudy name
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessor (detection bias) (patient-reported outcomes)
Blinding of outcome assessor (detection bias) (clinician-assessed outcomes)
Incomplete outcome data (attrition bias) (patient-reported outcomes)
Incomplete outcome data (attrition bias) (clinician-assessed outcomes)
Selective outcome reporting (reporting bias)
Other bias
ID, identifier.
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Appendix 3 WinBUGS code for network
meta-analysis
# random effects model for multi-arm trials
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi arm trial
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ∼ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ∼ dbin(p[i,k],n[i,k]) # binomial likelihood
logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) + # Deviance contribution
(n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))
}
resdev[i] <- sum(dev[i,1:na # summed residual deviance contribution for this trial
for (k in 2:na[i]) { # LOOP THROUGH ARMS
delta[i,k] ∼ dnorm(md[i,k],taud[i,k]) # trial-specific LOR distributions
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k] # mean of LOR distributions
taud[i,k] <- tau *2*(k-1)/k #precision of LOR distributions
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) #adjustment, multi-arm RCTs
sw[i,k] <- sum(w[i,1:k-1])/(k-1) # cumulative adjustment for multi-arm trials
}
}
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totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<- 0 # treatment effect is zero for reference treatment
for (k in 2:nt){
d[k] ∼ dnorm(0,.0001)
} # vague priors for treatment effects
sd ∼ dunif(0,5) tau <- pow(sd,-2)
# pairwise ORs and LORs for all possible pair-wise comparisons
for (c in 1:(nt-1)){
for (k in (c+1):nt){
or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- nt+1-rank(d[],k)
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (j in 1:nt) {
effectiveness[k,j] <- equals(rk[k],j )
}
}
for (k in 1:nt) {
for (j in 1:nt) {
cumeffectiveness[k,j] <- sum(effectiveness[k, 1:j])
}
}
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# SUCRAS
for (k in 1:nt) {
SUCRA[k] <- sum(cumeffectiveness[k,1:(nt-1)])/(nt-1)
}
} # *** PROGRAM ENDS
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Appendix 4 The PRISMA diagram for the clinical
effectiveness assessment
443 reports of
166 studies were
identified in the
existing Cochrane
reviews
Screening existing studies
included in Cochrane reviews
for relevance to ESTER:
• 406 reports of 147 included
   studies
• 1 report awaiting
   classification (Helmy 2012)284
• 1 report of one study
   (Wang 2008)285 incorporated
   into Wang 200937
35 reports of 17 studies
excluded: not relevant on
account of 
• Design, n = 5 studies 
• Comparison, n = 9 studies 
• Population, n = 3 studies
From the original Cochrane
reviews and the updated
searches:
• 502 reports of 147 Cochrane
   included studies were
   included in ESTER (of which
   100 reports were newly
   added during ESTER)
Updated searches new studies
identified:
• 64 reports of 28 new included 
   studies identified by the 
   ESTER update searches
Relevant for studies initially
included in Cochrane reviews:
• 2 additional reports of 
   studies subsequently 
   excluded after study 
   screening (reasons for
   exclusion given in left arm 
   of flow chart: 1 study 
   design; 1 comparison)
New studies:
• 21 reports of 10 studies
   excluded – not relevant
   due to:
   • Design, n = 3 studies
   • Comparison, n = 5 studies
   • Population, n = 2 studies
Relevant for studies initially
included in Cochrane reviews:
• 100 additional reports of
   studies already included in
   Cochrane reviews and
   included in ESTER
New studies:
• 114 reports of 63 potentially 
   relevant new studies:
 
   • 64 reports of 28 included
      studies 
   • 26 reports of 23 ongoing
      studies 
   • 2 reports of 2 studies 
      awaiting classification 
      (Pushkar 2011;286 Karmakar 
      2017287)
566 reports of 175 studies 
were included in the
qualitative synthesis. 
They were included in the 
pairwise analysis if data
were available
120 studies provided data 
for the network meta-analysis
591 records retrieved by
searching the Cochrane
Incontinence Group
Specialised Register were
screened
216 additional potentially
relevant records were 
identified and the full text
retrieved
375 records excluded
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Appendix 5 References to studies included in the
clinical effectiveness review
This appendix includes two lists of included studies:
1. Included studies identified from the eight Cochrane systematic reviews of surgery for UI. Listed by
Cochrane review in which they first appear (following the following hierarchy to avoid duplicates).
– Lapitan et al.5 – open retropubic colposuspension for UI in women
– Ford et al.8 and Ogah et al.18 – MUS operations for SUI in women
– Nambiar et al.9 – single-incision sling operations for UI in women
– Saraswat et al.7 and Rehman et al.19 – traditional suburethral sling operations for UI in women
– Freites et al.6 and Dean et al.20 – laparoscopic colposuspension for UI in women
– Glazener and Cooper11 – bladder neck needle suspension for UI in women
– Glazener and Cooper10 – anterior vaginal repair for UI in women
– Kirchin et al.12 – urethral injection therapy for UI in women.
2. New studies from the updated searches of the Cochrane Incontinence Group Specialised Register.
Key
a Primary reference where more than one report of a study was available; this is the name given to the study
as it appears in the main text of the ESTER report.
b Report from a more recent update of another of the Cochrane surgery for UI reviews.
c New further report of study found in updated search.
Note
Any relevant study and reference identifiers (IDs) are included in square brackets following each citation,
e.g. [database: identifier].
Identifiers containing ‘sr-incont’ relate to the Cochrane Incontinence Specialised Register; ‘CRSREF’ identifiers
refer to the Cochrane Register of Studies Web version (CRS-Web); ‘other’ is used to refer to either the study
acronym or the trial registration number from a number of trial registries; ‘Ref ID’ identifiers relate to those
records being processed for inclusion in the Cochrane Incontinence Specialised Register.
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1. Studies identified from the eight Cochrane systematic reviews of
surgery for urinary incontinence
(i) Cochrane review: Lapitan et al.5 – open retropubic colposuspension for UI in women
Albo 200782
Albo M, Wruck L, Baker J, Brubaker L, Chai T, Dandreo KJ, et al., for the Urinary Incontinence Treatment
Network. The relationships among measures of incontinence severity in women undergoing surgery for
stress urinary incontinence. J Urol 2007;177:1810–14. [Other: sr-incont23120]
aAlbo ME, Richter HE, Brubaker L, Norton P, Kraus SR, Zimmern PE, et al., for the Urinary Incontinence
Treatment Network. Burch colposuspension versus fascial sling to reduce urinary stress incontinence.
N Engl J Med 2007;356:2143–55. [Other: sr-incont23077]
Brubaker L, Barber MD, Nygaard I, Nager CW, Varner E, Schaffer J, et al. Quantification of vaginal
support: are continuous summary scores better than POPQ stage? Am J Obstet Gynecol 2010;203:512–16.
[Other: NCT00065845; other: sr-incont40592]
bBrubaker L, Chiang S, Zyczynski H, Norton P, Kalinoski DL, Stoddard A, et al. The impact of stress
incontinence surgery on female sexual function. Am J Obstet Gynecol 2009;200:562.e1-7. [CRSREF:
2843674; other: sr-incont31130]
Brubaker L, Richter HE, Norton PA, Albo M, Zyczynski HM, Chai TC, et al. 5-year continence rates,
satisfaction and adverse events of Burch urethropexy and fascial sling surgery for urinary incontinence.
J Urol 2012;187:1324–30. [Other: NCT00064662; other: TrialID.SISTEr.; other: sr-incont44723]
bBrubaker L, Rickey L, Xu Y, Markland A, Lemack G, Ghetti C, et al. Symptoms of combined prolapse and
urinary incontinence in large surgical cohorts. Obstet Gynecol 2010;115:310–16. [CRSREF: 2843676;
other: sr-incont39373]
bBrubaker L, Stoddard A, Richter H, Zimmern P, Moalli P, Kraus SR, et al. Mixed incontinence: comparing
definitions in women having stress incontinence surgery. Neurourol Urodyn 2009;28:268–73. [CRSREF:
2843677; other: 31415]
Brubaker L. Five year continence rates, satisfaction and adverse events of Burch urethropexy and fascial
sling surgery for urinary incontinence. Eur Urol Suppl 2012;11:e172. [Other: NCT00064662; other:
TrialID.SISTEr.; other: sr-incont62253]
Bump RC, Brubaker LT, Fine PL, Norton PA, Chancellor MB, Zyczynski H, et al. Randomised clinical trial of
Burch vs. sling procedure for stress urinary incontinence (known as SISTEr trial). CRISP database 2002.
[Other: sr-incont17205]
Burgio KL, Brubaker L, Richter HE, Wai CY, Litman HJ, France DB, et al. Patient satisfaction with stress
incontinence surgery. Neurourol Urodyn 2010;29:1403–9. [Other: sr-incont40322]
Chai T, Albo M, Richter H, Norton P, Dandreo K, Kenton K, et al. Adverse Events from a Randomized Trial
for the Surgical Treatment of Stress Urinary Incontinence. Proceedings of the International Continence
Society (ICS), 37th Annual Meeting, Rotterdam, 20–24 August 2007, abstract no. 512. [Other:
sr-incont23535]
Chai TC, Albo ME, Richter HE, Norton PA, Dandreo KJ, Kenton K, et al. Complications in women
undergoing Burch colposuspension versus autologous rectus fascial sling for stress urinary incontinence.
J Urol 2009;181:2192–7. [Other: sr-incont31150]
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Diokno AC, Richter HE, Kenton K, Norton P, Albo M, Kraus S, et al. Risk factors associated with failure of
surgical treatment for stress urinary incontinence at 24 months follow-up. Neurourol Urodyn 2007;26:745.
[Other: sr-incont23533]
FitzGerald MP, Burgio KL, Borello-France DF, Menefee SA, Schaffer J, Kraus S, et al. Pelvic-floor strength in
women with incontinence as assessed by the Brink scale. Phys Ther 2007;87:1316–24. [Other: sr-incont23825]
Kenton K, Tennstedt S, Litman H, Zimmern P, Getti C, Kusek JW, et al. Improvement in Quality of life in
Women at Two Years after Undergoing the Burch Colposuspension or Fascial Sling Procedure. Proceedings
of the International Continence Society (ICS), 38th Annual Meeting, Cairo, 20–24 October 2008, abstract
no. 206. [Other: sr-incont31863]
bKirby AC, Nager CW, Litman HJ, FitzGerald MP, Kraus S, Norton P, et al. Preoperative voiding
detrusor pressures and stress incontinence surgery outcomes. Neurourol Urodyn 2010;29:860–2.
[Other: sr-incont40122]
bKirby AC, Nager CW, Litman HJ, FitzGerald MP, Kraus S, Norton P, et al. Preoperative voiding detrusor
pressures do not predict stress incontinence surgery outcomes. Int Urogynecol J 2011;22:657–63.
[CRSREF: 2843685; other: sr-incont41732]
Kraus SR, Lemack GE, Sirls LT, Chai TC, Brubaker L, Albo M, et al. Urodynamic changes associated with
successful stress urinary incontinence surgery: is a little tension a good thing? Urology 2011;78:1257–62.
[Other: sr-incont42989]
Kraus SR, Markland A, Chai TC, Stoddard A, FitzGerald MP, Leng W, et al. Race and ethnicity do not
contribute to differences in preoperative urinary incontinence severity or symptom bother in women who
undergo stress incontinence surgery. Am J Obstet Gynecol 2007;197:92–6. [Other: sr-incont23802]
Lemack G, Krauss S, Litman H, FitzGerald M, Chai T, Nager C, et al. Preoperative urodynamic testing does
not predict postoperative voiding dysfunction among women undergoing surgery for SUI: results from a
prospective randomized trial comparing Burch versus pubovaginal sling. Neurourol Urodyn 2008;27:123.
[Other: sr-incont26919]
bLemack G, Litman H, Nager C, Brubaker L, Lowder J, Norton P, et al. Pre-operative clinical, demographic
and urodynamic measures associated with failure to demonstrate urodynamic stress incontinence in
women enrolled in two randomized clinical trials of surgery for stress urinary incontinence. Neurourol
Urodyn 2012;31:215. [CRSREF: 2843689; other: sr-incont62279]
bLemack GE, Krauss S, Litman H, FitzGerald MP, Chai T, Nager C, et al. Normal preoperative urodynamic
testing does not predict voiding dysfunction after Burch colposuspension versus pubovaginal sling.
J Urol 2008;180:2076–80. [CRSREF: 2843690; other: sr-incont27705]
bLemack GE, Litman HJ, Nager C, Brubaker L, Lowder J, Norton P, et al. Preoperative clinical, demographic,
and urodynamic measures associated with failure to demonstrate urodynamic stress incontinence in
women enrolled in two randomized clinical trials of surgery for stress urinary incontinence. Int Urogynecol J
2013;24:269–74. [CRSREF: 2843691; other: sr-incont47045]
Lemack GE, Xu Y, Brubaker L, Nager C, Chai T, Moalli P, et al, for the Urinary Incontinence Treatment
Network. Clinical and demographic factors associated with valsalva leak point pressure among women
undergoing Burch bladder neck suspension or autologous rectus fascial sling procedures. Neurourol
Urodyn 2007;26:392–6. [Other: sr-incont23233]
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bMallett VT, Brubaker L, Stoddard AM, Borello-France D, Tennstedt S, Hall L, et al. The expectations
of patients who undergo surgery for stress incontinence. Am J Obstet Gynecol 2008;198:308.e1-6.
[CRSREF: 2843693; other:sr-incont27182]
Markland AD, Kraus SR, Richter HE, Nager CW, Kenton K, Kerr L, et al. Prevalence and risk factors of fecal
incontinence in women undergoing stress incontinence surgery. Am J Obstet Gynecol 2007;197:662–7.
[Other: sr-incont26334]
Nager C, Chai T, FitzGerald M, Lemack G, Kraus S, Sirls L, et al., for the Urinary Incontinence Treatment
Network. Valsalva leak point pressure and detrusor overactivity do not predict, but urodynamic stress
incontinence does predict continence outcomes after Burch or pubovaginal sling procedures. Neurourol
Urodyn 2007;26:709–11. [Other: sr-incont23532]
bNager C, Kraus S, Zyczynski H, Chai T, Lloyd K, FitzGerald M, et al. Urodynamic measures do not predict
stress continence outcomes after surgery for stress urinary incontinence in women. J Pelvic Med Surg
2007;13:230–3. [CRSREF: 2843696; other: sr-incont34198]
bNager CW, Albo ME, FitzGerald MP, McDermott S, Wruck L, Kraus S, et al. Reference urodynamic values for
stress incontinent women. Neurourol Urodyn 2007;26:333–40. [CRSREF: 2843697; other: sr-incont23232]
bNager CW, Albo ME, FitzGerald MP, McDermott SM, Kraus S, Richter HE, et al. Process for development
of multicenter urodynamic studies. Urology 2007;69:63–7; discussion 67–8. [CRSREF: 2843698; other:
sr-incont23195]
bNager CW, FitzGerald M, Kraus SR, Chai TC, Zyczynski H, Sirls L, et al. Urodynamic measures do not
predict stress continence outcomes after surgery for stress urinary incontinence in selected women.
J Urol 2008;179:1470–4. [CRSREF: 2843699; other: sr-incont27210]
Nygaard I, Brubaker L, Chai TC, Markland AD, Menefee SA, Sirls L, et al. Risk factors for urinary tract
infection following incontinence surgery. Int Urogynecol J 2011;22:1255–65. [Other: sr-incont42698]
bRichter H, Goode P, Brubaker L, Zyczynski H, Stoddard A, Dandreo K, et al. Two-year outcomes after
surgery for stress urinary incontinence in older versus younger women. Neurourol Urodyn 2008;27:682–3.
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Appendix 6 Sample of excluded studies with
reasons for exclusion
Key
a Primary reference where more than one report of a study was available; this is the name given to the study
as it appears in the main text of the ESTER report.
b New further report of study found in updated search.
Note
Any relevant study and reference identifiers (IDs) are included in square brackets following each citation,
e.g. [database: identifier].
Identifiers containing ‘sr-incont’ relate to the Cochrane Incontinence Specialised Register; ‘CRSREF’ identifiers
refer to the Cochrane Register of Studies Web version (CRS-Web); ‘other’ is used to refer to either the study
acronym or the trial registration number from a number of trial registries; ‘Ref ID’ identifiers relate to those
records being processed for inclusion in the Cochrane Incontinence Specialised Register.
TABLE 31 Sample of excluded studies with reasons for exclusion
Study ID Reason for exclusion
Studies selected from Cochrane reviews but excluded on further assessment
Borstad 2010288 Not relevant comparison. TVT + concomitant prolapse surgery vs. TVT 3 months after
prolapse repair
Colombo 1997289 Not relevant population. Includes women with severe prolapse with clinical stress UI or
‘potential’ stress UI
Corcos 2005290 Not relevant study design. Randomisation to surgery and injectable. Which type of surgery to
have was decided based on surgeon’s preference
Kim 2004291 Not relevant comparison. One type of retropubic MUS vs. another type of retropubic MUS vs.
IRIS procedure (not relevant intervention)
Klarskov 1986292 Not relevant study design. Randomisation to surgery and PFMT. Which type of surgery to have
was decided based on VCUG and anatomy
Lee 2001293 Not relevant comparison. Injectables vs. no treatment (placebo)
Miranda 2011294 Not relevant population. Study participants do not have stress UI
Okulu 2013295 Not relevant comparison. One type of retropubic MUS vs. another
Osman 2003296 Not relevant study design. Randomisation to surgery and pharmacological treatment. Which type
of surgery to have was dictated by VLPP
Quadri 1985297 Not relevant population. Includes incontinent women with severe prolapse. Unclear if UI is
predominantly stress. Available as abstracts only with insufficient details
Teixeira 2008298 Not relevant comparison. One type of transobturator MUS vs. another
Teleb 2011299 Not relevant comparison. One type of traditional sling vs. another
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TABLE 31 Sample of excluded studies with reasons for exclusion (continued )
Study ID Reason for exclusion
ter Meulen 2009300 Not relevant comparison. Injectable vs. no treatment. Unsupervised PFMT (written instruction
only) considered equivalent to no active treatment
Tincello 2004301
(CARPET study)
Not relevant study design. 31 women included, of whom 4 were allocated by randomisation
and 27 by preference
van der Ploeg 2013302 Not relevant intervention. VPR +MUS vs. VPR alone
van Leijsen 2013303 Not relevant study design. Diagnostic cohort study with an embedded non-inferiority RCT.
Data pertinent to RCT not available
Wang 2008285 Duplicate. Included as part of the study with study ID Wang 200937
Zargham 2013304 Not relevant intervention. Anterior vaginal wall sling vs. retropubic MUS. Anterior vaginal wall
sling not a relevant intervention
New studies from update search
Campeau 2007305 Not relevant comparison. Retropubic MUS (TVT) vs. no treatment
Caremel 2013306 Not relevant comparison. Transobturator MUS vs. pharmacological treatment (anticholinergics).
Participants had MUI. Anticholinergics is generally for treatment of urgency UI
Choi 2006307 Not relevant study design. No clear evidence of randomisation. Available as abstract
Grigoriadis 2013308 Not relevant study design. No clear evidence of randomisation
Larsson 2014309 Not relevant population. Participants are patients not suitable for TVT operations. Injectable
vs. no treatment
Nikas 2012310 Not relevant comparison. Anterior repair vs. pharmacological treatment
Rose 2012311 Not relevant comparison. Injectables vs. pharmacological treatment vs. no treatment
Sung 2013312 Not relevant population. Ongoing trial with women with MUI. Not predominantly stress UI
Tuncer 2016313 Not relevant study design. Not RCT
Wadie 2016314 Not relevant comparison. Combined MUS and anterior repair vs. MUS alone
Awaiting assessment
Helmy 2012284 Awaiting classification in the open colposuspension Cochrane review.5 Unclear if this is related
to the study with study ID Albo 2007 (included study).82 Awaiting author response
Karmakar 2017287 Awaiting assessment. Secondary analysis. Unclear if data are related to SIMS (single-incision
mini-slings) trial (Mostafa 2013; included study)204 or pilot of SIMS174
Pushkar 2011286 Awaiting classification in the single-incision sling Cochrane review.9 In Russian with English
abstract. Study design unclear. Single-incision (TVT-S) vs. transobturator MUS (TVT-O)
ID, identifier; IRIS, innovative replacement of incontinence surgery; VCUG, voiding cystourethrography; VLPP, Valsalva leak
point pressure; VPR, vaginal prolapse repair.
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References for excluded studies
(i) Studies included in Cochrane reviews but excluded from ESTER, as they did not meet
the ESTER inclusion criteria
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Klarskov P, Belving D, Bischoff N, Dorph S, Gerstenberg T, Hald T, et al. Pelvic Floor Exercise versus Surgery
for Female Urinary Stress Incontinence: Preliminary Results. Proceedings of the International Continence
Society (ICS), 14th Annual Meeting, Innsbruck, September 1984. p. 159. [CRSREF: 3218453; other:
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aKlarskov P, Belving D, Bischoff N, Dorph S, Gerstenberg T, Okholm B, et al. Pelvic floor exercise
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Appendix 7 Ongoing trials
Key
a Primary reference where more than one report of a study was available; this is the name given to the study
as it appears in the main text of the ESTER report.
Note
Any relevant study and reference identifiers (IDs) are included in square brackets following each citation,
e.g. [database: identifier].
Identifiers containing ‘sr-incont’ relate to the Cochrane Incontinence Specialised Register; ‘CRSREF’ identifiers
refer to the Cochrane Register of Studies Web version (CRS-Web); ‘other’ is used to refer to either the study
acronym or the trial registration number from a number of trial registries; ‘Ref ID’ identifiers relate to those
records being processed for inclusion in the Cochrane Incontinence Specialised Register.
TABLE 32 List of ongoing trials
Study ID Interventions Start date End date
Trial registration
number
Abdel-Fattah
2014315
RP-TVT vs. transobturator
MUS (TO-TVT) vs. SIMS
1 December 2013 31 May 2019 3/069/13
Boyd 1996316 Open colposuspension vs.
laparoscopic
colposuspension
1 March 1994 28 February 1996 ISRCTN44339585
Cardozo 2002317 Retropubic MUS (TVT) vs.
periurethral injection of
collagen
1 March 2000 1 March 2002 N0116091776
Carr 2011318 Injectable (autologous
muscle-derived cells) vs.
control
December 2011 February 2016 NCT01382602
Cavkaytar
2013319
Retropubic MUS (TVT) vs.
transobturator MUS (TOT)
1 June 2013 1 June 2014 NCT01903590
Courtney-Watson
2002320
Retropubic MUS (TVT) vs.
injectable (Macroplastique)
1 May 1999 1 January 2002 N0280055971
Ding 2015321 Transobturator MUS
(TVT-O) vs. TVT-O plus
injectable (adipose-derived
mesenchymal stem cells)
NR NR ChiCTR-ICR-15006045
Elsokkary 2016322 Transobturator MUS (TOT)
vs. modified needleless
SIMS
1 February 2013 2 December 2015 PACTR201607001696163
Fu 2016323 Transobturator MUS
(inside-out TOT) vs.
innovative single-incision
sling (needleless)
NR NR ChiCTR-INR-16008068
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TABLE 32 List of ongoing trials (continued )
Study ID Interventions Start date End date
Trial registration
number
Hilton 2002324 Retropubic MUS (TVT) vs.
traditional sling (fascial
sling)
1 June 1998 1 November 1999 N0503016202
Innovation
2010325
Injectable (autologous
muscle-derived cells)
(ICES13; Innovacell
Biotechnologie, Innsbruck,
Austria) vs. placebo
18 April 2012 NR 2010–021871–10
Itkonen 2015326 Retropubic MUS (TVT) vs.
Bulkamid® (Contura
International A/S, Soeborg,
Denmark) injection
1 September 2015 1 December 2022 NCT02538991
Kaufman 2013327 Injectable (autologous
muscle-derived cells for
USR) vs. placebo
1 October 2013 1 December 2018 NCT01893138
Leitch 2016328 Retropubic MUS vs. SIMS 21 April 2016 31 December 2017 ACTRN12616000328471
Maslow 2013329 Transobturator MUS
(TVT-O) vs. single-incision
sling (MiniArc® Precise Pro;
American Medical Systems
Inc., Minnetonka, MN,
USA)
NR NR NCT01799122
Oliveira 2013330 Transobturator MUS vs.
Ophira® (Promedon,
Córdoba, Argentina) SIMS
1 January 2013 1 July 2014 NCT02540525
Reda 2014331 Retropubic MUS (TVT) vs.
SIMS
1 November 2014 1 June 2016 NCT02263534
Saaid 2008332 Retropubic MUS (TVT) vs.
transobturator MUS (TOT)
vs. Burch colposuspension
1 October 2008 1 May 2015 NCT03085979
Shen 2015333 Transobturator MUS
(modified TVT-O) vs. SIMS
‘TVT-Adjust’ [sic]
16 March 2015 16 September 2016 ChiCTR-IOR-15006140
SUITE 2009334 Injection (skeletal muscle-
derived cells) vs. SNRI
(duloxetine) vs. placebo
18 December 2009 NR 2009–011797–15
Sweed 2016335 Retropubic MUS (TVT) vs.
transobturator MUS (TOT)
vs. Burch colposuspension
1 May 2016 1 December 2018 NCT02775526
Zhu 2014336 Transobturator MUS
(TVT-O) vs. Regen Sling®
(Medprin Regenerative
Medical Technologies Co.,
Ltd., Guangzhou, China)
1 January 2014 1 December 2015 NCT02106299
Zhu 2015337 Transobturator MUS
(TVT-O) vs. single-incision
sling (TVT-S)
NR NR ChiCTR-IPR-15006967
ID, identifier; NR, not recorded; RP-TVT, retropubic tension-free vaginal tape; SIMS, single-incision mini-sling; SNRI, serotonin
and norepinephrine reuptake inhibitors; TVT-S, tension-free vaginal tape-secur; USR, urinary sphincter repair.
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References for ongoing trials
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registration number: NCT01903590. URL: http://clinicaltrials.gov/show/NCT01903590 (accessed
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Abdelwahab
2010155
Nambiar 9 I. Retro-MUS
II. Single incision
I. 30
II. 30
I. 39.2
II. 40.2
USI (DO excluded) No Yes (> 2 POP-Q excluded) NR
bAbouhashem
201438
Saraswat 60 I. Retro-MUS
II. Trad sling
Total 56 34.3 SUI No NR NR
bAdile 200339 Ford 36 I. Retro-MUS
II. Lap colpo
I. 67
II. 66
51 USI No NR No
Aigmüller 201483 Ford 3 I. Retro-MUS
II. Transob-MUS
I. 285
II. 269
I. 59.7
II. 58.6
USI (DO or
predominant OAB
excluded)
No except for
previous anterior
repair
NR No
Al-Azzawi 2014164 New 12 I. Transob-MUS
II. Trad sling
I. 40
II. 40
I. 42.8
II. 39.2
SUI, predominant
SUI
NR Yes (> 1 grade cystocele
excluded)
NR
Albo 200782 Lapitan 60 I. Open colpo
II. Trad sling
I. 329
II. 326
I. 52.2
II. 51.6
SUI, predominant
SUI
Yes Yes Yes
Alkady 2009120 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 15
II. 15
I. 48
II. 50
USI, SUI, MUI
(DO excluded)
No Yes (≥ 4 stage excluded) Yes
Amaro 2007151 Ford 36 I. Retro-MUS
II. Trad sling
I. 20
II. 21
I. 52
II. 49
USI (DI excluded) Yes NR NR
Amat 2011112 Nambiar 54 I. Transob-MUS
II. Single incision
I. 71
II. 87
I. 60.6
II. 59.9
SUI, MUI NR Yes Yes
Andonian 2007117 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 112
II. 78
I. 57–61
II. 56.2
SUI, MUI Yes Yes Yes
Andrada Hamer
2011156
Nambiar 12 I. Retro-MUS
II. Single incision
I. 69
II. 64
I. 48
II. 47
SUI, predominant
SUI
No NR No
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Aniuliene 200984 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 114
II. 150
I. 51
II. 49
SUI (OAB excluded) Yes Yes (> 2 stage excluded) NR
Aniuliene 2015121 New 12 I. Retro-MUS
II. Transob-MUS
I. 78
II. 76
I. 50
II. 67
SUI (predominant
OAB excluded)
No previous
suburethral sling
Yes (> 2 POP-Q excluded) NR
Ankardal 200185 Lapitan 12 I. Open colpo
II. Lap colpo
I. 120
II. 120
I. 42.6
II. 40.9
USI, predominant
SUI
No NR No
Araco 200886 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 120
II. 120
54 SUI (OAB
excluded)
No No NA
Arunkalaivanan
2003152
Ford 36 I. Retro-MUS
II. Trad sling
I. 68
II. 74
I. 54
II. 53
USI (DO excluded) Yes NR NR
Athanassopoulos
1996111
Lapitan 8–27 I. Open colpo
II. Bladder neck
needle
I. 27
II. 24
50 USI NR Yes NR
Bai 2005145 Lapitan 12 I. Retro-MUS
II. Open colpo
III. Trad sling
I. 31
II. 33
III. 28
I. 58.2
II. 56.5
III. 56.3
USI (DO excluded) NR Yes (> 2 grade excluded) NR
Bandarian 2011161 Lapitan 22 I. Transob-MUS
II. Open colpo
I. 31
II. 31
I. 49.4
II. 46.9
USI only (no MUI) No Yes (> 1 POP-Q stage
excluded)
NR
Barber 2008122 Ford 24 I. Retro-MUS
II. Transob-MUS
I. 88
II. 82
I. 52
II. 53
USI, MUI
(DO excluded)
No previous sling
surgery
Yes Yes
Barber 201287 Nambiar 24 I. Retro-MUS
II. Single incision
I. 127
II. 136
I. 54.6
II. 54.6
USI, MUI No previous sling
surgery
Yes Yes
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Barry 2008123 Ford 3 I. Retro-MUS
II. Transob-MUS
I. 107
II. 80
I. 53.6
II. 54.2
USI (some
had OAB)
Yes Yes Yes
Basok 2008153 Ford 12 I. Retro-MUS
II. Trad sling
I. 72
II. 67
I. 50.3
II. 47.4
SUI, MUI NR Yes (excluded uterine
prolapse, rectocele,
enterocoele, grade III or
IV cystocoele)
NR
Basu 2010157 Nambiar 36 I. Retro-MUS
I. Single incision
I. 33
II. 38
I. 48.2
II. 49.7
USI, SUI
(some had DO)
No Yes (> 2 POP-Q excluded) NR
Berglund 1996192 Lapitan 60–84 I. Open colpo
II. Ant repair
I. 30
II. 15
50 SUI only (no UUI) No Yes (included cystocele
but excluded other
gynaecological disease
requiring surgery)
NR
Bergman 1989a88 Lapitan 12 I. Open colpo
II. Bladder neck
needle
III. Ant repair
I. 101c
II. 98c
III. 99c 339
randomised
57 USI (DI excluded) No Yes (all) Yes (all)
Bergman 1989b188 Lapitan 60 I. Open colpo
II. Bladder neck
needle
III. Ant repair
I. 38c
II. 34c
III. 35c 127
randomised
55 USI No NR (excludes other
gynaecological disease
needing surgery)
No
Bianchi 201225 Nambiar 24 I. Transob-MUS
II. Single incision
I. 56
II. 66
I. 52.1
II. 54.1
USI (DO excluded;
some had urgency)
Yes Yes (> 2 POP-Q excluded) NR
bBurton 199440 Lapitan 60 I. Open colpo
II. Lap colpo
I. 30
II. 30
NR USI NR NR NR
Campos 2013176 New 12 I. Transob-MUS
II. Single incision
I. 28
II. 30
I. 59.1
II. 60.8
SUI, predominant
SUI
No Yes Yes
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Carey 200089 Lapitan 60 I. Open colpo
II. Lap colpo
I. 104
II. 96
I. 52.3
II. 50.7
USI, MUI No Yes (but excluded major
degrees of POP requiring
surgery other than a
simple rectocele repair)
Yes
bCervigni 200641 Ford NR (in-hospital
stay only?)
I. Retro-MUS
II. Transob-MUS
Total 118 57.4 SUI NR Yes (include ≥ 2 stage) Yes (all)
Chen 2010118 Ford NR I. Retro-MUS
II. Transob-MUS
I. 77
II. 110
I. 52.2
II. 47–52
USI only (no MUI) No Yes (> 2 grade cystocele
excluded)
NR
Chen 201290 Ford 24 I. Retro-MUS
II. Transob-MUS
I. 102
II. 103
NR USI only (no MUI) NR Yes NR
bChoe 201342 Ford NR (in-hospital
stay only?)
I. Retro-MUS
II. Transob-MUS
Total 41 I. 55.6
II. 53.7
SUI NR NR NR
Colombo 2000193 Lapitan 96–204 I. Open colpo
II. Ant repair
I. 37
II. 34
I. 54.9
II. 55.7
USI (DI excluded) No Yes (all had grade 2 or 3
cystocele)
Yes
Darabi Mahboub
201226
Ford 30 I. Retro-MUS
II. Transob-MUS
I. 50
II. 50
I. 52.0
II. 52.3
Predominant SUI NR Yes (> 2 grade excluded) NR
bDati 201243 New 6 I. Transob-MUS
II. Single incision
I. 58
II. 57
NR USI No Yes (> 3 stage POP
excluded)
Yes
David-Montefiore
2006124
Ford 48 I. Retro-MUS
II. Transob-MUS
I. 42
II. 46
I. 56.8
II. 53.4
USI, MUI Yes NR NR
bde Oliveira 200644 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 41d
II. 42d
52.6 SUI NR Yes (≥ 2 stage excluded) NR
D
O
I:10.3310/hta23140
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2019
VO
L.23
N
O
.14
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.This
w
ork
w
as
produced
by
Brazzelliet
al.under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,the
fullreport)m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:N
IH
R
Journals
Library,N
ationalInstitute
for
H
ealth
Research,Evaluation,Trials
and
Studies
C
oordinating
C
entre,A
lpha
H
ouse,U
niversity
of
Southam
pton
Science
Park,Southam
pton
SO
16
7N
S,U
K
.
207
Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
de Tayrac 2004125 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 31
II. 30
I. 53.6
II. 54.7
USI, predominant
SUI
Yes No NA
Deffieux 2010126 Ford 24 I. Retro-MUS
II. Transob-MUS
I. 75
II. 74
I. 54.6
II. 52.8
USI, MUI No Yes (> 1 stage POP-Q
excluded)
No
Demirci 2001103 Lapitan 12 I. Open colpo
II. Trad sling
I. 23
II. 23
I. 48.1
II. 48.9
USI (some had
UUI but not DI)
No Yes (severe POP excluded) Yes? (hysterectomy)
Di Palumbo
2003199
Glazner
2014
48 I. Bladder neck
needle
II. Ant repair
I. 28
II. 52
I. 60.6
II. 59.8
SUI, MUI, UUI,
urge-predominant
MUI (% not
reported)
NR Yes [all women had
urethrocystocele (anterior
prolapse) grade 3 or 4]
Yes? (hysterectomy)
bDiab 201245 Ford 26 I. Retro-MUS
II. Transob-MUS
I. 32
II. 31
NR SUI NR NR NR
Djehdian 201027 Nambiar 36 I. Transob-MUS
II. Single incision
I. 61
II. 69
I. 51.9
II. 54.2
USI, SUI (DO
excluded; some
had urgency)
Yes Yes (> 1 grade excluded) NR
bDrahoradova
200446
Lapitan 12 I. Retro-MUS
II. Open colpo
I. 79
II. 60
59 SUI NR NR NR
El-Barky 2005201 Lapitan 24 I. Retro-MUS
II. Open colpo
I. 25
II. 25
I. 50
II. 50
USI only (no MUI) No Yes (> 1 grade cystocele
excluded)
NR
bEl-Din Shawki
201247
Lapitan 3 I. Transob-MUS
II. Open colpo
III. Ant repair
Total 60 NR SUI NR NR NR
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
El-Hefnawy 2010127 Ford 24 I. Retro-MUS
II. Transob-MUS
I. 45
II. 42
I. 47
II. 45
USI, predominant
SUI
No pelvic or
vaginal surgery
within the
preceding
6 months
Yes (> 2 stage excluded) Yes
bEl-Hefnawy
2012127
New 12 I. Retro-MUS
II. Transob-MUS
Total 75 I. 47
II. 45
SUI, predominant
SUI
NR Yes Yes (‘grade II
cystocele or
rectocele were
only concomitant
procedure allowed
per protocol’)
bElshawaf 200949 Lapitan 6 I. Retro-MUS
II. Transob-MUS
I. 25
II. 25
III. 25
NR USI NR NR NR
Enzelsberger
1996186
Lapitan 48 I. Open colpo
II. Trad sling
I. 36
II. 36
I. 59.8
II. 56.3
SUI Yes
(all recurrent case)
Yes (grade 3 cysto- or
rectocele excluded)
No
Enzelsberger
2005104
Ford 15 I. Retro-MUS
II. Transob-MUS
I. 52
II. 53
51 SUI only (no MUI) No No NA
Enzelsberger
2010170
Nambiar 24 I. Transob-MUS
II. Single incision
I. 45
II. 45
I. 54
II. 53
SUI No NR NR
bEnzelsberger
201150
New 20 I. Transob-MUS
II. Single incision
I. 25
I. 25
NR SUI NR NR No
bFatthy 200151 Lapitan 18 I. Open colpo
II. Lap colpo
I. 40
II. 34
I. 42.9
II. 40.3
USI (DI excluded) Yes Yes (stage 3–4 excluded) NR
bFernandez 201552 New 27 I. Transob-MUS
II. Single incision
I. 98
II. 89
I. 57.8
II. 57.6
SUI, predominant
SUI
No Yes Yes
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
bFischer 200153 Lapitan 6 I. Open colpo
II. Trad sling
I. 11
II. 11
NR USI NR NR Yes
Foote 2006146 Ford 28.8 I. Retro-MUS
II. Lap colpo
I. 49
II. 48
I. 52.4
II. 51.2
USI (DO excluded) No previous
retropubic surgery
excluded
Yes (‘significant’ POP
excluded)
No
Foote 2015171 New 6 I. Transob-MUS
II. Single incision
I. 25
II. 25
I. 46.2
II. 49.6
USI No previous
retropubic UI
surgery
NR No? (‘other vaginal
surgical procedures
being performed
concurrently’
excluded)
Freeman 2011128 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 92
II. 100
I. 50
II. 54
USI, predominant
SUI
No Yes (POP extending
beyond the hymen
excluded)
NR
bFriedman 200954 Nambiar 12 I. Transob-MUS
II. Single incision
I. 42
II. 42
NR USI NR NR Yes
Gaber 201691 New 12 I. Transob-MUS
II. Single incision
I. 70
II. 140
I. 44.1
II. 43–44
USI only (no MUI) No Yes NR
German 1994190 Lapitan 24 I. Open colpo
II. Bladder neck
needle
I. 24
II. 26
I. 50
II. 53
USI Yes NR NR
Gilja 1998189 Lapitan 36 I. Open colpo
II. Bladder neck
needle
I. 56
II. 90
36 USI NR NR NR
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Gopinath 2013158
[Pilot RCT was
mentioned in a
qualitative research
paper; no further
detail provided on
the RCT]
New NR I. Retro-MUS
II. Single incision
NR NR NR NR NR NR
Guerrero 200892 Saraswat 120 I. Retro-MUS
II. Trad sling
I. 72
II. 129
I. 54.3
II. 52
USI (DO excluded) No Yes (> 2 POP-Q excluded) NR
bHalaska 200155 Lapitan 6 I. Retro-MUS
II. Open colpo
I. 15
II. 11
I. 58.3
II. 53.4
USI NR NR NR
bHammoud 201156 Ford NR I. Retro-MUS
II. Transob-MUS
I. 60
II. 50
I. 43
II. 42
SUI, MUI Yes Yes (included cystocele
grade 1–2)
NR
bHan 200169 Lapitan 6 I. Retro-MUS
II. Open colpo
I. 25
II. 25
NR USI NR NR NR
Henriksson 1978105 Lapitan 3 I. Open colpo
II. Trad sling
I. 15
II. 15
I. 56
II. 50
SUI only (no UUI) NR No NA
Hilton 1989198 Saraswat 24 I. Trad sling
II. Bladder neck
needle
I. 10
II. 10
I. 53.7
II. 57.1
USI, MUI Yes NR NR
Hinoul 2011172 Nambiar 12 I. Transob-MUS
II. Single incision
I. 98
II. 96
I. 53.2
II. 52.3
USI, SUI
(some had OAB)
No Yes (≥ 2 stage excluded) NR
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Holmes 1985194 Lapitan 24 I. Open colpo
II. Ant repair
I. 26
II. 25
I. 44.3
II. 47.1
USI, MUI No Yes Yes? (hysterectomy)
Hota 2012173 Nambiar 12 I. Transob-MUS
II. Single incision
I. 44
II. 43
I. 50.5
II. 52
USI, predominant
SUI
No previous
suburethral sling
Yes Yes
Jakimiuk 2012129 Ford 6 I. Retro-MUS
II. Transob-MUS
I. 19
II. 16
NR USI only (no MUI) No No NA
Jurakova 2016113 New 13 I. Transob-MUS
II. Single incision
I. 48
II. 45
I. 64.3
II. 62.3
USI, predominant
SUI
No No NA
bKamel 200958 Ford NR I. Retro-MUS
II. Transob-MUS
I. 60
II. 60
NR USI No NR NR
Kammerer-Doak
1999195
Lapitan 12 I. Open colpo
II. Ant repair
I. 19
II. 16
I. 44.5
II. 53
USI (DI excluded) Yes Yes Yes
Karateke 2009130 Ford NR I. Retro-MUS
II. Transob-MUS
I. 83
II. 84
I. 49.3
II. 49.1
USI (DO/OAB
excluded)
No Yes (> 1 stage POP-Q
excluded)
NR
Kiliç 2007131 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 10
II. 10
I. 55.8
II. 60.2
USI NR NR NR
Kim 2005132 Ford 3 I. Retro-MUS
II. Transob-MUS
I. 65
II. 65
I. 45.4
II. 45.7
SUI NR NR NR
bKim 201059 Nambiar NR I. Transob-MUS
II. Single incision
I. 20
II. 20
I. 50.7
II. 49.6
SUI NR NR NR
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Kitchener 200693 Lapitan 24 I. Open colpo
II. Lap colpo
I. 147
II. 144
I. 50.0
II. 50.5
USI (DO excluded) No previous
retropubic surgery
but allowed for
other previous UI
surgery
NR No
bKoelbl 200260 Lapitan NR (in-hospital
stay only?)
I. Retro-MUS
II. Open colpo
I. 83
II. 83
59.5 USI only (no MUI) NR No NA
Kondo 2006106 Ford 24 I. Retro-MUS
II. Trad sling
I. 32
II. 31
I. 59.1
II. 54.0
USI, MUI Yes NR Yes
Krofta 201094 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 149
II. 151
I. 57.2
II. 57.8
SUI only (no UUI) No Yes (≥ 2 stage POP-Q
excluded)
No
Labrie 201295 New 12 I. Transob-MUS
II. PFMT
I. 230
II. 230
I. 50.2
II. 50.0
SUI (some had
OAB)
No Yes (≥ 2 POP-Q excluded) NR
Laurikainen 200796 Ford 60 I. Retro-MUS
II. Transob-MUS
I. 136c
II. 132c
273
randomised
I. 53
II. 54
SUI No Yes [> 2 degree
(Baden-Walker) excluded]
NR
bLeanza 200961 Ford 45 I. Retro-MUS
II. Transob-MUS
I. 229
II. 211
NR USI NR Yes Yes? (‘other pelvic
defects were
solved during the
same operation for
a complete repair
of pelvic floor’)
Lee 2007107 Ford 13 I. Retro-MUS
II. Transob-MUS
I. 60
II. 60
I. 54.4
II. 51.1
USI, predominant
SUI
Yes No NA
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Lee 201228 Nambiar 36 I. Transob-MUS
II. Single incision
I. 118
II. 117
I. 51
II. 52.2
USI, SUI
(some had DO)
No previous MUS Yes Yes
bLee 201562 New 12 I. Retro-MUS
II. Single incision
Total 187 NR SUI NR NR NR
Liapis 1996200 Lapitan 60 I. Open colpo
II. Ant repair
I. 105c
II. 50c
170
randomised
50.6 USI (DI excluded) No NR Yes
Liapis 2002108 Lapitan 24 I. Retro-MUS
II. Open colpo
I. 36
II. 35
I. 46.5
II. 48.4
SUI only (no UUI) No Yes (included ≤ stage 1
cystocele)
NR
Liapis 2006133 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 46
II. 43
I. 53
II. 52
SUI (OAB/DO
excluded)
No NR No
Mackintosh
2010174
Nambiar 3 I. Transob-MUS
II. Single incision
I. 15
I. 14
I. 47.7
II. 50.6
SUI, predominant
SUI
No NR No
bMaher 200463 Ford 6 I. Retro-MUS
II. Lap colpo
I. 40
II. 42
NR SUI Yes No NA
Maher 2005102 Saraswat 12 I. Trad sling
II. Injectable
I. 22
II. 23
I. 63
II. 65
USI (some had DI) No previous sling
surgery but
allowed for other
surgery
NR No
Mak 2000182 Lapitan 12 I. Open colpo
II. Lap colpo
I. 43
II. 47
I. 50.4
II. 51.1
USI No NR Yes? (hysterectomy)
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
bMansoor 200364 Ford 6 I. Retro-MUS
II. Transob-MUS
I. 54
II. 48
NR SUI NR Yes NR
Masata 2012167 Nambiar 60 I. Transob-MUS
II. Single incision
I. 68
II. 129
I. 56.6
II. 55–58
USI, predominant
SUI
No Yes (≥ 2 stage excluded) No
Masata 2013101 New 24 I. Transob-MUS
II. Single incision
I. 50
II. 50
I. 58.9
II. 55.8
USI, predominant
SUI
No Yes (POP > 3 excluded) No
Maslow 2014175 New 12 I. Transob-MUS
II. Single incision
I. 50
II. 56
I. 48.7
II. 48.8
SUI (predominant
OAB excluded)
No Yes (> 1 stage POP
excluded)
NR
Mehdiyev 2010134 Ford NR I. Retro-MUS
II. Transob-MUS
I. 15
II. 17
NR SUI NR NR NR
bMelendez Munoz
201665
New 6 I. Transob-MUS
II. Single incision
I. 113
II. 111
NR SUI (some
had OAB)
No previous failed
suburethral tapes
NR NR
bMerali 201266 New 12 I. Transob-MUS
II. Single incision
I. 19
II. 18
NR SUI NR NR NR
Meschia 200797 Ford 6 I. Retro-MUS
II. Transob-MUS
I. 114
II. 117
I. 56
II. 58
USI (DO excluded) No Yes? (POP requiring
treatment excluded)
NR
bMirosh 200567 Ford 12 I. Retro-MUS
II. Lap colpo
I. 16
II. 14
NR USI only (no MUI) No Yes (POP-Q > 2 excluded) No
bMorris 200168 Lapitan 72 I. Open colpo
II. Lap colpo
I. 35
II. 38
NR USI NR NR NR
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Mostafa 2012204 Nambiar NR I. Transob-MUS
II. Single incision
I. 68
II. 69
I. 49.4
II. 52.6
SUI, predominant
SUI
No NR NR
Mundy 1983109 Lapitan 12 I. Open colpo
II. Bladder neck
needle
I. 26
II. 25
48 USI (no DI) Yes NR NR
Nerli 2009110 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 18
II. 18
I. 39.5
II. 50.2
SUI, predominant
SUI
NR Yes (stage 3–4 excluded) NR
Nyyssonen 2014135 Ford 46 I. Retro-MUS
II. Transob-MUS
I. 50
II. 50
I. 51
II. 54
SUI, predominant
SUI
No previous mini-
invasive operation
for SUI
NR No
Oliveira 2011168 Nambiar 24 I. Transob-MUS
II. Single incision
I. 30
II. 60
I. 52
II. 52.7
USI, SUI,
predominant SUI
No Yes (≥ 2 POP-Q excluded) NR
bO’Sullivan 200069 Lapitan 6 I. Retro-MUS
II. Open colpo
I. 11
II. 9
NR USI No Yes (‘clinically significant’
POP excluded)
NR
Palma 1985191 Lapitan 21 I. Open colpo
II. Bladder neck
needle
I. 30
II. 40
I. 46
II. 44
USI, SUI Yes NR NR
Palomba 200870
(Trial terminated
owing to poor
recruitment. No
results published)
Ford NR I. Retro-MUS
II. Transob-MUS
Total 15 NR SUI (DI excluded) No Yes (all had cystocele) NR
Paraiso 2004147 Ford 65 I. Retro-MUS
II. Lap colpo
I. 36
II. 36
I. 53.3
II. 54.8
USI (DO excluded) No Yes (POP-Q > 1 excluded) Yes? (hysterectomy
and adhesiolysis)
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Pastore 2016114 New 12 I. Transob-MUS
II. Single incision
I. 24
II. 24
I. 49.8
II. 50.2
SUI only (no UUI) No NR NR
Persson 2002148 Ford 12 I. Retro-MUS
II. Lap colpo
I. 38e
II. 32e
79 randomised
I. 48
II. 51
USI, predominant
SUI
No Yes (POP-Q > 1 excluded) No
Porena 2007136 Ford 99 I. Retro-MUS
II. Transob-MUS
I. 73
II. 75
I. 61.8
II. 60.6
SUI, predominant
SUI
No Yes (> 1 stage excluded) NR
Rechberger 200998 Ford 18 I. Retro-MUS
II. Transob-MUS
I. 269
II. 268
I. 55.6
II. 55.8
SUI NR Yes (> 1 grade POP-Q
excluded)
NR
Richter 201099 Ford 60 I. Retro-MUS
II. Transob-MUS
I. 298
II. 299
I. 52.7
II. 53.1
SUI, predominant
SUI
Yes Yes Yes
bRiva 200671 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 66
II. 65
NR SUI No Yes (urethro-cystocele of
grade 0–2)
NR
Ross 2009137 Ford 60 I. Retro-MUS
II. Transob-MUS
I. 105
II. 94
I. 51.8
II. 50.1
SUI (UUI included;
OAB excluded)
No NR No
Ross 2014159 New 12 I. Retro-MUS
II. Single incision
I. 40
II. 34
I. 47.2
II. 52.4
SUI, MUI No NR No
bRudnicki 201672 New 12 I. Retro-MUS
II. Transob-MUS
III. Single incision
I. 83
II. 67
III. 155
NR SUI, predominant
SUI
No Yes (> 2 POP-Q excluded) NR
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Salari 2010127 New 12 I. Transob-MUS
II. Ant repair
I. 30
II. 30
I. 44.1
II. 37.8
SUI only (no UUI) No Yes (all had stage 1 or 2
cystocele)
NR
bSalem 201473 Ford 60 I. Retro-MUS
II. Transob-MUS
I. 39
II. 37
35.3 SUI NR NR NR
Samiee 2009163 Freites NR I. Transob-MUS
II. Lap colpo
I. 19
II. 16
NR SUI (DO excluded) No Yes (excluded severe
anterior vaginal prolapse
and uterine prolapse)
NR
Sand 2000187 Lapitan 72 I. Open colpo
II. Trad sling
I. 19
II. 17
I. 61.3
II. 60.4
USI, MUI Yes Yes (significant pelvic
support defects excluded)
Yes
Scheiner 2012119 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 80
II. 80
I. 57.8
II. 57–5
SUI, predominant
SUI
No previous sling
surgery
Yes (a symptomatic
cystocele stage 2 or
higher according to the
POP-Q system was
corrected first.
Participants with
concomitant sling
insertion to repair
prolapse were included)
Yes
Schellart 2013177 New 36 I. Transob-MUS
II. Single incision
I. 96
II. 97
I. 53
II. 53
SUI No Yes (≥ 2 stage POP
excluded)
NR
Schierlitz 2008138 Ford 63 I. Retro-MUS
II. Transob-MUS
I. 82
II. 82
I. 60
II. 6
USI Yes NR Yes
Schweitzer 201229 Nambiar 12 I. Transob-MUS
II. Single incision
I. 56
II. 100
I. 48.3
II. 50.8
SUI No Yes (> 1 POP-Q excluded) NR
bSeo 201174 Nambiar 24 I. Transob-MUS
II. Single incision
I. 39
II. 41
I. 46.5
II. 46.9
SUI NR NR NR
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Sharifiaghdas
200881
Saraswat 126 I. Retro-MUS
II. Trad sling
I. 48
II. 52
I. 49.1
II. 55.0
USI, MUI NR Yes (> 1 POP-Q excluded) No? (gynaecological
problems which
need simultaneous
repairs such as
high-grade prolapse
excluded)
Sharifiaghdas
2015197
New 13.8 I. Trad sling
II. Single incision
Total 72 I. 52.2
II. 55.6
SUI Yes Yes (≥ 3 grade cystocele
excluded)
NR
bShawky 201575 New 12 I. Transob-MUS
II. Single incision
I. 28
II. 30
NR SUI NR NR NR
Silva-Filho 2006165 Ford 6 I. Transob-MUS
II. Trad sling
I. 10
II. 10
I. 55.2
II. 49.8
USI, SUI
(DO excluded)
No NR NR
Sivaslioglu 2007162 Lapitan 24 I. Transob-MUS
II. Open colpo
I. 49
II. 51
I. 45.4
II. 46.1
USI only (no UUI) No Yes (> 1 POPQ stage
excluded)
NR
Sivaslioglu 2012178 Nambiar 60 I. Transob-MUS
II. Single incision
I. 40
II. 40
I. 51.5
II. 54.0
USI only
(no UUI/MUI)
No NR NR
Smith 201130 Nambiar 15.3 I. Transob-MUS
II. Single incision
I. 49
II. 49
I. 48.9
II. 52.9
USI, predominant
SUI
No Yes (median stage 3) Yes
Song 2004154 Ford 20–37 I. Retro-MUS
II. Trad sling
I. 48
II. 19
I. 53
II. 71
SUI, MUI NR Yes NR
Sottner 2012169 Nambiar NR I. Transob-MUS
II. Single incision
I. 12
II. 31
NR Predominant SUI NR NR NR
bStangel-
Wojcikiewicz
200876
Lapitan 18 I. Open colpo
II. Lap colpo
I. 57
II. 51
NR USI (OAB excluded) NR Yes (> 2 POPQ grade
excluded)
NR
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Su 1997183 Lapitan 6 I. Open colpo
II. Lap colpo
I. 46
II. 46
I. 44.3
II. 42.4
USI (DO excluded) No Yes (> 1 degree cystocele
excluded)
Yes? (hysterectomy)
bSummitt 200077 Lapitan 12 I. Open colpo
II. Lap colpo
I. 28d
II. 34d
NR USI (DO excluded) No previous
retropubic
urethropexy,
needle suspension
or suburethral sling
NR No
Tang 2014179 New 24 I. Transob-MUS
II. Single incision
I. 48
II. 46
I. 51.3
II. 49.8
SUI only (no UUI) NR Yes (POP requiring
extensive surgery
excluded)
No
Tanuri 2010139 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 10
II. 20
NR SUI only Yes Yes (> 2 stage excluded) NR
bTapp 198978 Lapitan 6 I. Open colpo
II. PFMT
I. 24
II. 21
NR USI only (no MUI) No NR NR
Tarcan 201131 Ford 12 I. Retro-MUS
II. Transob-MUS
Total 54 54 USI, predominant
SUI
No Yes (≥ 3 stage excluded) Yes
Tcherniakovsky
2009166
Saraswat 12 I. Transob-MUS
II. Trad sling
I. 21
II. 20
I. 46.5
II. 52.1
USI Yes Yes NR
Téllez Martínez-
Fornés 2009202
Lapitan 36 I. Retro-MUS
II. Open colpo
I. 24
II. 25
I. 47.13
II. 50
USI (OAB excluded) No Yes (> I grade cystocele
excluded)
NR
Teo 2011140 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 66
II. 61
I. 52.4
II. 50.9
USI (DO excluded) No Yes (> 1 stage excluded) NR
Tommaselli 2010180 Nambiar 63 I. Transob-MUS
II. Single incision
I. 42
II. 42
I. 58.2
II. 57.8
USI, predominant
SUI
No Yes (≥ 2 POP-Q excluded) NR
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Trabuco 201432 Lapitan 6 I. Retro-MUS
II. Open colpo
I. 57
II. 56
I. 56
II. 56
SUI, predominant
SUI
Yes Yes (all; > 90% had
POP-Q ≥ 2)
Yes (all)
Tuygun 2006184 Lapitan 38.7 I. Open colpo
II. Lap colpo
I. 33
II. 27
I. 53
II. 52
SUI No Yes NR
Ustün 2003149 Ford 18 I. Retro-MUS
II. Lap colpo
I. 23
II. 23
I. 45.6
II. 45
USI NR No NA
Ustün 2005185 Lapitan 14.2 I. Open colpo
II. Lap colpo
I. 26
II. 26
I. 42.3
II. 43.6
USI (DI excluded) No NR Yes
Valpas 2004150 Ford 60 I. Retro-MUS
II. Lap colpo
I. 70
II. 51
I. 50
II. 48
USI No but allowed for
previous anterior
repair
NR No
bVan Rensburg
201579
New 12 I. Transob-MUS
II. Single incision
I. 41c
II. 51c
I. 55.7
II. 54.4
SUI, MUI Yes Yes Yes
Wadie 2005160 Ford 54 I. Retro-MUS
II. Ant repair
I. 28
II. 25
I. 44.9
II. 45.3
USI, predominant
SUI
No Yes (> 2 grade excluded) Yes
Wang 2003203 Lapitan 22 I. Retro-MUS
II. Open colpo
I. 49
II. 49
51.6 USI No No NA
Wang 2006141 Ford 9 I. Retro-MUS
II. Transob-MUS
I. 29
II. 31
I. 51.4
II. 50.5
USI No Yes (> 2 stage POP
excluded)
NR
Wang 200937 Ford 20 I. Retro-MUS
II. Transob-MUS
I. 160
II. 155
I. 55
II. 54.8
USI only (no UUI) Yes Yes Yes
Wang 2010142 Ford 12 I. Retro-MUS
II. Transob-MUS
I. 70
II. 70
I. 60
II. 58
USI only (no UUI) Yes Yes NR
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Study ID (first
author and year)
Source
reviewa
Length of FU
or last FU
(months) Intervention N randomised
Age
(mean or
median) UI diagnosis
Previous UI
surgery in some
or all participants
Co-existing POP in
some or all participants
Concomitant POP
surgery in some
or all participants
Wang 2011116 Ford and
Nambiar
12 I. Retro-MUS
II. Transob-MUS
III. Single incision
I. 32d
II. 36d
III. 34d
108 randomised
I. 56.6
II. 56.0
III. 57.3
SUI, predominant
SUI
No NR No
Ward 2002100 Lapitan 60 I. Retro-MUS
II. Open colpo
I. 175
II. 169
NR USI (DO excluded) No Yes (vaginal prolapse
requiring treatment
excluded)
No
Xin 2016115 New 12 I. Transob-MUS
II. Single incision
I. 184
II. 184
I. 56.5
II. 57.6
USI, predominant
SUI
No Yes (≥ 2 POP-Q excluded) NR
bYoon 201180 Nambiar 1 I. Transob-MUS
II. Single incision
I. 51
II. 52
I. 57.0
II. 52.9
SUI NR NR NR
Zhang 2014143 New 95 I. Retro-MUS
II. Transob-MUS
I. 70
II. 70
I. 55
II. 51
SUI only (no MUI) No Yes (> 1 stage POP
excluded)
NR
Zullo 2007144 Ford 60 I. Retro-MUS
II. Transob-MUS
I. 35
II. 37
I. 52.8
II. 53.4
SUI (DO/OAB
excluded)
No Yes (> 1 stage excluded) NR
Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle suspension; DI, detrusor instability; DO, detrusor overactivity; FU, follow-up; ID, identifier; lap colpo,
laparoscopic colposuspension; NR, not recorded; OAB, overactive bladder; open colpo, open colposuspension; POP, pelvic organ prolapse; POP-Q, pelvic organ prolapse quantification
system; retro-MUS, retropubic mid-urethral sling; single incision, single-incision sling; trad sling, traditional sling; transob-MUS, transobturator mid-urethral sling; USI, urodynamic
stress incontinence.
a Source Cochrane reviews: Ford, Ford et al.8 and Ogah et al.18 – MUS operations for SUI in women; Lapitan, Lapitan et al.5 – open retropubic colposuspension for UI in women; Freites,
Freites et al.6 and Dean et al.20 – laparoscopic colposuspension for UI in women; Saraswat, Saraswat et al.7 and Rehman et al.19 – traditional suburethral sling operations for UI in women;
Nambiar, Nambiar et al.9 – single-incision sling operations for UI in women; Glazener, Glazener and Cooper11 – bladder neck needle suspension for UI in women; new, studies identified
by update search.
b Abstract only.
c Number analysed.
d Number followed up.
e Number receiving intervention.
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Appendix 9 Risk-of-bias assessment of
175 included studies
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Source
reviewa
Study ID (first author
and year)
Interventionb Risk-of-bias assessment criterionb
1 2 3 1 2 3 4a 4b 4c 5 6a 6b 6c 7 8
Ford Aigmüller 201483 Retro-MUS Trans-MUS L L H H L
Ford Alkady 2009120 Retro-MUS Trans-MUS L L U U L
Ford Andonian 2007117 Retro-MUS Trans-MUS U U L L U
Ford Aniuliene 200984 Retro-MUS Trans-MUS U U U U L
New Aniuliene 2015121 Retro-MUS Trans-MUS U U H H H L L U U
Ford Araco 200886 Retro-MUS Trans-MUS L L U L H
Ford Barber 2008122 Retro-MUS Trans-MUS L L U L L
Ford Barry 2008123 Retro-MUS Trans-MUS U U U U L
Ford cCervigni 200641 Retro-MUS Trans-MUS L U U U L
Ford Chen 2010118 Retro-MUS Trans-MUS U U U U U
Ford Chen 201290 Retro-MUS Trans-MUS U U U U U
Ford cChoe 201342 Retro-MUS Trans-MUS U U U U U
Ford dDarabi Mahboub 201226 Retro-MUS Trans-MUS L U U U U U U H U
Ford David-Montefiore 2006124 Retro-MUS Trans-MUS L L U U U
Ford cde Oliveira 200644 Retro-MUS Trans-MUS U U U U U
Ford de Tayrac 2004125 Retro-MUS Trans-MUS L L U L U
Ford Deffieux 2010126 Retro-MUS Trans-MUS L L H U L
Ford cDiab 201245 Retro-MUS Trans-MUS U U U U U
Ford El-Hefnawy 2010127 Retro-MUS Trans-MUS U L U L L
New cEl-Hefnawy 201248 Retro-MUS Trans-MUS U U U U U U U U U
Lapitan cElshawaf 200949 Retro-MUS Trans-MUS Open colpo U U U U U U
Ford Enzelsberger 2005104 Retro-MUS Trans-MUS H H U U U
Ford Freeman 2011128 Retro-MUS Trans-MUS L L L U L
Ford cHammoud 201156 Retro-MUS Trans-MUS U U U U U
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Source
reviewa
Study ID (first author
and year)
Interventionb Risk-of-bias assessment criterionb
1 2 3 1 2 3 4a 4b 4c 5 6a 6b 6c 7 8
Ford Jakimiuk 2012129 Retro-MUS Trans-MUS L U L U U
Ford cKamel 200958 Retro-MUS Trans-MUS U U U U U
Ford Karateke 2009130 Retro-MUS Trans-MUS L U U L L
Ford Kiliç 2007131 Retro-MUS Trans-MUS U U U U U
Ford Kim 2005132 Retro-MUS Trans-MUS U U U U U
Ford Krofta 201094 Retro-MUS Trans-MUS L U H L L
Ford Laurikainen 200796 Retro-MUS Trans-MUS L L U U L
Ford cLeanza 200961 Retro-MUS Trans-MUS U U U U U
Ford Lee 2007107 Retro-MUS Trans-MUS H H U U U
Ford Liapis 2006133 Retro-MUS Trans-MUS U U U U L
Ford cMansoor 200364 Retro-MUS Trans-MUS L L U U U
Ford Mehdiyev 2010134 Retro-MUS Trans-MUS U U U U U
Ford Meschia 200797 Retro-MUS Trans-MUS L L U U L
Ford Nerli 2009110 Retro-MUS Trans-MUS H H U U U
Ford Nyyssonen 2014135 Retro-MUS Trans-MUS L L U U L
Ford cPalomba 200870 Retro-MUS Trans-MUS U U U U U
Ford Porena 2007136 Retro-MUS Trans-MUS L L U L L
Ford Rechberger 200998 Retro-MUS Trans-MUS U U U U L
Ford Richter 201099 Retro-MUS Trans-MUS L U U U U
Ford cRiva 200671 Retro-MUS Trans-MUS U U U U U
Ford Ross 2009137 Retro-MUS Trans-MUS L L U U L
New cRudnicki 201672 Retro-MUS Trans-MUS Single incision L U U U U U L H U
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Source
reviewa
Study ID (first author
and year)
Interventionb Risk-of-bias assessment criterionb
1 2 3 1 2 3 4a 4b 4c 5 6a 6b 6c 7 8
Ford cSalem 201473 Retro-MUS Trans-MUS U U U U U
Ford Scheiner 2012119 Retro-MUS Trans-MUS L U U U L
Ford Schierlitz 2008138 Retro-MUS Trans-MUS L U U U U
Ford Tanuri 2010139 Retro-MUS Trans-MUS U U U U L
Ford dTarcan 201131 Retro-MUS Trans-MUS L U U U U U U L U
Ford Teo 2011140 Retro-MUS Trans-MUS L L H H H
Ford Wang 2006141 Retro-MUS Trans-MUS L U U L L
Ford Wang 200937 Retro-MUS Trans-MUS L U U L L
Ford Wang 2010142 Retro-MUS Trans-MUS U U H L L
Ford Wang 2011116 Retro-MUS Trans-MUS Single incision L L U U L
New Zhang 2014143 Retro-MUS Trans-MUS L U H H L L L L U
Ford Zullo 2007144 Retro-MUS Trans-MUS L L U L L
Lapitan Bai 2005145 Retro-MUS Open colpo Trad sling U U U U U U
Lapitan cDrahoradova 200446 Retro-MUS Open colpo U U U H U U
Lapitan El-Barky 2005201 Retro-MUS Open colpo U U U U U U
Lapitan cHalaska 200155 Retro-MUS Open colpo U U U U U U
Lapitan cHan 200157 Retro-MUS Open colpo U U U U U U
Lapitan cKoelbl 200260 Retro-MUS Open colpo L U U U U U
Lapitan Liapis 2002108 Retro-MUS Open colpo H U U U U U
Lapitan cO’Sullivan 200069 Retro-MUS Open colpo U U U U U U
Lapitan Téllez Martínez-Fornés
2009202
Retro-MUS Open colpo U U H U U U
Lapitan dTrabuco 201432 Retro-MUS Open colpo L L H L L U U L U
Lapitan Wang 2003203 Retro-MUS Open colpo L U U U U U
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Source
reviewa
Study ID (first author
and year)
Interventionb Risk-of-bias assessment criterionb
1 2 3 1 2 3 4a 4b 4c 5 6a 6b 6c 7 8
Lapitan Ward 2002100 Retro-MUS Open colpo L L H U L U
Ford cAdile 200339 Retro-MUS Lap colpo U U U U U
Ford Foote 2006146 Retro-MUS Lap colpo L U U U U
Ford cMaher 200463 Retro-MUS Lap colpo L L U U U
Ford cMirosh 200567 Retro-MUS Lap colpo U U U U L
Ford Paraiso 2004147 Retro-MUS Lap colpo L L U U L
Ford Persson 2002148 Retro-MUS Lap colpo L L U L L
Ford Ustün 2003149 Retro-MUS Lap colpo U U U U L
Ford Valpas 2004150 Retro-MUS Lap colpo L L U U L
Saraswat cAbouhashem 201438 Retro-MUS Trad sling U U U U
Ford Amaro 2007151 Retro-MUS Trad sling U U L U U
Ford Arunkalaivanan 2003152 Retro-MUS Trad sling U U U U U
Ford Basok 2008153 Retro-MUS Trad sling U U U U U
Saraswat Guerrero 200892 Retro-MUS Trad sling L L L L
Ford Kondo 2006106 Retro-MUS Trad sling H H U U L
Saraswat Sharifiaghdas 200881 Retro-MUS Trad sling U U U L
Ford Song 2004154 Retro-MUS Trad sling U U U U U
Nambiar Abdelwahab 2010155 Retro-MUS Single incision U U U U L
Nambiar Andrada Hamer 2011156 Retro-MUS Single incision U L H L H
Nambiar Barber 201287 Retro-MUS Single incision L L L L H
Nambiar Basu 2010157 Retro-MUS Single incision L L L U L
New Gopinath 2013158 Retro-MUS Single incision U U U U U U U U U
New cLee 201562 Retro-MUS Single incision U U U U U U U L U
New Ross 2014159 Retro-MUS Single incision L L H L H L L L U
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Source
reviewa
Study ID (first author
and year)
Interventionb Risk-of-bias assessment criterionb
1 2 3 1 2 3 4a 4b 4c 5 6a 6b 6c 7 8
Ford Wadie 2005160 Retro-MUS Ant repair L L U U L
Lapitan Bandarian 2011161 Trans-MUS Open colpo U U U U U U
Lapitan cEl-Din Shawki 201247 Trans-MUS Open colpo Ant repair U U U U U U
Lapitan Sivaslioglu 2007162 Trans-MUS Open colpo L U H U L U
Freites Samiee 2009163 Trans-MUS Lap colpo U U U U U U U
New Al-Azzawi 2014164 Trans-MUS Trad sling L U H H U L L U U
Ford Silva-Filho 2006165 Trans-MUS Trad sling U U U U U
Saraswat Tcherniakovsky 2009166 Trans-MUS Trad sling U U U L
Nambiar Amat 2011112 Trans-MUS Single incision H U H U H
Nambiar dBianchi 201225 Trans-MUS Single incision L L U U L L L L U
New Campos 2013176 Trans-MUS Single incision L L H H U L L H U
New cDati 201243 Trans-MUS Single incision U U U U U U U H U
Nambiar dDjehdian 201027 Trans-MUS Single incision L L H H U L L L U
Nambiar Enzelsberger 2010170 Trans-MUS Single incision U U U U L
New cEnzelsberger 201150 Trans-MUS Single incision U U U U U U U U U
New cFernandez 201552 Trans-MUS Single incision L U U H H L L L U
New Foote 2015171 Trans-MUS Single incision U U U U H L L L U
Nambiar cFriedman 200954 Trans-MUS Single incision U U U U L
New Gaber 201691 Trans-MUS Single incision L U H L L L L H U
Nambiar Hinoul 2011172 Trans-MUS Single incision L U H U H
Nambiar Hota 2012173 Trans-MUS Single incision U L H U H
New Jurakova 2016113 Trans-MUS Single incision U U H H H L L L U
Nambiar cKim 201059 Trans-MUS Single incision U U U U U
Nambiar dLee 201228 Trans-MUS Single incision L L H H U U U L U
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Source
reviewa
Study ID (first author
and year)
Interventionb Risk-of-bias assessment criterionb
1 2 3 1 2 3 4a 4b 4c 5 6a 6b 6c 7 8
Nambiar Mackintosh 2010174 Trans-MUS Single incision L L H L L
Nambiar Masata 2012167 Trans-MUS Single incision L L H U U
New Masata 2013101 Trans-MUS Single incision L L H H U L L L U
New Maslow 2014175 Trans-MUS Single incision L L H U L H H L U
New cMelendez Munoz 201665 Trans-MUS Single incision L U H H U U U L U
New cMerali 201266 Trans-MUS Single incision U U U U U U L U U
Nambiar Mostafa 2012204 Trans-MUS Single incision L L H L U
Nambiar Oliveira 2011168 Trans-MUS Single incision U U U U L
New Pastore 2016114 Trans-MUS Single incision L U U U U L L L U
New Schellart 2013177 Trans-MUS Single incision U U H H H L L L U
Nambiar dSchweitzer 201229 Trans-MUS Single incision L L H L L H H L U
Nambiar cSeo 201174 Trans-MUS Single incision U U U U U
New cShawky 201575 Trans-MUS Single incision U U U U U U L H U
Nambiar Sivaslioglu 2012178 Trans-MUS Single incision L U U L L
Nambiar dSmith 201130 Trans-MUS Single incision L U H H H L L L U
Nambiar Sottner 2012169 Trans-MUS Single incision U U U U U
New Tang 2014179 Trans-MUS Single incision U U H H H L L L U
Nambiar Tommaselli 2010180 Trans-MUS Single incision L U H U H
New cVan Rensburg 201579 Trans-MUS Single incision L U H H U U U L U
New Xin 2016115 Trans-MUS Single incision L U U U L U U L U
Nambiar cYoon 201180 Trans-MUS Single incision U U U U U
New Salari 2010127 Trans-MUS Ant repair L U U U L L L L U
New Labrie 201295 Trans-MUS PFMT L H H H U L L L U
Lapitan Ankardal 200185 Open colpo Lap colpo U L U U U U
D
O
I:10.3310/hta23140
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2019
VO
L.23
N
O
.14
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.This
w
ork
w
as
produced
by
Brazzelliet
al.under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,the
fullreport)m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:N
IH
R
Journals
Library,N
ationalInstitute
for
H
ealth
Research,Evaluation,Trials
and
Studies
C
oordinating
C
entre,A
lpha
H
ouse,U
niversity
of
Southam
pton
Science
Park,Southam
pton
SO
16
7N
S,U
K
.
229
Source
reviewa
Study ID (first author
and year)
Interventionb Risk-of-bias assessment criterionb
1 2 3 1 2 3 4a 4b 4c 5 6a 6b 6c 7 8
Lapitan Burton 199440 Open colpo Lap colpo U U U U L U
Lapitan Carey 200089 Open colpo Lap colpo L U L L U U
Lapitan cFatthy 200151 Open colpo Lap colpo L L U U U U
Lapitan Kitchener 200693 Open colpo Lap colpo L L H H L U
Lapitan Mak 2000182 Open colpo Lap colpo L L U U U U
Lapitan cMorris 200168 Open colpo Lap colpo U U U U U U
Lapitan cStangel-Wojcikiewicz
200876
Open colpo Lap colpo U U U U U U
Lapitan Su 1997183 Open colpo Lap colpo L L U U U U
Lapitan cSummitt 200077 Open colpo Lap colpo U L U U U U
Lapitan Tuygun 2006184 Open colpo Lap colpo U U U U L U
Lapitan Ustün 2005185 Open colpo Lap colpo L L U U L U
Lapitan Albo 200782 Open colpo Trad sling L U H H L U
Lapitan Demirci 2001103 Open colpo Trad sling H H U U U U
Lapitan Enzelsberger 1996186 Open colpo Trad sling L U U U U U
Lapitan cFischer 200153 Open colpo Trad sling U U U U U U
Lapitan Henriksson 1978105 Open colpo Trad sling H H U U U U
Lapitan Sand 2000187 Open colpo Trad sling L U U U U U
Lapitan Athanassopoulos 1996111 Open colpo Bladder neck
needle
H H U U U U
Lapitan Bergman 1989a88 Open colpo Bladder neck
needle
Ant repair L U U U L U
Lapitan Bergman 1989b188 Open colpo Bladder neck
needle
Ant repair L U U U U U
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Source
reviewa
Study ID (first author
and year)
Interventionb Risk-of-bias assessment criterionb
1 2 3 1 2 3 4a 4b 4c 5 6a 6b 6c 7 8
Lapitan German 1994190 Open colpo Bladder neck
needle
U U U U U U
Lapitan Gilja 1998189 Open colpo Bladder neck
needle
L U U U H U
Lapitan Mundy 1983109 Open colpo Bladder neck
needle
H H U U U U
Lapitan Palma 1985191 Open colpo Bladder neck
needle
U U L L U U
Lapitan Berglund 1996192 Open colpo Ant repair U U U U U U
Lapitan Colombo 2000193 Open colpo Ant repair L H U U L U
Lapitan Holmes 1985194 Open colpo Ant repair L U U U U U
Lapitan Kammerer-Doak 1999195 Open colpo Ant repair L U U U U U
Lapitan Liapis 1996200 Open colpo Ant repair L U U U U U
Lapitan cTapp 198978 Open colpo PFMT U U U U U U
New Sharifiaghdas 2015197 Trad sling Single incision U U U U U U U L U
Saraswat Maher 2005102 Trad sling Injectable U U U L
Saraswat Hilton 1989198 Trad sling Bladder neck
needle
L U U L
Glazener Di Palumbo 2003199 Bladder neck
needle
Ant repair U L U L
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Source
reviewa
Study ID (first author
and year)
Interventionb Risk-of-bias assessment criterionb
1 2 3 1 2 3 4a 4b 4c 5 6a 6b 6c 7 8
Risk 1 2 3 4a 4b 4c 5 6a 6b 6c 7 8
Low, n (%) 85
(49)
49
(28)
8
(5)
20
(15)
4
(11)
8
(22)
1
(14)
54
(39)
18
(50)
21
(58)
24
(65)
0
(0)
Unclear risk, n (%) 80
(46)
116
(66)
123
(73)
107
(81)
17
(47)
20
(56)
6
(86)
76
(55)
16
(44)
13
(36)
7
(19)
82
(100)
High risk, n (%) 10
(6)
10
(6)
37
(22)
5
(4)
15
(42)
8
(22)
0
(0)
9
(6)
2
(6)
2
(6)
6
(16)
0
(0)
Total, n 175 175 168 132 36 36 7 139 36 36 37 82
Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle suspension; H, high; injectable, urethral injection therapy; L, low; lap colpo, laparoscopic colposuspension;
open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling; single incision, single-incision sling; trad sling, traditional sling; trans-MUS, transobturator mid-urethral sling;
U, unclear.
a Source Cochrane reviews: Ford, Ford et al.8 and Ogah et al.18 – MUS operations for SUI in women; Lapitan, Lapitan et al.5 – open retropubic colposuspension for UI in women; Freites,
Freites et al.6 and Dean et al.20 – laparoscopic colposuspension for UI in women; Saraswat, Saraswat et al.7 and Rehman et al.19 – traditional suburethral sling operations for UI in women;
Nambiar, Nambiar et al.9 – single-incision sling operations for UI in women; Glazener, Glazener and Cooper11 – bladder neck needle suspension for UI in women; new, studies identified
by update search.
b Assessment criteria (domain): 1, random sequence generation (selection bias); 2, allocation concealment (selection bias); 3, blinding of participants and personnel (performance bias);
4a, blinding of outcome assessment (detection bias) – all outcomes; 4b, blinding of outcome assessment (detection bias) – patient-reported outcomes; 4c, blinding of outcome assessment
(detection bias) – clinician-measured outcomes; 5, blinding (performance bias and detection bias); 6a, incomplete outcome data (attrition bias) – all outcomes; 6b, incomplete outcome
data (attrition bias) – patient-reported outcomes; 6c, incomplete outcome data (attrition bias) – clinician-measured outcomes; 7, selective reporting (reporting bias); 8, other bias.
c Available as abstract only.
d Risk-of-bias assessment was updated as a new full-text paper was found for the study previously available as abstract in a Cochrane review.
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Appendix 10 Network meta-analysis:
total number of trials included in each treatment
comparison for the number of women cured
or improved
Intervention comparison Cure, n (%) (N= 105) Improvement, n (%) (N= 120)
Transob-MUS vs. retro-MUS 36 (34.3) 40 (33.3)
Open colpo vs. retro-MUS 6 (5.7) 6 (5.0)
Lap colpo vs. retro-MUS 2 (1.9) 4 (3.3)
Trad sling vs. retro-MUS 6 (5.7) 6 (5.0)
Single incision vs. retro-MUS 6 (5.7) 6 (5.0)
Open colpo vs. transob-MUS 1 (1.0) 1 (0.8)
Trad sling vs. transob-MUS 1 (1.0) 1 (0.8)
Single incision vs. transob-MUS 21 (20.0) 28 (23.3)
Ant repair vs. transob-MUS 1 (1.0) 1 (0.8)
PFMT vs. transob-MUS 1 (1.0) 1 (0.8)
Lap colpo vs. open colpo 9 (8.6) 9 (7.5)
Trad sling vs. open colpo 3 (2.9) 3 (2.5)
Bladder neck needle vs. open colpo 3 (2.9) 3 (2.5)
Anterior repair vs. open colpo 3 (2.9) 3 (2.5)
PFMT vs. open colpo 1 (1.0) 1 (0.8)
Single incision vs. trad sling 0 (0) 1 (0.8)
Bladder neck needle vs. trad sling 1 (1.0) 1 (0.8)
Transob-MUS vs. single-incision vs. retro-MUS 1 (1.0) 2 (1.7)
Open colpo vs. trad sling vs. retro-MUS 1 (1.0) 1 (0.8)
Bladder neck needle vs. anterior repair vs. open colpo 2 (1.9) 2 (1.7)
Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle suspension; lap colpo, laparoscopic
colposuspension; open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling; single incision, single-incision
sling; trad sling, traditional sling; transob-MUS, transobturator mid-urethral sling.
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Appendix 11 Meta-analyses results: number of
women cured
Overall (I2 = 3.8%; p = 0.403)
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FIGURE 8 Transobturator MUS vs. retropubic MUS: cure.
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FIGURE 9 Open colposuspension vs. retropubic MUS: cure.
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FIGURE 10 Laparoscopic colposuspension vs. retropubic MUS: cure.
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FIGURE 11 Traditional sling vs. retropubic MUS: cure.
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FIGURE 12 Single incision vs. retropubic MUS: cure.
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FIGURE 13 Open colposuspension vs. transobturator MUS: cure.
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FIGURE 14 Traditional sling vs. transobturator MUS: cure.
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FIGURE 15 Single incision vs. transobturator MUS: cure.
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FIGURE 16 Anterior vaginal repair vs. transobturator MUS: cure.
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FIGURE 17 Pelvic floor muscle training vs. transobturator MUS: cure.
Overall (I2 = 60.7%; p = 0.009)
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FIGURE 18 Laparoscopic colposuspension vs. open colposuspension: cure.
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FIGURE 19 Traditional sling vs. open colposuspension: cure.
Overall (I2 = 0.0%; p = 0.542)
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FIGURE 20 Bladder neck needle suspension vs. open colposuspension: cure.
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FIGURE 21 Anterior vaginal repair vs. open colposuspension: cure.
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FIGURE 22 Pelvic floor muscle training vs. open colposuspension: cure.
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FIGURE 23 Bladder neck needle suspension vs. traditional sling: cure.
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FIGURE 24 Anterior vaginal repair vs. bladder neck needle suspension: cure.
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Appendix 12 Meta-analyses results: number of
women improved
Overall (I2 = 17.7%; p = 0.165)
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FIGURE 25 Transobturator MUS vs. retropubic MUS: improvement.
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FIGURE 26 Open colposuspension vs. retropubic MUS: improvement.
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FIGURE 27 Laparoscopic colposuspension vs. retropubic MUS: improvement.
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FIGURE 28 Traditional sling vs. retropubic MUS: improvement.
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FIGURE 29 Single-incision sling vs. retropubic MUS: improvement.
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FIGURE 30 Open colposuspension vs. transobturator MUS: improvement.
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FIGURE 31 Traditional sling vs. transobturator MUS: improvement.
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FIGURE 32 Single-incision sling vs. transobturator MUS: improvement.
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FIGURE 33 Anterior vaginal repair vs. transobturator MUS: improvement.
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FIGURE 34 Pelvic floor muscle training vs. transobturator MUS: improvement.
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FIGURE 35 Laparoscopic colposuspension vs. open colposuspension: improvement.
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FIGURE 37 Bladder neck needle suspension vs. open colposuspension: improvement.
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FIGURE 38 Anterior vaginal repair vs. open colposuspension: improvement.
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FIGURE 40 Single-incision sling vs. traditional sling: improvement.
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FIGURE 42 Anterior vaginal repair vs. bladder neck needle suspension: improvement.
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Appendix 13 Network meta-analysis: rankogram
for each intervention for the number of women cured
or improved
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FIGURE 43 Rankograms for each intervention for number of women cured. (a) Retropubic mid-urethral sling;
(b) transobturator mid-urethral sling; (c) open colposuspension; (d) laparoscopic colposuspension; (e) traditional sling;
(f) single-incision sling; (g) bladder neck needle suspension; (h) anterior vaginal repair; and (i) PFMT.
DOI: 10.3310/hta23140 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 14
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Brazzelli et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
255
Rank
1 2 3 4 5 6 7 8 9
(a)
Pr
o
b
ab
ili
ti
es
0.0
0.2
0.4
0.6
0.8
1.0
Rank
1 2 3 4 5 6 7 8 9
(b)
Pr
o
b
ab
ili
ti
es
0.0
0.2
0.4
0.6
0.8
1.0
Rank
1 2 3 4 5 6 7 8 9
(c)
Pr
o
b
ab
ili
ti
es
0.0
0.2
0.4
0.6
0.8
1.0
Rank
1 2 3 4 5 6 7 8 9
(d)
Pr
o
b
ab
ili
ti
es
0.0
0.2
0.4
0.6
0.8
1.0
Rank
1 2 3 4 5 6 7 8 9
(e)
Pr
o
b
ab
ili
ti
es
0.0
0.2
0.4
0.6
0.8
1.0
Rank
1 2 3 4 5 6 7 8 9
(f)
Pr
o
b
ab
ili
ti
es
0.0
0.2
0.4
0.6
0.8
1.0
Rank
1 2 3 4 5 6 7 8 9
(g)
Pr
o
b
ab
ili
ti
es
0.0
0.2
0.4
0.6
0.8
1.0
Rank
1 2 3 4 5 6 7 8 9
(h)
Pr
o
b
ab
ili
ti
es
0.0
0.2
0.4
0.6
0.8
1.0
Rank
1 2 3 4 5 6 7 8 9
(i)
Pr
o
b
ab
ili
ti
es
0.0
0.2
0.4
0.6
0.8
1.0
FIGURE 44 Rankograms for each intervention for number of women improved. (a) Retropubic mid-urethral sling;
(b) transobturator mid-urethral sling; (c) open colposuspension; (d) laparoscopic colposuspension; (e) traditional sling;
(f) single-incision sling; (g) bladder neck needle suspension; (h) anterior vaginal repair; and (i) PFMT.
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Appendix 14 Network meta-analysis:
inconsistency analysis and node-splitting analysis for
total number of women cured or improved
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FIGURE 45 Plot of the individual data points’ posterior mean deviance contributions for the consistency and
inconsistency model along with the line of equality for the number of women cured.
TABLE 33 Summary of node-splitting analysis for cure of incontinence on the log scale
Intervention comparison
Analysis, median (95% CI)
Bayesian
p-valueNMA Direct Indirect
Inconsistency
estimate
Transob-MUS vs. retro-MUS –0.304
(–0.532 to –0.080)
–0.240
(–0.485 to 0.006)
–0.658
(–1.224 to –0.102)
0.417
(–0.182 to 1.035)
0.170
Open colpo vs. retro-MUS –0.159
(–0.609 to 0.281)
–0.036
(–0.586 to 0.522)
–0.370
(–1.134 to 0.382)
0.335
(–0.593 to 1.270)
0.476
Lap colpo vs. retro-MUS –0.545
(–1.157 to 0.045)
–1.057
(–2.406 to 0.182)
–0.409
(–1.088 to 0.274)
–0.652
(–2.171 to 0.780)
0.370
Trad sling vs. retro-MUS 0.059
(–0.473 to 0.613)
–0.061
(–0.638 to 0.531)
0.945
(–0.574 to 2.696)
–1.007
(–2.823 to 0.630)
0.230
Single incision vs. retro-MUS –0.686
(–1.022 to –0.358)
–0.948
(–1.534 to –0.383)
–0.543
(–0.954 to –0.145)
–0.406
(–1.109 to 0.294)
0.250
Open colpo vs. transob-MUS 0.145
(–0.332 to 0.619)
–0.127
(–1.658 to 1.371)
0.174
(–0.330 to 0.679)
–0.300
(–1.914 to 1.284)
0.708
Trad sling vs. transob-MUS 0.363
(–0.206 to 0.962)
0.901
(–1.913 to 4.506)
0.353
(–0.238 to 0.964)
0.547
(–2.333 to 4.198)
0.720
Single incision vs. transob-MUS –0.380
(–0.672 to –0.098)
–0.343
(–0.666 to –0.023)
–0.513
(–1.191 to 0.148)
0.170
(–0.559 to 0.915)
0.652
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TABLE 33 Summary of node-splitting analysis for cure of incontinence on the log scale (continued )
Intervention comparison
Analysis, median (95% CI)
Bayesian
p-valueNMA Direct Indirect
Inconsistency
estimate
Ant repair vs. transob-MUS –0.775
(–1.580 to 0.023)
–0.723
(–2.313 to 0.825)
–1.359
(–2.202 to –0.531)
0.634
(–1.162 to 2.412)
0.482
PFMT vs. transob-MUS –1.211
(–1.953 to –0.473)
–1.623
(–2.756 to –0.496)
–2.610
(–5.073 to –0.546)
1.000
(–1.358 to 3.685)
0.420
Lap colpo vs. open colpo –1.813
(–2.817 to –0.847)
–0.315
(–0.811 to 0.185)
–0.952
(–2.358 to 0.378)
0.640
(–0.779 to 2.125)
0.380
Trad sling vs. open colpo –0.388
(–0.857 to 0.077)
1.320
(–0.088 to 2.986)
–0.060
(–0.786 to 0.665)
1.388
(–0.199 to 3.180)
0.088
Bladder neck needle vs. open
colpo
0.218
(–0.420 to 0.895
–0.909
(–1.619 to –0.208)
0.264
(–3.859 to 4.079)
–1.171
(–5.064 to 3.008)
0.530
Ant repair vs. open colpo –1.356
(–1.983 to –0.739)
–1.531
(–2.245 to –0.850)
–0.815
(–2.497 to 0.820)
–0.716
(–2.487 to 1.096)
0.424
PFMT vs. open colpo –1.957
(–3.018 to –0.940)
–2.697
(–5.173 to –0.661)
–1.734
(–2.977 to –0.499)
–0.979
(–3.699 to 1.425)
0.434
Bladder neck needle vs. trad
sling
–1.141
(–2.067 to –0.237)
0.008
(–3.834 to 3.861)
–1.239
(–2.205 to –0.316)
1.247
(–2.678 to 5.221)
0.506
Ant repair vs. bladder neck
needle
–0.437
(–1.190 to 0.304)
–0.162
(–1.060 to 0.737)
–0.784
(–1.900 to 0.313)
0.621
(–0.729 to 1.992)
0.368
Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle suspension; lap colpo, laparoscopic colposuspension;
open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling; single incision, single-incision sling; trad sling,
traditional sling; transob-MUS, transobturator mid-urethral sling.
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FIGURE 46 Plot of the individual data points’ posterior mean deviance contributions for the consistency and
inconsistency model along with the line of equality for the number of women improved.
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TABLE 34 Summary of node-splitting analysis for improvement on the log scale
Intervention comparison
Analysis, median (95% CrI)
MedianNMA Direct Indirect
Inconsistency
estimate
Transob-MUS vs. retro-MUS –0.279
(–0.532 to –0.023)
–0.236
(–0.513 to 0.043)
–0.460
(1.070 to 0.134)
0.223
(–0.426 to 0.888)
0.498
Open colpo vs. retro-MUS –0.436
(–0.894 to 0.021)
–0.152
(–0.750 to 0.464)
–0.806
(–1.536 to –0.104)
0.655
(–0.265 to 1.611)
0.160
Lap colpo vs. retro-MUS –0.653
(–1.230 to –0.092)
–0.761
(–1.633 to 0.093)
–0.575
(–1.349 to 0.201)
–0.187
(–1.350 to 0.974)
0.750
Trad sling vs. retro-MUS –0.372
(–0.947 to 0.230)
–0.405
(–1.101 to 0.297)
–0.265
(–1.345 to 0.867)
–0.141
(–1.466 to 1.151)
0.828
Single incision vs. retro-MUS –0.688
(–1.050 to –0.340)
–1.118
(–1.806 to –0.456)
–0.498
(–0.921 to –0.076)
–0.618
(–1.419 to 0.155)
0.116
Open colpo vs. transob-MUS –0.158
(–0.662 to 0.347)
–0.113
(–1.785 to 1.524)
–0.160
(–0.683 to 0.372)
0.043
(–1.697 to 1.762)
0.960
Trad sling vs. transob-MUS –0.094
(–0.707 to 0.540)
0.924
(–2.022 to 4.706)
–0.134
(–0.761 to 0.512)
1.057
(–1.947 to 4.900)
0.498
Single incision vs. transob-MUS –0.410
(–0.712 to –0.115)
–0.366
(–0.704 to –0.040)
–0.657
(–1.408 to 0.081)
0.290
(–0.526 to 1.101)
0.478
Ant repair vs. transob-MUS –1.442
(–2.253 to –0.641)
–0.013
(–1.842 to 1.825)
–1.775
(–2.662 to –0.902)
1.762
(–0.283 to 3.806)
0.088
PFMT vs. transob-MUS –0.580
(–1.662 to 0.575)
–1.712
(–2.925 to –0.506)
2.346
(0.321 to 4.583)
–4.060
(–6.629 to –1.701)
0.002
Lap colpo vs. open colpo –0.217
(–0.722 to 0.271)
–0.174
(–0.747 to 0.392)
–0.379
(–1.391 to 0.624)
0.203
(–0.946 to 1.357)
0.728
Trad sling vs. open colpo 0.063
(–0.614 to 0.767)
1.383
(–0.094 to 3.158)
–0.318
(–1.093 to 0.455)
1.709
(0.047 to 3.611)
0.044
Bladder neck needle vs.
open colpo
–0.962
(–1.697 to –0.216)
–0.971
(–1.774 to –0.190)
0.105
(–3.731 to 4.202)
–1.078
(–5.268 to 2.843)
0.566
Ant repair vs. open colpo –1.286
(–1.976 to –0.607)
–1.571
(–2.336 to –0.841)
0.268
(–1.636 to 2.208)
–1.846
(–3.921 to 0.196)
0.076
PFMT vs. open colpo –0.419
(–1.545 to 0.772)
2.342
(0.376 to 4.511)
–1.723
(–3.036 to –0.430)
4.080
(1.679 to 6.591)
< 0.001
Single incision vs. trad sling –0.317
(–0.986 to 0.327)
0.676
(–0.911 to 2.298)
–0.518
(–1.247 to 0.196)
1.192
(–0.552 to 3.004)
0.178
Bladder neck needle vs. trad
sling
–1.026
(–2.019 to –0.056)
–0.007
(–3.975 to 3.989)
–1.117
(–2.145 to –0.098)
1.106
(–2.974 to 5.199)
0.558
Ant repair vs. bladder neck
needle
–0.322
(–1.168 to 0.489)
–0.141
(–1.156 to 0.882)
–0.482
(–1.712 to 0.736)
0.340
(–1.177 to 1.881)
0.654
Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle suspension; CrI, credible interval; lap colpo,
laparoscopic colposuspension; open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling; single incision,
single-incision sling; trad sling, traditional sling; transob-MUS, transobturator mid-urethral sling.
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Appendix 15 Summary of meta-analyses of direct
head-to-head comparisons for adverse events and
resource use
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Transob-MUS and retro-MUS
< 12 months
12 – 60 months
> 60 months
Open colpo vs. retro-MUS
Follow-up unknown
Lap colpo vs. retro-MUS
Follow-up unknown
Trad sling vs. retro-MUS
12 months
120 months
Single incision vs. retro-MUS
6 months
36 months
Single incision vs. transob-MUS
6 months
12 months
24 months
36 months
> 36 months
Ant repair vs. open colpo
Follow-up unknown
Comparison
14/641
1/180
7/438
4/170
4/71
0/69
2/63
0/33
0/33
5/161
18/614
4/241
14/373
14/185
3/129
Treatment 2
7
2
5
1
2
1
1
1
1
3
10
4
5
3
2
Studies
1.37 (0.55 to 3.46)
24.57 (4.67 to 129.35)
4.06 (0.80 to 20.74)
1.47 (0.39 to 5.59)
1.11 (0.25 to 4.87)
12.64 (0.72 to 220.64)
1.62 (0.31 to 8.63)
22.33 (1.24 to 400.78)
18.67 (1.03 to 337.33)
1.60 (0.50 to 5.18)
1.57 (0.83 to 2.95)
1.71 (0.33 to 8.74)
1.36 (0.66 to 2.79)
1.42 (0.68 to 2.97)
13.95 (4.22 to 46.09)
ES (95% CI)
21/585
32/175
40/422
5/146
4/65
9/113
5/99
9/37
8/38
8/161
35/685
19/317
20/387
19/185
22/74
Treatment 1
Favours first treatment Favours second treatment
0.003 0.01 0.03 0.09 0.2 0.5 1 2 5 10 25 50
FIGURE 47 Repeat continence surgery. Ant repair, anterior vaginal repair; ES, effect estimate (OR); lap colpo,
laparoscopic colposuspension; open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling; single
incision, single-incision sling; trad sling, traditional sling; transob-MUS, transobturator mid-urethral sling.
Single incision vs. trad sling
Single incision vs. transob-MUS
Comparison Treatment 2
1/35
2/138
Studies
1
2
0.32 (0.01 to 8.23)
0.74 (0.05 to 11.41)
ES (95% CI) Treatment 1
0/35
1/138
Favours first treatment Favours second treatment
0.003 0.01 0.20.090.03 0.5 1 2 5 10 25 50
FIGURE 48 Haemorrhage. ES, effect estimate (OR); single incision, single-incision sling; trad sling, traditional sling;
transob-MUS, transobturator mid-urethral sling.
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Haematoma
Transob-MUS vs. retro-MUS
Transob-MUS vs. retro-MUS
Single incision vs. transob-MUS
Single incision vs. transob-MUS
Myocardial infarction on postoperative day 1
Single incision vs. retro-MUS
Single incision vs. retro-MUS
Lap colpo vs. retro-MUS
Single incision vs. trad sling
2
22
3
4
1
1
1
1
4/146
47/1966
3/95
2/234
2/32
0/49
0/33
8/35
0/148
10/2008
1/94
3/296
0/34
1/49
1/33
1/35
Major vascular complications
Comparison Treatment 2 StudiesES (95% CI) Treatment 1
Favours first treatment Favours second treatment
0.003 0.01 0.03 0.09 0.2 0.5 1 2 5 10 25 50
0.20 (0.02 to 1.80)
0.36 (0.21 to 0.64)
0.55 (0.09 to 3.48)
1.01 (0.21 to 4.94)
0.18 (0.01 to 3.83)
3.06 (0.12 to 77.02)
3.09 (0.12 to 78.70)
0.10 (0.01 to 0.84)
FIGURE 49 Haematoma, major vascular complications and myocardial infarction. ES, effect estimate (OR); lap colpo, laparoscopic colposuspension; retro-MUS, retropubic
mid-urethral sling; single incision, single-incision sling; trad sling, traditional sling; transob-MUS, transobturator mid-urethral sling.
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Transob-MUS vs. retro-MUS
Single incision vs. retro-MUS
Single incision vs. transob-MUS
> 200 ml
> 100 ml
Intraoperative bleeding
> 200 ml
> 500 ml
100 – 200 ml 1
≥ 200 ml
1
2
2
1
1
1
1/62
3/105
4/118
1/164
0/56
1/96
1/34
1/61
0/94
2/119
1/153
1/66
2/97
0/37
Comparison Treatment 2 StudiesES (95% CI) Treatment 1
Favours first treatment Favours second treatment
0.003 0.01 0.03 0.09 0.2 0.5 1 2 5 10 25 50
1.02 (0.06 to 16.63)
0.15 (0.01 to 3.04)
0.55 (0.11 to 2.68)
1.07 (0.11 to 10.36)
2.59 (0.10 to 64.79)
2.00 (0.18 to 22.43)
0.30 (0.01 to 7.56)
FIGURE 50 Bleeding. ES, effect estimate (OR); retro-MUS, retropubic mid-urethral sling; single incision, single-incision sling; transob-MUS, transobturator mid-urethral sling.
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Favours first treatment Favours second treatment
0.003 0.01 0.03 0.09 0.2 0.5 1 2 5 10 25 50
Transob-MUS vs. retro-MUS
Follow-up unknown
Follow-up unknown
12 – 60 months
> 60 months
Open colpo vs. retro-MUS
Lap colpo vs. retro-MUS
Open colpo vs. retro-MUS
Trad sling MUS vs. retro-MUS
Single incision vs. retro-MUS
Single incision vs. transob-MUS
Ant vs. transob-MUS
< 12 months
Follow-up unknown
Follow-up unknown
Follow-up unknown
Follow-up unknown
Follow-up unknown
Follow-up unknown
Unknown
1 month
6 months
12 months
24 months
36 months
> 36 months
Follow-up unknown
Follow-up unknown
Follow-up unknown
Anterior repair vs. open colpo
Bladder neck needle vs. open colpo
Trad sling vs. open colpo
Lap colpo vs. open colpo
120 months
Comparison Treatment 2 StudiesES (95% CI) Treatment 1
2
6
5
1
28
2
4
1
1
1
2
1
2
3
13
4
2
2
1
4
3
2
10/144
22/287
23/268
4/131
183/2321
3/83
8/148
5/32
1/49
3/46
9/265
6/36
5/95
4/117
55/597
21/214
5/107
15/154
2/30
6/137
10/150
7/100
12/113
28/249
22/267
3/122
172/2264
11/286
27/149
12/34
3/51
2/46
8/260
12/34
14/164
14/118
63/665
22/284
6/105
12/169
0/30
13/160
13/91
6/131
1.42 (0.58 to 3.45)
1.49 (0.81 to 2.75)
0.94 (0.49 to 1.79)
0.80 (0.18 to 3.65)
0.93 (0.74 to 1.17)
3.24 (0.90 to 11.68)
3.59 (1.57 to 8.23)
2.95 (0.90 to 9.64)
3.00 (0.30 to 29.87)
0.65 (0.10 to 4.09)
1.01 (0.17 to 6.15)
2.73 (0.89 to 8.39)
1.58 (0.54 to 4.61)
3.33 (1.08 to 10.23)
0.98 (0.66 to 1.46)
0.67 (0.35 to 1.27)
1.22 (0.35 to 4.32)
0.65 (0.29 to 1.45)
0.19 (0.01 to 4.06)
1.84 (0.61 to 5.52)
2.18 (0.84 to 5.70)
0.95 (0.30 to 3.04)
FIGURE 51 De novo symptoms of urgency or urgency incontinence. Ant repair, anterior vaginal repair; bladder
neck needle, bladder neck needle colposuspension; ES, effect estimate (OR); lap colpo, laparoscopic
colposuspension; open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling; single incision,
single-incision sling; trad sling, traditional sling; transob-MUS, transobturator mid-urethral sling.
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Favours first treatment Favours second treatment
0.003 0.01 0.03 0.09 0.2 0.5 1 2 5 10 25 50
Transob-MUS vs. retro-MUS
Open colpo vs. retro-MUS
Lap colpo vs. retro-MUS
Trad sling vs. retro-MUS
Trad sling vs. transob-MUS
Lap colpo vs. open colpo
Trad sling vs. open colpo
Bladder neck needle vs. open colpo
Ant repair vs. open colpo
Single incision vs. retro-MUS
3
3
4
1
1
6
3
2
2
1
11/206
18/237
10/163
0/28
2/40
23/288
5/69
2/56
14/129
2/33
Comparison Control StudiesES (95% CI) Experimental
13/196
21/214
8/162
1/25
2/40
28/278
5/62
6/45
6/74
2/37
1.24 (0.53 to 2.87)
1.25 (0.64 to 2.44)
0.71 (0.17 to 2.86)
3.49 (0.14 to 89.63)
1.00 (0.13 to 7.47)
1.24 (0.68 to 2.26)
1.13 (0.14 to 9.02)
3.32 (0.71 to 15.41)
0.77 (0.28 to 2.10)
0.89 (0.12 to 6.67)
FIGURE 52 Detrusor instability. Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle colposuspension; ES, effect estimate (OR); lap colpo, laparoscopic
colposuspension; open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling; single incision, single-incision sling; trad sling, traditional sling; transob-MUS,
transobturator mid-urethral sling.
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Transob-MUS vs. retro-MUS
Follow-up unknown
Postoperative
95 months
Open colpo vs. retro-MUS
Follow-up unknown
Lap colpo vs. retro-MUS
Follow-up unknown
Trad sling vs. retro-MUS
Follow-up unknown
120 months
Single incision vs. retro-MUS
Follow-up unknown
Open colpo vs. transob-MUS
Follow-up unknown
Trad sling vs. transob-MUS
Early complications
Late complications
Single incision vs. transob-MUS
Follow-up unknown
Peri-complications
1 month
6 months
12 months
24 months
36 months
> 36 months
Lap colpo vs. open colpo
Follow-up unknown
Trad sling vs. open colpo
Follow-up unknown
24 months
> 60 months
Bladder neck needle vs. open colpo
Follow-up unknown
Ant repair vs. open colpo
Follow-up unknown
Single incision vs. trad sling
Follow-up unknown
Bladder neck needle vs. trad sling
Follow-up unknown
Comparison ES (95% CI) Treatment 1
234/3109
7/70
12/58
31/413
9/177
26/255
10/100
7/128
2/80
1/40
2/40
1/36
31/689
11/191
21/219
45/802
3/98
10/178
3/144
30/309
2/85
0/329
1/229
9/77
3/56
6/35
4/10
Treatment 2
36
1
1
7
4
6
2
3
2
1
1
1
9
3
4
13
2
3
2
6
3
1
1
3
2
1
1
Studies
0.51 (0.40 to 0.64)
0.26 (0.05 to 1.32)
0.49 (0.18 to 1.34)
0.87 (0.41 to 1.82)
1.34 (0.54 to 3.34)
1.46 (0.84 to 2.53)
1.05 (0.41 to 2.67)
0.39 (0.09 to 1.69)
1.96 (0.33 to 11.73)
0.33 (0.01 to 8.22)
1.54 (0.24 to 9.75)
0.34 (0.01 to 8.71)
0.60 (0.33 to 1.08)
0.93 (0.27 to 3.19)
0.61 (0.09 to 4.25)
0.74 (0.45 to 1.21)
0.92 (0.18 to 4.65)
0.88 (0.25 to 3.15)
0.42 (0.05 to 3.34)
0.86 (0.48 to 1.55)
4.73 (1.12 to 20.05)
44.08 (2.65 to 731.90)
7.35 (0.90 to 60.27)
1.06 (0.19 to 5.78)
0.34 (0.04 to 3.18)
0.14 (0.02 to 1.25)
0.38 (0.05 to 2.77)
116/3110
2/70
7/62
29/374
12/161
40/259
11/131
2/133
4/82
0/40
3/40
0/34
23/835
14/261
7/234
43/899
3/105
9/173
1/167
27/293
10/79
20/326
7/224
9/75
0/40
1/35
2/10
Favours first treatment Favours second treatment
0.003 0.01 0.03 0.09 0.2 0.5 1 2 5 10 25 50
FIGURE 53 Voiding difficulty. Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle
colposuspension; ES, effect estimate (OR); lap colpo, laparoscopic colposuspension; open colpo, open
colposuspension; retro-MUS, retropubic mid-urethral sling; single incision, single-incision sling; trad sling,
traditional sling; transob-MUS, transobturator mid-urethral sling.
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FIGURE 54 Bladder or urethral perforation. ES, effect estimate (OR); lap colpo, laparoscopic colposuspension;
open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling; single incision, single-incision sling;
trad sling, traditional sling; transob-MUS, transobturator mid-urethral sling.
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FIGURE 55 Tape/mesh erosion or extrusion. ES, effect estimate (OR); lap colpo, laparoscopic colposuspension;
open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling; single incision, single-incision sling;
trad sling, traditional sling; transob-MUS, transobturator mid-urethral sling.
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FIGURE 56 Tape/mesh/implant exposure. ES, effect estimate (OR); retro-MUS, retropubic mid-urethral sling;
single incision, single-incision sling; trad sling, traditional sling; transob-MUS, transobturator mid-urethral sling.
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FIGURE 57 Groin pain. ES, effect estimate (OR); open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling; single incision, single-incision sling; trad sling,
traditional sling; transob-MUS, transobturator mid-urethral sling.
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FIGURE 58 Suprapubic pain. ES, effect estimate (OR); open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling; trad sling, traditional sling; transob-MUS,
transobturator mid-urethral sling.
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FIGURE 59 Pain. ES, effect estimate (OR); retro-MUS, retropubic mid-urethral sling; single incision, single-incision sling; transob-MUS, transobturator mid-urethral sling.
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FIGURE 60 Dyspareunia. Ant repair, anterior vaginal repair; ES, effect estimate (OR); open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling;
single incision, single-incision sling; trad sling, traditional sling; transob-MUS, transobturator mid-urethral sling.
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FIGURE 61 Urinary tract infection. ES, effect estimate (OR); open colpo, open colposuspension; retro-MUS,
retropubic mid-urethral sling; single incision, single-incision sling; trad sling, traditional sling; transob-MUS,
transobturator mid-urethral sling.
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FIGURE 62 Wound infection and infection related to use of synthetic mesh. ES, effect estimate (OR); retro-MUS, retropubic mid-urethral sling; single incision, single-incision
sling; transob-MUS, transobturator mid-urethral sling.
D
O
I:10.3310/hta23140
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2019
VO
L.23
N
O
.14
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.This
w
ork
w
as
produced
by
Brazzelliet
al.under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,the
fullreport)m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:N
IH
R
Journals
Library,N
ationalInstitute
for
H
ealth
Research,Evaluation,Trials
and
Studies
C
oordinating
C
entre,A
lpha
H
ouse,U
niversity
of
Southam
pton
Science
Park,Southam
pton
SO
16
7N
S,U
K
.
275
Perioperative
Transob-MUS vs. retro-MUS
Open colpo vs. retro-MUS
Lap colpo vs. retro-MUS
Trad sling vs. retro-MUS
Single incision vs. retro-MUS
Open colpo vs. transob-MUS
Trad sling vs. transob-MUS
Lap colpo vs. open colpo
Trad sling vs. open colpo
Bladder neck needle vs. open colpo
Ant repair vs. open colpo
Bladder neck needle vs. trad sling
Ant repair vs. bladder neck needle
Other inherent to procedure
Transob-MUS vs. retro-MUS
Single incision vs. retro-MUS
Open colpo vs. transob-MUS
Trad sling vs. open colpo
Bladder neck needle vs. open colpo
Ant repair vs. open colpo
Abdominal wound problem
Single incision vs. retro-MUS
Comparison
0.81 (0.55 to 1.19)
1.19 (0.68 to 2.08)
1.18 (0.63 to 2.22)
1.29 (0.52 to 3.17)
1.41 (0.22 to 9.01)
2.35 (0.63 to 8.81)
9.00 (1.98 to 40.93)
0.83 (0.40 to 1.70)
1.81 (1.34 to 2.45)
2.65 (0.42 to 16.56)
3.54 (0.85 to 14.72)
0.03 (0.00 to 0.37)
0.17 (0.01 to 4.43)
127/1084
97/338
28/269
14/103
3/37
8/31
12/20
16/133
211/394
36/75
14/40
2/10
0/52
150/1153
88/363
28/299
12/99
2/34
4/31
3/21
20/146
162/398
23/77
8/56
9/10
1/28
20/206
3/34
2/80
0/15
0/26
3/26
0/40
Treatment 2
15
6
7
2
1
1
1
4
4
3
2
1
1
2
1
2
1
1
1
1
Studies
0.18 (0.06 to 0.58)
0.12 (0.01 to 2.41)
0.60 (0.07 to 5.01)
6.74 (0.29 to 154.26)
8.24 (0.40 to 168.26)
0.13 (0.01 to 2.69)
21.18 (1.18 to 380.90)
ES (95% CI)
3/181
0/37
1/82
2/13
3/25
0/25
8/40
Treatment 1
Favours first treatment Favours second treatment
0.003 0.01 0.03 0.09 0.2 0.5 1 2 5 10 25 50
FIGURE 63 Complications. Ant repair, anterior vaginal repair; bladder neck needle, bladder neck needle colposuspension; ES, effect estimate (OR); lap colpo, laparoscopic
colposuspension; open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling; single incision, single-incision sling; trad sling, traditional sling; transob-MUS,
transobturator mid-urethral sling.
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FIGURE 64 Resource utilisation (hospital stay and operation time). Ant repair, anterior vaginal repair; bladder
neck needle, bladder neck needle colposuspension; ES, effect estimate (standardised mean difference); lap colpo,
laparoscopic colposuspension; open colpo, open colposuspension; retro-MUS, retropubic mid-urethral sling;
single incision, single-incision sling; trad sling, traditional sling; transob-MUS, transobturator mid-urethral sling.
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Appendix 16 Additional reports of trials
identified by an updated search of the Cochrane
Incontinence Group Specialised Register on
9 October 2017
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Citation for newly identified trial report Sample size Intervention Notes
Extra reports of already included studies
Richter 201099
Chai TC, Moalli PA, Richter HE, Lake AG, Kim H-Y,
Nager CW, et al. Preoperative urodynamic
parameters (Valsalva leak point pressure and
maximum urethral closure pressure), urinary
collagen and plasma vitamin D levels as
predictors of mid urethral sling surgery outcome.
J Urol 2016;196:819–23. [Ref ID: 77662]
This study report not relevant to ESTER Retro-MUS vs. transob-MUS Extra report of the already included study: Richter
2010 [TOMUS (Trial of Midurethral Slings)]
Design: RCT
Trial registration number: NCT00325039
(Not directly relevant to the ESTER project)
Thomas TN, Siff LN, Jelovsek JE, Barber M.
Surgical pain after transobturator and
retropubic midurethral sling placement. Obstet
Gynecol 2017;130:118–25. [Ref ID: 76639]
Pain at up to 24 months. Not clear
how many participants in each arm
contributed data at 24 months. At
6 months: transob-MUS, n = 276;
retropubic-MUS, n = 274
Retro-MUS vs. transob-MUS Extra report of the already included study: Richter
2010 (TOMUS)
Design: RCT
Trial registration number: NCT00325039
‘At 24 months, seven participants in the
transobturator group and four participants in the
retropubic group reported any pain related to
the incontinence operation’
Some labels missing from some of the tables,
so not clear what some of the information is
Rudnicki 201672
Rudnicki M, von Bothmer-Ostling K, Holstad A,
Magnusson C, Majida M, Merkel C, et al.
Adjustable mini-sling compared with conventional
mid-urethral slings in women with urinary
incontinence. A randomised controlled trial.
Acta Obstet Gynecol Scand 2017;96:1347–56.
[Ref ID: 76834]
At 12 months: single incision, n = 135;
MUS, n = 129
Single incision vs. MUS
(either retro-MUS or transob-MUS)
Full report of the already included study: Rudnicki
2016 (previously only two conference abstracts
and a ClinicalTrials.gov registration were
available)
Design: RCT
Trial registration number: NCT01754558
Intervention: single incision (Ajust) vs. MUS
[either retro-MUS (TVT) or transob-MUS (TVT-O
or Monarc)]
Length of follow-up: 12 months
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Citation for newly identified trial report Sample size Intervention Notes
Aigmüller 201483
Tammaa A, Aigmüller T, Hanzal E, Umek W,
Kropshofer S, Lang PFJ, et al. Retropubic versus
transobturator tension-free vaginal tape
(TVT vs. TVT-O): five-year results of the Austrian
randomized trial. Neurourol Urodyn
2018;37:331–8. [Ref ID: 76933]
Overall, 331 (58%) of operated patients
were available for follow-up at 5 years
(331 completed questionnaires, 277
were also examined clinically)
Retro-MUS (TVT) vs. transob-MUS
(TVT-O)
Extra report of the already included study:
Aigmüller 2014 (full-text report of the 5-year
follow-up; previously only available as a
conference abstract)
Design: RCT
Trial registration number: NCT00441454
Melendez Munoz 201665
Melendez MJ, Braverman M, Rosamilia A,
Young N, Leitch A, Lee J. Miniarc vs. TVT
abbrevo midurethral sling in women with
stress urinary incontinence – an RCT-6 and
12-month follow-up. Neurourol Urodyn
2017;36(Suppl. S3):S517–S519. [Ref ID: 77508]
At 12 months: single incision, n = 88;
transob-MUS, n = 82
Single incision (MiniArc) vs.
transob-MUS (TVT Abbrevo)
Extra conference abstract report of the already
included new study: Melendez Munoz 2016
(only conference abstract available for inclusion)
includes 6- and 12-month follow-up
Design: RCT
Trial registration number: ACTRN12611001151921
Schellart 2013177
Schellart RP, Zwolsman SE, Lucot JP, De Ridder
DJMK, Dijkgraaf MGW, Roovers JWR. A
randomized, nonblinded extension study of
single-incision versus transobturator midurethral
sling in women with stress urinary incontinence.
Int Urogynecol J 2018;29:37–44. [Ref ID: 76921]
71 patients (73%) in the MiniArc group
and 74 patients (77%) in the Monarc
group could be analyzed for subjective
cure, and 75 (77%) and 75 (78%),
respectively, for objective cure at
36 months
Single incision (MiniArc) vs.
transob-MUS (Monarc)
Extra report of the already included Schellart
2013 (full-text report of 36 months; previously
only available as a conference abstract)
Design: RCT
Trial registration number: NTR3783
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Citation for newly identified trial report Sample size Intervention Notes
Extra reports of studies listed in main report as ongoing
Abdel-Fattah 2014
Abdel-Fattah M, MacLennan G, Kilonzo M,
Assassa RP, McCormick K, Davidson T, et al.
The SIMS trial: adjustable anchored single-
incision mini-slings versus standard tension-free
midurethral slings in the surgical management
of female stress urinary incontinence. A study
protocol for a pragmatic, multicentre, non-
inferiority randomised controlled trial. BMJ
Open 2017;7:e015111. [Ref ID: 76746]
Target, n = 650 (325 in each arm) Single incision vs. MUS (retro-MUS
or transob-MUS)
Protocol for a study listed as ongoing study in the
main ESTER report: Abdel-Fattah 2014
Design: RCT
Trial registration number: ISRCTN93264234
Ages: ≥ 18 years
Condition: ‘urodynamic stress incontinence or
urodynamic MUI with predominant SUI bothering
symptoms’
Recruitment start date: 4 February 2014
Follow-up end date: February 2020
Place: UK, 20 research centres
Funding: Health Technology Assessment (HTA)
Programme
Fu 2016
Fu Q, Lv J, Fang W, Jiang C, Gu Y, Leng J, et al.
The clinical efficacy of needleless sling
technique and TOT in the treatment of female
stress urinary incontinence: a prospective
randomized controlled trial. Int J Clin Exp Med
2017;10:7084–90. [Ref ID: 77232]
At 12 months, data available: single
incision, n = 78; transob-MUS, n = 86
Single incision (needleless) vs.
transob-MUS
Full text report for the study listed as ongoing in
the main ESTER report: Fu 2016
Design: RCT
Trial registration number: ChiCTR-INR-16008068
Diagnosis: USI
Ages: 35–70 years
Place: Shanghai, China
Funding: ‘SHDC1201591’
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Citation for newly identified trial report Sample size Intervention Notes
New ongoing studies
Leitch A, Ow LL. Efficacy of mini sling
versus retropubic sling in women with
stress urinary incontinence – a RCT study
(Mini Retro). 2017. Trial registration number:
ACTRN12617000167369. URL: www.anzctr.
org.au/ACTRN12617000167369.aspx (accessed
27 November 2017). [Ref ID: 76200]
Target sample size, n = 176 Single incision (Altis) vs.
retro-MUS (TVT)
Design: RCT
Trial registration number: ACTRN12617000167369
Recruitment start date: April 2017
Recruitment end date: April 2019
Diagnosis: USI
Ages: 18–80 years
Place: Monash Medical Centre, Australia
Funding: Coloplast Corp.
Luo D, Shen H. Comparison of the efficacy and
safety of TVT-EXACT vs. TVT-ABBREVO in the
treatment of female stress urinary incontinence.
2017. Trial registration number: ChiCTR-IOR-
17011788. URL: www.chictr.org.cn/showproj.
aspx?proj = 20086 (accessed 27 November
2017). [Ref ID: 76204]
Target, n = 150 (75 each arm) Retro-MUS (TVT-Exact) vs.
transob-MUS (TVT-Abbrevo)
Design: RCT
Trial registration number: ChiCTR-IOR-17011788
Recruitment start date: 1 April 2015
Recruitment end date: 31 October 2018
Ages: 40–75 years
Place: Chengdu, China
Funding: National Nature Science Foundation of
China
Retro-MUS, retropubic mid-urethral sling; single incision, single-incision sling; transob-MUS, transobturator mid-urethral sling; USI, urodynamic stress incontinence.
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Appendix 17 Economic search strategy
TABLE 35 Economic search strategy
Number Search term Facet Results
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations
1 exp models, economic/ Economic evaluations 12,189
2 *models, theoretical/ 50,817
3 *models, organizational/ 5483
4 Markov chains/ 11,679
5 monte carlo method/ 23,376
6 exp decision theory/ 10,620
7 (Markov* or monte carlo).ti,ab. 49,644
8 econom* model*.ti,ab. 2789
9 (decision* adj2 (tree* or analy* or model*)).ti,ab. 16,267
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 145,603
11 URINARY INCONTINENCE/ Disease 19,864
12 URINARY INCONTINENCE, STRESS/ 10,063
13 ((stress$or mix$or urg$or urin$) adj3 incontinen$).tw. 25,719
14 colporrhaphy.tw. 519
15 colpoperineoplast$.tw. 28
16 Sling procedure$.tw. 898
17 Sling$procedure$.tw. 905
18 Bladder neck needle suspensions suspension$.tw. 7
19 Anterior vaginal repair$.tw. 45
20 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 37,510
21 10 and 20 Final numbers 139
EMBASE
1 URINE INCONTINENCE/ Disease 41,326
2 STRESS INCONTINENCE/ 19,497
3 URGE INCONTINENCE/ 6053
4 MIXED INCONTINENCE/ 1624
5 ((stress$or mix$or urg$or urin$) adj3 incontinen$).tw. 39,155
6 URINARY URGENCY/ 5368
7 URINARY FREQUENCY/ 6154
8 ((urgency adj frequency) or (frequency adj urgency)).tw. 1930
9 ((urinary adj frequency) or (urinary adj urgency)).tw. 3722
10 colporrhaphy.tw. 948
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TABLE 35 Economic search strategy (continued )
Number Search term Facet Results
11 colposuspension$.tw. 1337
12 Sling procedure$.tw. 1554
13 Sling$procedure$.tw. 1572
14 Bladder neck needle suspensions suspension$.tw. 7
15 Anterior vaginal repair$.tw. 83
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or
14 or 15
69,648
17 statistical model/ Economic evaluations 149,789
18 exp economic aspect/ 1,386,763
19 17 and 18 21,900
20 *theoretical model/ 27,446
21 *nonbiological model/ 4142
22 stochastic model/ 9838
23 decision theory/ 2696
24 decision tree/ 9013
25 monte carlo method/ 30,151
26 (Markov* or monte carlo).ti,ab. 52,002
27 econom* model*.ti,ab. 4018
28 (decision* adj2 (tree* or analy* or model*)).ti,ab. 22,474
29 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 144,098
30 16 and 29 Final numbers 269
NHS Economic Evaluation
1 URINARY INCONTINENCE/ Disease 31
2 URINARY INCONTINENCE, STRESS/ 34
3 ((stress$or mix$or urg$or urin$) adj3 incontinen$).tw. 97
4 colporrhaphy.tw. 3
5 colpoperineoplast$.tw. 0
6 sling procedure$.tw. 4
7 sling$procedure$.tw. 4
8 Bladder neck needle suspensions suspension$.tw. 0
9 anterior vaginal repair$.tw. 0
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 Final numbers 100
Health Management Information Consortium
1 URINARY INCONTINENCE/ Disease 110
2 URINARY INCONTINENCE, STRESS/ 0
3 ((stress$or mix$or urg$or urin$) adj3 incontinen$).tw. 174
4 colporrhaphy.tw. 0
5 colpoperineoplast$.tw. 0
APPENDIX 17
NIHR Journals Library www.journalslibrary.nihr.ac.uk
286
TABLE 35 Economic search strategy (continued )
Number Search term Facet Results
6 Sling procedure$.tw. 0
7 Sling$procedure$.tw. 0
8 Bladder neck needle suspensions suspension$.tw. 0
9 Anterior vaginal repair$.tw. 0
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 Final numbers 220
Cost-effectiveness Analysis Registry
1 URINARY INCONTINENCE Disease 32
2 STRESS URINARY INCONTINENCE 14
3 Mixed incontinence 1
4 URINARY 72
5 Incontinent 3
6 colporrhaphy 0
7 olposuspension 6
8 sling procedure 1
9 Bladder neck needle suspensions suspension 0
10 anterior vaginal repair 0
11 Sling 14
12 Incontinence 50
13 or/1–12 Final numbers 93
TABLE 36 Total number of studies retrieved by database
Database Numbers retrieved
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations 139
EMBASE 269
NHS Economic Evaluation Database 100
Health Management Information Consortium 220
Cost-effectiveness Analysis Registry 93
Total 821
DOI: 10.3310/hta23140 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 14
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Brazzelli et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
287

Appendix 18 Quality assessment of
economic studies
Quality assessment of the economic studies evaluating surgical treatments for SUI using theDrummond checklist.338
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Item
Study
Von
Bargen
2015226
Jacklin
2010228
Kilonzo
2004229
Laudano
2013230
Richardson
2014233
Sand
2014234
Seklehner
2014235
Weber
2000236
Wu
2007237
Oremus
2010232
Oremus
2003231
Kunkle
2015225
Das
Gupta
2006227
Holtzer-Goor
2015238
Weber
2000239
Weber
2002240
Imamura
2010241
1. Was a well-defined question posed
in answerable form?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
1.1. Did the study examine both costs
and effects of the service(s) or
programme(s)?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
1.2. Did the study involve a
comparison of alternatives?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
1.3. Was a viewpoint for the analysis
stated and was the study placed in
any particular decision-making
context?
Yes Yes Yes No Yes Yes Yes NC Yes Yes Yes No Yes Yes Yes Yes No
2. Was a comprehensive description
of the competing alternatives given
(i.e. can you tell who did what to
whom, where and how often)?
Yes Yes Yes No Yes Yes No Yes Yes No Yes Yes Yes Yes Yes Yes Yes
2.1. Were there any important
alternatives omitted?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No
2.2. Was (should) a do-nothing
alternative be considered?
No No No No No No No No No No No No No No No No No
3. Was the effectiveness of the
programme or services established?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
3.1. Was this done through a
randomised controlled clinical trial?
If so, did the trial protocol reflect what
would happen in regular practice?
No No No No Yes No No No No Yes No No Yes No No No No
3.2. Was effectiveness established
through an overview of clinical
studies?
Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes No No No Yes Yes Yes
3.3. Were observational data or
assumptions used to establish
effectiveness? If so, what are the
potential biases in results?
No No No No Yes No No No Yes No No Yes Yes Yes No No No
4. Were all the important and relevant
costs and consequences for each
alternative identified?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
4.1. Was the range wide enough for
the research question at hand?
NC NC Yes Yes Yes Yes Yes Yes Yes Yes No NC Yes NC Yes Yes Yes
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Item
Study
Von
Bargen
2015226
Jacklin
2010228
Kilonzo
2004229
Laudano
2013230
Richardson
2014233
Sand
2014234
Seklehner
2014235
Weber
2000236
Wu
2007237
Oremus
2010232
Oremus
2003231
Kunkle
2015225
Das
Gupta
2006227
Holtzer-Goor
2015238
Weber
2000239
Weber
2002240
Imamura
2010241
4.2. Did it cover all relevant
viewpoints? (Possible viewpoints
include the community or social
viewpoint, and those of patients and
third-party payers. Other viewpoints
may also be relevant depending on
the particular analysis.)
Yes No No NC No No No Yes No No No No No Yes Yes Yes No
4.3. Were the capital costs, as well as
operating costs, included?
Yes Yes No No No No No Yes No No No No Yes Yes Yes Yes Yes
5. Were costs and consequences
measured accurately in appropriate
physical units (e.g. hours of nursing
time, number of physician visits, lost
work-days, gained life-years)?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
5.1. Were any of the identified items
omitted from measurement? If so,
does this mean that they carried no
weight in the subsequent analysis?
No No No No No No No No No No No No No No No No No
5.2. Were there any special
circumstances (e.g. joint use of
resources) that made measurement
difficult? Were these circumstances
handled appropriately?
No No No No No No No No No No Yes Yes No No No No No
6. Were the cost and consequences
valued credibly?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
6.1. Were the sources of all values
clearly identified? (Possible sources
include market values, patient or client
preferences and views, policy-makers’
views and health professionals’
judgements.)
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes
6.2. Were market values employed for
changes involving resources gained or
depleted?
N/A N/A No Yes N/A No Yes Yes Yes Yes No No No Yes N/A N/A N/A
6.3. Where market values were absent
(e.g. volunteer labour), or market
values did not reflect actual values
(such as clinic space donated at a
reduced rate), were adjustments made
to approximate market values?
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
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Item
Study
Von
Bargen
2015226
Jacklin
2010228
Kilonzo
2004229
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2013230
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2014233
Sand
2014234
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2014235
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2000236
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2007237
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2010232
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Kunkle
2015225
Das
Gupta
2006227
Holtzer-Goor
2015238
Weber
2000239
Weber
2002240
Imamura
2010241
6.4. Was the valuation of
consequences appropriate for the
question posed (i.e. has the
appropriate type or types of analysis –
cost-effectiveness, cost–benefit,
cost–utility – been selected)?
Yes Yes Yes Yes Yes No Yes Yes Yes Yes No Yes Yes Yes No No Yes
7. Were costs and consequences
adjusted for differential timing?
Yes Yes Yes Yes N/A Yes Yes NC Yes N/A N/A N/A Yes NC N/A N/A Yes
7.1. Were costs and consequences
that occur in the future ‘discounted’
to their present values?
Yes Yes Yes Yes N/A Yes Yes NC Yes N/A N/A N/A Yes NC N/A N/A Yes
7.2. Was there any justification given
for the discount rate used?
No Yes No Yes N/A No Yes N/A Yes N/A N/A N/A No No N/A N/A Yes
8. Was an incremental analysis of
costs and consequences of alternatives
performed?
Yes Yes Yes Yes Yes No Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes
8.1. Were the additional (incremental)
costs generated by one alternative
over another compared with the
additional effects, benefits or utilities
generated?
Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes
9. Was allowance made for
uncertainty in the estimates of costs
and consequences?
Yes No Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes No No Yes
9.1. If data on costs and
consequences were stochastic
(randomly determined sequence of
observations), were appropriate
statistical analyses performed?
NC No Yes Yes No N/A Yes N/A N/A Yes No Yes Yes Yes No No Yes
9.2. If a sensitivity analysis was
employed, was justification provided
for the range of values (or for key
study parameters)?
Yes No No No Yes Yes No Yes Yes Yes No Yes Yes Yes Yes Yes Yes
9.3. Were the study results sensitive to
changes in the values (within the
assumed range for sensitivity analysis,
or within the confidence interval
around the ratio of costs to
consequences)?
NC Yes Yes Yes Yes No Yes Yes Yes Yes No Yes Yes No Yes Yes Yes
10. Did the presentation and
discussion of study results include all
issues of concern to users?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes
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10.1. Were the conclusions of the
analysis based on some overall index
or ratio of costs to consequences (e.g.
cost-effectiveness ratio)? If so, was the
index interpreted intelligently or in a
mechanistic fashion?
Yes Yes Yes Yes Yes N/A Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes
10.2. Were the results compared with
those of others who have investigated
the same question? If so, were
allowances made for potential
differences in study methodology?
Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
10.3. Did the study discuss the
generalisability of the results to other
settings and patient/client groups?
Yes No No No Yes Yes Yes Yes Yes Yes Yes No No No No No No
10.4. Did the study allude to, or take
account of, other important factors
in the choice or decision under
consideration (e.g. distribution of costs
and consequences, or relevant ethics
issues)?
No No No No No No No No No No No No No No No No Yes
10.5. Did the study discuss issues of
implementation, such as the feasibility
of adopting the ‘preferred’ programme
given existing financial or other
constraints, and whether or not any
freed resources could be redeployed
to other worthwhile programmes?
No No No No No No No No No No No No No No No No No
N/A, not applicable; NC, not clear.
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Appendix 19 Economic model structure
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Initial surgery
Cured SUI and
no SUI
Urge
incontinence
Retreatment
Containment
Death
Clone 1: RMUS
Clone 1: RMUS
Clone 1: RMUS
Clone 1: RMUS
Clone 1: RMUS
Clone 1: RMUS
Clone 1: RMUS
Clone 1: RMUS
AVR
Decision node
RMUS
BNNS
OARC
LRC
TSRS
TMUS
SISP
PUI
Survive
Die
Survive
Die
Survive
Die
Survive
Die
Survive
Die
Successful
Cured SUI and
no UI
No UI
Recurrence of
UI
SUI
retreatment
SUI
retreatment
No further
surgery for SUI
No further
surgery for SUI
First-line
treatment
Second-line
treatment
Third-line
treatment
Stay cured from
SUI
Recurrence of
SUI
Retreatment 1
Retreatment 2
Retreatment
Urge incontinence
SUI
retreatment
No further
surgery for SUI
Cured SUI but
UI exists
Failed
Death
Death
Treatment for
UI
No further
treatment 
for UI
Death
Retreatment
Not yet
Death
Death
UI treatment
No treatment
for UI
Stay cured from
SUI
Recurrence of
SUI
Cured SUI and no UI
Cured SUI and no UI
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FIGURE 65 Economic model structure. AVR, anterior vaginal repair (anterior colporrhaphy); BNNS, bladder neck
needle suspension; LRC, laparoscopic retropubic colposuspension; MUS, mid-urethral sling; OARC, open abdominal
retropubic colposuspension; PUI, periurethral injection (injectable bulking agents); RMUS, retropubic mid-urethral
sling; TMUS, transobturator mid-urethral sling; TSRS, traditional suburethral retropubic sling procedures;
SISP, single-incision sling procedure.
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Appendix 20 Results of database analysis
T ables 36 and 37 and Figure 66 provide the results from analysing data from AMND.
TABLE 37 Frequency of different SUI surgeries in the data from AMND
SUI operation
Number of SUI surgery
TotalOne (%) Two (%) Three (%) Four (%)
Abdominal retropubic procedure 285 (89.0) 28 (9.0) 5 (2.0) 1 (0.3) 319
MUS 331 (97.0) 10 (3.0) 1 (0.3) 0 (0.0) 342
Colporrhaphy 66 (83.0) 13 (16.0) 1 (1.0) 0 (0.0) 80
Urethral injection therapy 5 (5.0) 2 (20.0) 2 (20.0) 1 (10.0) 10
Total 687 53 9 2 751
TABLE 38 Different selection criteria for the different fitted hazard function forms
Model Obs ll (null) ll (model) df AIC BIC
Exponential 750 –302.621 –291.366 4 590.7 609.2
Gompertz 750 –298.106 –286.081 5 582.2 605.3
Log-logistic 750 –297.233 –285.114 5 580.2 603.3
Log-normal 750 –295.889 –284.734 5 579.5 602.6
Weibull 750 –297.391 –286.166 5 582.3 605.4
df, degree of freedom; obs, observations.
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FIGURE 66 Fitted vs. observed survival in data from AMND. K–M, Kaplan–Meier. (continued )
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Appendix 21 Deterministic sensitivity analyses
Assuming that all women in the model have stress urinary incontinence
The results from this SA, in which it is assumed that all women in the model have SUI, show that, compared
with the base-case analysis, all strategies have a lower total cost and greater effectiveness (Table 39).
Retropubic MUS remains the least costly strategy compared with the alternative surgical interventions but
traditional sling is the most cost-effective option with an ICER of £8024 per QALY gained. Table 40 shows
that the probability of being cost-effective with a £20,000 WTP was 25.5% and 31.0% for retropubic MUS
and traditional sling, respectively.
TABLE 39 Results from deterministic sensitivity analyses assuming that all women in the model have only SUI
(lifetime time horizon)
Strategy Cost (£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/ΔQALY)
Probability
cost-effective
for different
threshold (%)
£20,000 £30,000
Base-case analysis: 52% of the women in the model have SUI and 48% have MUI
Retropubic MUS 8099 24.22 25.8 24.6
Traditional sling 8522 423 24.22 0.01 60,863 27.0 26.2
Urethral injection therapy 9554 1032 23.86 –0.36 Dominated 10.5 10.5
Single-incision sling 9649 1127 23.59 –0.63 Dominated 3.2 3.2
Transobturator MUS 9665 1142 23.71 –0.51 Dominated 4.1 4.1
Bladder neck needle
suspension
10,125 1603 23.69 –0.53 Dominated 5.4 5.4
Open colposuspension 10,977 2455 24.10 –0.12 Dominated 14.1 15.0
Anterior vaginal repair 11,057 2535 23.54 –0.69 Dominated 3.9 4.1
Laparoscopic
colposuspension
11,797 3274 23.83 –0.40 Dominated 6.2 6.8
SA assuming all women in the model have SUI
Retropubic MUS 5282 25.11 32.1 30.5
Traditional sling 5668 385 25.16 0.05 8024 36.9 36.2
Transobturator MUS 7820 2153 24.22 –0.94 Dominated 1.9 1.9
Urethral injection therapy 7947 2280 24.34 –0.81 Dominated 5.8 6.1
Single-incision sling 8220 2553 23.94 –1.22 Dominated 1.0 1.1
Open colposuspension 8498 2831 24.87 –0.29 Dominated 14.9 16.0
Bladder neck needle
suspension
8648 2980 24.09 –1.06 Dominated 2.6 2.7
Laparoscopic
colposuspension
9877 4209 24.39 –0.77 Dominated 3.9 4.4
Anterior vaginal repair 9971 4303 23.80 –1.36 Dominated 1.0 1.2
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TABLE 40 Results from deterministic sensitivity analyses changing the likelihood that a woman would seek
retreatment if primary treatment failed (lifetime time horizon)
Strategy Cost (£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective
for different
threshold (%)
£20,000 £30,000
Base-case analysis: 75% of women whose first treatment was not successful would seek retreatment and 30% of women
whose first retreatment failed would seek second retreatment
Retropubic MUS 8099 24.22 25.8 24.6
Traditional sling 8522 423 24.22 0.01 60,863 27.0 26.2
Urethral injection therapy 9554 1032 23.86 –0.36 Dominated 10.5 10.5
Single-incision sling 9649 1127 23.59 –0.63 Dominated 3.2 3.2
Transobturator MUS 9665 1142 23.71 –0.51 Dominated 4.1 4.1
Bladder neck needle
suspension
10,125 1603 23.69 –0.53 Dominated 5.4 5.4
Open colposuspension 10,977 2455 24.10 –0.12 Dominated 14.1 15.0
Anterior vaginal repair 11,057 2535 23.54 –0.69 Dominated 3.9 4.1
Laparoscopic
colposuspension
11,797 3274 23.83 –0.40 Dominated 6.2 6.8
SA using data from the linked database analysis to estimate proportion of the women who will seek retreatment after
failure of each surgical treatment
Retropubic MUS 8067 24.03 25.5 24.2
Traditional sling 8477 410 24.08 0.05 8114 31.0 30.0
Transobturator MUS 9472 995 23.48 –0.60 Dominated 3.9 4.0
Single-incision sling 9587 1110 23.28 –0.81 Dominated 1.9 1.9
Urethral injection therapy 9602 1125 23.74 –0.35 Dominated 14.4 14.7
Bladder neck needle
suspension
10,134 1657 23.35 –0.73 Dominated 3.1 3.2
Open colposuspension 10,937 2460 23.89 –0.19 Dominated 13.7 14.8
Anterior vaginal repair 11,045 2568 23.18 –0.90 Dominated 1.4 1.6
Laparoscopic
colposuspension
11,752 3275 23.56 –0.52 Dominated 5.0 5.6
SA assuming 50% of women whose first treatment was not successful would seek retreatment and 20% of women whose
first retreatment failed would seek second retreatment
Retropubic MUS 8061 24.14 27.0 25.6
Traditional sling 8479 418 24.15 0.01 35,896 29.0 28.3
Transobturator MUS 9551 1072 23.59 –0.57 Dominated 4.2 4.1
Urethral injection therapy 9579 1100 23.72 –0.43 Dominated 9.1 9.1
Single-incision sling 9584 1106 23.44 –0.71 Dominated 2.8 2.7
Bladder neck needle
suspension
10,090 1611 23.54 –0.61 Dominated 4.8 4.9
Open colposuspension 10,930 2451 24.01 –0.15 Dominated 14.6 15.7
Anterior vaginal repair 11,003 2525 23.38 –0.78 Dominated 2.4 2.7
Laparoscopic
colposuspension
11,739 3261 23.71 –0.44 Dominated 6.3 6.9
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Assuming alternative values for the proportion of women who will seek
retreatment after failure of each surgical treatment
In this SA, in which data from the linked database were applied, results show that the effectiveness of all
surgical interventions is reduced slightly compared with the base-case analysis, and traditional sling, with
an ICER of £8114 per QALY gained, is the most cost-effective option compared with the other surgical
treatments. In the additional SA, in which it was assumed that 50% of women whose first treatment was
not successful would seek retreatment and 20% of women whose first retreatment failed would seek
second retreatment, total costs and effectiveness are reduced for most of the surgical interventions
compared with the base-case analysis. Results from this SA show that retropubic MUS remains the least
costly strategy compared with the alternative surgical interventions and is the most cost-effective option.
When 10% and 0% were assumed for the rates of first and second treatments, traditional sling procedure
was a cost-effective option with an ICER of £14,748, which is lower than £20,000 (Table 40).
Applying lower success rate for repeating same surgeries
In this SA, the effect of assuming lower cure rates (90% and 75%, respectively) when the same surgeries
are being conducted for a second or third time was explored. As would be expected, the results of these
sensitivity analyses show that all strategies have a higher cost and lower effectiveness. However, traditional
sling is the most cost-effective option compared with other surgical treatments at a WTP threshold value of
£20,000 (Table 41).
TABLE 40 Results from deterministic sensitivity analyses changing the likelihood that a woman would seek
retreatment if primary treatment failed (lifetime time horizon) (continued )
Strategy Cost (£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective
for different
threshold (%)
£20,000 £30,000
SA assuming 10% of women whose first treatment was not successful would seek retreatment and 0% of women whose
first retreatment failed would seek second retreatment
Retropubic MUS 8069 24.00 29.2 27.9
Traditional sling 8482 413 24.03 0.03 14,748 33.4 32.4
Transobturator MUS 9493 1011 23.42 –0.61 Dominated 3.8 3.7
Single-incision sling 9608 1126 23.22 –0.81 Dominated 1.8 1.7
Urethral injection therapy 9693 1211 23.50 –0.53 Dominated 6.0 6.2
Bladder neck needle
suspension
10,141 1659 23.32 –0.71 Dominated 3.5 3.7
Open colposuspension 10,937 2455 23.85 –0.18 Dominated 15.4 16.6
Anterior vaginal repair 11,041 2559 23.14 –0.89 Dominated 1.4 1.6
Laparoscopic
colposuspension
11,752 3270 23.53 –0.50 Dominated 5.5 6.2
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TABLE 41 Results from deterministic sensitivity analyses assuming lower success rate for repeating same surgeries
(lifetime time horizon)
Strategy Cost (£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective for
different WTP
thresholds (%)
£20,000 £30,000
Base-case analysis: assuming same cure rates when the same surgeries are being conducted for a second or third time
Retropubic MUS 8099 24.22 25.8 24.6
Traditional sling 8522 423 24.22 0.01 60,863 27.0 26.2
Urethral injection therapy 9554 1032 23.86 –0.36 Dominated 10.5 10.5
Single-incision sling 9649 1127 23.59 –0.63 Dominated 3.2 3.2
Transobturator MUS 9665 1142 23.71 –0.51 Dominated 4.1 4.1
Bladder neck needle
suspension
10,125 1603 23.69 –0.53 Dominated 5.4 5.4
Open colposuspension 10,977 2455 24.10 –0.12 Dominated 14.1 15.0
Anterior vaginal repair 11,057 2535 23.54 –0.69 Dominated 3.9 4.1
Laparoscopic colposuspension 11,797 3274 23.83 –0.40 Dominated 6.2 6.8
SA assuming lower cure rates (90%) when the same surgeries are being conducted for a second or third time
Retropubic MUS 8703 24.07 27.6 26.3
Traditional sling 9079 377 24.10 0.03 12,623 31.5 30.5
Transobturator MUS 10,554 1475 23.53 –0.58 Dominated 4.3 4.4
Urethral injection therapy 10,586 1507 23.61 –0.49 Dominated 7.4 7.6
Single-incision sling 10,809 1730 23.34 –0.76 Dominated 2.3 2.3
Bladder neck needle
suspension
11,252 2172 23.43 –0.67 Dominated 4.4 4.5
Open colposuspension 11,689 2610 23.95 –0.15 Dominated 15.2 16.3
Anterior vaginal repair 12,309 3229 23.27 –0.84 Dominated 2.0 2.2
Laparoscopic
colposuspension
12,735 3656 23.63 –0.47 Dominated 5.4 6.0
SA assuming lower cure rates (75%) when the same surgeries are being conducted for a second or third time
Retropubic MUS 8889 24.04 27.9 26.3
Traditional sling 9239 349 24.07 0.03 12,036 32.6 31.7
Transobturator MUS 10,846 1607 23.45 –0.61 Dominated 4.0 4.1
Urethral injection therapy 10,907 1668 23.53 –0.53 Dominated 6.6 6.8
Single-incision sling 11,160 1921 23.26 –0.81 Dominated 2.5 2.5
Bladder neck needle
suspension
11,586 2347 23.36 –0.71 Dominated 3.8 4.0
Open colposuspension 11,912 2673 23.88 –0.19 Dominated 14.8 15.9
Anterior vaginal repair 12,685 3447 23.17 –0.89 Dominated 2.0 2.2
Laparoscopic
colposuspension
13,023 3784 23.56 –0.51 Dominated 5.9 6.6
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Incorporating different health utility values and effect of natural decline
in health utility over time
In this SA, EQ-5D scores were adjusted and lower values were used for MUI health states compared with
women with only SUI. The results from this SA show that traditional sling is the most cost-effective option
(with an ICER of £7183 per QALY gained) compared with other surgical treatments. The impact of the
natural decline in health utility over time was also considered in further SA. Results from this SA show that
retropubic MUS remains the least costly strategy compared with the alternative surgical interventions and is
the most cost-effective option (Table 42).
TABLE 42 Results from deterministic sensitivity analyses incorporating different health utility values for MUI and
effect of natural decline in health utility over time (lifetime time horizon)
Strategy Cost (£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective for
different WTP
thresholds (%)
£20,000 £30,000
Base-case analysis assuming health states values are the same for women with SUI and MUI and fixed utility values over time
Retropubic MUS 8099 24.22 25.8 24.6
Traditional sling 8522 423 24.22 0.01 60,863 27.0 26.2
Urethral injection therapy 9554 1032 23.86 –0.36 Dominated 10.5 10.5
Single-incision sling 9649 1127 23.59 –0.63 Dominated 3.2 3.2
Transobturator MUS 9665 1142 23.71 –0.51 Dominated 4.1 4.1
Bladder neck needle
suspension
10,125 1603 23.69 –0.53 Dominated 5.4 5.4
Open colposuspension 10,977 2455 24.10 –0.12 Dominated 14.1 15.0
Anterior vaginal repair 11,057 2535 23.54 –0.69 Dominated 3.9 4.1
Laparoscopic
colposuspension
11,797 3274 23.83 –0.40 Dominated 6.2 6.8
SA assuming lower health utility value for MUI health states
Retropubic MUS 8104 23.70 30.4 29.1
Traditional sling 8526 423 23.75 0.06 7183 37.4 36.4
Urethral injection therapy 9551 1025 23.09 –0.67 Dominated 6.9 7.0
Single-incision sling 9648 1122 22.63 –1.13 Dominated 1.1 1.1
Transobturator MUS 9668 1142 22.86 –0.89 Dominated 1.9 2.0
Bladder neck needle
suspension
10,125 1599 22.78 –0.98 Dominated 2.8 3.0
Open colposuspension 1097 2452 23.49 –0.26 Dominated 14.5 15.7
Anterior vaginal repair 11,057 2531 22.53 –1.23 Dominated 1.3 1.3
Laparoscopic
colposuspension
11,797 3271 23.04 –0.71 Dominated 3.9 4.6
continued
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TABLE 42 Results from deterministic sensitivity analyses incorporating different health utility values for MUI and
effect of natural decline in health utility over time (lifetime time horizon) (continued )
Strategy Cost (£)
Incremental
cost (£) QALY
Incremental
QALY
ICER (£)
(ΔCost/
ΔQALY)
Probability
cost-effective for
different WTP
thresholds (%)
£20,000 £30,000
SA incorporating the impact of the natural decline in health utility over time
Retropubic MUS 8096 21.81 26.9 25.4
Traditional sling 8523 427 21.79 –0.01 Dominated 27.6 26.8
Urethral injection therapy 9552 1456 21.48 –0.33 Dominated 10.6 10.6
Single-incision sling 9647 1552 21.24 –0.56 Dominated 3.5 3.4
Transobturator MUS 9666 1570 21.36 –0.45 Dominated 4.3 4.4
Bladder neck needle
suspension
10,124 2028 21.33 –0.48 Dominated 5.8 6.1
Open colposuspension 10,978 2882 21.68 –0.12 Dominated 12.5 13.5
Anterior vaginal repair 11,063 2967 21.20 –0.61 Dominated 3.4 3.6
Laparoscopic
colposuspension
11,798 3702 21.46 –0.35 Dominated 5.5 6.3
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